{"PMC7120757": [["Nature of Modern Taxonomy ::: Taxonomy of Microorganisms in Aquatic EnvironmentsModern taxonomy is the science of biological classification.", [["Microorganisms", "PROBLEM", 42, 56], ["Microorganisms", "OBSERVATION", 42, 56]]]], "PMC7313499": [["In fall 2019, more than 80% of college students used Instagram, their most preferred social media platform [7]; as digital activity has increased during the pandemic [8], this proportion is now likely even higher.Study sample ::: MethodsInstagram promotions are regular posts (i.e., a photo or video with caption and hashtags) that are typically used to increase brand awareness (e.g., likes, views, shares) and/or sales (e.g., links to merchandise on a website) among a targeted audience.", [["caption", "TREATMENT", 305, 312], ["hashtags", "TREATMENT", 317, 325], ["increased", "OBSERVATION_MODIFIER", 136, 145]]], ["We used Instagram promotions to advertise this study using our Instagram Business Profile account (), which operates via Facebook Ad Manager.", [["this study", "TEST", 42, 52]]], ["Prices were based on cost per click and determined according to Instagram's internal algorithms, incorporating factors such as the selected audience and ad feedback.Study sample ::: MethodsWe used four Instagram promotions over 5 days.", [["Prices", "TREATMENT", 0, 6], ["MethodsWe", "TREATMENT", 182, 191]]], ["Promotions used similar text (i.e., \u201cCollege Students: Complete an online survey about your experiences during the COVID-19 pandemic.", [["the COVID", "TEST", 111, 120], ["pandemic", "PROBLEM", 124, 132]]], ["The first two promotions (age target: 18\u201322 years; gender: male or female; geographic location: USA) ran from April 24 to 27, 2020, and each reached (i.e., was seen by) more than 12,800 people.", [["people", "ORGANISM", 186, 192], ["people", "SPECIES", 186, 192]]], ["We then created two additional promotions that reached more than 6,000 young adults (aged 18\u201322 years) in the USA, targeting specific geographic locations (e.g., cities with high proportions of people of color, rural states) and diverse colleges (e.g., names of Hispanic-serving institutions and historically black colleges and universities as \u201cInterests\u201d); one of these two promotions specifically targeted men because women are more likely to participate in survey research [10].", [["men", "ORGANISM", 408, 411], ["women", "ORGANISM", 420, 425], ["people", "SPECIES", 194, 200], ["men", "SPECIES", 408, 411], ["women", "SPECIES", 420, 425]]], ["We spent $150 on the first round of promotions (April 25\u201327, 2020) and an additional $119 on the second round of promotions (April 28\u201329, 2020, which was cut short given that we reached capacity).Study sample ::: MethodsThe four promotions were viewed 41,101 times (because views were summed across ads, some people may have viewed more than one promotion), and 2,887 individuals clicked on the link to the screening questionnaire.", [["people", "ORGANISM", 309, 315], ["people", "SPECIES", 309, 315], ["Methods", "TREATMENT", 213, 220], ["views", "TEST", 274, 279]]], ["Of those, 1,590 nonduplicated individuals started the screening questionnaire (which determined status as a full-time USA college student aged 18\u201322 years), which was 55.1% of those who viewed the screening questionnaire; and 1,331 nonduplicated individuals completed the screening questionnaire (83.7% of those who started the screening questionnaire).", [["individuals", "ORGANISM", 30, 41], ["individuals", "ORGANISM", 246, 257], ["the screening questionnaire", "TEST", 193, 220], ["the screening questionnaire", "TEST", 268, 295]]], ["Most (n = 1,225, 92.0%) qualified for the study and provided informed consent.", [["the study", "TEST", 38, 47]]], ["To further confirm current college student status, participants provided a .edu email address in the screening questionnaire, to which we sent a link to the full survey.", [["participants", "SPECIES", 51, 63]]], ["Participants completed the survey via Qualtrics until we reached maximum capacity (n = 725); the median time to complete the survey was 34.5 minutes (interquartile range: 26.6\u201347.4 minutes).", [["Participants", "SPECIES", 0, 12]]], ["All participants received a $10 Amazon.com gift card within three business days of survey completion; we had a maximum capacity of 725 participants owing to the funds available for incentives.", [["participants", "SPECIES", 4, 16], ["participants", "SPECIES", 135, 147]]], ["Data collection occurred from April 25, 2020, to April 30, 2020; we prioritized completing data collection before any reopening began (some locations in the USA began to reopen on May 1, 2020).Study sample ::: MethodsThe study was approved by the Fordham University Institutional Review Board.Survey measures ::: MethodsWe designed most of the survey measures (Appendix Table 1); we also used items from the Stop AAPI Hate Survey [11] to measure discrimination.Data analyses ::: MethodsDescriptive statistics and chi-square tests were calculated in Stata (StataCorp, College Station, TX), version 16.1.", [["Data collection", "TEST", 0, 15], ["any reopening", "TREATMENT", 114, 127], ["Methods", "TREATMENT", 210, 217], ["The study", "TEST", 217, 226], ["chi-square tests", "TEST", 513, 529]]], ["Confidence intervals (95% CIs) were calculated using http://vassarstats.net/prop1.html.Symptoms and testing ::: Coronavirus disease 2019 health experiences ::: ResultsMore than one-third of participants (35.3%, 95% CI: 31.9%\u201338.9%) experienced COVID-19\u2013related symptoms (as established by the CDC [14] and/or emerging research) since February 2020.", [["Coronavirus disease", "DISEASE", 112, 131], ["participants", "ORGANISM", 190, 202], ["participants", "SPECIES", 190, 202], ["Confidence intervals", "TEST", 0, 20], ["Coronavirus disease", "PROBLEM", 112, 131], ["CI", "TEST", 215, 217], ["COVID", "TEST", 244, 249], ["19\u2013related symptoms", "PROBLEM", 250, 269]]], ["Among those who experienced any symptoms (n = 256), 4.7% (95% CI: 2.7%\u20138.0%) got tested for COVID-19, 9.8% (95% CI: 6.7%\u201314.0%) attempted to get tested but were not successful and 85.6% (95% CI: 80.1%\u201389.3%) did not attempt to get tested.", [["any symptoms", "PROBLEM", 28, 40], ["CI", "TEST", 62, 64], ["COVID", "TEST", 92, 97], ["CI", "TEST", 112, 114], ["CI", "TEST", 191, 193]]], ["Of the 12 people who experienced symptoms and got tested, two tested positive, nine tested negative, and one did not yet have results.", [["people", "ORGANISM", 10, 16], ["people", "SPECIES", 10, 16], ["symptoms", "PROBLEM", 33, 41]]], ["(Among those who did not experience any symptoms (n = 469), .9% (95% CI: .3%\u20132.2%) were tested for COVID-19, .6% (95% CI: .02%\u20131.9%) attempted to get tested but were not tested, and 98.5% (95% CI: 97.0%\u201399.3%) did not attempt to get tested.", [["any symptoms", "PROBLEM", 36, 48], ["CI", "TEST", 69, 71], ["COVID", "TEST", 99, 104], ["CI", "TEST", 118, 120], ["CI", "TEST", 193, 195]]], ["Of the four people who did not have symptoms but got tested for COVID-19, one tested positive, two tested negative, and one did not yet have results.)Behaviors when symptomatic ::: Coronavirus disease 2019 health experiences ::: ResultsAmong those who had any symptoms (n = 256), 46.9% (95% CI: 40.9%\u201353.0%) stayed at home exclusively while they had symptoms (Table 2).", [["Coronavirus disease", "DISEASE", 181, 200], ["people", "ORGANISM", 12, 18], ["people", "SPECIES", 12, 18], ["symptoms", "PROBLEM", 36, 44], ["COVID", "TEST", 64, 69], ["Coronavirus disease", "PROBLEM", 181, 200], ["any symptoms", "PROBLEM", 256, 268], ["CI", "TEST", 291, 293], ["symptoms", "PROBLEM", 350, 358]]], ["An additional 35.5% (95% CI: 29.9%\u201341.2%) stayed at home more than usual (but not exclusively).", [["CI", "TEST", 25, 27]]], ["Nevertheless, many were still in public: 30.1% (95% CI: 24.8%\u201336.0%) reported attending class, 14.5% (95% CI: 10.7%\u201319.3%) went to work, and 13.7% (95% CI: 10.0%\u201318.4%) attended social gatherings.", [["CI", "TEST", 52, 54], ["CI", "TEST", 106, 108], ["CI", "TEST", 152, 154]]], ["Only 16.4% (95% CI: 12.4%\u201321.4%) sought health care (remotely and/or in person).Social contact ::: Opportunities for coronavirus disease 2019 transmission ::: ResultsParticipants attended a variety of in-person social gatherings of different sizes since March 1, 2020 (Table 3).", [["coronavirus disease", "DISEASE", 117, 136], ["coronavirus", "ORGANISM", 117, 128], ["person", "SPECIES", 72, 78], ["CI", "TEST", 16, 18], ["coronavirus disease", "PROBLEM", 117, 136], ["coronavirus disease", "OBSERVATION", 117, 136]]], ["For most group categories (250+, 50\u2013249, 10\u201349 people), academic programming was the most common type of gathering (e.g., 47.5% (95% CI: 40.4%\u201354.8%) of the 181 \u2265 250-person gatherings).", [["people", "ORGANISM", 47, 53], ["people", "SPECIES", 47, 53], ["person", "SPECIES", 167, 173], ["CI", "TEST", 133, 135]]], ["For gatherings of 2\u20139 people (not including people from the participant's household), social events were the most common activity.Social contact ::: Opportunities for coronavirus disease 2019 transmission ::: ResultsAlmost two-thirds of participants (62.8%, 95% CI: 59.2%\u201366.2%) traveled \u226550 miles at least once in March 2020, for a total of 531 trips (Appendix Table 3).", [["coronavirus disease", "DISEASE", 167, 186], ["people", "ORGANISM", 22, 28], ["people", "ORGANISM", 44, 50], ["coronavirus", "ORGANISM", 167, 178], ["participants", "ORGANISM", 237, 249], ["people", "SPECIES", 22, 28], ["people", "SPECIES", 44, 50], ["participant", "SPECIES", 60, 71], ["participants", "SPECIES", 237, 249], ["coronavirus disease", "PROBLEM", 167, 186], ["CI", "TEST", 262, 264], ["coronavirus disease", "OBSERVATION", 167, 186]]], ["In comparison, only 15.2% (95% CI: 12.7%\u201318.0%) of participants traveled \u226550 miles at least once in April 2020, for a total of 108 trips.", [["participants", "ORGANISM", 51, 63], ["participants", "SPECIES", 51, 63], ["CI", "TEST", 31, 33]]], ["In both March and April 2020, the majority of these trips were by car: 65.0% (95% CI: 60.8%\u201368.9%) of trips in March and 89.8% (95% CI: 82.7%\u201394.2%) of trips in April.Social contact ::: Opportunities for coronavirus disease 2019 transmission ::: ResultsApproximately three-quarters (77.2%, 95% CI: 74.1%\u201380.1%) of participants reported behaviors in compliance with CDC-recommended social distancing (i.e., 6 feet away from anyone outside your household) over the last 4 weeks (effectively, April 2020) (Table 4).", [["coronavirus disease", "DISEASE", 204, 223], ["coronavirus", "ORGANISM", 204, 215], ["participants", "ORGANISM", 314, 326], ["participants", "SPECIES", 314, 326], ["CI", "TEST", 82, 84], ["trips", "TEST", 102, 107], ["CI", "TEST", 132, 134], ["coronavirus disease", "PROBLEM", 204, 223], ["CI", "TEST", 294, 296], ["coronavirus disease", "OBSERVATION", 204, 223]]], ["Notably, 25.0% (95% CI: 22.0%\u201328.3%) reported being within 6 feet of family and friends for whom they were not providing care.", [["CI", "TEST", 20, 22]]], ["Participants also estimated the number of people of whom they had been within 6 feet across different categories and had the most uncertainty for the number of essential workers to whom they were exposed.", [["people", "ORGANISM", 42, 48], ["Participants", "SPECIES", 0, 12], ["people", "SPECIES", 42, 48]]], ["Only 4.3% (95% CI: 3.0%\u20136.0%) of participants were in close contact with people they knew to have COVID-19 symptoms.Social contact ::: Opportunities for coronavirus disease 2019 transmission ::: ResultsWe also asked about exposure to prepared food obtained, by themselves and/or members of their household, via pickup or delivery.", [["coronavirus disease", "DISEASE", 153, 172], ["participants", "ORGANISM", 33, 45], ["people", "ORGANISM", 73, 79], ["coronavirus", "ORGANISM", 153, 164], ["participants", "SPECIES", 33, 45], ["people", "SPECIES", 73, 79], ["CI", "TEST", 15, 17], ["COVID-19 symptoms", "PROBLEM", 98, 115], ["coronavirus disease", "PROBLEM", 153, 172], ["delivery", "TREATMENT", 321, 329], ["coronavirus disease", "OBSERVATION", 153, 172]]], ["In the last 4 weeks, more than half of participants (54.8%, 95% CI: 51.1%\u201358.4%) reported that neither they nor any household members had food delivered, 29.0% (95% CI: 25.8%\u201332.4%) had delivery 1\u20133 times, and 16.3% (95% CI: 13.8%\u201319.1%) had delivery at least once per week.", [["participants", "ORGANISM", 39, 51], ["participants", "SPECIES", 39, 51], ["CI", "TEST", 64, 66], ["CI", "TEST", 165, 167], ["delivery", "TEST", 186, 194], ["CI", "TEST", 221, 223], ["delivery", "TREATMENT", 242, 250]]], ["Pickup was more common: in the last 4 weeks, 22.8% (95% CI: 19.9%\u201325.6%) never picked up food, 45.8% (95% CI: 42.2%\u201349.4%) collected pickup 1\u20133 times, and 31.4% (95% CI: 28.2%\u201334.9%) collected pickup at least once per week.Hygiene behaviors ::: Opportunities for coronavirus disease 2019 transmission ::: ResultsParticipants generally followed public health guidance when the survey was conducted, but incompletely (Appendix Table 4).", [["Hygiene behaviors", "DISEASE", 223, 240], ["coronavirus disease", "DISEASE", 263, 282], ["coronavirus", "ORGANISM", 263, 274], ["CI", "TEST", 56, 58], ["CI", "TEST", 106, 108], ["collected pickup", "TEST", 123, 139], ["CI", "TEST", 166, 168], ["coronavirus disease", "PROBLEM", 263, 282], ["the survey", "TEST", 372, 382], ["coronavirus disease", "OBSERVATION", 263, 282]]], ["For example, more than three-quarters of people reported never coughing or sneezing into their hands or without covering their mouth at all, and almost half reported never touching their eyes, nose, and/or mouth without first washing their hands when outside their home.", [["mouth", "ANATOMY", 127, 132], ["eyes", "ANATOMY", 187, 191], ["nose", "ANATOMY", 193, 197], ["mouth", "ANATOMY", 206, 211], ["people", "ORGANISM", 41, 47], ["mouth", "ORGANISM_SUBDIVISION", 127, 132], ["eyes", "ORGAN", 187, 191], ["nose", "ORGANISM_SUBDIVISION", 193, 197], ["mouth", "ORGANISM_SUBDIVISION", 206, 211], ["people", "SPECIES", 41, 47], ["coughing", "PROBLEM", 63, 71], ["sneezing into their hands", "PROBLEM", 75, 100], ["eyes", "ANATOMY", 187, 191], ["nose", "ANATOMY", 193, 197], ["mouth", "ANATOMY", 206, 211]]], ["Approximately half (50.8%, 95% CI: 47.1%\u201354.4%) always wore a face mask or covering in public.", [["CI", "TEST", 31, 33], ["a face mask", "TREATMENT", 60, 71]]], ["However, while 72.5% (95% CI: 69.2%\u201375.7%) reported always washing their hands for the recommended duration of \u226520 seconds and/or using hand sanitizer that is \u226560% alcohol after being in a public place, only 37.6% (95% CI: 34.2%\u201341.2%) always do so after blowing their nose, and only 31.3% (95% CI: 28.0%\u201334.8%) always do so after coughing or sneezing.Sheltering in place ::: Opportunities for coronavirus disease 2019 transmission ::: ResultsAlmost all (94.8%, 95% CI: 92.9%\u201396.2%) participants had sheltered in place or stayed at home (leaving only for essential services, essential work, and/or exercise) in spring 2020.", [["hand", "ANATOMY", 136, 140], ["alcohol", "CHEMICAL", 164, 171], ["sneezing", "DISEASE", 343, 351], ["coronavirus disease", "DISEASE", 394, 413], ["alcohol", "CHEMICAL", 164, 171], ["hand", "ORGANISM_SUBDIVISION", 136, 140], ["alcohol", "SIMPLE_CHEMICAL", 164, 171], ["nose", "ORGANISM_SUBDIVISION", 269, 273], ["coronavirus", "ORGANISM", 394, 405], ["participants", "SPECIES", 483, 495], ["CI", "TEST", 26, 28], ["hand sanitizer", "TREATMENT", 136, 150], ["CI", "TEST", 219, 221], ["CI", "TEST", 295, 297], ["coughing", "PROBLEM", 331, 339], ["sneezing", "PROBLEM", 343, 351], ["coronavirus disease", "PROBLEM", 394, 413], ["ResultsAlmost", "TEST", 436, 449], ["CI", "TEST", 466, 468], ["nose", "ANATOMY", 269, 273], ["sneezing", "OBSERVATION", 343, 351], ["coronavirus disease", "OBSERVATION", 394, 413]]], ["Among those who had sheltered in place at any time (n = 687), 98.3% (95% CI: 97.0%\u201399.0%) were currently doing so when they completed the survey.", [["CI", "TEST", 73, 75]]], ["Of the 1.8% (95% CI: 1.0%\u20133.0%) who had stopped sheltering in place, approximately half had stopped in the first half of April and the rest had stopped in the second half of April.Sheltering in place ::: Opportunities for coronavirus disease 2019 transmission ::: ResultsMore than half of participants (53.1%, 95% CI: 49.5%\u201356.7%) started sheltering in place before any state had an official stay-at-home order (California was the first, on March 19), and more than one-third started sheltering in place before any region had an official stay-at-home order (the San Francisco Bay Area was the first, on March 17) (Table 5).", [["coronavirus disease", "DISEASE", 222, 241], ["coronavirus", "ORGANISM", 222, 233], ["participants", "ORGANISM", 289, 301], ["participants", "SPECIES", 289, 301], ["CI", "TEST", 17, 19], ["coronavirus disease", "PROBLEM", 222, 241], ["CI", "TEST", 314, 316], ["coronavirus disease", "OBSERVATION", 222, 241]]], ["Most participants (81.1%, 95% CI: 78.1%\u201383.8%) last ate at a dine-in setting before any municipality or state had an official stay-at-home order (before March 17).Perceived impact ::: Psychosocial and economic experiences ::: ResultsParticipants who received financial aid for college were more concerned about COVID-19's economic (chi-square test p-value = .01) and emotional (chi-square test p-value = .01) impacts on their lives than those who did not receive financial aid, but the daily responsibility impacts were relatively similar (chi-square test p-value = .25) (Appendix Table 5).", [["participants", "SPECIES", 5, 17], ["CI", "TEST", 30, 32], ["COVID", "TEST", 311, 316], ["p-value", "TEST", 348, 355], ["emotional (chi-square test p-value", "TEST", 367, 401], ["chi-square test p-value", "TEST", 540, 563], ["Appendix", "ANATOMY", 572, 580]]], ["Less than one-quarter of participants (24.2% [95% CI: 20.7%\u201328.2%] of those receiving financial aid [n = 495] and 21.7% [95% CI: 16.9%\u201327.5%] of those not receiving financial aid [n = 230]) reported that COVID-19 had changed their postcollege career plans.Level of stress ::: Psychosocial and economic experiences ::: ResultsMore than one-third of the sample agreed (9.8%, 95% CI: 7.8%\u201312.2%) or somewhat agreed (29.2%, 95% CI: 26.1%\u201332.7%) with the statement, \u201cI am so anxious about COVID-19 that I can't pay attention to anything else.\u201d", [["participants", "ORGANISM", 25, 37], ["participants", "SPECIES", 25, 37], ["CI", "TEST", 50, 52], ["financial aid", "TEST", 86, 99], ["CI", "TEST", 125, 127], ["financial aid", "TEST", 165, 178], ["CI", "TEST", 377, 379], ["CI", "TEST", 424, 426], ["anxious", "PROBLEM", 470, 477], ["COVID", "TEST", 484, 489]]], ["We also asked participants about their level of stress regarding COVID-19's health, educational, and economic implications, for themselves, their families, and American society (Appendix Table 6).", [["participants", "SPECIES", 14, 26]]], ["Participants were much more concerned about COVID-19's health implications for their families and for American society than themselves, but much more concerned about COVID-19's educational implications for themselves than for their families (and slightly more concerned about themselves than American society).", [["Participants", "SPECIES", 0, 12]]], ["They were most concerned about COVID-19's economic implications for American society, then their families, and then themselves.Employment ::: Psychosocial and economic experiences ::: ResultsMost participants (61.7%, 95% CI: 58.1%\u201365.1%) were employed in February 2020, but only 32.4% (95% CI: 29.1%\u201335.9%) were currently employed (i.e., in late April 2020).", [["participants", "SPECIES", 196, 208], ["CI", "TEST", 221, 223], ["CI", "TEST", 290, 292]]], ["More than half (52.6%, 95% CI: 47.9%\u201357.2%) of those employed in February 2020 (n = 447) were no longer employed in late April 2020%; 8.3% (95% CI: 5.6%\u201312.1%) of those who were not employed in February 2020 (n = 278) were employed in late April 2020 (some participants mentioned, for example, taking on gig work as a food delivery driver).", [["participants", "SPECIES", 257, 269], ["CI", "TEST", 27, 29], ["CI", "TEST", 144, 146], ["no longer", "UNCERTAINTY", 94, 103]]], ["Among those who were employed in both February 2020 and late April 2020 (n = 212), 44.8% (95% CI: 38.3%\u201351.5%) had had their take-home pay decreased owing to the COVID-19 pandemic.Discrimination ::: Psychosocial and economic experiences ::: ResultsRelatively few (9.2%, 95% CI: 7.3%\u201311.6%) reported experiencing discrimination related to the coronavirus outbreak.", [["coronavirus", "DISEASE", 342, 353], ["coronavirus", "ORGANISM", 342, 353], ["CI", "TEST", 94, 96], ["the COVID", "TEST", 158, 167], ["pandemic", "PROBLEM", 171, 179], ["CI", "TEST", 274, 276], ["the coronavirus outbreak", "PROBLEM", 338, 362], ["coronavirus", "OBSERVATION", 342, 353]]], ["Most of the people who reported experiencing discrimination (n = 67) were Asian or Asian-American (65.7%; 95% CI: 53.7%\u201375.9%).", [["people", "ORGANISM", 12, 18], ["people", "SPECIES", 12, 18], ["CI", "TEST", 110, 112]]], ["Of the people who experienced discrimination (n = 67), 62.7% (95% CI: 50.7%\u201373.3%) suspected it was because of their race/ethnicity, 16.4% (95% CI: 9.4%\u201327.1%) suspected it was because of their face mask or clothing, and the rest suspected it was because of gender, language, religion, food, or something else.Perspectives about coronavirus disease 2019 ::: ResultsParticipants were very open to continuing current restrictions (i.e., restrictions as of April 25\u201330, 2020) to reduce pandemic spread.", [["coronavirus disease", "DISEASE", 329, 348], ["people", "ORGANISM", 7, 13], ["coronavirus", "ORGANISM", 329, 340], ["people", "SPECIES", 7, 13], ["CI", "TEST", 66, 68], ["ethnicity", "TEST", 122, 131], ["CI", "TEST", 144, 146], ["their face mask", "TREATMENT", 188, 203], ["clothing", "TREATMENT", 207, 215], ["pandemic spread", "PROBLEM", 483, 498], ["coronavirus disease", "OBSERVATION", 329, 348]]], ["Only 2.3% (95% CI: 1.5%\u20133.7%) wanted the current restrictions to be lifted immediately.", [["CI", "TEST", 15, 17]]], ["Approximately one-third (36.5%, 95% CI: 33.0%\u201340.0%) thought the restrictions should be lifted in the next month, 23.6% (95% CI: 20.6%\u201326.8%) thought the restrictions should be lifted in 1\u20132 months, 9.9% (95% CI: 8.0%\u201312.3%) thought the restrictions should be lifted in >2 months, and 27.7% (95% CI: 24.6%\u201331.1%) thought the restrictions should be lifted only once a vaccine or treatment became available.Perspectives about coronavirus disease 2019 ::: ResultsParticipants had more trust in more local levels of government (i.e., state more than federal, local more than state) for doing everything possible to prevent the spread of COVID-19 and providing trustworthy information about COVID-19 (Appendix Table 7).", [["coronavirus disease", "DISEASE", 424, 443], ["coronavirus", "ORGANISM", 424, 435], ["CI", "TEST", 36, 38], ["CI", "TEST", 125, 127], ["CI", "TEST", 209, 211], ["CI", "TEST", 296, 298], ["a vaccine", "TREATMENT", 365, 374], ["treatment", "TREATMENT", 378, 387], ["COVID", "TEST", 686, 691], ["coronavirus disease", "OBSERVATION", 424, 443]]], ["Nevertheless, for each level of government, a relatively small proportion of participants had complete trust.Perspectives about coronavirus disease 2019 ::: ResultsParticipants also expressed some optimism (Appendix Figure 1).", [["coronavirus disease", "DISEASE", 128, 147], ["coronavirus", "ORGANISM", 128, 139], ["participants", "SPECIES", 77, 89], ["small", "OBSERVATION_MODIFIER", 57, 62], ["coronavirus disease", "OBSERVATION", 128, 147]]], ["More than three-quarters (78.9%, 95% CI: 75.8%\u201381.7%) were inspired by seeing how other people are working hard to respond to this crisis, and almost half (49.5%, 95% CI: 45.9%\u201353.2%) agreed that we are all in this together and feel more connected to the rest of the country.", [["people", "ORGANISM", 88, 94], ["people", "SPECIES", 88, 94], ["CI", "TEST", 37, 39], ["this crisis", "PROBLEM", 126, 137], ["CI", "TEST", 167, 169]]], ["They also noted the power of politicians, with 89.5% (95% CI: 87.1%\u201391.6%) noticing how consequential political leaders' decisions are for people's everyday life through this pandemic.", [["people", "ORGANISM", 139, 145], ["people", "SPECIES", 139, 145], ["CI", "TEST", 58, 60]]], ["They also saw the helpful things that young people like them could do for their communities in times like this (73.3% [95% CI: 70.0%\u201376.3%] agreed).Public health implications ::: DiscussionWe found that a low proportion of college students with COVID-19 symptoms got tested and that less than half of those with symptoms stayed at home exclusively while symptomatic.", [["people", "ORGANISM", 44, 50], ["people", "SPECIES", 44, 50], ["CI", "TEST", 123, 125], ["COVID", "TEST", 245, 250], ["symptoms", "PROBLEM", 254, 262], ["symptoms", "PROBLEM", 312, 320], ["symptomatic", "PROBLEM", 354, 365]]], ["Furthermore, students' hygiene behaviors in April 2020 suggest they are protecting themselves (e.g., washing their hands) but could do more to prevent transmission to others (e.g., wearing a mask).", [["a mask", "TREATMENT", 189, 195]]], ["Returning to extensive in-person academic instruction will require widespread testing and contact tracing [15].", [["widespread testing", "TEST", 67, 85], ["contact tracing", "TEST", 90, 105]]], ["However, contact tracing among college students will be challenging and require creative solutions because students participate in a myriad of activities with many different people and participants struggled to recall the number of the people with whom they had close contact (within 6 feet).Public health implications ::: DiscussionBecause many participants restricted their behaviors before official stay-at-home orders went into effect, they may continue to do so after stay-at-home orders are lifted per their own risk calculations.", [["people", "ORGANISM", 174, 180], ["people", "ORGANISM", 236, 242], ["feet", "ORGANISM_SUBDIVISION", 286, 290], ["people", "SPECIES", 174, 180], ["participants", "SPECIES", 185, 197], ["people", "SPECIES", 236, 242], ["participants", "SPECIES", 346, 358], ["creative solutions", "TREATMENT", 80, 98]]], ["For example, more than one-quarter thought that the restrictions in place in late April 2020 (i.e., stay at home/shelter in place almost everywhere in the USA) should be maintained until a vaccine or treatment becomes available.", [["a vaccine", "TREATMENT", 187, 196], ["treatment", "TREATMENT", 200, 209]]], ["This suggests that some students may not return to campus in person, if a vaccine or treatment is not yet available.", [["person", "SPECIES", 61, 67], ["a vaccine", "TREATMENT", 72, 81], ["treatment", "TREATMENT", 85, 94]]], ["In addition, because more than half of participants expressed high stress regarding their family's health, students may opt to stay on campus during some of the shorter breaks, rather than risk bringing COVID-19 home.Public health implications ::: DiscussionCollege students' behaviors changed rapidly this spring, leading to increased isolation from their established social and academic communities, and all domains of their lives were affected, including economically.", [["participants", "ORGANISM", 39, 51], ["participants", "SPECIES", 39, 51], ["increased isolation", "PROBLEM", 326, 345], ["increased", "OBSERVATION_MODIFIER", 326, 335], ["isolation", "OBSERVATION", 336, 345]]], ["We found that many participants were stressed owing to COVID-19.", [["COVID-19", "CHEMICAL", 55, 63], ["COVID-19", "DNA", 55, 63], ["participants", "SPECIES", 19, 31], ["COVID", "TEST", 55, 60]]], ["It will be essential to monitor the mental health sequelae of COVID-19.Social implications ::: DiscussionAs unemployment skyrockets nationwide, college students are also affected: most of those employed in February 2020 were no longer employed in April 2020, and among those still employed, almost half were earning less.", [["COVID-19", "CHEMICAL", 62, 70], ["COVID", "TEST", 62, 67]]], ["Given the finding that students were largely inspired by others (including young people) who are working hard during the crisis, they may be inspired to join public service efforts for public health that others have recommended creating [16].Social implications ::: DiscussionWhile relatively few participants reported experiencing discrimination related to COVID-19, most of the students who were discriminated against were Asian or Asian-American.", [["people", "ORGANISM", 81, 87], ["people", "SPECIES", 81, 87], ["participants", "SPECIES", 297, 309]]], ["As the COVID-19 pandemic continues, and as antiracism movements expand in response to George Floyd's death, it will be important to continue to monitor changes in racist attitudes, perceived discrimination, and who experiences discrimination.Social implications ::: DiscussionWe also note that the 2020 U.S. Census may overcount college students.", [["death", "DISEASE", 101, 106], ["the COVID", "TEST", 3, 12], ["pandemic", "PROBLEM", 16, 24]]], ["This is likely because many college students had left campus by Census Day (April 1, 2020), but colleges still sent counts of students in dorms earlier that spring to the Census [17].", [["likely", "UNCERTAINTY", 8, 14], ["left", "ANATOMY_MODIFIER", 49, 53]]], ["This must be examined further to inform how 2020 U.S. Census data are used for resource allocation.Limitations ::: DiscussionWe also note important limitations of this study.", [["this study", "TEST", 163, 173]]], ["This may be because we used Instagram to recruit participants.", [["participants", "SPECIES", 49, 61]]], ["Part-time college students may be even more negatively affected by COVID-19 because they are more likely to have had more COVID-19\u2013related disruptions that increased financial and familial responsibilities; we encourage future researchers to specifically study this population.", [["COVID", "TEST", 67, 72], ["increased financial and familial responsibilities", "PROBLEM", 156, 205], ["increased", "OBSERVATION_MODIFIER", 156, 165]]], ["COVID-19's impacts are occurring inequitably; we encourage future researchers to look at these outcomes by social factors.", [["COVID", "TEST", 0, 5]]]], "a56ce5fa4ee093c053550da1a5c51a4a9e6192db": [["INTRODUCTIONBovine coronavirus (BCV) is an enteropathogenic coronavirus that causes severe diarrhea in neonatal calves.", [["enteropathogenic coronavirus", "DISEASE", 43, 71], ["diarrhea", "DISEASE", 91, 99], ["INTRODUCTIONBovine coronavirus", "ORGANISM", 0, 30], ["BCV", "ORGANISM", 32, 35], ["enteropathogenic coronavirus", "ORGANISM", 43, 71], ["calves", "ORGANISM", 112, 118], ["coronavirus", "SPECIES", 19, 30], ["coronavirus", "SPECIES", 60, 71], ["calves", "SPECIES", 112, 118], ["INTRODUCTIONBovine coronavirus", "SPECIES", 0, 30], ["BCV", "SPECIES", 32, 35], ["INTRODUCTIONBovine coronavirus (BCV", "PROBLEM", 0, 35], ["an enteropathogenic coronavirus", "PROBLEM", 40, 71], ["severe diarrhea in neonatal calves", "PROBLEM", 84, 118], ["enteropathogenic coronavirus", "OBSERVATION", 43, 71], ["severe", "OBSERVATION_MODIFIER", 84, 90], ["diarrhea", "OBSERVATION", 91, 99], ["neonatal calves", "ANATOMY", 103, 118]]], ["The genome of BCV is a single-stranded RNA with positive polarity of approximately 30 kb in length and encodes four major structural proteins, which are the nucleocapsid protein (N; 52K), the matrix protein (M; 25K), the spike protein (S; 1 BOK) and the hemagglutinin/esterase (HE; 65K) (King and Brian, 1982; Cry-Coat et a/., 1988) .INTRODUCTIONThe S glycoprotein is the major viral component possessing functions responsible for cell binding (Collins ef al., 1982) , cell fusion (Sturman et al., 1985; Yoo et a/., 1991) , and induction of neutralizing antibody response ; for a review, see Spaan et a/., 1988) .", [["cell", "ANATOMY", 431, 435], ["cell", "ANATOMY", 469, 473], ["BCV", "GENE_OR_GENE_PRODUCT", 14, 17], ["N; 52K", "GENE_OR_GENE_PRODUCT", 179, 185], ["matrix", "CELLULAR_COMPONENT", 192, 198], ["M; 25K", "GENE_OR_GENE_PRODUCT", 208, 214], ["S; 1 BOK", "GENE_OR_GENE_PRODUCT", 236, 244], ["esterase", "GENE_OR_GENE_PRODUCT", 268, 276], ["S glycoprotein", "GENE_OR_GENE_PRODUCT", 350, 364], ["cell", "CELL", 431, 435], ["cell", "CELL", 469, 473], ["BCV", "DNA", 14, 17], ["structural proteins", "PROTEIN", 122, 141], ["nucleocapsid protein", "PROTEIN", 157, 177], ["N", "PROTEIN", 179, 180], ["52K", "PROTEIN", 182, 185], ["matrix protein", "PROTEIN", 192, 206], ["25K", "PROTEIN", 211, 214], ["spike protein", "PROTEIN", 221, 234], ["S", "PROTEIN", 236, 237], ["BOK", "PROTEIN", 241, 244], ["hemagglutinin", "PROTEIN", 254, 267], ["esterase", "PROTEIN", 268, 276], ["HE", "PROTEIN", 278, 280], ["65K", "PROTEIN", 282, 285], ["S glycoprotein", "PROTEIN", 350, 364], ["BCV", "SPECIES", 14, 17], ["the nucleocapsid protein", "TEST", 153, 177], ["the matrix protein", "TEST", 188, 206], ["the spike protein", "TEST", 217, 234], ["S", "TEST", 236, 237], ["BOK", "TEST", 241, 244], ["the hemagglutinin/esterase", "TEST", 250, 276], ["Cry", "TEST", 310, 313], ["S glycoprotein", "TREATMENT", 350, 364], ["neutralizing antibody response", "PROBLEM", 541, 571], ["BCV", "ANATOMY", 14, 17], ["stranded RNA", "OBSERVATION_MODIFIER", 30, 42], ["positive polarity", "OBSERVATION_MODIFIER", 48, 65], ["30 kb", "OBSERVATION_MODIFIER", 83, 88], ["four major", "OBSERVATION_MODIFIER", 111, 121], ["structural proteins", "OBSERVATION", 122, 141]]], ["The BCV S glycoprotein is posttranslationally cleaved into two subunits at amino acids 768-769 (Abraham et a/., 1990) .", [["amino acids 768-769", "CHEMICAL", 75, 94], ["amino acids", "CHEMICAL", 75, 86], ["BCV S glycoprotein", "GENE_OR_GENE_PRODUCT", 4, 22], ["amino acids", "AMINO_ACID", 75, 86], ["BCV S glycoprotein", "PROTEIN", 4, 22], ["The BCV S glycoprotein", "TEST", 0, 22], ["amino acids", "TEST", 75, 86], ["BCV", "ANATOMY", 4, 7]]], ["Accumulated information suggests that the carboxy-terminal S2 subunit is an integral membrane protein comprising the stalk ' To whom reprint requests should be addressed. portion of the peplomer whereas the amino-terminal Sl subunit constitutes the bulbous part of the peplomer.", [["membrane", "ANATOMY", 85, 93], ["Sl", "CHEMICAL", 222, 224], ["carboxy", "CHEMICAL", 42, 49], ["membrane", "CELLULAR_COMPONENT", 85, 93], ["Sl subunit", "GENE_OR_GENE_PRODUCT", 222, 232], ["carboxy-terminal S2 subunit", "PROTEIN", 42, 69], ["integral membrane protein", "PROTEIN", 76, 101], ["amino-terminal", "PROTEIN", 207, 221], ["Sl subunit", "PROTEIN", 222, 232], ["the carboxy-terminal S2 subunit", "PROBLEM", 38, 69], ["an integral membrane protein", "TREATMENT", 73, 101], ["amino-terminal", "OBSERVATION_MODIFIER", 207, 221], ["bulbous", "OBSERVATION_MODIFIER", 249, 256]]], ["Recently, the nucleotide sequence of the BCV S glycoprotein gene has been determined Abraham et a/., 1990; Boireau et a/., 1990) .INTRODUCTIONWhen the deduced amino acid sequence of the BCV S glycoprotein was compaired to that of mouse hepatitis coronavirus (MHV) (Luytjes et a/., 1987; Schmidt et al., 1987) , a large additional sequence of 49 and 138 amino acids was identified in the BCV Sl subunit that was not present in MHV strains JHM and A59, respectively.", [["nucleotide", "CHEMICAL", 14, 24], ["amino acid", "CHEMICAL", 159, 169], ["hepatitis coronavirus", "DISEASE", 236, 257], ["amino acids", "CHEMICAL", 353, 364], ["nucleotide", "CHEMICAL", 14, 24], ["amino acid", "CHEMICAL", 159, 169], ["amino acids", "CHEMICAL", 353, 364], ["BCV S glycoprotein", "GENE_OR_GENE_PRODUCT", 41, 59], ["amino acid", "AMINO_ACID", 159, 169], ["BCV S glycoprotein", "GENE_OR_GENE_PRODUCT", 186, 204], ["mouse hepatitis coronavirus", "ORGANISM", 230, 257], ["MHV", "ORGANISM", 259, 262], ["amino acids", "AMINO_ACID", 353, 364], ["Sl subunit", "GENE_OR_GENE_PRODUCT", 391, 401], ["MHV strains JHM", "ORGANISM", 426, 441], ["A59", "CELL", 446, 449], ["BCV S glycoprotein gene", "DNA", 41, 64], ["deduced amino acid sequence", "PROTEIN", 151, 178], ["BCV S glycoprotein", "PROTEIN", 186, 204], ["Sl subunit", "PROTEIN", 391, 401], ["mouse", "SPECIES", 230, 235], ["hepatitis coronavirus", "SPECIES", 236, 257], ["mouse hepatitis coronavirus", "SPECIES", 230, 257], ["MHV", "SPECIES", 259, 262], ["BCV", "SPECIES", 387, 390], ["MHV", "SPECIES", 426, 429], ["the nucleotide sequence", "TEST", 10, 33], ["the deduced amino acid sequence", "TEST", 147, 178], ["the BCV S glycoprotein", "TEST", 182, 204], ["mouse hepatitis coronavirus", "PROBLEM", 230, 257], ["a large additional sequence", "TEST", 311, 338], ["amino acids", "TEST", 353, 364], ["Sl subunit", "PROBLEM", 391, 401], ["BCV", "ANATOMY", 186, 189], ["BCV", "ANATOMY", 387, 390]]], ["The function of this additional sequence present in the BCV Sl subunit is not yet clearly defined.", [["Sl subunit", "GENE_OR_GENE_PRODUCT", 60, 70], ["Sl subunit", "PROTEIN", 60, 70], ["BCV", "SPECIES", 56, 59], ["this additional sequence", "TEST", 16, 40], ["the BCV", "TEST", 52, 59], ["BCV", "ANATOMY", 56, 59], ["not yet", "UNCERTAINTY", 74, 81]]], ["However, recent studies have identified a region of 142 to 159 amino acids similar to the BCV Sl additional sequence in the N-terminal half (Sl counterpart) of the spike glycoprotein of wild type MHV-4 coronavirus .", [["amino acids", "CHEMICAL", 63, 74], ["Sl", "CHEMICAL", 94, 96], ["amino acids", "CHEMICAL", 63, 74], ["N", "CHEMICAL", 124, 125], ["amino acids", "AMINO_ACID", 63, 74], ["wild type MHV-4 coronavirus", "ORGANISM", 186, 213], ["N-terminal half", "PROTEIN", 124, 139], ["Sl counterpart", "PROTEIN", 141, 155], ["spike glycoprotein", "PROTEIN", 164, 182], ["MHV-4 coronavirus", "SPECIES", 196, 213], ["BCV", "SPECIES", 90, 93], ["MHV-4 coronavirus", "SPECIES", 196, 213], ["recent studies", "TEST", 9, 23], ["amino acids", "TEST", 63, 74], ["the BCV", "TEST", 86, 93], ["Sl additional sequence", "TEST", 94, 116], ["wild type MHV", "PROBLEM", 186, 199], ["BCV", "ANATOMY", 90, 93]]], ["This region is highly polymorphic in different neutralization resistant MHV-4 variants, suggesting its important role in MHV-4 pathogenicity.", [["MHV-4", "ORGANISM", 72, 77], ["MHV-4", "ORGANISM", 121, 126], ["neutralization resistant MHV-4 variants", "DNA", 47, 86], ["MHV-4", "SPECIES", 72, 77], ["MHV-4", "SPECIES", 121, 126], ["highly", "OBSERVATION_MODIFIER", 15, 21], ["polymorphic", "OBSERVATION_MODIFIER", 22, 33], ["different", "OBSERVATION_MODIFIER", 37, 46], ["neutralization resistant MHV", "OBSERVATION", 47, 75], ["MHV", "OBSERVATION_MODIFIER", 121, 124], ["4 pathogenicity", "OBSERVATION_MODIFIER", 125, 140]]], ["Considerable homology in the amino acid sequences between the Sl subunits of MHV-4 and BCV suggests that the additional sequence of amino acid residues 456-592 within the BCV Sl subunit may be a polymorphic domain similar to that found in MHV-4.", [["amino acid", "CHEMICAL", 29, 39], ["amino acid residues 456-592", "CHEMICAL", 132, 159], ["Sl", "CHEMICAL", 175, 177], ["amino acid", "CHEMICAL", 29, 39], ["amino acid", "CHEMICAL", 132, 142], ["amino acid", "AMINO_ACID", 29, 39], ["Sl subunits", "GENE_OR_GENE_PRODUCT", 62, 73], ["MHV-4", "ORGANISM", 77, 82], ["BCV", "ORGANISM", 87, 90], ["amino acid", "AMINO_ACID", 132, 142], ["-592", "AMINO_ACID", 155, 159], ["Sl subunit", "GENE_OR_GENE_PRODUCT", 175, 185], ["MHV-4", "ORGANISM", 239, 244], ["amino acid sequences", "PROTEIN", 29, 49], ["Sl subunits", "PROTEIN", 62, 73], ["MHV-4", "PROTEIN", 77, 82], ["BCV", "PROTEIN", 87, 90], ["Sl subunit", "PROTEIN", 175, 185], ["MHV-4", "SPECIES", 239, 244], ["the amino acid sequences", "TEST", 25, 49], ["MHV", "TEST", 77, 80], ["amino acid residues", "TEST", 132, 151], ["the BCV", "TEST", 167, 174], ["a polymorphic domain", "PROBLEM", 193, 213], ["MHV", "ANATOMY", 77, 80], ["BCV", "ANATOMY", 171, 174], ["may be", "UNCERTAINTY", 186, 192], ["MHV", "ANATOMY", 239, 242]]], ["Recently, individual subunits of the BCV S glycoprotein have been expressed in insect cells using recombinant baculoviruses, and two major BCV neutralizing epitopes were localized to the Sl subunit .INTRODUCTIONThus, in order to examine if the major BCV neutralizing epitopes were associated with the probable BCV polymorphic region, we constructed a series of Sl deletion mutants and expressed then in insect cells.", [["cells", "ANATOMY", 86, 91], ["cells", "ANATOMY", 410, 415], ["BCV S glycoprotein", "GENE_OR_GENE_PRODUCT", 37, 55], ["insect cells", "CELL", 79, 91], ["BCV", "ORGANISM", 139, 142], ["Sl", "GENE_OR_GENE_PRODUCT", 187, 189], ["BCV", "ORGANISM", 250, 253], ["Sl", "GENE_OR_GENE_PRODUCT", 361, 363], ["insect cells", "CELL", 403, 415], ["BCV S glycoprotein", "PROTEIN", 37, 55], ["insect cells", "CELL_TYPE", 79, 91], ["BCV neutralizing epitopes", "PROTEIN", 139, 164], ["Sl subunit", "PROTEIN", 187, 197], ["BCV neutralizing epitopes", "PROTEIN", 250, 275], ["BCV polymorphic region", "DNA", 310, 332], ["Sl deletion mutants", "DNA", 361, 380], ["insect cells", "CELL_TYPE", 403, 415], ["BCV", "SPECIES", 139, 142], ["BCV", "SPECIES", 250, 253], ["BCV", "SPECIES", 310, 313], ["the BCV S glycoprotein", "TREATMENT", 33, 55], ["recombinant baculoviruses", "TREATMENT", 98, 123], ["two major BCV neutralizing epitopes", "TREATMENT", 129, 164], ["the major BCV neutralizing epitopes", "PROBLEM", 240, 275], ["BCV polymorphic region", "PROBLEM", 310, 332], ["Sl deletion mutants", "PROBLEM", 361, 380], ["BCV", "ANATOMY", 37, 40]]], ["Here we describe the location of two antigenic determinants and the identification of two domains in the Sl subunit critical for the formation of these antigenic determinants, and discuss the possible involvement of the probable polymorphic region of the Sl subunit in BCV antigenicity.Cells, viruses, and antibodiesSpodopfera frugiperda cells (Sf9, ATCC CRL 1711) were grown in suspension in Grace's medium supplemented with 0.3% yeastolate, 0.3% lactalbumin, and 10% fetal bovine serum (GIBCO) at 28\" (Summers and Smith, 1987) .", [["Cells", "ANATOMY", 286, 291], ["cells", "ANATOMY", 338, 343], ["Sf9", "ANATOMY", 345, 348], ["ATCC CRL 1711", "ANATOMY", 350, 363], ["fetal bovine serum", "ANATOMY", 469, 487], ["yeastolate", "CHEMICAL", 431, 441], ["lactalbumin", "CHEMICAL", 448, 459], ["yeastolate", "CHEMICAL", 431, 441], ["lactalbumin", "CHEMICAL", 448, 459], ["Sl", "GENE_OR_GENE_PRODUCT", 105, 107], ["Sl", "GENE_OR_GENE_PRODUCT", 255, 257], ["BCV", "ORGANISM", 269, 272], ["Cells", "CELL", 286, 291], ["Spodopfera frugiperda cells", "CELL", 316, 343], ["Sf9", "CELL", 345, 348], ["ATCC CRL 1711", "CELL", 350, 363], ["yeastolate", "SIMPLE_CHEMICAL", 431, 441], ["lactalbumin", "SIMPLE_CHEMICAL", 448, 459], ["bovine", "ORGANISM", 475, 481], ["serum", "ORGANISM_SUBSTANCE", 482, 487], ["GIBCO", "ORGANISM_SUBSTANCE", 489, 494], ["Sl subunit", "PROTEIN", 105, 115], ["antigenic determinants", "PROTEIN", 152, 174], ["Sl subunit", "PROTEIN", 255, 265], ["antibodiesSpodopfera frugiperda cells", "CELL_LINE", 306, 343], ["Sf9", "CELL_LINE", 345, 348], ["ATCC CRL 1711", "CELL_LINE", 350, 363], ["Spodopfera frugiperda", "SPECIES", 316, 337], ["bovine", "SPECIES", 475, 481], ["BCV", "SPECIES", 269, 272], ["Spodopfera frugiperda", "SPECIES", 316, 337], ["ATCC CRL 1711", "SPECIES", 350, 363], ["Cells", "TEST", 286, 291], ["viruses", "TEST", 293, 300], ["antibodies", "TEST", 306, 316], ["ATCC CRL", "TEST", 350, 358], ["10% fetal bovine serum", "TREATMENT", 465, 487], ["probable", "UNCERTAINTY", 220, 228], ["polymorphic", "OBSERVATION_MODIFIER", 229, 240], ["Sl subunit", "OBSERVATION_MODIFIER", 255, 265], ["BCV", "ANATOMY", 269, 272], ["antigenicity", "OBSERVATION", 273, 285], ["viruses", "OBSERVATION", 293, 300], ["suspension", "OBSERVATION_MODIFIER", 379, 389]]], ["Autographa californica nuclear polyhedrosis baculovirus (AcNPV) and recombinant baculoviruses were propagated and titrated on monolayers of Sf9 cells (Summers and Smith, 1987) .", [["monolayers", "ANATOMY", 126, 136], ["Sf9 cells", "ANATOMY", 140, 149], ["Autographa californica", "ORGANISM", 0, 22], ["nuclear polyhedrosis baculovirus", "ORGANISM", 23, 55], ["AcNPV", "GENE_OR_GENE_PRODUCT", 57, 62], ["recombinant baculoviruses", "ORGANISM", 68, 93], ["monolayers", "CELL", 126, 136], ["Sf9 cells", "CELL", 140, 149], ["nuclear polyhedrosis baculovirus", "PROTEIN", 23, 55], ["AcNPV", "PROTEIN", 57, 62], ["recombinant baculoviruses", "PROTEIN", 68, 93], ["Sf9 cells", "CELL_LINE", 140, 149], ["Autographa californica", "SPECIES", 0, 22], ["polyhedrosis baculovirus", "SPECIES", 31, 55], ["Autographa californica", "SPECIES", 0, 22], ["polyhedrosis baculovirus", "SPECIES", 31, 55], ["AcNPV", "SPECIES", 57, 62], ["baculoviruses", "SPECIES", 80, 93], ["Autographa californica nuclear polyhedrosis baculovirus (AcNPV", "TREATMENT", 0, 62], ["recombinant baculoviruses", "TREATMENT", 68, 93], ["polyhedrosis baculovirus", "OBSERVATION", 31, 55]]], ["Polyclonal rabbit anti-BCV antiserum and mouse ascitic fluids of monoclonal antibodies, HBlO-4, JB5-6, HF8-8, HE7-3, and BB7-14, were prepared as described ).Construction of DNA clones and recombinant transfer vectorsRestriction enzymes and DNA modifying enzymes were purchased from Pharmacia.", [["ascitic fluids", "ANATOMY", 47, 61], ["rabbit", "ORGANISM", 11, 17], ["anti-BCV antiserum", "ORGANISM_SUBSTANCE", 18, 36], ["mouse", "ORGANISM", 41, 46], ["ascitic", "ORGANISM_SUBSTANCE", 47, 54], ["HBlO-4", "GENE_OR_GENE_PRODUCT", 88, 94], ["JB5-6", "CELL", 96, 101], ["HF8-8", "CELL", 103, 108], ["HE7-3", "CELL", 110, 115], ["BB7-14", "CELL", 121, 127], ["DNA", "CELLULAR_COMPONENT", 174, 177], ["recombinant transfer vectorsRestriction enzymes", "GENE_OR_GENE_PRODUCT", 189, 236], ["DNA", "CELLULAR_COMPONENT", 241, 244], ["monoclonal antibodies", "PROTEIN", 65, 86], ["HBlO", "PROTEIN", 88, 92], ["JB5", "PROTEIN", 96, 99], ["HF8", "PROTEIN", 103, 106], ["HE7", "PROTEIN", 110, 113], ["BB7", "PROTEIN", 121, 124], ["DNA clones", "DNA", 174, 184], ["recombinant transfer vectorsRestriction enzymes", "PROTEIN", 189, 236], ["DNA modifying enzymes", "PROTEIN", 241, 262], ["rabbit", "SPECIES", 11, 17], ["mouse", "SPECIES", 41, 46], ["rabbit", "SPECIES", 11, 17], ["anti-BCV", "SPECIES", 18, 26], ["mouse", "SPECIES", 41, 46], ["Polyclonal rabbit anti-BCV antiserum", "TEST", 0, 36], ["mouse ascitic fluids", "TEST", 41, 61], ["monoclonal antibodies", "TEST", 65, 86], ["HBlO", "TEST", 88, 92], ["JB5", "TEST", 96, 99], ["HF8", "TEST", 103, 106], ["HE7", "TEST", 110, 113], ["BB7", "TEST", 121, 124], ["DNA clones", "TREATMENT", 174, 184], ["recombinant transfer vectorsRestriction enzymes", "TEST", 189, 236], ["DNA modifying enzymes", "TEST", 241, 262], ["ascitic", "ANATOMY", 47, 54]]], ["Plasmid pCVS1 was used as the source of DNA sequence encoding the Sl subunit of BCV (Quebec strain) .Construction of DNA clones and recombinant transfer vectorsStrategies for the construction of Sl deletion mutants are illustrated in Fig. 1 .", [["pCVS1", "GENE_OR_GENE_PRODUCT", 8, 13], ["DNA", "CELLULAR_COMPONENT", 40, 43], ["Sl subunit", "GENE_OR_GENE_PRODUCT", 66, 76], ["BCV", "ORGANISM", 80, 83], ["DNA", "CELLULAR_COMPONENT", 117, 120], ["Sl", "GENE_OR_GENE_PRODUCT", 195, 197], ["pCVS1", "DNA", 8, 13], ["DNA sequence", "DNA", 40, 52], ["Sl subunit", "PROTEIN", 66, 76], ["DNA clones", "DNA", 117, 127], ["Sl deletion mutants", "DNA", 195, 214], ["BCV", "SPECIES", 80, 83], ["Plasmid pCVS1", "TREATMENT", 0, 13], ["DNA sequence", "PROBLEM", 40, 52], ["DNA clones", "TREATMENT", 117, 127], ["recombinant transfer vectorsStrategies", "TREATMENT", 132, 170], ["Sl deletion mutants", "PROBLEM", 195, 214]]], ["Truncated fragments of Apu, Abx, and Apt were generated by digestion of the Sl gene with restriction enzymes Pvull, BstXI, and Pstl, respectively.", [["fragments", "ANATOMY", 10, 19], ["Apu", "GENE_OR_GENE_PRODUCT", 23, 26], ["Abx", "GENE_OR_GENE_PRODUCT", 28, 31], ["Apt", "GENE_OR_GENE_PRODUCT", 37, 40], ["Sl", "GENE_OR_GENE_PRODUCT", 76, 78], ["Pvull", "GENE_OR_GENE_PRODUCT", 109, 114], ["BstXI", "GENE_OR_GENE_PRODUCT", 116, 121], ["Pstl", "GENE_OR_GENE_PRODUCT", 127, 131], ["Apu", "PROTEIN", 23, 26], ["Abx", "PROTEIN", 28, 31], ["Apt", "PROTEIN", 37, 40], ["Sl gene", "DNA", 76, 83], ["restriction enzymes", "PROTEIN", 89, 108], ["Pvull", "PROTEIN", 109, 114], ["BstXI", "PROTEIN", 116, 121], ["Pstl", "PROTEIN", 127, 131], ["Abx", "TREATMENT", 28, 31], ["Apt", "TREATMENT", 37, 40], ["restriction enzymes", "TEST", 89, 108], ["Pvull", "TEST", 109, 114], ["BstXI", "TEST", 116, 121], ["fragments", "OBSERVATION_MODIFIER", 10, 19]]], ["The 3' terminus of all fragments was blunt-ended by Klenow fragment, and a translational termination sequence (5'-GCTTAATTAATTAAGC-3') was attached.", [["fragments", "ANATOMY", 23, 32], ["3'", "CELLULAR_COMPONENT", 4, 6], ["3' terminus", "DNA", 4, 15], ["Klenow fragment", "DNA", 52, 67], ["translational termination sequence", "DNA", 75, 109], ["5'-GCTTAATTAATTAAGC-3')", "DNA", 111, 134], ["all fragments", "PROBLEM", 19, 32], ["blunt", "PROBLEM", 37, 42], ["Klenow fragment", "PROBLEM", 52, 67], ["a translational termination sequence", "TEST", 73, 109], ["GCTTAATTAATTAAGC", "TEST", 114, 130], ["terminus", "OBSERVATION_MODIFIER", 7, 15], ["all", "OBSERVATION_MODIFIER", 19, 22], ["fragments", "OBSERVATION_MODIFIER", 23, 32], ["blunt", "OBSERVATION_MODIFIER", 37, 42], ["Klenow fragment", "OBSERVATION", 52, 67]]], ["Deletion fragments All1 and AV were constructed by partial digestion of pCVS1 with Hincll.", [["fragments", "ANATOMY", 9, 18], ["All1", "GENE_OR_GENE_PRODUCT", 19, 23], ["pCVS1", "GENE_OR_GENE_PRODUCT", 72, 77], ["Deletion fragments", "DNA", 0, 18], ["All1", "DNA", 19, 23], ["AV", "DNA", 28, 30], ["pCVS1", "PROTEIN", 72, 77], ["Hincll", "PROTEIN", 83, 89], ["Deletion fragments", "PROBLEM", 0, 18], ["AV", "TREATMENT", 28, 30], ["pCVS1", "TREATMENT", 72, 77], ["Hincll", "TREATMENT", 83, 89], ["AV", "ANATOMY", 28, 30]]], ["For fragment AVI, Apu was digested with Accl and HindIll, and a 1.3-kb fragment was isolated.", [["Apu", "GENE_OR_GENE_PRODUCT", 18, 21], ["Accl", "GENE_OR_GENE_PRODUCT", 40, 44], ["Apu", "DNA", 18, 21], ["Accl", "DNA", 40, 44], ["HindIll", "DNA", 49, 56], ["1.3-kb fragment", "DNA", 64, 79], ["fragment AVI", "PROBLEM", 4, 16], ["Accl", "TREATMENT", 40, 44], ["HindIll", "TREATMENT", 49, 56], ["a 1.3-kb fragment", "TREATMENT", 62, 79]]], ["The 1.3-kb fragment was then cloned into pCVS1 which was linearized by complete digestion with Hindll and HindIll.", [["pCVS1", "GENE_OR_GENE_PRODUCT", 41, 46], ["Hindll", "SIMPLE_CHEMICAL", 95, 101], ["HindIll", "SIMPLE_CHEMICAL", 106, 113], ["1.3-kb fragment", "DNA", 4, 19], ["pCVS1", "DNA", 41, 46], ["HindIll", "PROTEIN", 106, 113], ["The 1.3-kb fragment", "TREATMENT", 0, 19], ["pCVS1", "TREATMENT", 41, 46], ["Hindll", "TREATMENT", 95, 101], ["HindIll", "TREATMENT", 106, 113]]], ["Fragments Apu, Abx, and Apt were subcloned into the BarnHI site of transfer vector pVL941 (Luckow and Summers, 1989) or pAcYM 1 (Matsuura et a/., 1987) , and fragments AIII, AV, and AVI were subcloned into the Nhel site of transfer vector pJVP1 OZ (Vialard et a/., 1990) .Construction of DNA clones and recombinant transfer vectorsDNA transfection, screening of recombinant viruses, and plaque assay Extracellular virions (AcNPV) were purified by linear equilibrium centrifugation in a 25-55% sucrose gradient and the viral DNA was prepared with trypsin and sarkosyl treatment followed by phenol extraction (Summers and Smith, 1987) .", [["plaque", "ANATOMY", 387, 393], ["Extracellular virions", "ANATOMY", 400, 421], ["sucrose", "CHEMICAL", 493, 500], ["sarkosyl", "CHEMICAL", 558, 566], ["phenol", "CHEMICAL", 589, 595], ["sucrose", "CHEMICAL", 493, 500], ["sarkosyl", "CHEMICAL", 558, 566], ["phenol", "CHEMICAL", 589, 595], ["Apu", "GENE_OR_GENE_PRODUCT", 10, 13], ["Abx", "GENE_OR_GENE_PRODUCT", 15, 18], ["Apt", "GENE_OR_GENE_PRODUCT", 24, 27], ["pVL941", "GENE_OR_GENE_PRODUCT", 83, 89], ["AIII", "GENE_OR_GENE_PRODUCT", 168, 172], ["AV", "GENE_OR_GENE_PRODUCT", 174, 176], ["AVI", "GENE_OR_GENE_PRODUCT", 182, 185], ["DNA", "CELLULAR_COMPONENT", 288, 291], ["sucrose", "SIMPLE_CHEMICAL", 493, 500], ["DNA", "CELLULAR_COMPONENT", 524, 527], ["trypsin", "GENE_OR_GENE_PRODUCT", 546, 553], ["sarkosyl", "SIMPLE_CHEMICAL", 558, 566], ["phenol", "SIMPLE_CHEMICAL", 589, 595], ["Apu, Abx, and Apt", "DNA", 10, 27], ["BarnHI site", "DNA", 52, 63], ["pAcYM 1", "DNA", 120, 127], ["AIII", "DNA", 168, 172], ["AV", "DNA", 174, 176], ["AVI", "DNA", 182, 185], ["Nhel site", "DNA", 210, 219], ["DNA clones", "DNA", 288, 298], ["viral DNA", "DNA", 518, 527], ["trypsin", "PROTEIN", 546, 553], ["Fragments Apu", "TREATMENT", 0, 13], ["Abx", "TREATMENT", 15, 18], ["Apt", "TREATMENT", 24, 27], ["fragments AIII", "PROBLEM", 158, 172], ["AV", "TREATMENT", 174, 176], ["AVI", "PROBLEM", 182, 185], ["DNA clones", "PROBLEM", 288, 298], ["recombinant transfer vectorsDNA transfection", "TREATMENT", 303, 347], ["recombinant viruses", "PROBLEM", 362, 381], ["plaque assay Extracellular virions (AcNPV", "TREATMENT", 387, 428], ["a 25-55% sucrose gradient", "TREATMENT", 484, 509], ["the viral DNA", "PROBLEM", 514, 527], ["trypsin", "TREATMENT", 546, 553], ["sarkosyl treatment", "TREATMENT", 558, 576], ["phenol extraction", "TREATMENT", 589, 606], ["fragments AIII", "OBSERVATION", 158, 172], ["AV", "ANATOMY", 174, 176], ["viral DNA", "OBSERVATION", 518, 527]]], ["Plasmid DNA was prepared through CsCl gradients according to standard procedures.", [["Plasmid", "ANATOMY", 0, 7], ["CsCl", "CHEMICAL", 33, 37], ["Plasmid DNA", "CELLULAR_COMPONENT", 0, 11], ["Plasmid DNA", "TREATMENT", 0, 11], ["CsCl gradients", "TREATMENT", 33, 47], ["standard procedures", "TREATMENT", 61, 80]]], ["Approximately 2 X 1 O6 Sf9 cells were cotransfected with 1 pg of AcNPV viral DNA and 2 pg of transfer vector plasmid DNA by calcium precipitation as described previously .", [["Sf9 cells", "ANATOMY", 23, 32], ["plasmid", "ANATOMY", 109, 116], ["calcium", "CHEMICAL", 124, 131], ["calcium", "CHEMICAL", 124, 131], ["Sf9 cells", "CELL", 23, 32], ["DNA", "CELLULAR_COMPONENT", 77, 80], ["DNA", "CELLULAR_COMPONENT", 117, 120], ["calcium", "SIMPLE_CHEMICAL", 124, 131], ["X 1 O6 Sf9 cells", "CELL_LINE", 16, 32], ["AcNPV viral DNA", "DNA", 65, 80], ["plasmid DNA", "DNA", 109, 120], ["1 O6 Sf9 cells", "TREATMENT", 18, 32], ["AcNPV viral DNA", "TREATMENT", 65, 80], ["transfer vector plasmid DNA", "TREATMENT", 93, 120], ["calcium precipitation", "TREATMENT", 124, 145], ["calcium precipitation", "OBSERVATION", 124, 145]]], ["Transfected cells were incubated at 28\" for 3 days and the culture supernatants were harvested and plated on Sf9 cell monolayers for plaque assay.", [["cells", "ANATOMY", 12, 17], ["supernatants", "ANATOMY", 67, 79], ["Sf9 cell monolayers", "ANATOMY", 109, 128], ["plaque", "ANATOMY", 133, 139], ["cells", "CELL", 12, 17], ["Sf9 cell monolayers", "CELL", 109, 128], ["Sf9 cell monolayers", "CELL_LINE", 109, 128], ["Sf9", "SPECIES", 109, 112], ["Transfected cells", "PROBLEM", 0, 17], ["the culture supernatants", "TEST", 55, 79], ["Sf9 cell monolayers", "TREATMENT", 109, 128], ["plaque assay", "TEST", 133, 145], ["Sf9 cell monolayers", "OBSERVATION", 109, 128], ["plaque", "OBSERVATION", 133, 139]]], ["Plaque assays were performed in 35-mm dishes with 1.5% agarose overlay as described (Summers and Smith, 1987) .", [["Plaque", "ANATOMY", 0, 6], ["agarose", "SIMPLE_CHEMICAL", 55, 62], ["Plaque assays", "TEST", 0, 13], ["1.5% agarose overlay", "TREATMENT", 50, 70]]], ["Recombinant plaques produced with pAcYM1 or pVL941 were screened either by the absence of polyhedrin or by plaque hybridization.Construction of DNA clones and recombinant transfer vectorsFor screening of recombinant plaques produced with transfer vector pJVP1 OZ, 1 ml of medium containing 150 of Bluo-Gal (BRL) was added to the agarose overlay on Day 4 of incubation.", [["plaques", "ANATOMY", 12, 19], ["plaque", "ANATOMY", 107, 113], ["plaques", "ANATOMY", 216, 223], ["OZ", "CHEMICAL", 260, 262], ["Bluo-Gal", "CHEMICAL", 297, 305], ["BRL", "CHEMICAL", 307, 310], ["pAcYM1", "GENE_OR_GENE_PRODUCT", 34, 40], ["pVL941", "GENE_OR_GENE_PRODUCT", 44, 50], ["polyhedrin", "GENE_OR_GENE_PRODUCT", 90, 100], ["DNA", "CELLULAR_COMPONENT", 144, 147], ["Bluo-Gal", "GENE_OR_GENE_PRODUCT", 297, 305], ["BRL", "ORGANISM", 307, 310], ["agarose", "SIMPLE_CHEMICAL", 329, 336], ["pAcYM1", "PROTEIN", 34, 40], ["pVL941", "PROTEIN", 44, 50], ["polyhedrin", "DNA", 90, 100], ["DNA clones", "DNA", 144, 154], ["Recombinant plaques", "PROBLEM", 0, 19], ["pAcYM1", "TREATMENT", 34, 40], ["polyhedrin", "TREATMENT", 90, 100], ["plaque hybridization", "PROBLEM", 107, 127], ["DNA clones", "TREATMENT", 144, 154], ["recombinant transfer vectors", "TREATMENT", 159, 187], ["recombinant plaques", "PROBLEM", 204, 223], ["transfer vector pJVP1 OZ", "TREATMENT", 238, 262], ["Bluo-Gal (BRL", "TREATMENT", 297, 310], ["plaques", "OBSERVATION", 12, 19], ["plaque", "OBSERVATION", 107, 113]]], ["Blue plaques were picked and further purified by several rounds of plaque assay.", [["Blue plaques", "ANATOMY", 0, 12], ["plaque", "ANATOMY", 67, 73], ["Blue plaques", "PROBLEM", 0, 12], ["plaque assay", "TEST", 67, 79], ["plaques", "OBSERVATION", 5, 12], ["plaque", "OBSERVATION", 67, 73]]], ["Purified recombinant plaques were amplified and the stocks with titers of approximately 10' PFU/ml were used in the study.Radiolabeling and immunoprecipitationSf9 cells were infected at an m.o.i. of 5-l 0 PFU/cell.", [["plaques", "ANATOMY", 21, 28], ["immunoprecipitationSf9 cells", "ANATOMY", 140, 168], ["cell", "ANATOMY", 209, 213], ["immunoprecipitationSf9 cells", "CELL", 140, 168], ["cell", "CELL", 209, 213], ["immunoprecipitationSf9 cells", "CELL_LINE", 140, 168], ["Purified recombinant plaques", "PROBLEM", 0, 28], ["titers", "TREATMENT", 64, 70], ["the study", "TEST", 112, 121], ["Radiolabeling", "TEST", 122, 135], ["immunoprecipitationSf9 cells", "PROBLEM", 140, 168], ["recombinant", "OBSERVATION_MODIFIER", 9, 20], ["plaques", "OBSERVATION", 21, 28]]], ["At 24 hr postinfection, cells were starved for 1 hr in cysteine-free Grace's medium followed by labeling for 2 hr with 50 &i/ml of [35S]cysteine (Amersham; specific activity 3000 Ci/mmol).", [["cells", "ANATOMY", 24, 29], ["cysteine", "CHEMICAL", 55, 63], ["[35S]cysteine", "CHEMICAL", 131, 144], ["cysteine", "CHEMICAL", 55, 63], ["[35S]cysteine", "CHEMICAL", 131, 144], ["cells", "CELL", 24, 29], ["cysteine", "SIMPLE_CHEMICAL", 55, 63], ["[35S]cysteine", "SIMPLE_CHEMICAL", 131, 144], ["Amersham", "SIMPLE_CHEMICAL", 146, 154], ["cells", "TEST", 24, 29], ["cysteine (Amersham", "TREATMENT", 136, 154]]], ["For glycosylation studies, virus-infected cells were treated with 10 fig/ml of tunicamycin (Sigma) for 1 hr and labeled in the presence of tunicamycin.", [["cells", "ANATOMY", 42, 47], ["tunicamycin", "CHEMICAL", 79, 90], ["tunicamycin", "CHEMICAL", 139, 150], ["tunicamycin", "CHEMICAL", 79, 90], ["tunicamycin", "CHEMICAL", 139, 150], ["cells", "CELL", 42, 47], ["tunicamycin", "SIMPLE_CHEMICAL", 79, 90], ["tunicamycin", "SIMPLE_CHEMICAL", 139, 150], ["virus-infected cells", "CELL_TYPE", 27, 47], ["glycosylation studies", "TEST", 4, 25], ["virus", "PROBLEM", 27, 32], ["infected cells", "PROBLEM", 33, 47], ["tunicamycin", "TREATMENT", 79, 90], ["tunicamycin", "TREATMENT", 139, 150], ["infected cells", "OBSERVATION", 33, 47]]], ["Cells were scraped and harvested by centrifugation at 2000 rpm for 10 min.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5]]], ["The cells were lysed with 0.5% Triton X-l 00, 150 mM NaCI, 50 mll/l Tris-HCI, pH 7.5, and the cytoplasmic fraction was used for immunoprecipitation.Radiolabeling and immunoprecipitationFor secretion experiments, cells were labeled for 12 hr at 24 hr postinfection, and the culture media were immunoprecipitated.Radiolabeling and immunoprecipitationFor immunoprecipitation, samples were incubated with antibody at room temperature for 2 hr, and 10 mg of Protein A-Sepharose beads (Pharmacia) were added.", [["cells", "ANATOMY", 4, 9], ["cytoplasmic", "ANATOMY", 94, 105], ["cells", "ANATOMY", 212, 217], ["samples", "ANATOMY", 373, 380], ["Triton X-l", "CHEMICAL", 31, 41], ["NaCI", "CHEMICAL", 53, 57], ["Tris-HCI", "CHEMICAL", 68, 76], ["NaCI", "CHEMICAL", 53, 57], ["Tris-HCI", "CHEMICAL", 68, 76], ["cells", "CELL", 4, 9], ["Triton X-l 00", "SIMPLE_CHEMICAL", 31, 44], ["NaCI", "SIMPLE_CHEMICAL", 53, 57], ["Tris-HCI", "SIMPLE_CHEMICAL", 68, 76], ["cytoplasmic", "ORGANISM_SUBSTANCE", 94, 105], ["cells", "CELL", 212, 217], ["NaCI", "TEST", 53, 57], ["Tris", "TEST", 68, 72], ["HCI", "TEST", 73, 76], ["pH", "TEST", 78, 80], ["the cytoplasmic fraction", "TEST", 90, 114], ["immunoprecipitation", "PROBLEM", 128, 147], ["Radiolabeling", "TREATMENT", 148, 161], ["immunoprecipitation", "TEST", 166, 185], ["secretion experiments", "PROBLEM", 189, 210], ["the culture media", "TEST", 269, 286], ["Radiolabeling", "TREATMENT", 311, 324], ["immunoprecipitation", "TEST", 329, 348], ["immunoprecipitation", "TEST", 352, 371], ["samples", "TEST", 373, 380], ["antibody", "TEST", 401, 409], ["Protein A-Sepharose beads (Pharmacia", "TREATMENT", 453, 489]]], ["The mixtures in RIPA buffer (1% Triton X-l 00, 1% sodium deoxycholate, 150 m/l/l NaCI, 50 mn/r Tris-HCI, pH 7.5, 10 ml/l EDTA) containing 0.5% SDS were incubated overnight at 4\" with continuous shaking.", [["Triton X-l", "CHEMICAL", 32, 42], ["sodium deoxycholate", "CHEMICAL", 50, 69], ["NaCI", "CHEMICAL", 81, 85], ["sodium deoxycholate", "CHEMICAL", 50, 69], ["Tris-HCI", "CHEMICAL", 95, 103], ["EDTA", "CHEMICAL", 121, 125], ["Triton X-l 00", "SIMPLE_CHEMICAL", 32, 45], ["sodium deoxycholate", "SIMPLE_CHEMICAL", 50, 69], ["Tris-HCI", "SIMPLE_CHEMICAL", 95, 103], ["The mixtures", "TREATMENT", 0, 12], ["RIPA buffer", "TREATMENT", 16, 27], ["1% sodium deoxycholate", "TREATMENT", 47, 69], ["NaCI", "TREATMENT", 81, 85], ["Tris", "TEST", 95, 99], ["HCI", "TEST", 100, 103], ["pH", "TEST", 105, 107]]], ["Immune complexes were washed three times with RIPA buffer and dissociated by boiling for 5 min in 10% SDS, 25% glycerol, 10% mercaptoethanol, 0.02% bromophenol blue, 10 mMTris-HCI, pH 6.8.", [["glycerol", "CHEMICAL", 111, 119], ["mercaptoethanol", "CHEMICAL", 125, 140], ["bromophenol blue", "CHEMICAL", 148, 164], ["mMTris-HCI", "CHEMICAL", 169, 179], ["glycerol", "CHEMICAL", 111, 119], ["mercaptoethanol", "CHEMICAL", 125, 140], ["bromophenol blue", "CHEMICAL", 148, 164], ["mMTris-HCI", "CHEMICAL", 169, 179], ["glycerol", "SIMPLE_CHEMICAL", 111, 119], ["mercaptoethanol", "SIMPLE_CHEMICAL", 125, 140], ["bromophenol blue", "SIMPLE_CHEMICAL", 148, 164], ["mMTris-HCI", "SIMPLE_CHEMICAL", 169, 179], ["Immune complexes", "PROTEIN", 0, 16], ["Immune complexes", "TREATMENT", 0, 16], ["RIPA buffer", "TREATMENT", 46, 57], ["glycerol", "TREATMENT", 111, 119], ["mercaptoethanol", "TREATMENT", 125, 140], ["pH", "TEST", 181, 183]]], ["The polypeptides were analysed on 12% SDS-polyacrylamide gels followed by autoradiography.Western blot analysisCell lysates were resolved by SDS-PAGE and transferred to nitrocellulose membrane (Schleicher & Schuel) by electroblotting in Tris-glycine buffer(20 mM Tris-HCI, pH 8.3, 190 mM glycine) containing 20% methanol.", [["Cell lysates", "ANATOMY", 111, 123], ["membrane", "ANATOMY", 184, 192], ["Tris-glycine", "CHEMICAL", 237, 249], ["Tris-HCI", "CHEMICAL", 263, 271], ["glycine", "CHEMICAL", 288, 295], ["methanol", "CHEMICAL", 312, 320], ["SDS", "CHEMICAL", 38, 41], ["polyacrylamide", "CHEMICAL", 42, 56], ["nitrocellulose", "CHEMICAL", 169, 183], ["Tris-glycine", "CHEMICAL", 237, 249], ["Tris-HCI", "CHEMICAL", 263, 271], ["glycine", "CHEMICAL", 288, 295], ["methanol", "CHEMICAL", 312, 320], ["Cell lysates", "ORGANISM_SUBSTANCE", 111, 123], ["membrane", "CELLULAR_COMPONENT", 184, 192], ["Tris-glycine", "SIMPLE_CHEMICAL", 237, 249], ["Tris-HCI", "SIMPLE_CHEMICAL", 263, 271], ["glycine", "SIMPLE_CHEMICAL", 288, 295], ["methanol", "SIMPLE_CHEMICAL", 312, 320], ["The polypeptides", "TREATMENT", 0, 16], ["polyacrylamide gels", "TREATMENT", 42, 61], ["autoradiography", "TEST", 74, 89], ["blot analysis", "TEST", 98, 111], ["Cell lysates", "TEST", 111, 123], ["nitrocellulose membrane", "TREATMENT", 169, 192], ["glycine buffer", "TREATMENT", 242, 256], ["Tris", "TEST", 263, 267], ["HCI", "TEST", 268, 271], ["pH", "TEST", 273, 275], ["mM glycine)", "TREATMENT", 285, 296], ["20% methanol", "TREATMENT", 308, 320]]], ["Membranes were blocked with 3% skim milk powder in 10 mM PBS overnight at 4\".", [["Membranes", "ANATOMY", 0, 9], ["milk", "ANATOMY", 36, 40], ["Membranes", "ORGANISM_SUBSTANCE", 0, 9], ["milk", "ORGANISM_SUBSTANCE", 36, 40], ["3% skim milk powder", "TREATMENT", 28, 47]]], ["Membranes were then incubated with monoclonal antibodies (1:200 dilution) in PBS containing 0.05% Tween 20 (PBST) and 1% skim milk powder (PBSTS) for 2 hr at room temperature.", [["Membranes", "ANATOMY", 0, 9], ["Tween 20", "CHEMICAL", 98, 106], ["Membranes", "ORGANISM_SUBSTANCE", 0, 9], ["Tween 20", "SIMPLE_CHEMICAL", 98, 106], ["skim", "SIMPLE_CHEMICAL", 121, 125], ["milk", "ORGANISM_SUBSTANCE", 126, 130], ["monoclonal antibodies", "PROTEIN", 35, 56], ["monoclonal antibodies", "TREATMENT", 35, 56], ["1% skim milk powder", "TREATMENT", 118, 137]]], ["Blots were washed with PBST for 2 hr and then incubated with a 1:2000 dilution of horseradish peroxidase-conjugated goat anti-mouse IgG in PBSTS for 90 min at room temperature.", [["PBSTS", "CHEMICAL", 139, 144], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 82, 104], ["PBSTS", "SIMPLE_CHEMICAL", 139, 144], ["horseradish peroxidase", "PROTEIN", 82, 104], ["conjugated goat anti-mouse IgG", "PROTEIN", 105, 135], ["horseradish", "SPECIES", 82, 93], ["goat", "SPECIES", 116, 120], ["anti-mouse", "SPECIES", 121, 131], ["goat", "SPECIES", 116, 120], ["PBST", "TREATMENT", 23, 27], ["a 1:2000 dilution of horseradish peroxidase", "TREATMENT", 61, 104], ["conjugated goat anti-mouse IgG", "TREATMENT", 105, 135]]], ["Membranes were developed by reaction with hydrogen peroxide and 0.059/o 4-chloro-1 -naphthol substrate (Bio-Rad) for 20 min or more.Expression of the Sl deletion mutant polypeptides in insect ceilsA series of neutralizing monoclonal antibodies specific for the BCV S glycoprotein were previously developed and classified by competitive antibody binding assays into two nonoverlapping groups, A and B .", [["Membranes", "ANATOMY", 0, 9], ["hydrogen peroxide", "CHEMICAL", 42, 59], ["4-chloro-1 -naphthol", "CHEMICAL", 72, 92], ["hydrogen peroxide", "CHEMICAL", 42, 59], ["0.059/o 4-chloro-1 -naphthol", "CHEMICAL", 64, 92], ["Bio-Rad", "CHEMICAL", 104, 111], ["Membranes", "ORGANISM_SUBSTANCE", 0, 9], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 42, 59], ["4-chloro-1 -naphthol substrate", "SIMPLE_CHEMICAL", 72, 102], ["Bio-Rad", "SIMPLE_CHEMICAL", 104, 111], ["Sl", "GENE_OR_GENE_PRODUCT", 150, 152], ["BCV S glycoprotein", "GENE_OR_GENE_PRODUCT", 261, 279], ["B", "CELL", 398, 399], ["Sl deletion mutant polypeptides", "PROTEIN", 150, 181], ["neutralizing monoclonal antibodies", "PROTEIN", 209, 243], ["BCV S glycoprotein", "PROTEIN", 261, 279], ["BCV", "SPECIES", 261, 264], ["hydrogen peroxide", "TREATMENT", 42, 59], ["chloro", "TREATMENT", 74, 80], ["naphthol substrate", "TREATMENT", 84, 102], ["the Sl deletion mutant polypeptides", "PROBLEM", 146, 181], ["neutralizing monoclonal antibodies", "TEST", 209, 243], ["the BCV S glycoprotein", "TEST", 257, 279], ["competitive antibody binding assays", "PROBLEM", 324, 359]]], ["These monoclonal antibodies were reactive with the Sl subunit, and the reactions were sensitive to reducing agents but resistant to ionic detergents, indicating that both antigenic determinants were dependent upon intramolecular disulfide linkages.", [["disulfide", "CHEMICAL", 229, 238], ["monoclonal antibodies", "PROTEIN", 6, 27], ["Sl subunit", "PROTEIN", 51, 61], ["These monoclonal antibodies", "TEST", 0, 27], ["the reactions", "PROBLEM", 67, 80], ["reducing agents", "TREATMENT", 99, 114], ["ionic detergents", "TREATMENT", 132, 148], ["intramolecular disulfide linkages", "PROBLEM", 214, 247], ["reactive", "OBSERVATION_MODIFIER", 33, 41], ["intramolecular disulfide linkages", "OBSERVATION", 214, 247]]], ["To characterize the structure of the antigenic determinants interacting with these monoclonal antibodies, cDNAs encoding the six forms of mutant Sl polypeptides were constructed and inserted into the genome of AcNPV baculoviruses.", [["Sl polypeptides", "GENE_OR_GENE_PRODUCT", 145, 160], ["AcNPV baculoviruses", "ORGANISM", 210, 229], ["monoclonal antibodies", "PROTEIN", 83, 104], ["cDNAs", "DNA", 106, 111], ["AcNPV baculoviruses", "PROTEIN", 210, 229], ["AcNPV baculoviruses", "SPECIES", 210, 229], ["these monoclonal antibodies", "TREATMENT", 77, 104], ["mutant", "PROBLEM", 138, 144], ["Sl polypeptides", "TREATMENT", 145, 160], ["AcNPV baculoviruses", "TREATMENT", 210, 229], ["AcNPV baculoviruses", "OBSERVATION", 210, 229]]], ["Three Sl derivatives, Apu, Abx, and Apt were constructed to truncate at approximately 100 amino acids downstream, upstream, and in the middle of the probable polymorphic region, respectively ( Fig. 1 ) Derivatives Alll, AV, and AVI were constructed to delete various lengths from the N-terminus of the Sl, but the first 29 N-terminal amino acids were included so as to retain a membrane translocational signal.", [["membrane", "ANATOMY", 378, 386], ["Sl", "CHEMICAL", 6, 8], ["amino acids", "CHEMICAL", 90, 101], ["amino acids", "CHEMICAL", 334, 345], ["Sl", "CHEMICAL", 6, 8], ["amino acids", "CHEMICAL", 90, 101], ["N", "CHEMICAL", 284, 285], ["N", "CHEMICAL", 323, 324], ["amino acids", "CHEMICAL", 334, 345], ["Sl derivatives", "SIMPLE_CHEMICAL", 6, 20], ["Apu", "GENE_OR_GENE_PRODUCT", 22, 25], ["Abx", "GENE_OR_GENE_PRODUCT", 27, 30], ["Apt", "GENE_OR_GENE_PRODUCT", 36, 39], ["amino acids", "AMINO_ACID", 90, 101], ["Sl", "GENE_OR_GENE_PRODUCT", 302, 304], ["amino acids", "AMINO_ACID", 334, 345], ["membrane", "CELLULAR_COMPONENT", 378, 386], ["Abx", "PROTEIN", 27, 30], ["Apt", "PROTEIN", 36, 39], ["N-terminus", "PROTEIN", 284, 294], ["Sl", "PROTEIN", 302, 304], ["29 N-terminal amino acids", "PROTEIN", 320, 345], ["Sl derivatives", "TREATMENT", 6, 20], ["Apu", "TREATMENT", 22, 25], ["Abx", "TREATMENT", 27, 30], ["amino acids downstream", "TEST", 90, 112], ["Derivatives", "TREATMENT", 202, 213], ["AV, and AVI", "TREATMENT", 220, 231], ["terminal amino acids", "TEST", 325, 345], ["a membrane translocational signal", "PROBLEM", 376, 409], ["middle", "ANATOMY_MODIFIER", 135, 141], ["probable", "UNCERTAINTY", 149, 157], ["polymorphic", "OBSERVATION_MODIFIER", 158, 169], ["region", "ANATOMY_MODIFIER", 170, 176], ["AV", "ANATOMY", 220, 222], ["Sl", "ANATOMY", 302, 304]]], ["A translational termination codon was attached at the 3'terminus of each derivative.Expression of the Sl deletion mutant polypeptides in insect ceilsExpression of the Sl deletion products in Sf9 cells was determined at 24 hr postinfection by immunoprecipitation of the baculovirus-infected cell lysates. deduced from nucleotide sequences, suggesting that the mutant polypeptides synthesized in Sf9 cells were glycosylated.Expression of the Sl deletion mutant polypeptides in insect ceilsGlycosylation and extracellular transport of the Sl deletion productsExpression of the Sl deletion mutant polypeptides in insect ceilsIn order to confirm that the immunoprecipitable mutant polypeptides were glycosylated, the mutant polypeptides were radiolabeled in the presence of tunicamycin (Fig. 3) .", [["Sf9 cells", "ANATOMY", 191, 200], ["cell lysates", "ANATOMY", 290, 302], ["Sf9 cells", "ANATOMY", 394, 403], ["extracellular", "ANATOMY", 505, 518], ["nucleotide", "CHEMICAL", 317, 327], ["tunicamycin", "CHEMICAL", 769, 780], ["nucleotide", "CHEMICAL", 317, 327], ["tunicamycin", "CHEMICAL", 769, 780], ["Sl", "GENE_OR_GENE_PRODUCT", 102, 104], ["Sl", "GENE_OR_GENE_PRODUCT", 167, 169], ["Sf9 cells", "CELL", 191, 200], ["baculovirus", "ORGANISM", 269, 280], ["cell lysates", "CELL", 290, 302], ["Sf9 cells", "CELL", 394, 403], ["Sl", "GENE_OR_GENE_PRODUCT", 440, 442], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 505, 518], ["Sl", "GENE_OR_GENE_PRODUCT", 574, 576], ["tunicamycin", "SIMPLE_CHEMICAL", 769, 780], ["translational termination codon", "DNA", 2, 33], ["3'terminus", "DNA", 54, 64], ["Sl deletion mutant polypeptides", "PROTEIN", 102, 133], ["Sl deletion products", "PROTEIN", 167, 187], ["Sf9 cells", "CELL_LINE", 191, 200], ["Sf9 cells", "CELL_LINE", 394, 403], ["Sl deletion mutant polypeptides", "PROTEIN", 440, 471], ["Sl deletion products", "PROTEIN", 536, 556], ["Sl deletion mutant polypeptides", "PROTEIN", 574, 605], ["immunoprecipitable mutant polypeptides", "PROTEIN", 650, 688], ["Sf9", "SPECIES", 191, 194], ["baculovirus", "SPECIES", 269, 280], ["Sf9", "SPECIES", 394, 397], ["A translational termination codon", "TREATMENT", 0, 33], ["the Sl deletion mutant polypeptides", "TREATMENT", 98, 133], ["the Sl deletion products", "TREATMENT", 163, 187], ["Sf9 cells", "PROBLEM", 191, 200], ["the baculovirus", "PROBLEM", 265, 280], ["infected cell lysates", "PROBLEM", 281, 302], ["nucleotide sequences", "TEST", 317, 337], ["the mutant polypeptides synthesized in Sf9 cells", "PROBLEM", 355, 403], ["the Sl deletion mutant polypeptides", "TREATMENT", 436, 471], ["insect ceilsGlycosylation", "TREATMENT", 475, 500], ["extracellular transport", "TREATMENT", 505, 528], ["the Sl deletion products", "TREATMENT", 532, 556], ["the Sl deletion mutant polypeptides", "PROBLEM", 570, 605], ["the immunoprecipitable mutant polypeptides", "PROBLEM", 646, 688], ["the mutant polypeptides", "PROBLEM", 708, 731], ["tunicamycin (Fig.", "TREATMENT", 769, 786], ["baculovirus", "ANATOMY", 269, 280], ["infected cell lysates", "OBSERVATION", 281, 302]]], ["As shown previously , 10 pg/ml oftunicamycin moderately inhibited glycosylation in Sf9 cell, and lower molecular- (lane 14) were immunoprecipitated in addition to the corresponding glycosylated polypeptides (lanes 1, 3, 5, 7, 9, 1 1, 13).", [["Sf9 cell", "ANATOMY", 83, 91], ["oftunicamycin", "CHEMICAL", 31, 44], ["oftunicamycin", "CHEMICAL", 31, 44], ["oftunicamycin", "SIMPLE_CHEMICAL", 31, 44], ["Sf9 cell", "CELL", 83, 91], ["Sf9 cell", "CELL_LINE", 83, 91], ["10 pg/ml oftunicamycin", "TREATMENT", 22, 44], ["moderately inhibited glycosylation in Sf9 cell", "PROBLEM", 45, 91], ["the corresponding glycosylated polypeptides (lanes", "TREATMENT", 163, 213], ["Sf9 cell", "OBSERVATION", 83, 91], ["lower", "ANATOMY_MODIFIER", 97, 102]]], ["These results confirmed that the mutant polypeptides were all glycosylated.", [["the mutant polypeptides", "PROBLEM", 29, 52]]], ["Deletion All1 produced a single species of the nonglycosylated, 25K polypeptide (lane 10).", [["All1", "GENE_OR_GENE_PRODUCT", 9, 13], ["All1", "PROTEIN", 9, 13], ["nonglycosylated, 25K polypeptide", "PROTEIN", 47, 79], ["Deletion All1", "PROBLEM", 0, 13], ["the nonglycosylated", "TREATMENT", 43, 62], ["25K polypeptide (lane", "TREATMENT", 64, 85]]], ["This suggests that the immunoprecipitable 39K and 35K polypeptides produced by deletion All1 (lanes 9-10) are the incompletely glycosylated forms of the 43K mutant polypeptide.Expression of the Sl deletion mutant polypeptides in insect ceilsSince the completely denatured S glycoprotein of BCV did not react with conformational monoclonal antibodies , we were interested in the conformation of the mutant fragments of the BCV Sl protein.", [["K", "CHEMICAL", 52, 53], ["39K", "GENE_OR_GENE_PRODUCT", 42, 45], ["35K polypeptides", "GENE_OR_GENE_PRODUCT", 50, 66], ["Sl", "GENE_OR_GENE_PRODUCT", 194, 196], ["BCV", "ORGANISM", 290, 293], ["BCV", "ORGANISM", 422, 425], ["Sl", "GENE_OR_GENE_PRODUCT", 426, 428], ["immunoprecipitable 39K and 35K polypeptides", "PROTEIN", 23, 66], ["deletion All1", "DNA", 79, 92], ["43K mutant polypeptide", "PROTEIN", 153, 175], ["Sl deletion mutant polypeptides", "PROTEIN", 194, 225], ["S glycoprotein", "PROTEIN", 272, 286], ["BCV", "PROTEIN", 290, 293], ["conformational monoclonal antibodies", "PROTEIN", 313, 349], ["mutant fragments", "PROTEIN", 398, 414], ["BCV Sl protein", "PROTEIN", 422, 436], ["the immunoprecipitable", "TEST", 19, 41], ["K polypeptides", "TEST", 52, 66], ["deletion All1 (lanes", "TEST", 79, 99], ["the 43K mutant polypeptide", "TREATMENT", 149, 175], ["the Sl deletion mutant polypeptides", "PROBLEM", 190, 225], ["the completely denatured S glycoprotein of BCV", "PROBLEM", 247, 293], ["conformational monoclonal antibodies", "PROBLEM", 313, 349], ["the mutant fragments", "PROBLEM", 394, 414], ["the BCV Sl protein", "TEST", 418, 436], ["denatured", "OBSERVATION", 262, 271]]], ["To determine the conformational changes of the mutant polypeptides, we attempted to measure the relative rates of secretion of the mutant Sl polypeptides.", [["Sl polypeptides", "GENE_OR_GENE_PRODUCT", 138, 153], ["mutant Sl polypeptides", "PROTEIN", 131, 153], ["the mutant polypeptides", "TREATMENT", 43, 66], ["the mutant Sl polypeptides", "TREATMENT", 127, 153]]], ["It has been established that native conformation is essential for transport of proteins through intracellular secretory pathways (for a review, see Rose and Doms, 1988) .", [["intracellular", "ANATOMY", 96, 109], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 96, 109]]], ["Secretion of the BCV Sl subunit protein from insect cells has been previously demonstrated .", [["cells", "ANATOMY", 52, 57], ["BCV Sl subunit", "GENE_OR_GENE_PRODUCT", 17, 31], ["insect cells", "CELL", 45, 57], ["BCV Sl subunit protein", "PROTEIN", 17, 39], ["insect cells", "CELL_TYPE", 45, 57], ["BCV", "SPECIES", 17, 20], ["the BCV Sl subunit protein", "TEST", 13, 39], ["insect cells", "PROBLEM", 45, 57], ["insect cells", "OBSERVATION", 45, 57]]], ["Insect cells producing the mutant Sl polypeptides were labeled for 12 hr begining at 24 hr postinfection and the secreted polypeptides in the medium were immunoprecipitated (Fig. 4) .", [["cells", "ANATOMY", 7, 12], ["Insect cells", "CELL", 0, 12], ["Sl polypeptides", "GENE_OR_GENE_PRODUCT", 34, 49], ["Insect cells", "PROBLEM", 0, 12], ["Sl polypeptides", "PROBLEM", 34, 49], ["the secreted polypeptides", "PROBLEM", 109, 134]]], ["At 36 hr postinfection, no Apt product was detected in the medium (Fig. 4B, lane 4) even though the Apt product was present in the cell pellet (Fig. 4A, lane 4) .", [["cell pellet", "ANATOMY", 131, 142], ["cell", "CELL", 131, 135], ["Apt product", "PROTEIN", 27, 38], ["Apt product", "PROTEIN", 100, 111], ["postinfection", "OBSERVATION", 9, 22], ["no", "UNCERTAINTY", 24, 26]]], ["Similarly, deletion AV was present in the cell lysate in large quantities (Fig. 4A, lane 6 ), but only a trace amount was detected in the medium (Fig. 4B, lane 6) .", [["cell lysate", "ANATOMY", 42, 53], ["cell lysate", "ORGANISM_SUBSTANCE", 42, 53], ["deletion AV", "PROBLEM", 11, 22], ["the cell lysate", "TEST", 38, 53], ["a trace amount", "PROBLEM", 103, 117], ["cell lysate", "OBSERVATION", 42, 53], ["large", "OBSERVATION_MODIFIER", 57, 62], ["quantities", "OBSERVATION_MODIFIER", 63, 73], ["trace", "OBSERVATION_MODIFIER", 105, 110], ["amount", "OBSERVATION_MODIFIER", 111, 117]]], ["In contrast, other polypeptides, Apu, Alll, and AVI and the intact Sl protein were efficiently secreted into the media (Fig. 4B , lanes 2, 5, 7, 8).", [["Apu", "GENE_OR_GENE_PRODUCT", 33, 36], ["Alll", "GENE_OR_GENE_PRODUCT", 38, 42], ["AVI", "GENE_OR_GENE_PRODUCT", 48, 51], ["Sl", "GENE_OR_GENE_PRODUCT", 67, 69], ["Apu", "PROTEIN", 33, 36], ["Alll", "PROTEIN", 38, 42], ["AVI", "PROTEIN", 48, 51], ["Sl protein", "PROTEIN", 67, 77], ["Apu", "TEST", 33, 36], ["Alll, and AVI", "PROBLEM", 38, 51], ["the intact Sl protein", "PROBLEM", 56, 77], ["intact", "OBSERVATION_MODIFIER", 60, 66], ["Sl protein", "OBSERVATION", 67, 77], ["media", "ANATOMY", 113, 118]]], ["A significant amount of the truncated Abx polypeptide also accumulated in the medium (Fig. 4B , lane 3) even though the amount of intracellular Abx was small (Fig. 4A, lane 3) .", [["intracellular", "ANATOMY", 130, 143], ["Abx", "GENE_OR_GENE_PRODUCT", 38, 41], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 130, 143], ["Abx", "SIMPLE_CHEMICAL", 144, 147], ["truncated Abx polypeptide", "PROTEIN", 28, 53], ["intracellular Abx", "PROTEIN", 130, 147], ["the truncated Abx polypeptide", "TREATMENT", 24, 53], ["intracellular Abx", "TREATMENT", 130, 147], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["amount", "OBSERVATION_MODIFIER", 14, 20], ["truncated", "OBSERVATION_MODIFIER", 28, 37], ["Abx", "OBSERVATION", 38, 41], ["medium", "OBSERVATION_MODIFIER", 78, 84], ["amount", "OBSERVATION_MODIFIER", 120, 126], ["intracellular", "OBSERVATION_MODIFIER", 130, 143], ["Abx", "OBSERVATION", 144, 147]]], ["These observations indicate that extracellular transport of the Apt and AV was significantly inhibited, suggesting the altered conformation of mutants Apt and AV.Expression of the Sl deletion mutant polypeptides in insect ceilsAntigenic location and identification of domains essential for the antigenic determinants Antigenic structure of the Sl subunit was evaluated by determining the immunoreactivities of the derivatives of the Sl subunit with pooled monoclonal antibodies representing group A or with monoclonal antibody BB7-14 representing group B (Fig. 5) The Abx and Apt polypeptides were not immunoprecipitated by any of the monoclonal antibodies (Fig. 5A, lanes 3, 4; Fig. 5B , lanes 3,4) while the Apu product, extending 203 amino acids from the C-terminus of the Apt, was immunoprecipitated by both group A and B monoclonal antibodies (Fig. 5A, lane 2; Fig. 5B, lane 2) .", [["extracellular", "ANATOMY", 33, 46], ["amino acids", "CHEMICAL", 737, 748], ["amino acids", "CHEMICAL", 737, 748], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 33, 46], ["Apt", "GENE_OR_GENE_PRODUCT", 64, 67], ["AV", "GENE_OR_GENE_PRODUCT", 72, 74], ["Apt", "GENE_OR_GENE_PRODUCT", 151, 154], ["Sl", "GENE_OR_GENE_PRODUCT", 180, 182], ["Sl subunit", "GENE_OR_GENE_PRODUCT", 344, 354], ["Sl subunit", "GENE_OR_GENE_PRODUCT", 433, 443], ["Abx", "GENE_OR_GENE_PRODUCT", 568, 571], ["Apt polypeptides", "GENE_OR_GENE_PRODUCT", 576, 592], ["amino acids", "AMINO_ACID", 737, 748], ["Apt", "GENE_OR_GENE_PRODUCT", 776, 779], ["Apt", "PROTEIN", 64, 67], ["AV", "PROTEIN", 72, 74], ["Apt", "PROTEIN", 151, 154], ["AV", "PROTEIN", 159, 161], ["Sl deletion mutant polypeptides", "PROTEIN", 180, 211], ["Sl subunit", "PROTEIN", 344, 354], ["Sl subunit", "PROTEIN", 433, 443], ["monoclonal antibodies", "PROTEIN", 456, 477], ["group A", "PROTEIN", 491, 498], ["monoclonal antibody BB7", "PROTEIN", 507, 530], ["group B", "PROTEIN", 547, 554], ["Abx", "PROTEIN", 568, 571], ["monoclonal antibodies", "PROTEIN", 635, 656], ["Fig. 5A, lanes 3, 4; Fig. 5B", "PROTEIN", 658, 686], ["lanes 3,4", "PROTEIN", 689, 698], ["Apu product", "PROTEIN", 710, 721], ["C-terminus", "PROTEIN", 758, 768], ["Apt", "PROTEIN", 776, 779], ["group A and B monoclonal antibodies", "PROTEIN", 812, 847], ["Fig. 5A, lane 2", "PROTEIN", 849, 864], ["Fig. 5B, lane 2", "PROTEIN", 866, 881], ["AV", "TREATMENT", 72, 74], ["the altered conformation of mutants Apt", "PROBLEM", 115, 154], ["AV", "TREATMENT", 159, 161], ["the Sl deletion mutant polypeptides", "PROBLEM", 176, 211], ["the Sl subunit", "TREATMENT", 429, 443], ["pooled monoclonal antibodies", "TEST", 449, 477], ["monoclonal antibody BB7", "TEST", 507, 530], ["The Abx and Apt polypeptides", "TREATMENT", 564, 592], ["the monoclonal antibodies", "TEST", 631, 656], ["lanes", "TEST", 667, 672], ["amino acids", "TEST", 737, 748]]], ["These results initially demonstrated that a region of 203 amino acids between residues 5 17-720 constituted a domain important for Sl antigenicity.", [["amino acids", "CHEMICAL", 58, 69], ["residues 5 17-720", "CHEMICAL", 78, 95], ["amino acids", "CHEMICAL", 58, 69], ["amino acids", "AMINO_ACID", 58, 69], ["Sl", "GENE_OR_GENE_PRODUCT", 131, 133], ["Sl", "PROTEIN", 131, 133], ["amino acids", "TEST", 58, 69], ["Sl antigenicity", "PROBLEM", 131, 146]]], ["Deletions All1 and AV were not immunoprecipitated by any of the monoclonal antibodies (Fig. 5A, lanes 5, 6; Fig. 58, lanes 5, 6) .", [["All1", "GENE_OR_GENE_PRODUCT", 10, 14], ["All1", "DNA", 10, 14], ["AV", "DNA", 19, 21], ["monoclonal antibodies", "PROTEIN", 64, 85], ["Deletions All1", "PROBLEM", 0, 14], ["AV", "TREATMENT", 19, 21], ["the monoclonal antibodies", "TEST", 60, 85], ["lanes", "TEST", 96, 101], ["AV", "ANATOMY", 19, 21]]], ["This observation led us to conclude that the domain 517-720 was important for antigenic determinants A and B; however, another domain located upstream from residue 403 was also required for the formation of both antigenie determinants.", [["517-720", "CHEMICAL", 52, 59], ["B", "GENE_OR_GENE_PRODUCT", 107, 108], ["residue 403", "AMINO_ACID", 156, 167], ["domain 517-720", "PROTEIN", 45, 59], ["B", "PROTEIN", 107, 108], ["antigenie determinants", "PROTEIN", 212, 234]]], ["The nonspecific, high molecular weight bands in lanes 5 and 6 represented P-galactosidase overexpressed by baculovirus transfer vector pJVP1 OZ (Vialard et a/., 1990) .Expression of the Sl deletion mutant polypeptides in insect ceilsIn order to identify the upstream domain involved in the completion of the antigenicity, deletion AVI was constructed.", [["baculovirus", "ORGANISM", 107, 118], ["Sl", "GENE_OR_GENE_PRODUCT", 186, 188], ["P-galactosidase", "PROTEIN", 74, 89], ["Sl deletion mutant polypeptides", "PROTEIN", 186, 217], ["upstream domain", "DNA", 258, 273], ["deletion AVI", "DNA", 322, 334], ["baculovirus", "SPECIES", 107, 118], ["The nonspecific, high molecular weight bands in lanes", "PROBLEM", 0, 53], ["the Sl deletion mutant polypeptides", "PROBLEM", 182, 217], ["deletion AVI", "TREATMENT", 322, 334], ["nonspecific", "OBSERVATION_MODIFIER", 4, 15], ["high", "OBSERVATION_MODIFIER", 17, 21], ["molecular", "OBSERVATION_MODIFIER", 22, 31], ["weight bands", "OBSERVATION_MODIFIER", 32, 44]]], ["Deletion AVI overlapped with deletion AV but extended 79 amino acids towards the N-terminus (Fig. 1) .", [["amino acids", "CHEMICAL", 57, 68], ["amino acids", "CHEMICAL", 57, 68], ["amino acids", "AMINO_ACID", 57, 68], ["AVI", "DNA", 9, 12], ["deletion AV", "DNA", 29, 40], ["N-terminus", "PROTEIN", 81, 91], ["Deletion AVI", "PROBLEM", 0, 12], ["deletion AV", "TREATMENT", 29, 40], ["amino acids", "TEST", 57, 68]]], ["The AVI mutant polypeptide was immunoprecipitated well by both group A and B monoclonal antibodies (Fig. 5A, lane 7; Fig. 56, lane 7) .", [["AVI", "GENE_OR_GENE_PRODUCT", 4, 7], ["AVI mutant polypeptide", "PROTEIN", 4, 26], ["B monoclonal antibodies", "PROTEIN", 75, 98], ["Fig. 5A, lane 7", "PROTEIN", 100, 115], ["The AVI mutant polypeptide", "PROBLEM", 0, 26]]], ["These observations, together with the results from deletions Apu and Apt, demonstrate that antigenic determinants A and B are both located on a region between residues 324 and 720, and that a short region composed of residues 324-403 contained a second domain necessary for the formation of BCV Sl conformational epitopes. lmmunoprecipitation results of the mutant polypeptides obtained with conformational monoclonal antibodies were confirmed by Western blot analysis (Fig. 6 ) since the previous data characterizing these monoclonal antibodies indicated that, in the absence of pmercaptoethanol, the antigens transferred to a membrane retained sufficient conformation for monoclonal antibody recognition .", [["membrane", "ANATOMY", 628, 636], ["pmercaptoethanol", "CHEMICAL", 580, 596], ["pmercaptoethanol", "CHEMICAL", 580, 596], ["A", "GENE_OR_GENE_PRODUCT", 114, 115], ["B", "GENE_OR_GENE_PRODUCT", 120, 121], ["pmercaptoethanol", "SIMPLE_CHEMICAL", 580, 596], ["membrane", "CELLULAR_COMPONENT", 628, 636], ["B", "PROTEIN", 120, 121], ["Sl conformational epitopes", "PROTEIN", 295, 321], ["conformational monoclonal antibodies", "PROTEIN", 392, 428], ["monoclonal antibodies", "PROTEIN", 524, 545], ["antigens", "PROTEIN", 602, 610], ["monoclonal antibody", "PROTEIN", 674, 693], ["BCV", "SPECIES", 291, 294], ["a short region", "PROBLEM", 190, 204], ["a second domain", "TREATMENT", 244, 259], ["Sl conformational epitopes", "PROBLEM", 295, 321], ["the mutant polypeptides", "PROBLEM", 354, 377], ["conformational monoclonal antibodies", "TEST", 392, 428], ["blot analysis", "TEST", 455, 468], ["the previous data", "TEST", 485, 502], ["these monoclonal antibodies", "TEST", 518, 545], ["pmercaptoethanol", "TREATMENT", 580, 596], ["monoclonal antibody recognition", "TEST", 674, 705], ["BCV", "ANATOMY", 291, 294], ["conformational epitopes", "OBSERVATION", 298, 321]]], ["As with the results of immunoprecipitation, only the Apu and AVI constructs were recognized by groups A and B monoclonal antibodies (Fig. 6A, lanes 2, 7; Fig. 6B, lanes 2, 7) indicating that only deletions Apu and AVI contained both domains necessary for forming proper conformation of the Sl protein.", [["Apu", "GENE_OR_GENE_PRODUCT", 53, 56], ["AVI", "GENE_OR_GENE_PRODUCT", 61, 64], ["Sl", "GENE_OR_GENE_PRODUCT", 290, 292], ["Apu and AVI constructs", "DNA", 53, 75], ["B monoclonal antibodies", "PROTEIN", 108, 131], ["Fig. 6A, lanes 2, 7; Fig. 6B, lanes 2, 7", "PROTEIN", 133, 173], ["Apu", "PROTEIN", 206, 209], ["AVI", "DNA", 214, 217], ["Sl protein", "PROTEIN", 290, 300], ["immunoprecipitation", "TEST", 23, 42], ["the Apu and AVI constructs", "PROBLEM", 49, 75], ["A and B monoclonal antibodies", "TEST", 102, 131], ["lanes", "TEST", 142, 147], ["deletions Apu", "PROBLEM", 196, 209], ["AVI", "TREATMENT", 214, 217]]], ["The contention of two domains on the Apu and AVI polypeptides was further confirmed by comparing Western blots in the absence and presence of fl-mercaptoethanol.Expression of the Sl deletion mutant polypeptides in insect ceilsWhen /3-mercaptoethanol was included in the sample buffer, deletions Apu, and AVI were no longer recognized by monoclonal antibodies A and B (Fig. 6C, lanes 3, 4; Fig. 6D , lanes 3, 4) demonstrating the role of two domains in antibody recognition.DISCUSSIONContinuous epitopes are generally mapped by measuring reactivities of the short peptides with specific antibodies.", [["fl-mercaptoethanol", "CHEMICAL", 142, 160], ["3-mercaptoethanol", "CHEMICAL", 232, 249], ["fl-mercaptoethanol", "CHEMICAL", 142, 160], ["3-mercaptoethanol", "CHEMICAL", 232, 249], ["Apu", "GENE_OR_GENE_PRODUCT", 37, 40], ["AVI", "GENE_OR_GENE_PRODUCT", 45, 48], ["fl-mercaptoethanol", "SIMPLE_CHEMICAL", 142, 160], ["Sl", "GENE_OR_GENE_PRODUCT", 179, 181], ["3-mercaptoethanol", "SIMPLE_CHEMICAL", 232, 249], ["Apu", "GENE_OR_GENE_PRODUCT", 295, 298], ["AVI", "GENE_OR_GENE_PRODUCT", 304, 307], ["Sl deletion mutant polypeptides", "PROTEIN", 179, 210], ["monoclonal antibodies A", "PROTEIN", 337, 360], ["B", "PROTEIN", 365, 366], ["epitopes", "PROTEIN", 494, 502], ["specific antibodies", "PROTEIN", 577, 596], ["the Apu and AVI polypeptides", "TREATMENT", 33, 61], ["fl-mercaptoethanol", "TREATMENT", 142, 160], ["the Sl deletion mutant polypeptides", "PROBLEM", 175, 210], ["mercaptoethanol", "TREATMENT", 234, 249], ["deletions Apu", "TREATMENT", 285, 298], ["AVI", "TREATMENT", 304, 307], ["monoclonal antibodies", "TEST", 337, 358], ["the short peptides", "PROBLEM", 553, 571], ["no longer", "UNCERTAINTY", 313, 322]]], ["This can be achieved by either synthetic peptide technology (Geysen eT al., 1984) or alternatively by expressing DNA fragments generated by DNase or restriction enzymes in Escherichia co/i (Mehra et a/., 1984; Nunberg et al., 1986) .", [["DNA", "CELLULAR_COMPONENT", 113, 116], ["DNase", "GENE_OR_GENE_PRODUCT", 140, 145], ["DNA fragments", "DNA", 113, 126], ["DNase", "PROTEIN", 140, 145], ["restriction enzymes", "PROTEIN", 149, 168], ["DNA fragments", "PROBLEM", 113, 126], ["restriction enzymes", "TEST", 149, 168], ["Escherichia co", "TEST", 172, 186]]], ["Such an approach has been utilized for the identification of continuous epitopes of the spike glycoproteins of mouse hepatitis coronavirus (Talbot et al., 1988; Luy-tjes et a/., 1989) infectious bronchitis virus (Lenstra et al., 1989) and transmissible gastroenteritis virus (Delmas et a/., 1990; Correa et al., 1990) .", [["hepatitis coronavirus", "DISEASE", 117, 138], ["infectious bronchitis virus", "DISEASE", 184, 211], ["transmissible gastroenteritis", "DISEASE", 239, 268], ["mouse", "ORGANISM", 111, 116], ["hepatitis coronavirus", "ORGANISM", 117, 138], ["infectious bronchitis virus", "ORGANISM", 184, 211], ["spike glycoproteins", "PROTEIN", 88, 107], ["mouse", "SPECIES", 111, 116], ["hepatitis coronavirus", "SPECIES", 117, 138], ["infectious bronchitis virus", "SPECIES", 184, 211], ["transmissible gastroenteritis virus", "SPECIES", 239, 274], ["mouse hepatitis coronavirus (Talbot et al., 1988; Luy-tjes et a/., 1989) infectious bronchitis virus", "SPECIES", 111, 211], ["transmissible gastroenteritis virus", "SPECIES", 239, 274], ["mouse hepatitis coronavirus", "PROBLEM", 111, 138], ["Luy", "TEST", 161, 164], ["infectious bronchitis virus", "PROBLEM", 184, 211], ["transmissible gastroenteritis virus", "PROBLEM", 239, 274], ["infectious", "OBSERVATION_MODIFIER", 184, 194], ["bronchitis", "OBSERVATION", 195, 205], ["gastroenteritis virus", "OBSERVATION", 253, 274]]], ["However, attempts to study conformational epitopes using synthetic peptides or prokaryotic expression systems often result in the inability of antibodies to recognize these recombinant proteins or peptides (Delmas et al., 1990) .", [["antibodies", "PROTEIN", 143, 153], ["recombinant proteins", "PROTEIN", 173, 193], ["conformational epitopes", "TREATMENT", 27, 50], ["synthetic peptides", "TREATMENT", 57, 75], ["prokaryotic expression systems", "TREATMENT", 79, 109], ["the inability of antibodies", "PROBLEM", 126, 153]]], ["This problem is most probably due to the lack of proper posttranslational modification and consequently resulting in altered protein conformation.DISCUSSIONOur approach to express a series of deletion mutants in eukaryotic insect cells has proven useful for the study of conformational epitopes within the BCV Sl spike glycoprotein.", [["cells", "ANATOMY", 230, 235], ["eukaryotic insect cells", "CELL", 212, 235], ["Sl spike glycoprotein", "GENE_OR_GENE_PRODUCT", 310, 331], ["deletion mutants", "PROTEIN", 192, 208], ["eukaryotic insect cells", "CELL_TYPE", 212, 235], ["conformational epitopes", "PROTEIN", 271, 294], ["BCV Sl spike glycoprotein", "PROTEIN", 306, 331], ["proper posttranslational modification", "TREATMENT", 49, 86], ["altered protein conformation", "PROBLEM", 117, 145], ["deletion mutants in eukaryotic insect cells", "PROBLEM", 192, 235], ["the study", "TEST", 258, 267], ["conformational epitopes", "PROBLEM", 271, 294], ["most probably due to", "UNCERTAINTY", 16, 36], ["protein conformation", "OBSERVATION", 125, 145]]], ["All of the Sl derivatives were constructed to include a membrane translocational signal of the BCV S glycoprotein so as to be properly glycosylated and transported through the secretory pathway.", [["membrane", "ANATOMY", 56, 64], ["Sl", "CHEMICAL", 11, 13], ["Sl derivatives", "SIMPLE_CHEMICAL", 11, 25], ["membrane", "CELLULAR_COMPONENT", 56, 64], ["BCV S glycoprotein", "GENE_OR_GENE_PRODUCT", 95, 113], ["BCV S glycoprotein", "PROTEIN", 95, 113], ["the Sl derivatives", "TREATMENT", 7, 25], ["the BCV S glycoprotein", "TREATMENT", 91, 113], ["BCV", "ANATOMY", 95, 98]]], ["Samples were boiled for 2 min and resolved by SDS-PAGE.", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7]]], ["Separated proteins were transferred to nitrocellulose membranes and the membranes were incubated with a pool of the antigenic group A monoclonal antibodies HBlO-4, JB5-6, and HF8-8 (A, C) or with antigenic group B monoclonal antibody 887-14 (B, D).", [["membranes", "ANATOMY", 54, 63], ["membranes", "ANATOMY", 72, 81], ["nitrocellulose", "CHEMICAL", 39, 53], ["membranes", "CELLULAR_COMPONENT", 54, 63], ["membranes", "CELLULAR_COMPONENT", 72, 81], ["JB5-6", "SIMPLE_CHEMICAL", 164, 169], ["HF8-8", "SIMPLE_CHEMICAL", 175, 180], ["A, C", "SIMPLE_CHEMICAL", 182, 186], ["B, D", "SIMPLE_CHEMICAL", 242, 246], ["antigenic group A monoclonal antibodies", "PROTEIN", 116, 155], ["HBlO", "PROTEIN", 156, 160], ["JB5", "PROTEIN", 164, 167], ["HF8", "PROTEIN", 175, 178], ["antigenic group B monoclonal antibody 887-14", "PROTEIN", 196, 240], ["nitrocellulose membranes", "TREATMENT", 39, 63], ["A monoclonal antibodies HBlO", "TEST", 132, 160], ["JB5", "TEST", 164, 167], ["HF8", "TEST", 175, 178], ["antigenic group B monoclonal antibody", "TEST", 196, 233]]], ["Reactions were detected using HRP-conjugated goat anti-mouse IgG antibody.", [["HRP", "SIMPLE_CHEMICAL", 30, 33], ["HRP-conjugated goat anti-mouse IgG antibody", "PROTEIN", 30, 73], ["goat", "SPECIES", 45, 49], ["anti-mouse", "SPECIES", 50, 60], ["goat", "SPECIES", 45, 49], ["HRP", "TEST", 30, 33], ["conjugated goat anti-mouse IgG antibody", "TEST", 34, 73]]], ["Substrate used was 4-chloro-1 naphthol and color was developed for 20-60 min.", [["4-chloro-1 naphthol", "CHEMICAL", 19, 38], ["4-chloro-1 naphthol", "CHEMICAL", 19, 38], ["4-chloro-1 naphthol", "SIMPLE_CHEMICAL", 19, 38], ["chloro", "TREATMENT", 21, 27]]], ["A, B: without ,&mercaptoethanol.", [["&mercaptoethanol", "CHEMICAL", 15, 31], ["&mercaptoethanol", "CHEMICAL", 15, 31], ["&mercaptoethanol", "SIMPLE_CHEMICAL", 15, 31], ["&mercaptoethanol", "TREATMENT", 15, 31]]], ["C, D: lanes 1, 2; without @-mercaptoethanol (-); lanes 3, 4; with fl-mercaptoethanol (+).DISCUSSIONThe intracellular Sl mutant polypeptides in Sf9 cells 1988).", [["intracellular", "ANATOMY", 103, 116], ["Sf9 cells", "ANATOMY", 143, 152], ["fl-mercaptoethanol", "CHEMICAL", 66, 84], ["@-mercaptoethanol", "CHEMICAL", 26, 43], ["fl-mercaptoethanol", "CHEMICAL", 66, 84], ["C", "SIMPLE_CHEMICAL", 0, 1], ["@-mercaptoethanol", "SIMPLE_CHEMICAL", 26, 43], ["fl-mercaptoethanol", "SIMPLE_CHEMICAL", 66, 84], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 103, 116], ["Sf9 cells", "CELL", 143, 152], ["intracellular Sl mutant polypeptides", "PROTEIN", 103, 139], ["Sf9 cells 1988", "CELL_LINE", 143, 157], ["fl-mercaptoethanol", "TREATMENT", 66, 84], ["intracellular Sl mutant polypeptides in Sf9 cells", "PROBLEM", 103, 152]]], ["Deletions Apu, AVI, Alll, that all three enzymes generated fragments with simiand AV were secreted efficiently whereas secretion of lar size and other characteristics which suggested that deletions Apt and AV was significantly inhibited (Fig. the unique sequence Glu-Arg-Lys (349-351) in a hy-4).", [["fragments", "ANATOMY", 59, 68], ["Glu-Arg-Lys", "CHEMICAL", 263, 274], ["Glu-Arg-Lys", "CHEMICAL", 263, 274], ["AV", "GENE_OR_GENE_PRODUCT", 82, 84], ["Apt", "GENE_OR_GENE_PRODUCT", 198, 201], ["AVI", "DNA", 15, 18], ["AVI", "PROBLEM", 15, 18], ["simiand AV", "TREATMENT", 74, 84], ["secretion of lar size", "PROBLEM", 119, 140], ["deletions Apt", "PROBLEM", 188, 201], ["AV", "PROBLEM", 206, 208], ["the unique sequence Glu-Arg", "TEST", 243, 270], ["Lys", "TEST", 271, 274], ["fragments", "OBSERVATION", 59, 68], ["lar", "OBSERVATION_MODIFIER", 132, 135], ["size", "OBSERVATION_MODIFIER", 136, 140]]], ["Since addition of N-linked oligosaccharides is re-drophilic locale, was cleaved by all three enzymes. quired for the secretion of the BCV Sl glycoprotein in Given the above, the lysine at 621, also in a hydrophilic insect cells Jarvis et al., 1990) , the locale, was indicated as the only lysine that could gensecreted Sl deletion products are likely all glycosy-erate a 37K fragment.", [["cells", "ANATOMY", 222, 227], ["lysine", "CHEMICAL", 178, 184], ["lysine", "CHEMICAL", 289, 295], ["N", "CHEMICAL", 18, 19], ["lysine", "CHEMICAL", 178, 184], ["lysine", "CHEMICAL", 289, 295], ["Sl glycoprotein", "GENE_OR_GENE_PRODUCT", 138, 153], ["enzymes", "PROTEIN", 93, 100], ["Sl glycoprotein", "PROTEIN", 138, 153], ["Sl deletion products", "PROTEIN", 319, 339], ["glycosy-erate", "PROTEIN", 355, 368], ["37K fragment", "PROTEIN", 371, 383], ["BCV", "SPECIES", 134, 137], ["N-linked oligosaccharides", "TREATMENT", 18, 43], ["Sl glycoprotein", "TREATMENT", 138, 153], ["the lysine", "TREATMENT", 174, 184], ["Sl deletion products", "PROBLEM", 319, 339], ["BCV", "ANATOMY", 134, 137], ["Sl deletion", "OBSERVATION", 319, 330], ["37K fragment", "OBSERVATION", 371, 383]]], ["Although the Apt and AV polypeptides were not tides Apu and AVI included residues 351-621 were secreted, the intracellular Apt and AV were glycosy-immunoreactive (Figs.", [["intracellular", "ANATOMY", 109, 122], ["351-621", "CHEMICAL", 82, 89], ["Apt", "GENE_OR_GENE_PRODUCT", 13, 16], ["AV polypeptides", "GENE_OR_GENE_PRODUCT", 21, 36], ["-621", "AMINO_ACID", 85, 89], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 109, 122], ["Apt", "GENE_OR_GENE_PRODUCT", 123, 126], ["AV", "GENE_OR_GENE_PRODUCT", 131, 133], ["Apt", "PROTEIN", 13, 16], ["intracellular Apt", "PROTEIN", 109, 126], ["AV", "PROTEIN", 131, 133], ["the Apt", "TEST", 9, 16], ["AV polypeptides", "TREATMENT", 21, 36], ["residues", "TEST", 73, 81], ["the intracellular Apt", "TEST", 105, 126], ["glycosy", "TEST", 139, 146], ["AV", "ANATOMY", 131, 133]]], ["This observation suplated like other mutant polypeptides (Fig. 3, lanes 7 , ports the previous suggestion for the location of sites A 11).", [["This observation", "TEST", 0, 16], ["other mutant polypeptides", "PROBLEM", 31, 56], ["ports", "TREATMENT", 76, 81]]], ["Therefore, inhibition of the Apt and AV polypep-and B within the 37K fragment.", [["37K fragment", "ANATOMY", 65, 77], ["Apt", "GENE_OR_GENE_PRODUCT", 29, 32], ["AV", "GENE_OR_GENE_PRODUCT", 37, 39], ["B", "GENE_OR_GENE_PRODUCT", 52, 53], ["Apt", "PROTEIN", 29, 32], ["AV", "PROTEIN", 37, 39], ["37K fragment", "DNA", 65, 77], ["the Apt", "TREATMENT", 25, 32], ["AV polypep", "TREATMENT", 37, 47], ["B within the 37K fragment", "TREATMENT", 52, 77]]], ["When the first domain tides in their intracellular transport seems to occur was aligned with the 37K fragment, residues 351-403 after glycosylation. overlapped (Fig. 7, E) .", [["intracellular", "ANATOMY", 37, 50], ["residues 351-403", "CHEMICAL", 111, 127], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 37, 50], ["37K fragment", "DNA", 97, 109], ["glycosylation", "TREATMENT", 134, 147]]], ["This overlapping region (domain The results established that the BCV antigenic determinants A and B are located in a segment between residues 324 and 720 (Fig. 7, B) .", [["A", "GENE_OR_GENE_PRODUCT", 92, 93], ["B", "GENE_OR_GENE_PRODUCT", 98, 99], ["BCV antigenic determinants", "PROTEIN", 65, 91], ["B", "PROTEIN", 98, 99], ["This overlapping region", "PROBLEM", 0, 23], ["the BCV antigenic", "TEST", 61, 78], ["segment", "ANATOMY_MODIFIER", 117, 124]]], ["Formation of the determinants A and B appeared to be dependent upon two separate domains.", [["B", "GENE_OR_GENE_PRODUCT", 36, 37], ["B", "PROTEIN", 36, 37], ["dependent", "OBSERVATION", 53, 62]]], ["One of the domains was localized within residues 325-403, approximately 50 amino acids upstream from the probable BCV polymorphic region.", [["amino acids", "CHEMICAL", 75, 86], ["amino acids", "CHEMICAL", 75, 86], ["amino acids", "AMINO_ACID", 75, 86], ["BCV polymorphic region", "DNA", 114, 136], ["probable", "UNCERTAINTY", 105, 113], ["BCV", "ANATOMY", 114, 117], ["polymorphic", "ANATOMY_MODIFIER", 118, 129], ["region", "ANATOMY_MODIFIER", 130, 136]]], ["The other domain was identified within residues 517-720, which included the carboxyl half of the probable BCV polymorphic region (Fig. 7, C) .", [["carboxyl", "CHEMICAL", 76, 84], ["517-720", "AMINO_ACID", 48, 55], ["carboxyl half", "PROTEIN", 76, 89], ["BCV polymorphic region", "DNA", 106, 128], ["BCV polymorphic region", "PROBLEM", 106, 128], ["probable", "UNCERTAINTY", 97, 105], ["BCV", "ANATOMY", 106, 109], ["polymorphic region", "OBSERVATION", 110, 128]]], ["Earlier studies mapped BCV antigenic determinants A and B to a 37K tt-ypsin fragment generated by proteolysis of antigen-antibody complexes (Deregt et a/., 1989) .", [["antigen-antibody", "GENE_OR_GENE_PRODUCT", 113, 129], ["BCV antigenic determinants A", "PROTEIN", 23, 51], ["B", "PROTEIN", 56, 57], ["37K tt-ypsin fragment", "DNA", 63, 84], ["antigen-antibody complexes", "PROTEIN", 113, 139], ["Earlier studies", "TEST", 0, 15], ["a 37K tt-ypsin fragment", "PROBLEM", 61, 84], ["antigen", "TEST", 113, 120], ["antibody complexes", "TEST", 121, 139], ["BCV", "ANATOMY", 23, 26]]], ["Based upon the potential hydrophilic trypsin cleavage sites of the amino acid sequence, the proteolytic cleavage patterns generated with three specific proteolytic enzymes, and other considerations such as the number of glycosylation sites, 37K fragment was tentatively suggested to extend from residues 351 (after Arg at 350) to 621 (Lys) of the Sl subunit (Fig. 7, D) (Deregt, 199 .", [["amino acid", "CHEMICAL", 67, 77], ["K", "CHEMICAL", 243, 244], ["amino acid", "CHEMICAL", 67, 77], ["Arg", "CHEMICAL", 315, 318], ["Lys", "CHEMICAL", 335, 338], ["trypsin", "GENE_OR_GENE_PRODUCT", 37, 44], ["amino acid", "AMINO_ACID", 67, 77], ["hydrophilic trypsin cleavage sites", "PROTEIN", 25, 59], ["amino acid sequence", "PROTEIN", 67, 86], ["proteolytic enzymes", "PROTEIN", 152, 171], ["glycosylation sites", "PROTEIN", 220, 239], ["37K fragment", "PROTEIN", 241, 253], ["Sl subunit", "PROTEIN", 347, 357], ["the potential hydrophilic trypsin cleavage", "TREATMENT", 11, 53], ["the amino acid sequence", "TEST", 63, 86], ["the proteolytic cleavage patterns", "PROBLEM", 88, 121], ["specific proteolytic enzymes", "TEST", 143, 171], ["glycosylation sites", "TREATMENT", 220, 239], ["37K fragment", "PROBLEM", 241, 253], ["Arg", "TEST", 315, 318], ["the Sl subunit", "TREATMENT", 343, 357]]], ["Circles with vertical bar (top) indicate the potential N-linked glycosylation sites and vertical lines (bottom) indicate the location of cysteine residues.", [["N", "CHEMICAL", 55, 56], ["cysteine", "CHEMICAL", 137, 145], ["cysteine", "AMINO_ACID", 137, 145], ["N-linked glycosylation sites", "DNA", 55, 83], ["vertical lines", "CELL_LINE", 88, 102], ["N-linked glycosylation sites", "TREATMENT", 55, 83], ["vertical lines (bottom", "TREATMENT", 88, 110], ["cysteine residues", "PROBLEM", 137, 154], ["vertical bar", "OBSERVATION_MODIFIER", 13, 25], ["glycosylation sites", "OBSERVATION", 64, 83], ["vertical lines", "OBSERVATION", 88, 102], ["cysteine residues", "OBSERVATION", 137, 154]]], ["Darkened area at the N terminus indicates membrane translocational signal, and shaded areas indicate the probable BCV polymorphic region.", [["membrane", "ANATOMY", 42, 50], ["membrane", "CELLULAR_COMPONENT", 42, 50], ["N terminus", "PROTEIN", 21, 31], ["BCV polymorphic region", "DNA", 114, 136], ["Darkened area", "PROBLEM", 0, 13], ["membrane translocational signal, and shaded areas", "PROBLEM", 42, 91], ["BCV polymorphic region", "PROBLEM", 114, 136], ["membrane", "OBSERVATION_MODIFIER", 42, 50], ["translocational signal", "OBSERVATION", 51, 73], ["probable", "UNCERTAINTY", 105, 113], ["BCV", "ANATOMY", 114, 117], ["polymorphic", "OBSERVATION", 118, 129]]], ["Numbers indicate amino acid positions of the St protein: A, probable BCV polymorphic region; B, location of the antigenie sites A and B; C, two identified domains important for the formation of antigenic sites; D. The 37K trypsin fragment (Deregt et al., 1989) ; E, predicted location of the two actual domains.", [["amino acid", "CHEMICAL", 17, 27], ["amino acid", "CHEMICAL", 17, 27], ["amino acid", "AMINO_ACID", 17, 27], ["A", "GENE_OR_GENE_PRODUCT", 57, 58], ["B; C", "GENE_OR_GENE_PRODUCT", 134, 138], ["St protein", "PROTEIN", 45, 55], ["BCV polymorphic region", "PROTEIN", 69, 91], ["antigenie sites", "DNA", 112, 127], ["B", "PROTEIN", 134, 135], ["37K trypsin fragment", "PROTEIN", 218, 238], ["amino acid positions", "PROBLEM", 17, 37], ["the St protein", "TEST", 41, 55], ["BCV polymorphic region", "PROBLEM", 69, 91], ["antigenic sites", "PROBLEM", 194, 209], ["The 37K trypsin fragment", "PROBLEM", 214, 238], ["amino acid", "OBSERVATION", 17, 27], ["probable", "UNCERTAINTY", 60, 68], ["BCV", "ANATOMY", 69, 72], ["polymorphic", "OBSERVATION", 73, 84], ["antigenic sites", "OBSERVATION", 194, 209]]], ["I) appears to include three cysteines at positions 356, 374, and 386.", [["cysteines", "CHEMICAL", 28, 37]]], ["One or more of these three cysteines may be involved in the formation of the antigenic determinants by forming disulfide linkages.", [["cysteines", "CHEMICAL", 27, 36], ["disulfide", "CHEMICAL", 111, 120], ["cysteines", "OBSERVATION", 27, 36], ["may be", "UNCERTAINTY", 37, 43], ["disulfide linkages", "OBSERVATION", 111, 129]]], ["Similarly, residues 517-621 of the second domain overlapped with the 37K fragment.", [["517-621", "AMINO_ACID", 20, 27], ["37K fragment", "DNA", 69, 81], ["residues", "TEST", 11, 19], ["the second domain", "PROBLEM", 31, 48], ["the 37K fragment", "TREATMENT", 65, 81], ["37K fragment", "OBSERVATION", 69, 81]]], ["Thus, we propose that domain II is located within a region spanned by amino acids 517-621 (Fig. 7, E) .DISCUSSIONPolypeptides Apu and AVI contained both domains I and II, and polypeptides All1 and Abxcontained neither of the domains.", [["amino acids 517-621", "CHEMICAL", 70, 89], ["amino acids", "CHEMICAL", 70, 81], ["amino acids", "AMINO_ACID", 70, 81], ["517-621", "AMINO_ACID", 82, 89], ["All1", "GENE_OR_GENE_PRODUCT", 188, 192], ["domain II", "PROTEIN", 22, 31], ["Apu", "PROTEIN", 126, 129], ["AVI", "DNA", 134, 137], ["domains I and II", "PROTEIN", 153, 169], ["All1", "PROTEIN", 188, 192], ["amino acids", "TEST", 70, 81], ["DISCUSSIONPolypeptides", "TEST", 103, 125], ["polypeptides All1", "TREATMENT", 175, 192]]], ["In contrast, polypeptides Apt and AV contained only one of the domains.", [["Apt", "GENE_OR_GENE_PRODUCT", 26, 29], ["Apt", "PROTEIN", 26, 29], ["AV", "PROTEIN", 34, 36], ["AV", "TREATMENT", 34, 36], ["AV", "ANATOMY", 34, 36]]], ["It has been documented that correct folding and oligomeric assembly is required for transport of proteins from the endoplasmic reticulum to the cell surface (Kreis and Lodish, 1986; Gething eta/., 1986; Rose and Doms, 1988) .", [["endoplasmic reticulum", "ANATOMY", 115, 136], ["cell surface", "ANATOMY", 144, 156], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 115, 136], ["cell surface", "CELLULAR_COMPONENT", 144, 156], ["endoplasmic reticulum", "ANATOMY", 115, 136], ["cell", "ANATOMY_MODIFIER", 144, 148], ["surface", "ANATOMY_MODIFIER", 149, 156]]], ["Glycosylation indirectly promotes intracellular transport by influencing protein folding or oligomerization (Pitta et al., 1989) .", [["intracellular", "ANATOMY", 34, 47], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 34, 47], ["Glycosylation", "TREATMENT", 0, 13]]], ["Therefore, the secretion inhibition of mutants Apt and AV seems likely due to the unfavorable conformation of these mutant polypeptides, implicating an important association between these two domains.DISCUSSIONPolypeptides All1 and Abx contained neither domain and were secreted efficiently.", [["Apt", "GENE_OR_GENE_PRODUCT", 47, 50], ["All1", "GENE_OR_GENE_PRODUCT", 223, 227], ["Abx", "GENE_OR_GENE_PRODUCT", 232, 235], ["Apt", "PROTEIN", 47, 50], ["AV", "PROTEIN", 55, 57], ["mutant polypeptides", "PROTEIN", 116, 135], ["DISCUSSIONPolypeptides", "PROTEIN", 200, 222], ["All1", "PROTEIN", 223, 227], ["Abx", "PROTEIN", 232, 235], ["the secretion inhibition of mutants Apt", "PROBLEM", 11, 50], ["AV", "TREATMENT", 55, 57], ["these mutant polypeptides", "PROBLEM", 110, 135], ["DISCUSSIONPolypeptides All1", "TREATMENT", 200, 227], ["Abx", "TREATMENT", 232, 235], ["seems likely due to", "UNCERTAINTY", 58, 77]]], ["A possible explanation for this is that, since the Abx and All1 polypeptides represent the N-terminal and C-terminal portion of the Sl protein, respectively, these portions may be insignificantly linked with either domains, forming a relatively independent conformation.", [["C", "CHEMICAL", 106, 107], ["Abx", "GENE_OR_GENE_PRODUCT", 51, 54], ["All1", "GENE_OR_GENE_PRODUCT", 59, 63], ["Sl", "GENE_OR_GENE_PRODUCT", 132, 134], ["Abx and All1 polypeptides", "PROTEIN", 51, 76], ["N-terminal and C-terminal portion", "PROTEIN", 91, 124], ["Sl protein", "PROTEIN", 132, 142], ["the Abx", "TREATMENT", 47, 54], ["All1 polypeptides", "TREATMENT", 59, 76], ["the N-terminal and C-terminal portion of the Sl protein", "PROBLEM", 87, 142], ["possible explanation for", "UNCERTAINTY", 2, 26], ["terminal", "ANATOMY_MODIFIER", 108, 116], ["Sl protein", "ANATOMY", 132, 142]]], ["Thus, the folding of the fragmented polypeptides representing these portions may easily mimic the native conformation, resulting in efficient secretion.DISCUSSIONRecently, have identified a polymorphic region on the Sl subunit in MHV-4.", [["Sl", "GENE_OR_GENE_PRODUCT", 216, 218], ["MHV-4", "ORGANISM", 230, 235], ["Sl subunit", "PROTEIN", 216, 226], ["the fragmented polypeptides", "PROBLEM", 21, 48], ["efficient secretion", "PROBLEM", 132, 151], ["a polymorphic region", "PROBLEM", 188, 208], ["efficient", "OBSERVATION_MODIFIER", 132, 141], ["secretion", "OBSERVATION", 142, 151], ["polymorphic", "OBSERVATION_MODIFIER", 190, 201], ["MHV", "ANATOMY", 230, 233]]], ["Furthermore, these point mutations were selectable by neutralizing monoclonal antibodies, and the mutant viruses displayed decreased virulence, indicating that the polymorphic region is directly involved in the MHV-4 pathogenicity (Gallagher et al., 1990) .", [["mutant viruses", "ORGANISM", 98, 112], ["MHV-4", "ORGANISM", 211, 216], ["monoclonal antibodies", "PROTEIN", 67, 88], ["MHV-4", "SPECIES", 211, 216], ["these point mutations", "PROBLEM", 13, 34], ["neutralizing monoclonal antibodies", "TEST", 54, 88], ["the mutant viruses", "PROBLEM", 94, 112], ["decreased virulence", "PROBLEM", 123, 142], ["the polymorphic region", "PROBLEM", 160, 182], ["decreased virulence", "OBSERVATION", 123, 142], ["MHV", "ANATOMY", 211, 214]]], ["We have mapped BCV antigenie determinants A and B to residues 324-720, and this segment includes the probable BCV polymorphic region (Fig. 7, B) .", [["BCV antigenie determinants", "PROTEIN", 15, 41], ["BCV polymorphic region", "DNA", 110, 132], ["BCV polymorphic region", "PROBLEM", 110, 132], ["probable", "UNCERTAINTY", 101, 109], ["BCV", "ANATOMY", 110, 113], ["polymorphic", "OBSERVATION_MODIFIER", 114, 125]]], ["Even though it is not clear whether determinants A and B reside on domains I and/or II, or on the third region, the probable BCV polymorphic region (Fig. 7, A) seems to be associated with these antigenie determinants since the probable polymorphic region is comprised of the most part of domain II and the region between two domains (Fig. 7 , B, C, E).", [["A", "GENE_OR_GENE_PRODUCT", 49, 50], ["B", "GENE_OR_GENE_PRODUCT", 55, 56], ["B", "PROTEIN", 55, 56], ["domains I and/or II", "PROTEIN", 67, 86], ["BCV polymorphic region", "DNA", 125, 147], ["antigenie determinants", "PROTEIN", 194, 216], ["domain II", "PROTEIN", 288, 297], ["B", "PROTEIN", 343, 344], ["BCV polymorphic region (Fig", "PROBLEM", 125, 152], ["polymorphic region", "PROBLEM", 236, 254], ["Fig.", "TEST", 334, 338], ["clear", "OBSERVATION", 22, 27], ["probable", "UNCERTAINTY", 116, 124], ["BCV", "ANATOMY", 125, 128], ["probable", "UNCERTAINTY", 227, 235], ["polymorphic", "OBSERVATION_MODIFIER", 236, 247], ["region", "ANATOMY_MODIFIER", 306, 312]]], ["Sequence homology with perfectly conserved cysteine residues in the polymorphic region between BCV and MHV-4 and the involvement of this region in BCV antigenicity (Fig. 7, B, D) further support the association of BCV antigenic determinants with the probable polymorphic region.", [["cysteine", "CHEMICAL", 43, 51], ["cysteine", "AMINO_ACID", 43, 51], ["MHV-4", "ORGANISM", 103, 108], ["BCV", "ORGANISM", 147, 150], ["B", "GENE_OR_GENE_PRODUCT", 173, 174], ["BCV", "ORGANISM", 214, 217], ["BCV and MHV-4", "DNA", 95, 108], ["BCV antigenic determinants", "PROTEIN", 214, 240], ["BCV", "SPECIES", 147, 150], ["BCV", "SPECIES", 214, 217], ["Sequence homology", "TEST", 0, 17], ["perfectly conserved cysteine residues", "PROBLEM", 23, 60], ["BCV antigenic determinants", "PROBLEM", 214, 240], ["polymorphic region", "PROBLEM", 259, 277], ["cysteine residues", "OBSERVATION", 43, 60], ["polymorphic", "OBSERVATION_MODIFIER", 68, 79], ["region", "ANATOMY_MODIFIER", 80, 86], ["BCV", "ANATOMY", 95, 98], ["MHV", "ANATOMY", 103, 106], ["BCV", "ANATOMY", 147, 150], ["BCV", "ANATOMY", 214, 217], ["antigenic", "OBSERVATION", 218, 227], ["probable", "UNCERTAINTY", 250, 258], ["polymorphic", "OBSERVATION_MODIFIER", 259, 270]]], ["Since no potential glycosylation sites are found in this region (Fig. 7) , glycosylation of the Sl protein does not seem to be directly involved in the proper formation of the antigenic determinants.", [["Sl", "GENE_OR_GENE_PRODUCT", 96, 98], ["Sl protein", "PROTEIN", 96, 106], ["antigenic determinants", "PROTEIN", 176, 198], ["potential glycosylation sites", "PROBLEM", 9, 38], ["glycosylation of the Sl protein", "TREATMENT", 75, 106], ["glycosylation sites", "OBSERVATION", 19, 38]]], ["This is in agreement with the previous finding that unglycosylated forms of the Sl protein were recognized by both groups of monoclonal antibodies .", [["Sl", "GENE_OR_GENE_PRODUCT", 80, 82], ["Sl protein", "PROTEIN", 80, 90], ["monoclonal antibodies", "PROTEIN", 125, 146], ["the Sl protein", "TEST", 76, 90], ["monoclonal antibodies", "TEST", 125, 146], ["monoclonal antibodies", "OBSERVATION", 125, 146]]], ["This portion of the Sl subunit contains 15 cysteine residues (Fig. 7) and manyp-turns as revealed by secondary structure analysis (data not shown, Chou and Fasman, 1978) , suggesting that the BCV polymorphic region forms an extremely complex bulbous structure.", [["bulbous structure", "ANATOMY", 242, 259], ["cysteine", "CHEMICAL", 43, 51], ["Sl", "GENE_OR_GENE_PRODUCT", 20, 22], ["Sl subunit", "PROTEIN", 20, 30], ["manyp", "PROTEIN", 74, 79], ["BCV polymorphic region", "DNA", 192, 214], ["the Sl subunit", "TREATMENT", 16, 30], ["15 cysteine residues", "TREATMENT", 40, 60], ["secondary structure analysis", "TEST", 101, 129], ["the BCV polymorphic region", "PROBLEM", 188, 214], ["an extremely complex bulbous structure", "PROBLEM", 221, 259], ["15 cysteine", "OBSERVATION_MODIFIER", 40, 51], ["BCV", "ANATOMY", 192, 195], ["extremely", "OBSERVATION_MODIFIER", 224, 233], ["complex", "OBSERVATION_MODIFIER", 234, 241], ["bulbous structure", "OBSERVATION", 242, 259]]], ["This structural characteristic may represent an important in viva function of the spike protein in coronavirus pathogenesis.", [["coronavirus", "ORGANISM", 99, 110], ["spike protein", "PROTEIN", 82, 95], ["coronavirus", "SPECIES", 99, 110], ["the spike protein", "PROBLEM", 78, 95], ["coronavirus pathogenesis", "PROBLEM", 99, 123], ["may represent", "UNCERTAINTY", 31, 44], ["coronavirus pathogenesis", "OBSERVATION", 99, 123]]], ["Minor factors may easily direct conformational changes of the Sl polymorphic region, and facilitate the escape of BCVfrom immunological selective pressure.", [["Sl polymorphic region", "DNA", 62, 83], ["Minor factors", "PROBLEM", 0, 13], ["the Sl polymorphic region", "PROBLEM", 58, 83]]], ["Fine mapping within the probable polymorphic region and analysis of neutralization resistant BCV mutants will help to better understand the antigenic structure of the BCV S glycoprotein.", [["BCV", "ORGANISM", 93, 96], ["BCV S glycoprotein", "GENE_OR_GENE_PRODUCT", 167, 185], ["BCV S glycoprotein", "PROTEIN", 167, 185], ["BCV", "SPECIES", 167, 170], ["Fine mapping", "TEST", 0, 12], ["neutralization resistant BCV mutants", "PROBLEM", 68, 104], ["probable", "UNCERTAINTY", 24, 32], ["polymorphic", "OBSERVATION_MODIFIER", 33, 44], ["BCV", "ANATOMY", 167, 170]]], ["Such studies are presently in progress.", [["Such studies", "TEST", 0, 12]]]], "6f25d2706a7d4ae7d2c81f0c5ece56f1db5593cb": [["At this current point in human history (April 2020), global society faces a Herculean challenge in combating the pandemic COVID-19.", [["human", "ORGANISM", 25, 30], ["human", "SPECIES", 25, 30], ["human", "SPECIES", 25, 30], ["a Herculean challenge", "TREATMENT", 74, 95], ["the pandemic COVID", "TEST", 109, 127]]], ["Presently, there is lack of a vaccine that would lead to immunization against this virus, but here are some of the characteristics that various seaweeds have and which may provide a glimpse into potential solutions of this global health problem in the near future and possibly forearm us for any future such pandemics.", [["a vaccine", "TREATMENT", 28, 37], ["immunization", "TREATMENT", 57, 69], ["this virus", "PROBLEM", 78, 88]]]], "0754b3dfbc754cb56414561949598d207df827bc": [["SRAGEn octubre de 2004, la OMS public\u00f3 dos documentos que suponen la \u00faltima recopilaci\u00f3n de normas, directrices y recomendaciones para la vigilancia del s\u00edndrome respiratorio agudo grave (SRAG) (www.who.int/csr/resources/publications/SARSNEWGUIDANCE), y para establecer el riesgo y la preparaci\u00f3n de la respuesta frente a esta infecci\u00f3n (www.who.int/csr/resources/publications/ WHO_CDS_CSR_ARO_2004_2/en/).SRAGEstos documentos suponen una actualizaci\u00f3n de los anteriormente publicados (14 de agosto de 2004).Etiolog\u00edaEl SRAG es una enfermedad asociada a un nuevo coronavirus (CoV-SRAG).", [["nuevo coronavirus", "DISEASE", 557, 574], ["nuevo coronavirus", "ORGANISM", 557, 574], ["SRAGEstos", "TEST", 406, 415], ["Etiolog\u00edaEl SRAG", "TEST", 508, 524], ["a un nuevo coronavirus", "PROBLEM", 552, 574]]], ["El 22 de marzo del a\u00f1o 2003, a partir de una biopsia pulmonar de un paciente con SRAG, se consigui\u00f3 aislar en cultivos celulares un virus que se identific\u00f3 por sus caracter\u00edsticas morfol\u00f3gicas mediante microscopia electr\u00f3nica como un coronavirus [1] [2] [3] .", [["morfol\u00f3gicas", "TEST", 180, 192], ["microscopia", "TEST", 202, 213], ["electr\u00f3nica como un coronavirus", "TEST", 214, 245]]], ["Los estudios sobre su biolog\u00eda, su origen y su evoluci\u00f3n siguen realiz\u00e1ndose activamente en la actualidad.Etiolog\u00edaLos coronavirus (orden Nidovirales, familia Coronaviridae, g\u00e9nero Coronavirus) son un grupo diverso de virus.", [["Etiolog\u00edaLos coronavirus", "DISEASE", 106, 130], ["Etiolog\u00edaLos coronavirus", "ORGANISM", 106, 130], ["orden Nidovirales", "ORGANISM", 132, 149], ["familia Coronaviridae", "ORGANISM", 151, 172], ["g\u00e9nero Coronavirus", "ORGANISM", 174, 192], ["grupo diverso de virus", "ORGANISM", 201, 223], ["coronavirus", "SPECIES", 119, 130], ["Etiolog\u00edaLos coronavirus", "SPECIES", 106, 130], ["Etiolog\u00edaLos coronavirus", "PROBLEM", 106, 130], ["Nidovirales", "TREATMENT", 138, 149], ["familia Coronaviridae", "TREATMENT", 151, 172]]], ["Espec\u00edficos del ser humano son el CoV-229E del grupo 1 y el CoV-OC43 del grupo 2.", [["OC43", "DNA", 64, 68], ["Espec\u00edficos del ser humano son el CoV-229E del grupo 1 y el CoV-OC43 del grupo", "SPECIES", 0, 78]]], ["Recientemente se han descubierto dos nuevos coronavirus en muestras de pacientes: CoV-NL63 del grupo 1 y el CoV-HKU1 del grupo 2 ( fig. 1 ).Etiolog\u00edaLas part\u00edculas virales son grandes y presentan una envuelta.", [["CoV", "ORGANISM", 82, 85], ["CoV", "TEST", 82, 85]]], ["Este genoma se presenta muy conservado, aunque se han descrito mutaciones que contribuyen a la diversidad gen\u00e9tica del virus [5] [6] [7] .", [["a la diversidad gen\u00e9tica del virus", "TREATMENT", 90, 124]]], ["El orden de los genes es el siguiente: 5\u0408 -replicasa-esp\u00edcula (S)-envuelta (E)-membrana (M)-nucleoc\u00e1psida (N)-3\u0408.", [["envuelta (E)-membrana (M)-nucleoc\u00e1psida (N)-3\u0408.", "SIMPLE_CHEMICAL", 66, 113], ["replicasa", "TEST", 43, 52]]], ["Dos tercios del genoma lo forma el gen que codifica para la replicasa o Los virus respiratorios fueron descubiertos progresivamente a partir del a\u00f1o 1950 gracias a la posibilidad de aislarlos en cultivos celulares.", [["a la posibilidad de aislarlos en cultivos celulares", "TREATMENT", 162, 213]]], ["No hubo m\u00e1s descubrimientos hasta 2001 con el metapneumovirus humano asociado a brotes de bronquiolitis en ni\u00f1os.", [["metapneumovirus humano", "DISEASE", 46, 68], ["hubo", "PROBLEM", 3, 7]]], ["Un a\u00f1o despu\u00e9s, en noviembre de 2002, apareci\u00f3 el s\u00edndrome respiratorio agudo grave (SRAG) definido como una neumon\u00eda at\u00edpica, al que se asoci\u00f3 un nuevo virus como agente etiol\u00f3gico perteneciente a la familia de los coronavirus.", [["los coronavirus", "DISEASE", 212, 227], ["coronavirus", "PROBLEM", 216, 227]]], ["En 2004 se descubri\u00f3 otro coronavirus (CoV-NL63) y en 2005 se ha publicado el descubrimiento de un tercer coronavirus humano (CoV-HKU1).", [["coronavirus humano", "DISEASE", 106, 124], ["otro coronavirus", "ORGANISM", 21, 37], ["CoV-HKU1", "ORGANISM", 126, 134], ["otro coronavirus", "SPECIES", 21, 37], ["descubri\u00f3 otro coronavirus (CoV-NL63) y en 2005 se ha publicado el descubrimiento de un tercer coronavirus", "SPECIES", 11, 117], ["coronavirus", "TEST", 26, 37], ["CoV", "TEST", 39, 42]]], ["Adem\u00e1s, varios subtipos del virus de la gripe A, que hasta ahora se pensaba que eran pat\u00f3genos exclusivos de aves, se han transmitido directamente al ser humano.", [["Adem\u00e1s", "TEST", 0, 6]]], ["Metapneumovirus humano.SARS, avian influenza, and human metapneumovirus infectionBeginning in the 1950s respiratory viruses have been gradually discovered by isolation in cell cultures The last were the coronaviruses in the 1960s.", [["cell cultures", "ANATOMY", 171, 184], ["SARS", "DISEASE", 23, 27], ["avian influenza", "DISEASE", 29, 44], ["human metapneumovirus infectionBeginning", "DISEASE", 50, 90], ["respiratory viruses", "DISEASE", 104, 123], ["avian influenza", "ORGANISM", 29, 44], ["human metapneumovirus", "ORGANISM", 50, 71], ["cell cultures", "CELL", 171, 184], ["cell cultures", "CELL_LINE", 171, 184], ["avian influenza", "SPECIES", 29, 44], ["human", "SPECIES", 50, 55], ["metapneumovirus", "SPECIES", 56, 71], ["human metapneumovirus", "SPECIES", 50, 71], ["Metapneumovirus humano", "TREATMENT", 0, 22], ["SARS", "PROBLEM", 23, 27], ["avian influenza", "PROBLEM", 29, 44], ["human metapneumovirus infectionBeginning", "PROBLEM", 50, 90], ["respiratory viruses", "PROBLEM", 104, 123], ["cell cultures", "TEST", 171, 184], ["the coronaviruses", "PROBLEM", 199, 216], ["metapneumovirus", "OBSERVATION", 56, 71], ["coronaviruses", "OBSERVATION", 203, 216]]], ["No new respiratory viruses were discovered until 2001 when human metapneumovirus was found in respiratory specimens from children with bronchiolitis.", [["respiratory specimens", "ANATOMY", 94, 115], ["bronchiolitis", "DISEASE", 135, 148], ["human", "ORGANISM", 59, 64], ["metapneumovirus", "ORGANISM", 65, 80], ["children", "ORGANISM", 121, 129], ["human", "SPECIES", 59, 64], ["children", "SPECIES", 121, 129], ["human metapneumovirus", "SPECIES", 59, 80], ["new respiratory viruses", "PROBLEM", 3, 26], ["human metapneumovirus", "PROBLEM", 59, 80], ["bronchiolitis", "PROBLEM", 135, 148], ["new", "OBSERVATION_MODIFIER", 3, 6], ["respiratory viruses", "OBSERVATION", 7, 26], ["metapneumovirus", "OBSERVATION", 65, 80], ["respiratory", "ANATOMY", 94, 105], ["bronchiolitis", "OBSERVATION", 135, 148]]], ["A year later, in November 2002, severe acute respiratory syndrome (SARS) suddenly appeared as atypical pneumonia.", [["acute respiratory syndrome", "DISEASE", 39, 65], ["SARS", "DISEASE", 67, 71], ["pneumonia", "DISEASE", 103, 112], ["severe acute respiratory syndrome", "PROBLEM", 32, 65], ["SARS", "PROBLEM", 67, 71], ["atypical pneumonia", "PROBLEM", 94, 112], ["severe", "OBSERVATION_MODIFIER", 32, 38], ["acute", "OBSERVATION_MODIFIER", 39, 44], ["respiratory syndrome", "OBSERVATION", 45, 65], ["atypical", "OBSERVATION_MODIFIER", 94, 102], ["pneumonia", "OBSERVATION", 103, 112]]], ["A novel virus belonging to the Coronaviridae family was found to be a cause of this infection.", [["infection", "DISEASE", 84, 93], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 31, 44], ["A novel virus", "PROBLEM", 0, 13], ["this infection", "PROBLEM", 79, 93], ["infection", "OBSERVATION", 84, 93]]], ["In 2004, a second coronavirus was discovered (CoV-NL63) and in 2005 a third new coronavirus was described (CoV-HKU1).", [["coronavirus", "ORGANISM", 18, 29], ["CoV", "ORGANISM", 46, 49], ["coronavirus", "ORGANISM", 80, 91], ["CoV", "ORGANISM", 107, 110], ["a second coronavirus", "PROBLEM", 9, 29], ["CoV", "TEST", 46, 49], ["a third new coronavirus", "PROBLEM", 68, 91], ["CoV", "TEST", 107, 110], ["coronavirus", "OBSERVATION", 80, 91]]], ["In addition, several subtypes of the polimerasa que est\u00e1 dividido en 2 ORF.", [["ORF", "DNA", 71, 74], ["the polimerasa", "TEST", 33, 47]]], ["Cada uno de los ORF (ORF1 y ORF2) codifica 2 poliprote\u00ednas mediante un proceso cotraduccional.", [["los ORF", "DNA", 12, 19], ["ORF1", "DNA", 21, 25], ["ORF2", "DNA", 28, 32], ["proceso cotraduccional", "DNA", 71, 93], ["ORF1 y ORF2", "TREATMENT", 21, 32], ["los ORF", "OBSERVATION", 12, 19]]], ["En el CoV-SRAG no se ha encontrado el gen de la hemaglutininaesterasa, presente en el grupo 2 y en algunos coronavirus del grupo 3.Epidemiolog\u00edaEn noviembre de 2002, empezaron a aparecer en Guandong, provincia de China, los primeros casos de SRAG, una nueva enfermedad que no fue reconocida hasta el mes de febrero de 2003.", [["En el CoV", "TEST", 0, 9]]], ["El 5 de julio la OMS declar\u00f3 que la cadena de infecci\u00f3n se hab\u00eda interrumpido.", [["El 5 de julio", "CHEMICAL", 0, 13]]], ["Seg\u00fan datos del 31 de diciembre de 2003, aproximadamente 8.096 personas se vieron afectadas en 26 pa\u00edses y se contabilizaron 774 muertes, la mayor\u00eda en China con afectaci\u00f3n del personal sanitario que ascendi\u00f3 a 1.706 personas.", [["aproximadamente", "TEST", 41, 56]]], ["Solamente en uno de estos accidentes hubo transmisi\u00f3n secundaria ajena al laboratorio.", [["Solamente", "TREATMENT", 0, 9]]], ["El cuarto incidente se extendi\u00f3 a 4 personas en Guangzhou, Provincia de Guangdong (China), que se atribuyeron a una exposici\u00f3n con un animal infectado o por fuentes medioambientales.Epidemiolog\u00edaLa transmisi\u00f3n nosocomial es una de las caracter\u00edsticas m\u00e1s importantes del brote de SRAG.", [["Epidemiolog\u00edaLa", "PROBLEM", 182, 197]]], ["No existe evidencia de transmisi\u00f3n de la infecci\u00f3n antes de desarrollar los s\u00edntomas.Epidemiolog\u00edaBas\u00e1ndose en los cuadros cl\u00ednicos de los pacientes de Canad\u00e1, China, Hong Kong, Singapur, Vietnam y Estados Unidos el porcentaje de mortalidad var\u00eda entre el 0 y el 50%, dependiendo del grupo de edad.", [["los s\u00edntomas", "OBSERVATION", 72, 84]]], ["Se ha asociado mayor mortalidad en hombres que en mujeres.Epidemiolog\u00edaTras la contenci\u00f3n del brote mundial de SRAG en el verano de 2003, la posibilidad de la reaparici\u00f3n de la enfermedad sigue siendo una gran preocupaci\u00f3n para los sistemas sanitarios.", [["Se", "CHEMICAL", 0, 2], ["Epidemiolog\u00edaTras", "TEST", 58, 75]]], ["Estas fases condicionan los niveles de actividad y se definen como: fase 0, ausencia de la circulaci\u00f3n del CoV-SRAG en poblaciones humanas; fase 1, detecci\u00f3n de casos espor\u00e1dicos en humanos; fase 2, cadenas de transmisi\u00f3n entre humanos a nivel local o a nivel de provincia; fase 3, evidencia de una extensi\u00f3n de la enfermedad a nivel internacional; fase 4, per\u00edodo postepid\u00e9mico con disminuci\u00f3n del n\u00famero de casos, y fase 5, no circulaci\u00f3n del CoV-SRAG (tabla 1).PatogeniaSe cree que el CoV-SRAG es un virus animal que cruz\u00f3 la barrera interespecie y fue capaz de infectar a seres humanos debido a cambios ecol\u00f3gicos o a cambios en el comportamiento de los humanos que incrementaron las posibilidades para que se produjera una exposici\u00f3n al virus o una adaptaci\u00f3n de este, permitiendo una transmisi\u00f3n entre humanos 8 .", [["ausencia", "TEST", 76, 84], ["CoV", "TEST", 107, 110], ["SRAG", "TEST", 111, 115], ["humanas", "TEST", 131, 138], ["fase", "TEST", 140, 144], ["fase", "TEST", 349, 353], ["PatogeniaSe", "TEST", 464, 475], ["el CoV", "TEST", 485, 491], ["SRAG", "TEST", 492, 496]]], ["Estos mercados constituyen una interfase para la transmisi\u00f3n interespecie del virus desde los animales al hombre.", [["Estos", "TEST", 0, 5]]], ["Se ha demostrado que el CoV-SRAG replica en ratones BALB/c, h\u00e1msteres y mono verde africano, tras la administraci\u00f3n a trav\u00e9s del tracto respiratorio.", [["el CoV", "TEST", 21, 27]]], ["La replicaci\u00f3n del virus alcanza pronto un m\u00e1ximo de carga viral que se aclara r\u00e1pidamente en ausencia de enfermedad cl\u00ednica.", [["La replicaci\u00f3n del virus alcanza pronto un m\u00e1ximo", "TREATMENT", 0, 49]]], ["Esta replicaci\u00f3n viral est\u00e1 acompa\u00f1ada por enfermedad pulmonar en los h\u00e1msteres y en el mono verde africano.", [["Esta replicaci\u00f3n", "TEST", 0, 16]]], ["Los ratones infectados, h\u00e1msteres y primates no humanos desarrollan una respuesta de anticuerpos neutralizantes en suero y est\u00e1n protegidos de la reinfecci\u00f3n 28 d\u00edas despu\u00e9s de la infecci\u00f3n primaria.", [["Los ratones infectados", "PROBLEM", 0, 22]]], ["Estos modelos se utilizar\u00e1n para investigar aspectos todav\u00eda no claros de la patogenia del SRAG.PatogeniaComo en otras infecciones respiratorias virales, la gran variaci\u00f3n encontrada en la patogenia del SRAG puede ser el resultado de una respuesta proinflamatoria del hu\u00e9sped frente al virus.", [["PatogeniaComo", "TEST", 96, 109], ["respiratorias", "TEST", 131, 144], ["virales", "TEST", 145, 152], ["la gran variaci\u00f3n", "TEST", 154, 171]]], ["En los casos leves la respuesta del interfer\u00f3n es alta en las primeras 48 h y va disminuyendo durante el curso de los siguientes 8 d\u00edas.PatogeniaAtendiendo al cuadro cl\u00ednico, el sistema respiratorio es la primera diana del CoV-SRAG, siendo los pulmones los \u00f3rganos principalmente afectados 3,10,11 .", [["SRAG", "PROBLEM", 227, 231], ["afectados", "TEST", 280, 289]]], ["Recientemente se est\u00e1 trabajando en la afectaci\u00f3n del aparato digestivo 12 .Definici\u00f3n de caso (tabla 2)Primera semana de infecci\u00f3n.", [["Recientemente se est\u00e1 trabajando en la afectaci\u00f3n del aparato digestivo", "TREATMENT", 0, 71], ["Definici\u00f3n de caso (tabla", "TREATMENT", 76, 101]]], ["Los s\u00edntomas m\u00e1s comunes son: fiebre, mialgia, dolor de cabeza y rigidez.", [["mialgia", "PROBLEM", 38, 45]]], ["No existe un s\u00edntoma o grupos de s\u00edntomas espec\u00edficos, aunque la fiebre es el s\u00edntoma m\u00e1s com\u00fan, pero puede no presentarse.Definici\u00f3n de caso (tabla 2)Segunda semana de infecci\u00f3n.", [["Definici\u00f3n de caso (tabla", "TREATMENT", 123, 148]]], ["Se caracteriza por una instauraci\u00f3n de un cuadro respiratorio con tos, que en un principio es seca, disnea y diarrea.", [["Se", "CHEMICAL", 0, 2], ["disnea y diarrea", "PROBLEM", 100, 116]]], ["Hasta el 70% de los pacientes desarrollan diarrea acuosa con gran volumen de sangre y moco.", [["Hasta el", "TEST", 0, 8]]], ["Se ha comprobado que durante esta semana se produce la transmisi\u00f3n a personas sanas.Definici\u00f3n de caso (tabla 2)Casos geri\u00e1tricos, pedi\u00e1tricos y embarazo.", [["Se", "CHEMICAL", 0, 2], ["Definici\u00f3n de caso (tabla", "TREATMENT", 84, 109], ["Casos geri\u00e1tricos", "TREATMENT", 112, 129], ["pedi\u00e1tricos y embarazo", "TREATMENT", 131, 153]]], ["Tanto en ni\u00f1os como en ancianos las situaciones cr\u00f3nicas y la mayor visita al m\u00e9dico de cabecera y hospitales, enmascararon la transmisi\u00f3n nosocomial al principio del brote de SRAG.", [["Tanto en ni\u00f1os como", "TREATMENT", 0, 19], ["enmascararon la", "TREATMENT", 111, 126]]], ["En los Casas ni\u00f1os, el SRAG es una infecci\u00f3n de gravedad media 13 .", [["En los Casas ni\u00f1os", "TREATMENT", 0, 18]]], ["Existen muy pocos estudios en mujeres embarazadas pero se sugiere que existe riesgo de aborto si la infecci\u00f3n se produce al principio del embarazo y mortalidad de la madre si se produce al final.Definici\u00f3n de caso (tabla 2)Hallazgos radiol\u00f3gicos.", [["muy pocos estudios en mujeres embarazadas", "TREATMENT", 8, 49], ["riesgo de aborto si la infecci\u00f3n", "TREATMENT", 77, 109], ["al principio del embarazo y mortalidad", "TREATMENT", 121, 159], ["Definici\u00f3n de caso (tabla 2)Hallazgos radiol\u00f3gicos", "TREATMENT", 195, 245]]], ["Seg\u00fan avanza la infecci\u00f3n se visualiza una consolidaci\u00f3n que empieza con una lesi\u00f3n perif\u00e9rica unilateral que progresa a m\u00faltiples lesiones.", [["Seg\u00fan avanza la infecci\u00f3n", "PROBLEM", 0, 25], ["a m\u00faltiples lesiones", "PROBLEM", 119, 139]]], ["Las observaciones durante los estados m\u00e1s avanzados incluyen neumot\u00f3rax y fibrosis subpleural.Definici\u00f3n de caso (tabla 2)SRAG en m\u00e9dicos y en trabajadores sanitarios.", [["fibrosis", "DISEASE", 74, 82], ["neumot\u00f3rax y fibrosis subpleural", "PROBLEM", 61, 93], ["Definici\u00f3n de caso (tabla", "TREATMENT", 94, 119], ["SRAG en m\u00e9dicos y en trabajadores sanitarios", "TREATMENT", 122, 166], ["fibrosis", "OBSERVATION", 74, 82], ["subpleural", "ANATOMY_MODIFIER", 83, 93]]], ["Se debe realizar una b\u00fasqueda exhaustiva del origen de la infecci\u00f3n y de las posibles causas de la trasmisi\u00f3n basadas en la monitorizaci\u00f3n de todo el equipo m\u00e9dico.Diagn\u00f3sticoDefinici\u00f3n de caso confirmado: una persona que presenta alg\u00fan resultado de laboratorio positivo a CoV-SRAG por cualquiera de las t\u00e9cnicas validadas que se comentan seguidamente y realizadas en un laboratorio que tenga capacidad de realizar este tipo de an\u00e1lisis.Diagn\u00f3stico diferencialComo en el resto de las infecciones respiratorias, los s\u00edntomas cl\u00ednicos no permiten establecer un diagn\u00f3stico de la infecci\u00f3n debido a que son inespec\u00edficos.", [["a CoV", "TEST", 271, 276]]], ["El diagn\u00f3stico diferencial de la infecci\u00f3n de SRAG incluye pat\u00f3genos comunes de la infecci\u00f3n respiratoria como son los virus de la gripe, el virus respiratorio sincitial (VRS), parainfluenzavirus, adenovirus y otros coronavirus humanos (CoV-229E y CoV-OC43).", [["adenovirus y otros coronavirus", "ORGANISM", 197, 227], ["otros coronavirus", "SPECIES", 210, 227], ["adenovirus y otros coronavirus", "SPECIES", 197, 227], ["CoV-229E y CoV-OC43", "SPECIES", 237, 256], ["el virus respiratorio", "TEST", 138, 159], ["parainfluenzavirus", "PROBLEM", 177, 195], ["adenovirus", "PROBLEM", 197, 207], ["CoV", "TEST", 237, 240]]], ["Adem\u00e1s, se investiga la presencia de bacterias incluidas en los protocolos de diagn\u00f3stico de una neumon\u00eda.", [["una neumon\u00eda", "OBSERVATION", 93, 105]]], ["As\u00ed, hay que descartar la presencia de Streptococcus pneumoniae y Haemophilus influenzae como agentes causales de la neumon\u00eda \"t\u00edpica\" que se acompa\u00f1a de los mismos s\u00edntomas cl\u00ednicos (fiebre, cuadro respiratorio, tos y disnea) y que, en general, responde bien al tratamiento antibi\u00f3tico.", [["Streptococcus pneumoniae", "PROBLEM", 39, 63], ["Haemophilus influenzae", "PROBLEM", 66, 88], ["al tratamiento antibi\u00f3tico", "TREATMENT", 260, 286]]], ["Los microorganismos m\u00e1s comunes incluyen Mycoplasma pneumoniae, Chlamydia spp., Legionella pneumophila y Coxiella burnetii.Diagn\u00f3stico de laboratorioA lo largo de estos \u00faltimos a\u00f1os (2003-2005) se ha avanzado en la consolidaci\u00f3n del diagn\u00f3stico etiol\u00f3gico del SRAG.", [["Chlamydia spp.", "DISEASE", 64, 78], ["Legionella pneumophila", "DISEASE", 80, 102], ["Coxiella burnetii", "DISEASE", 105, 122], ["Los", "ORGANISM", 0, 3], ["microorganismos m\u00e1s comunes incluyen Mycoplasma pneumoniae", "ORGANISM", 4, 62], ["Chlamydia spp.", "ORGANISM", 64, 78], ["Legionella pneumophila", "ORGANISM", 80, 102], ["Coxiella burnetii", "ORGANISM", 105, 122], ["Mycoplasma pneumoniae", "SPECIES", 41, 62], ["Chlamydia spp.", "SPECIES", 64, 78], ["Legionella pneumophila", "SPECIES", 80, 102], ["Coxiella burnetii", "SPECIES", 105, 122], ["Mycoplasma pneumoniae", "SPECIES", 41, 62], ["Chlamydia spp.", "SPECIES", 64, 78], ["Legionella pneumophila", "SPECIES", 80, 102], ["Coxiella burnetii", "SPECIES", 105, 122], ["Los microorganismos", "TEST", 0, 19], ["m\u00e1s", "TEST", 20, 23], ["comunes", "TEST", 24, 31], ["Mycoplasma pneumoniae", "PROBLEM", 41, 62], ["Chlamydia spp.", "PROBLEM", 64, 78], ["Legionella pneumophila y Coxiella burnetii", "PROBLEM", 80, 122], ["ha avanzado en la consolidaci\u00f3n", "TREATMENT", 197, 228], ["Mycoplasma pneumoniae", "OBSERVATION", 41, 62], ["Coxiella burnetii", "OBSERVATION", 105, 122]]], ["Han aparecido nuevos ensayos y las t\u00e9cnicas iniciales se han modificado para ser m\u00e1s sensibles y m\u00e1s espec\u00edficas, dado que el conocimiento del virus cada vez es mayor.Diagn\u00f3stico de laboratorioLas aproximaciones fundamentales son: a) detecci\u00f3n de ARN espec\u00edfico del CoV-SRAG para alcanzar una detecci\u00f3n temprana y r\u00e1pida de la infecci\u00f3n en los casos sospechosos, y b) an\u00e1lisis serol\u00f3gicos para la confirmaci\u00f3n de la presencia de inmunoglobulinas M y G (IgM e IgG) espe c\u00edficas que permitan establecer estudios de seroprevalencia en una poblaci\u00f3n, en un centro m\u00e9dico o en una residencia.Diagn\u00f3stico de laboratorioEl aislamiento del virus en cultivo celular es muy dif\u00edcil y es necesario realizar todo el proceso en laboratorios de seguridad biol\u00f3gica de nivel 3.", [["CoV", "TEST", 266, 269], ["SRAG", "TEST", 270, 274], ["para", "TEST", 275, 279], ["IgM e IgG", "TEST", 453, 462], ["Diagn\u00f3stico de laboratorioEl aislamiento del virus", "TREATMENT", 587, 637]]], ["Se debe utilizar un m\u00e9todo validado de amplificaci\u00f3n gen\u00f3mica (RT-PCR).", [["Se debe utilizar un m\u00e9todo validado", "TREATMENT", 0, 35]]], ["Un resultado positivo ser\u00e1 informado si: a) es positivo en dos muestras cl\u00ednicas diferentes (p. ej., exudado nasofar\u00edngeo, heces, plasma), o b) utilizando la misma muestra cl\u00ednica pero tomada en diferentes d\u00edas de la infecci\u00f3n, o c) ensayos diferentes de un mismo m\u00e9todo de RT-PCR usando ARN extra\u00eddo en dos veces diferentes a partir de una \u00fanica muestra cl\u00ednica.Diagn\u00f3stico de laboratorio2.", [["plasma", "ORGANISM_SUBSTANCE", 130, 136]]], ["Se deben analizar muestras de suero tomadas en la fase aguda y en la fase convaleciente de la infecci\u00f3n o se debe obtener un aumento de t\u00edtulo de anticuerpos de cuatro veces (seroconversi\u00f3n) entre la fase aguda y la convaleciente.Diagn\u00f3stico de laboratorioSe han desarrollado ensayos comerciales tanto para la detecci\u00f3n de ARN viral en muestras cl\u00ednicas como para la determinaci\u00f3n de anticuerpos IgG frente a CoV-SRAG en suero.Interpretaci\u00f3n de los resultados de laboratorioEs muy importante saber que un diagn\u00f3stico de laboratorio nunca se basa en un resultado positivo obtenido por un \u00fanico m\u00e9todo de diagn\u00f3stico, o en una \u00fanica muestra en una \u00fanica determinaci\u00f3n.Interpretaci\u00f3n de los resultados de laboratorioEl tipo de muestra cl\u00ednica condiciona el diagn\u00f3stico, ya que los m\u00e9todos dependen crucialmente de la muestra cl\u00ednica, tanto de la toma como de la rapidez del transporte al laboratorio.", [["Se deben analizar muestras", "TREATMENT", 0, 26], ["desarrollado", "TEST", 263, 275]]], ["La posibilidad de detectar ARN viral en las muestras cl\u00ednicas mediante RT-PCR debe ser un proceso organizado en el que todos los profesionales sanitarios y no sanitarios trabajen en equipo.Interpretaci\u00f3n de los resultados de laboratorioLa existencia de seroconversi\u00f3n o de un aumento del t\u00edtulo de anticuerpos en un paciente puede no ir acompa\u00f1ado de un resultado positivo de RT-PCR por haber habido un aclaramiento viral o por un mal almacenamiento de la muestra.TratamientoEl primer tratamiento antibi\u00f3tico de los pacientes con sospecha de SRAG se instaura a la recepci\u00f3n del paciente en el hospital con objeto de tratar la posible neumon\u00eda asociada a la comunidad o la neumon\u00eda at\u00edpica, con las que se puede confundir.", [["La posibilidad", "TEST", 0, 14], ["PCR", "TEST", 74, 77], ["TratamientoEl primer", "TREATMENT", 464, 484]]], ["Si no existe una respuesta positiva a este tratamiento se evidencia una sospecha a\u00fan mayor del caso.", [["Si", "CHEMICAL", 0, 2]]], ["CasasProfilaxisGracias a la experiencia en la preparaci\u00f3n de vacunas de coronavirus animales, el desarrollo de las vacunas frente a SRAG ha partido de una posici\u00f3n muy ventajosa.", [["coronavirus animales", "DISEASE", 72, 92], ["Casas", "TEST", 0, 5], ["a la experiencia en la preparaci\u00f3n", "TREATMENT", 23, 57]]], ["Sin embargo, una alternativa a estas vacunas que en definitiva utilizan virus vivo, son las basadas en la introducci\u00f3n de modificaciones en el genoma viral para evitar el peligro de reversi\u00f3n al \"virus salvaje\".", [["una alternativa a estas vacunas", "TREATMENT", 13, 44]]], ["Tambi\u00e9n se est\u00e1 trabajando en el uso de virus de bajo poder patog\u00e9nico para la producci\u00f3n masiva de virus recombinantes que posean determinados genes seleccionados que codifiquen para prote\u00ednas de superficie implicadas en la producci\u00f3n de la respuesta inmunitaria 14 .", [["Tambi\u00e9n se est\u00e1 trabajando en el uso de virus", "TREATMENT", 0, 45], ["para la producci\u00f3n masiva", "TREATMENT", 71, 96]]], ["Los principales esfuerzos se centran actualmente en la glucoprote\u00edna de la c\u00e1psida del CoV-SRAG, prote\u00edna S o de la esp\u00edcula, que se une al receptor celular ACE2 en el inicio de la infecci\u00f3n, por lo que se considera un ant\u00edgeno prometedor para el desarrollo de una vacuna anti-SRAG.Gripe aviarEl subtipo H5N1 del virus de la gripe A se ha considerado siempre como un pat\u00f3geno exclusivo de las aves hasta que en 1997 se detectaron los primeros casos de infecci\u00f3n en seres humanos, en un brote ocurrido en Hong Kong.", [["Gripe aviarEl subtipo H5N1", "ORGANISM", 282, 308], ["Los principales", "TEST", 0, 15], ["esfuerzos", "TEST", 16, 25], ["centran", "TEST", 29, 36], ["actualmente", "TEST", 37, 48], ["CoV", "TEST", 87, 90], ["SRAG", "PROBLEM", 91, 95], ["prote\u00edna S o de la esp\u00edcula", "TREATMENT", 97, 124], ["que se une al receptor celular ACE2 en el inicio de la infecci\u00f3n", "TREATMENT", 126, 190]]], ["En aquella ocasi\u00f3n fueron hospitalizadas 18 personas con s\u00edntomas de infecci\u00f3n respiratoria aguda y seis de ellas fallecieron.", [["En aquella ocasi\u00f3n fueron hospitalizadas", "TREATMENT", 0, 40]]], ["Los estudios epidemiol\u00f3gicos y moleculares que se realizaron demostraban por primera vez que la transmisi\u00f3n del virus aviar se hab\u00eda producido directamente desde aves a personas.", [["Los estudios", "TEST", 0, 12]]], ["La capacidad del subtipo H5N1 para infectar directamente al ser humano se ha podido demostrar recientemente en otras dos ocasiones.", [["La capacidad del subtipo", "TREATMENT", 0, 24], ["al ser humano se ha podido demostrar recientemente", "TREATMENT", 57, 107]]], ["Por otra, en enero de 2004 las autoridades sanitarias de Vietnam y Tailandia informan de los primeros casos humanos de infecci\u00f3n por el virus de la gripe aviar H5N1.", [["gripe aviar H5N1", "ORGANISM", 148, 164], ["H5N1", "PROBLEM", 160, 164]]], ["Estas cifras, que se corresponden con el n\u00famero de casos oficialmente reconocidos por la OMS, con toda probabilidad no representan la verdadera magnitud de los casos de infecci\u00f3n.Gripe aviarTodos los casos humanos descritos hasta ahora han estado precedidos por brotes de gripe aviar H5N1 altamente patog\u00e9nica existentes en las explotaciones av\u00edcolas del entorno.", [["H5N1 altamente patog\u00e9nica existentes", "TREATMENT", 284, 320]]], ["Obviamente, cuanto m\u00e1s se prolongue la presencia del subtipo H5N1 en las aves dom\u00e9sticas, tanto mayores ser\u00e1n las oportunidades para que ocurran m\u00e1s casos de infecci\u00f3n en seres humanos, as\u00ed como para que aparezca un virus con potencial pand\u00e9mico.", [["Obviamente", "TEST", 0, 10]]], ["En este escenario sin precedentes el riesgo de aparici\u00f3n de una cepa de virus influenza pand\u00e9mico es evidente, y la OMS ya est\u00e1 alertando de ello.Potencial pand\u00e9mico del virus H5N1Un virus de la gripe A pand\u00e9mico puede generarse de dos maneras.", [["pand\u00e9mico del virus H5N1Un virus", "ORGANISM", 156, 188], ["Potencial pand\u00e9mico del virus", "TREATMENT", 146, 175]]], ["Una de ellas ser\u00eda mediante el intercambio (del ingl\u00e9s reassortment) de material gen\u00e9tico entre dos subtipos diferentes (en este caso entre el subtipo H5N1 y cualquiera de los dos subtipos que infectan habitualmente al hombre, H1N1 o H3N2) cuando coinfectan una misma c\u00e9lula, tal y como ya ocurri\u00f3 en las pandemias de 1957 y 1968.", [["Una de ellas ser\u00eda mediante el intercambio (del ingl\u00e9s reassortment", "TREATMENT", 0, 67], ["H3N2", "PROBLEM", 234, 238]]], ["La otra forma ser\u00eda por mutaciones puntuales en el genoma del subtipo H5N1 en su proceso de adaptaci\u00f3n a nuevos hospedadores, sea el ser humano u otros mam\u00edferos.Potencial pand\u00e9mico del virus H5N1Para el comienzo de una nueva pandemia por el virus de la gripe se han identificado tres prerrequisitos.", [["Potencial pand\u00e9mico del virus", "TEST", 162, 191]]], ["Y tercero, el nuevo virus deber\u00eda poder transmitirse persona-persona de manera efectiva.", [["el nuevo virus", "ORGANISM", 11, 25], ["deber\u00eda poder transmitirse persona-persona de manera efectiva", "ORGANISM", 26, 87], ["nuevo virus", "SPECIES", 14, 25], ["transmitirse persona", "SPECIES", 40, 60], ["Y tercero", "SPECIES", 0, 9]]], ["El tercero, afortunadamente, a\u00fan no se ha observado.Potencial pand\u00e9mico del virus H5N1Hasta ahora pr\u00e1cticamente todos los casos de infecci\u00f3n en seres humanos se han atribuido a la transmisi\u00f3n directa del virus desde las aves al hombre, bien por contacto directo con aves infectadas, bien con material contaminado por sus excreciones, descart\u00e1ndose la transmisi\u00f3n efectiva de persona a persona.", [["Potencial pand\u00e9mico del virus", "PROBLEM", 52, 81], ["a la transmisi\u00f3n", "TREATMENT", 175, 191]]], ["Por supuesto, los casos puntuales de transmisi\u00f3n persona a persona no deber\u00edan entenderse como ejemplos de transmisi\u00f3n efectiva entre personas, que se reflejar\u00e1 como la existencia de varias cadenas de transmisi\u00f3n sostenidas en el tiempo causando brotes comunitarios relativamente amplios en cuanto al n\u00famero de personas afectadas.Potencial pand\u00e9mico del virus H5N1La transmisi\u00f3n no efectiva de persona a persona era algo que ya pon\u00edan de manifiesto los estudios serol\u00f3gicos que se realizaron despu\u00e9s del brote de Hong Kong en 1997, donde se observaba una mayor tasa de seropositivos espec\u00edficos para el subtipo H5 en familiares de personas infectadas 16 , as\u00ed como en los profesionales sanitarios expuestos a pacientes infectados 17 .Etiolog\u00edaLos virus de la gripe pertenecen a la familia Orthomyxoviridae, y se caracterizan por contener un genoma segmentado constituido por ocho fragmentos de ARN en el caso de los tipos A y B y siete en el tipo C, y de polaridad negativa.", [["Etiolog\u00edaLos virus", "PROBLEM", 734, 752], ["a la familia Orthomyxoviridae", "TREATMENT", 776, 805], ["A y B y siete en el tipo C", "TREATMENT", 922, 948]]], ["Los virus de la gripe tipos A y B causan epidemias de gripe pr\u00e1cticamente cada a\u00f1o, sin embargo, el ti po C, que causa infecci\u00f3n respiratoria leve, no produce epidemias.", [["Los virus", "PROBLEM", 0, 9], ["epidemias", "PROBLEM", 159, 168], ["no", "UNCERTAINTY", 148, 150], ["epidemias", "OBSERVATION", 159, 168]]], ["Hasta el momento se han identificado 16 hemaglutininas y 9 neuraminidasas diferentes, que se combinan entre s\u00ed generando una amplia variedad de subtipos virales.", [["hemaglutininas", "TEST", 40, 54], ["subtipos virales", "OBSERVATION", 144, 160]]], ["En la actualidad dos subtipos, H1N1 y H3N2, son los que infectan habitualmente al ser humano, aunque recientemente el espectro se ha ampliado con los casos de infecci\u00f3n por los subtipos H5N1, H7N7 (Holanda), H7N3 (Canad\u00e1) y H9N2 (China).Epidemiolog\u00edaTodos los subtipos conocidos del virus de la gripe A est\u00e1n presentes en aves acu\u00e1ticas, en particular en patos silvestres, que constituyen su hospedador natural.", [["H1N1 y H3N2", "DISEASE", 31, 42], ["H5N1", "PROBLEM", 186, 190], ["H7N7 (Holanda)", "TREATMENT", 192, 206], ["H7N3 (Canad\u00e1)", "TREATMENT", 208, 221], ["Epidemiolog\u00edaTodos los", "PROBLEM", 237, 259], ["del virus", "PROBLEM", 279, 288]]], ["Estas aves est\u00e1n perfectamente adaptadas a los diferentes subtipos del virus de la gripe de manera que no muestran ning\u00fan s\u00edntoma de enfermedad cuando est\u00e1n infectadas, limit\u00e1ndose \u00fanicamente a excretar virus en sus heces.", [["Estas", "TEST", 0, 5]]], ["La conducta migratoria de estos animales y la gran resistencia que muestran los virus de la gripe en el agua desempe\u00f1an un papel muy importante en la dispersi\u00f3n de los virus y en la infecci\u00f3n, por contacto directo o indirecto, de las aves de explotaciones av\u00edcolas, principalmente pollos y pavos, que son especialmente susceptibles.", [["La conducta migratoria", "PROBLEM", 0, 22]]], ["Las aves dom\u00e9sticas infectadas excretan grandes cantidades de virus en las heces y en secreciones nasales y oculares.", [["Las aves dom\u00e9sticas", "TEST", 0, 19]]], ["Cuando la densidad de animales es elevada la transmisi\u00f3n a\u00e9rea tambi\u00e9n puede llegar a ser importante.Epidemiolog\u00edaSeg\u00fan la gravedad de la enfermedad observada en las aves dom\u00e9sticas, el virus de la gripe aviar puede ser de alta virulencia (HPAI, del ingl\u00e9s highly pathogenic avian influenza), causante de una enfermedad aguda con una elevada tasa de mortalidad en aves, o de baja virulencia (LPAI, del ingl\u00e9s low pathogenic avian influenza), bastante m\u00e1s com\u00fan y que causa, en general, una enfermedad leve, que puede incluso pasar desapercibida si no se realiza una vigilancia activa con regularidad.", [["avian influenza", "DISEASE", 275, 290], ["avian influenza", "DISEASE", 424, 439], ["Epidemiolog\u00edaSeg\u00fan", "TEST", 101, 119], ["el virus", "PROBLEM", 183, 191], ["ser de alta virulencia", "PROBLEM", 216, 238], ["HPAI", "PROBLEM", 240, 244], ["influenza", "PROBLEM", 281, 290], ["del ingl\u00e9s low pathogenic avian influenza)", "PROBLEM", 398, 440], ["alta virulencia", "OBSERVATION", 223, 238]]], ["No obstante, todas las variantes altamente patog\u00e9nicas identificadas pertenecen a los subtipos H5 y H7.", [["obstante", "PROBLEM", 3, 11]]], ["Hasta ahora se pensaba que no hab\u00eda un reservorio natural para las variantes HPAI, y que estas surg\u00edan por mutaciones producidas en variantes LPAI despu\u00e9s de haber infectado a las aves dom\u00e9sticas a lo largo de un per\u00edodo de tiempo impredecible.", [["Hasta ahora", "TEST", 0, 11]]], ["No obstante, en el brote del sudeste asi\u00e1tico se ha demostrado por primera vez la existencia de aves acu\u00e1ticas y otras aves migratorias infectadas con la variante HPAI del virus sin mostrar signos de enfermedad, sugiriendo que la evoluci\u00f3n y mantenimiento de estas cepas virulentas en esta regi\u00f3n podr\u00eda estar cambiando, con tendencia a establecerse de manera permanente en determinadas zonas de Asia.Epidemiolog\u00edaSin duda, uno de los hallazgos m\u00e1s sorprendentes es que el virus H5N1 ha ampliado su rango de animales con susceptibilidad de ser infectados a determinadas especies de mam\u00edferos, como tigres 18 y cerdos 19 infectados de manera natural, as\u00ed como ratones 20 y gatos 21 , que han podido ser infectados de manera experimental.", [["obstante", "PROBLEM", 3, 11], ["infectadas", "PROBLEM", 136, 146], ["Epidemiolog\u00edaSin duda", "TREATMENT", 401, 422]]], ["No hubo evidencia de transmisi\u00f3n tigre a tigre.", [["hubo", "PROBLEM", 3, 7]]], ["No obstante, cuando fueron infectados experimentalmente otros felinos se pudo evidenciar la existencia de transmisi\u00f3n gato a gato.", [["obstante", "PROBLEM", 3, 11]]], ["La infecci\u00f3n natural de cerdos con el subtipo H5N1 del virus de la gripe es un hallazgo preocupante en tanto que estos poseen receptores en las c\u00e9lulas epiteliales de su tracto respiratorio superior que los hace susceptibles a la infecci\u00f3n por virus aviares y humanos, pudiendo entonces hacer de \"coctelera\" en caso de que un cerdo sea infectado simult\u00e1neamente por un virus aviar y otro humano y fa cilitando el intercambio de material gen\u00e9tico entre am bos.PatogeniaEn aves, la diferencia principal entre una cepa LPAI y otra HPAI es la capacidad de infecci\u00f3n que tienen una y otra.", [["La infecci\u00f3n", "PROBLEM", 0, 12], ["natural de cerdos con el subtipo H5N1 del virus de la gripe", "TREATMENT", 13, 72], ["a la infecci\u00f3n", "PROBLEM", 225, 239], ["PatogeniaEn aves", "PROBLEM", 459, 475]]], ["As\u00ed, las cepas LPAI se limitan a producir una infecci\u00f3n localizada, normalmente en el tracto digestivo, en tanto que las cepas HPAI se caracterizan por provocar una infecci\u00f3n sist\u00e9mica en la que pr\u00e1cticamente todos los \u00f3rganos se ven afectados.", [["As\u00ed", "TEST", 0, 3]]], ["Los mecanismos moleculares por los que se originan cepas HPAI, a partir de cepas LPAI, y que explican estas diferencias en el tropismo por los tejidos, afectan a m\u00e1s de un gen y no se conocen completamente.", [["HPAI", "PROBLEM", 57, 61]]], ["No obstante, se sabe que determinadas mutaciones producidas en el gen de la hemaglutinina, que afectar\u00e1n a su posterior activaci\u00f3n mediante prote\u00f3lisis, est\u00e1n entre los factores responsables.", [["obstante", "PROBLEM", 3, 11]]], ["Podemos diferenciar dos tipos de mutaciones, aquellas que implican una inserci\u00f3n de amino\u00e1cidos b\u00e1sicos (Lys y Arg) en la regi\u00f3n conocida con el nombre de p\u00e9ptido de conexi\u00f3n, y que es el lugar donde se produce la escisi\u00f3n proteol\u00edtica de la hemaglutinina, y aquellas que implican la desaparici\u00f3n de una cadena carbohidratada que en la estructura secundaria de la prote\u00edna se ubica en la vecindad del p\u00e9ptido de conexi\u00f3n 22, 23 .PatogeniaExisten dos clases de proteasas capaces de escindir la hemaglutinina nativa (HA 0 ) en los dos fragmentos (HA 1 y HA 2 ) que hacen que la prote\u00edna sea funcional.", [["Lys y Arg", "CHEMICAL", 105, 114], ["PatogeniaExisten dos clases", "TREATMENT", 429, 456]]], ["El grupo de proteasas similares a la tripsina, que son las \u00fanicas con capacidad para realizar la prote\u00f3lisis de la hemaglutinina de cepas LPAI, se encuentran en un n\u00famero muy reducido de c\u00e9lulas localizadas en el tracto respiratorio de los mam\u00edferos o en el tracto intestinal de las aves.", [["intestinal", "ANATOMY", 265, 275]]], ["Si en Hong Kong en 1997 lleg\u00f3 a ser del 33% (6/18), en el brote del sudeste asi\u00e1tico la cifra llega a ser alarmante y alcanza el 76% (42/55).", [["Si", "CHEMICAL", 0, 2], ["a ser del", "TEST", 30, 39]]], ["Seg\u00fan las series publicadas de pacientes con infecci\u00f3n por H5N1 de Hong Kong 24 y Vietnam 25 se sabe que en las fases iniciales de la infecci\u00f3n no es posible establecer diferencias con la gripe debida a infecci\u00f3n con los subtipos habituales H1N1 o H3N2, observ\u00e1ndose fiebre superior a 38 \u00b0C, tos, disnea, mialgias y dolores articulares.", [["H1N1", "PROBLEM", 241, 245], ["H3N2", "PROBLEM", 248, 252], ["disnea", "PROBLEM", 297, 303]]], ["El tiempo estimado entre la exposici\u00f3n al virus y el inicio de los s\u00edntomas sugiere un per\u00edodo de incubaci\u00f3n que oscila entre 2 y 4 d\u00edas.", [["El tiempo estimado entre la", "TREATMENT", 0, 27]]], ["La neumon\u00eda es primaria, no se debe a sobreinfecci\u00f3n bacteriana.", [["La neumon\u00eda es primaria", "PROBLEM", 0, 23], ["a sobreinfecci\u00f3n bacteriana", "PROBLEM", 36, 63], ["no", "UNCERTAINTY", 25, 27]]], ["Los niveles elevados de transaminasas en suero as\u00ed como las concentraciones anormales de creatinina observados apuntan hacia un deterioro de las funciones hep\u00e1ticas y renal.Manifestaciones cl\u00ednicasEl espectro cl\u00ednico de enfermedades en las que cabe sospechar infecci\u00f3n por H5N1 podr\u00eda ser m\u00e1s amplio.", [["renal", "ANATOMY", 167, 172], ["renal", "ORGAN", 167, 172], ["Los niveles", "TEST", 0, 11], ["renal", "ANATOMY", 167, 172]]], ["En uno de estos casos se pudo incluso aislar un virus viable de las heces, hecho que tiene una enorme repercusi\u00f3n en cuanto a que ampl\u00eda las posibilidades de v\u00edas de transmisi\u00f3n y dificulta el control de la infecci\u00f3n.Diagn\u00f3sticoLas recomendaciones de la OMS para realizar el diagn\u00f3stico de infecci\u00f3n por H5N1 est\u00e1n disponibles en la p\u00e1gina web http://www.who. int/csr/disease/avian_influenza/ guidelines/labtests/en/.", [["csr", "GENE_OR_GENE_PRODUCT", 364, 367], ["int/csr/disease/avian_influenza/ guidelines/labtests/en/.", "SPECIES", 360, 417], ["disease", "PROBLEM", 368, 375], ["disease", "OBSERVATION", 368, 375]]], ["El env\u00edo de las muestras hasta el laboratorio debe realizarse de manera segura en el triple contenedor homologado, cuyas caracter\u00edsticas se pueden revisar en la p\u00e1gina web http://www. who.int/csr/disease/avian_influenza/guidelines/transport/ en/.Diagn\u00f3sticoEl subtipo H5N1 puede ser cultivado en c\u00e9lulas Madin Darby de ri\u00f1\u00f3n de perro, que son las que se utilizan habitualmente para el aislamiento de virus de la gripe.", [["csr", "GENE_OR_GENE_PRODUCT", 192, 195], ["H5N1", "SPECIES", 268, 272], ["Diagn\u00f3sticoEl subtipo H5N1", "TREATMENT", 246, 272], ["ser cultivado", "TREATMENT", 279, 292], ["disease", "OBSERVATION", 196, 203]]], ["El efecto citop\u00e1tico aparece 4-5 d\u00edas despu\u00e9s de inoculado y se debe confirmar realizando una RT-PCR espec\u00edfica del cultivo o fluorescencia utilizando anticuerpos monoclonales espec\u00edficos de subtipo H5.", [["El efecto", "TEST", 0, 9], ["aparece", "TEST", 21, 28], ["una RT", "TEST", 90, 96], ["PCR", "TEST", 97, 100], ["fluorescencia", "PROBLEM", 126, 139]]], ["Estas dos t\u00e9cnicas pueden ser utilizadas tambi\u00e9n para realizar un diagn\u00f3stico r\u00e1pido mediante detecci\u00f3n directa del virus a partir de la muestra cl\u00ednica.", [["Estas dos", "TEST", 0, 9]]], ["El protocolo utilizado de RT-PCR debe haberse optimizado para obtener la m\u00e1xima sensibilidad cuando se realiza partiendo directamente de muestra cl\u00ednica en vez de cultivo celular.", [["PCR", "TEST", 29, 32], ["para", "TEST", 57, 61]]], ["Por \u00faltimo, tambi\u00e9n se puede diagnosticar la infecci\u00f3n por H5N1 mediante ensayos serol\u00f3gicos espec\u00edficos para anticuerpos anti-H5.Diagn\u00f3sticoEs necesario recordar que el cultivo celular o cualquier otra t\u00e9cnica que requiera la propagaci\u00f3n del virus debe realizarse en laboratorios con un nivel 3 de bioseguridad (BSL3), para el resto de t\u00e9cnicas es suficiente con un laboratorio BSL2.TratamientoExisten dos clases de antivirales espec\u00edficos para el tratamiento de la gripe.", [["tambi\u00e9n", "TREATMENT", 12, 19], ["Diagn\u00f3sticoEs", "TEST", 130, 143], ["t\u00e9cnica", "TEST", 203, 210], ["la propagaci\u00f3n del virus", "TEST", 224, 248], ["TratamientoExisten dos clases", "TREATMENT", 384, 413]]], ["La segunda clase de antivirales son los inhibidores de la neuraminidasa, oseltamivir y zanamivir, bastante m\u00e1s caros en cuanto a su producci\u00f3n, que es limitada, y almacenamiento.", [["oseltamivir y zanamivir", "TREATMENT", 73, 96], ["bastante m\u00e1s caros", "TREATMENT", 98, 116]]], ["Oseltamivir (75 mg, 2 veces al d\u00eda, 5 d\u00edas) ha demostrado ser efectivo en los casos de gripe aviar en el ser humano en Vietnam y Tailandia, siempre y cuando sea administrado dentro de los primeros 2 d\u00edas despu\u00e9s del inicio de los s\u00edntomas.", [["Oseltamivir", "CHEMICAL", 0, 11], ["Oseltamivir", "CHEMICAL", 0, 11], ["Oseltamivir", "SIMPLE_CHEMICAL", 0, 11], ["Oseltamivir", "TREATMENT", 0, 11], ["ha demostrado ser efectivo en los casos", "TREATMENT", 44, 83], ["los s\u00edntomas", "OBSERVATION", 226, 238]]], ["Este mismo antiviral est\u00e1 siendo utilizado tambi\u00e9n con fines profil\u00e1cticos (75 mg/d\u00eda, 7 d\u00edas) en familiares de enfermos y personal sanitario expuesto a enfermos.ProfilaxisEn aves, la medida de control de la gripe aviar m\u00e1s efectiva contin\u00faa siendo el sacrificio masivo de aves infectadas y la desinfecci\u00f3n de las explotaciones afectadas.", [["Este mismo antiviral est\u00e1 siendo utilizado tambi\u00e9n con fines profil\u00e1cticos", "TREATMENT", 0, 74], ["ProfilaxisEn aves", "TREATMENT", 162, 179]]], ["No obstante, se puede utilizar la vacunaci\u00f3n como medida suplementaria y es una decisi\u00f3n que debe ser tomada por el gobierno del pa\u00eds afectado.", [["obstante", "PROBLEM", 3, 11]]], ["Las Casas I, Pozo F. S\u00edndrome respiratorio agudo grave, gripe aviar e infecci\u00f3n por metapneumovirus humano 444 Enferm Infecc Microbiol Clin 2005;23 (7):438-48 vacunas disponibles en la actualidad, que se elaboran con virus inactivados, reducen la gravedad y la mortalidad de la infecci\u00f3n, pero las aves infectadas contin\u00faan eliminando virus, de manera que pueden contribuir a que la infecci\u00f3n se haga end\u00e9mica en una determinada regi\u00f3n.", [["metapneumovirus humano", "DISEASE", 84, 106], ["Microbiol Clin", "TEST", 125, 139], ["vacunas", "TEST", 159, 166], ["que se elaboran con virus inactivados", "TREATMENT", 197, 234]]], ["Otro problema que presentan las vacunas actuales es la falta de inmunogenizaci\u00f3n cruzada entre unas cepas virales y otras, un hecho que obliga a utilizar como cepa inmun\u00f3gena la misma cepa causante del brote.", [["cepa", "SPECIES", 184, 188], ["Otro problema", "PROBLEM", 0, 13]]], ["Las vacunas de nueva generaci\u00f3n o recombinantes, a\u00fan no disponibles comercialmente, resolver\u00e1n todos estos problemas.ProfilaxisPor ahora no existe una vacuna espec\u00edfica que pueda prevenir la infecci\u00f3n por gripe H5N1 en el ser humano.", [["Profilaxis", "TEST", 117, 127], ["una vacuna", "TEST", 147, 157]]], ["Aunque se han elaborado vacunas espec\u00edficas utilizando la cepa que ocasion\u00f3 el brote de Hong Kong en 1997, la eficacia de las mismas es, al menos, cuestionable para prevenir la infecci\u00f3n con las cepas que actualmente circulan en el sudeste asi\u00e1tico teniendo en cuenta las variaciones antig\u00e9nicas observadas entre unas y otras cepas 28 .", [["al menos", "TEST", 137, 145]]], ["Se recomienda no obstante la vacunaci\u00f3n de personal de riesgo, como trabajadores de explotaciones av\u00edcolas, trabajadores implicados en el sacrificio de aves o personal sanitario de las zonas afectadas, con la vacuna de la gripe de la temporada en curso, de manera que, aunque s\u00f3lo proteger\u00e1 de infecciones ocasionadas por los subtipos H1 y H3 del virus influenza circulante, se minimizan las posibilidades de coinfecci\u00f3n con una cepa humana y otra aviar.ProfilaxisEn el siglo pasado la carta de presentaci\u00f3n de las pandemias de gripe era, en mayor o menor medida, la aparici\u00f3n repentina de un enorme n\u00famero de casos acompa\u00f1ados de unas tasas de mortalidad y morbilidad muy elevados, provocando adem\u00e1s alarma social, enormes p\u00e9rdidas econ\u00f3micas y el colapso de los sistemas sanitarios en todo el mundo.", [["Se", "CHEMICAL", 0, 2], ["cepa humana", "SPECIES", 429, 440], ["H1 y H3 del virus influenza circulante", "PROBLEM", 335, 373]]], ["No puede predecirse si estamos en el preludio de la primera pandemia de gripe del siglo XXI, pero de ocurrir no deber\u00eda llegar sin que estemos preparados.Infecciones por metapneumovirus humano Etiolog\u00edaEn el a\u00f1o 2001 se descubri\u00f3 un nuevo virus respiratorio tras el estudio de muestras respiratorias de ni\u00f1os en Holanda 29 .", [["metapneumovirus", "ORGANISM", 170, 185], ["metapneumovirus", "SPECIES", 170, 185], ["Infecciones", "PROBLEM", 154, 165]]], ["Este virus nuevo se asign\u00f3 a la familia Paramyxoviridae, subfamilia Pneumovirinae, g\u00e9nero Metapneumovirus, en funci\u00f3n de estudios morfol\u00f3gicos de la part\u00edcula viral por microscopia electr\u00f3nica y por estudios moleculares.", [["a la familia Paramyxoviridae", "TREATMENT", 27, 55], ["subfamilia Pneumovirinae", "TREATMENT", 57, 81], ["g\u00e9nero Metapneumovirus", "PROBLEM", 83, 105]]], ["Se denomin\u00f3 metapneumovirus humano (HMNV).", [["Se", "CHEMICAL", 0, 2], ["metapneumovirus", "ORGANISM", 12, 27], ["metapneumovirus", "SPECIES", 12, 27], ["HMNV", "SPECIES", 36, 40], ["metapneumovirus", "OBSERVATION", 12, 27]]], ["La especie tipo del g\u00e9nero es el metapneumovirus aviar, anteriormente conocido como el virus de la rinotraque\u00edtis del pavo.Infecciones por metapneumovirus humano Etiolog\u00edaLa morfolog\u00eda del viri\u00f3n ( fig. 2 ) es aquella definida en general para los paramyxovirus: part\u00edculas pleom\u00f3rficas, con un tama\u00f1o de 150-600 nm, con una envuelta que presenta proyecciones cortas o esp\u00edculas de 13-17 nm y con un genoma constituido por una \u00fanica mol\u00e9cula de ARN de polaridad negativa con una longitud de 13.378 nt.", [["metapneumovirus aviar", "DISEASE", 33, 54], ["metapneumovirus", "ORGANISM", 139, 154], ["metapneumovirus humano", "SPECIES", 139, 161], ["La especie", "TEST", 0, 10], ["Infecciones", "PROBLEM", 123, 134], ["metapneumovirus", "PROBLEM", 139, 154], ["esp\u00edculas", "TEST", 368, 377]]], ["Adem\u00e1s, no presentan actividad hemaglutinante con eritrocitos de pavo, pollo y cobayas y su ciclo de replicaci\u00f3n depende de la presencia de tripsina.Infecciones por metapneumovirus humano Etiolog\u00edaLa diferenciaci\u00f3n de la subfamilia Pneumovirinae en 2 g\u00e9neros (Metapneumovirus y Pneumovirus) se debe a que el g\u00e9nero metapneumovirus carece de prote\u00ednas no estructurales NS1 y NS2 y a que el orden de los genes es diferente.", [["metapneumovirus carece", "DISEASE", 315, 337], ["metapneumovirus", "ORGANISM", 165, 180], ["metapneumovirus", "ORGANISM", 315, 330], ["metapneumovirus", "SPECIES", 165, 180], ["metapneumovirus", "SPECIES", 315, 330], ["Infecciones", "PROBLEM", 149, 160], ["metapneumovirus", "PROBLEM", 165, 180], ["Pneumovirinae en 2 g\u00e9neros (Metapneumovirus y Pneumovirus)", "TREATMENT", 232, 290], ["no", "UNCERTAINTY", 8, 10]]], ["La especie tipo del g\u00e9nero pneumovirus es el VRS que presenta un orden gen\u00f3mico: 3\u0408 NS1-NS2-N-P-M-SH-G-F-M2-L-5\u0408; sin embargo, el HMNV presenta el siguiente orden: 3\u0408 N-P-M-F-M2-SH-G-L-5\u0408 (N: nucleoprote\u00edna; P: fosfoprote\u00edna; M: prote\u00edna de la matriz; F: prote\u00edna de fusi\u00f3n; M2: prote\u00edna de matriz 22K; SH: prote\u00edna hidrof\u00f3bica peque\u00f1a; G: glucoprote\u00edna de anclaje con el receptor celular; L: polimerasa).Infecciones por metapneumovirus humano Etiolog\u00edaSe han definido 2 genotipos A y B que a su vez se subdividen en cuatro subgenotipos, A1, A2 y B1, B2, en funci\u00f3n de las secuencias de los genes que codifican para las prote\u00ednas F y G.Epidemiolog\u00edaOriginariamente el virus se aisl\u00f3 de muestras respiratorias de 28 pacientes no relacionados epidemiol\u00f3gicamente en Holanda, que presentaban una infecci\u00f3n respiratoria.", [["F-M2-SH-G-L-5\u0408", "SIMPLE_CHEMICAL", 173, 187], ["metapneumovirus", "ORGANISM", 421, 436], ["metapneumovirus", "SPECIES", 421, 436], ["La especie", "TEST", 0, 10], ["pneumovirus", "TEST", 27, 38], ["presenta", "TEST", 53, 61], ["gen\u00f3mico", "TEST", 71, 79], ["NS1", "TEST", 84, 87], ["NS2", "TEST", 88, 91], ["P", "TEST", 94, 95], ["SH", "TEST", 98, 100], ["G", "TEST", 101, 102], ["M2", "TEST", 105, 107], ["embargo", "TEST", 118, 125], ["el", "TEST", 127, 129], ["N-P", "TEST", 167, 170], ["F-M2-SH-G", "TEST", 173, 182], ["nucleoprote\u00edna", "TEST", 192, 206], ["P", "TEST", 208, 209], ["fosfoprote\u00edna", "TEST", 211, 224], ["prote\u00edna", "TEST", 229, 237], ["prote\u00edna", "TEST", 255, 263], ["fusi\u00f3n", "TEST", 267, 273], ["M2", "TEST", 275, 277], ["prote\u00edna", "TEST", 279, 287], ["matriz", "TEST", 291, 297], ["SH", "TEST", 303, 305], ["prote\u00edna", "TEST", 307, 315], ["hidrof\u00f3bica", "TEST", 316, 327], ["peque\u00f1a", "TEST", 328, 335], ["G", "TEST", 337, 338], ["glucoprote\u00edna", "TEST", 340, 353], ["Infecciones", "PROBLEM", 405, 416], ["M2", "ANATOMY", 105, 107]]], ["Actualmente se sabe que el HMNV produce una infecci\u00f3n respiratoria aguda no s\u00f3lo en ni\u00f1os sino tambi\u00e9n en ancianos y en pacientes inmunodeprimidos.", [["Actualmente", "TEST", 0, 11]]], ["Actualmente existen trabajos de descripci\u00f3n de casos de bronquiolitis asociada a HMNV en Alemania, Dinamarca, Australia, Jap\u00f3n, Grecia, Espa\u00f1a, Estados Unidos, Reino Unido, Finlandia, Hong Kong.PatogeniaCuando el HMNV fue descubierto una de la primeras preguntas a contestar fue si el virus era realmente aviar y hab\u00eda infectado a humanos o si por el contrario era propiamente humano.", [["Dinamarca", "PROBLEM", 99, 108], ["Grecia", "PROBLEM", 128, 134], ["Espa\u00f1a", "TREATMENT", 136, 142]]], ["Se cree que el HMNV lleva circulando en la especie humana m\u00e1s de 50 a\u00f1os.", [["Se cree", "TEST", 0, 7], ["lleva", "TEST", 20, 25], ["circulando", "TEST", 26, 36]]], ["Si se comparan los cuadros cl\u00ednicos asociados a VRS y a HMNV se pueden encontrar ligeras diferencias, ya que la infecci\u00f3n por HMNV es ligeramente menos grave y se presenta con un cuadro asm\u00e1tico (16%), menor disnea, menor dificultad para comer, menor hipoxemia, menor porcentaje de pacientes que requieren administraci\u00f3n de ox\u00edgeno y mayor frecuencia de instauraci\u00f3n de administraci\u00f3n de antibi\u00f3ticos (60%).Aislamiento en cultivos celularesEl HMNV se ha identificado recientemente por un crecimiento dif\u00edcil en c\u00e9lulas permisivas, en concreto c\u00e9lulas terciarias de ri\u00f1\u00f3n de mono.", [["Si", "CHEMICAL", 0, 2], ["menor disnea", "PROBLEM", 202, 214], ["menor hipoxemia", "PROBLEM", 245, 260], ["Aislamiento", "TEST", 407, 418]]], ["En la actualidad se ha podido comprobar que el aislamiento del virus se puede realizar en l\u00edneas continuas celulares como son LLC-MK2 (c\u00e9lulas de ri\u00f1\u00f3n de mono Rhesus), VERO (c\u00e9lulas de ri\u00f1\u00f3n de mono verde africano) y HEp-2.", [["En la actualidad se ha podido comprobar que el aislamiento del virus", "TREATMENT", 0, 68], ["MK2 (c\u00e9lulas de ri\u00f1\u00f3n de mono Rhesus)", "TREATMENT", 130, 167], ["VERO (c\u00e9lulas de ri\u00f1\u00f3n de mono verde africano", "TREATMENT", 169, 214], ["LLC", "ANATOMY", 126, 129]]], ["En las figuras 2 y 3 se muestran virus liberados y virus en fase de liberaci\u00f3n cultivado a partir de c\u00e9lulas LLC-MK2 en el Laboratorio de Gripe y Virus Respiratorios del CNM (Instituto de Salud Carlos III).Detecci\u00f3n molecular mediante amplificaci\u00f3n gen\u00f3micaSe han utilizado diferentes muestras respiratorias como son exudados nasofar\u00edngeos y lavados bronquioalveolares y se ha encontrado un buen rendimiento de diagn\u00f3stico.", [["En las figuras", "TREATMENT", 0, 14], ["muestran virus liberados y virus", "TREATMENT", 24, 56], ["LLC", "ANATOMY", 109, 112]]], ["Los m\u00e9todos desarrollados hasta la fecha no son comerciales y los diferentes grupos de investigaci\u00f3n han desarrollado t\u00e9cnicas moleculares en distintos genes diana: F, N, L, M, G. Se considera que los m\u00e9todos de amplificaci\u00f3n gen\u00f3mica son de gran utilidad, ya que se pueden generar resultados positivos de una posible infecci\u00f3n en un tiempo mucho menor que el aislamiento en cultivos celulares.", [["que el aislamiento en cultivos celulares", "TREATMENT", 353, 393]]], ["Dado que el aislamiento de HMNV es muy dif\u00edcil, los m\u00e9todos de amplificaci\u00f3n gen\u00f3mica representan la \u00fanica alternativa junto con la investigaci\u00f3n de los ant\u00edgenos virales en las c\u00e9lulas epiteliales presentes en las muestras cl\u00ednicas mediante inmunofluorescencia directa.", [["gen\u00f3mica", "TEST", 77, 85], ["virales", "TEST", 163, 170]]], ["Al no existir anticuerpos monoclonales espec\u00edficos de HMNV suficientemente extendidos comercialmente, la RT-PCR supone una muy buena alternativa para el diagn\u00f3stico.", [["la RT", "TEST", 102, 107]]], ["Recientemente la PCR a tiempo real va siendo instaurada como m\u00e9todo de diagn\u00f3stico molecular para algunos virus en los diferentes laboratorios del Sistema Nacional de Salud.", [["Recientemente la PCR", "TEST", 0, 20]]], ["Seguramente se instaurar\u00e1n en dichos laboratorios este tipo de m\u00e9todos despu\u00e9s de haber sido validados.", [["Seguramente", "TREATMENT", 0, 11]]], ["Existen trabajos en los que se describen m\u00e9todos para la detecci\u00f3n espec\u00edfica de HMNV en tiempo real 31 .Serolog\u00edaNinguno de los m\u00e9todos desarrollados sirve para an\u00e1lisis seroepidemiol\u00f3gicos a gran escala porque hasta el momento no han sido validados completamente.", [["Serolog\u00edaNinguno", "TEST", 105, 121]]], ["En estos ensayos se han utilizado diferentes ant\u00edgenos virales obtenidos tras el cultivo viral en c\u00e9lulas (lisado celular) o ant\u00edgenos virales obtenidos mediante recombinaci\u00f3n: prote\u00edna de la matriz M y nucleoprote\u00edna N 32 .", [["ant\u00edgenos", "TEST", 45, 54]]], ["Realmente, los sistemas de an\u00e1lisis de los anticuerpos de los pacientes son m\u00e9todos de inmunofluorescencia en donde se utilizan las c\u00e9lulas infectadas fijadas en un porta de cristal.TratamientoSe han iniciado estudios para producir anticuerpos monoclonales y policlonales que puedan neutralizar al HMNV y ser administrados como tratamiento de la infecci\u00f3n tal y como se est\u00e1 llevando a cabo con el VRS.ProfilaxisSe est\u00e1 intentando producir vacunas vivas atenuadas de HMNV en diferentes laboratorios de Estados Unidos, Canad\u00e1, Europa y Australia.", [["porta", "ANATOMY", 165, 170], ["TratamientoSe han iniciado", "TREATMENT", 182, 208], ["para producir", "TREATMENT", 218, 231], ["ProfilaxisSe", "TEST", 402, 414], ["porta", "ANATOMY", 165, 170]]], ["Estas quimeras podr\u00edan expresar de manera bivalente prote\u00ednas de diferentes virus (VRS y HMNV) por los que la inmunizaci\u00f3n ser\u00eda doble.Bibliograf\u00edaLos art\u00edculos publicados en la secci\u00f3n \"Formaci\u00f3n M\u00e9dica Continuada\" forman parte de grupos tem\u00e1ticos espec\u00edficos (antibiograma, antimicrobianos, etc.).", [["Estas", "TEST", 0, 5]]], ["Una vez finalizada la publicaci\u00f3n de cada tema, se ir\u00e1n presentando al Sistema Espa\u00f1ol de Acreditaci\u00f3n de la Formaci\u00f3n M\u00e9dica Continuada (SEAFORMEC) para la obtenci\u00f3n de cr\u00e9ditos.Bibliograf\u00edaUna vez concedida la acreditaci\u00f3n, esta se anunciar\u00e1 oportunamente en la Revista y se abrir\u00e1 un per\u00edodo de inscripci\u00f3n gratuito para los socios de la SEIMC y suscriptores de la Revista, al cabo del cual se iniciar\u00e1 la evaluaci\u00f3n, durante un mes, que se realizar\u00e1 a trav\u00e9s de la web de Ediciones Doyma. a) Aislamiento del paciente en habitaciones habilitadas para tal fin y vigilancia estricta del personal sanitario que interviene en sus cuidados. b) Cuarentena total del hospital evitando la entrada y salida a los familiares del resto de los pacientes. c) Ingreso de los familiares y amigos del paciente con sospecha con los que hubiera habido un contacto entre la llegada del viaje y el inicio de los s\u00edntomas. d) Cierre total del hospital y limpieza y desinfecci\u00f3n de todo el complejo. e) No admisi\u00f3n del paciente y traslado a otro hospital.El intercambio de material gen\u00e9tico entre dos subtipos diferentes del virus de la gripe tipo A:a) Se realizar\u00e1 exclusivamente en c\u00e9lulas epiteliales del tracto respiratorio superior de los cerdos, puesto que son las \u00fanicas que tienen receptores de membrana para subtipos aviares y subtipos humanos. b) Se realizar\u00e1 en c\u00e9lulas epiteliales del tracto gastrointestinal de los patos, que son los reservorios naturales de todos los subtipos del virus de la gripe. c) Podr\u00eda ocurrir en c\u00e9lulas humanas, puesto que los seres humanos pueden infectarse directamente con subtipos aviares. d) Es la \u00fanica manera posible para que se pueda originar un subtipo del virus de la gripe con potencial pand\u00e9mico. e) Es el proceso que dio origen a las cuatro pandemias de gripe ocurridas en el siglo XX.", [["Una", "TEST", 0, 3], ["Bibliograf\u00edaUna", "TEST", 179, 194], ["a) Aislamiento del paciente en habitaciones habilitadas para tal fin y vigilancia estricta", "TREATMENT", 493, 583], ["Podr\u00eda ocurrir en c\u00e9lulas humanas", "TREATMENT", 1498, 1531], ["Es la", "TEST", 1618, 1623], ["a las cuatro pandemias", "TREATMENT", 1762, 1784], ["los s\u00edntomas", "OBSERVATION", 891, 903]]], ["Con respecto a la transmisi\u00f3n de persona a persona del subtipo H5N1 del virus de la gripe:. a) Con toda probabilidad se ha producido en brotes familiares, lo cual demuestra la transmisi\u00f3n efectiva entre personas. b) Con toda probabilidad se ha producido en brotes familiares, pero esto no debe ser entendido como transmisi\u00f3n efectiva entre personas. c) La transmisi\u00f3n no efectiva entre personas ya se sospechaba al observar que la tasa de seropositivos espec\u00edficos anti-H5 es id\u00e9ntica tanto en personal sanitario expuesto a enfermos como en los no expuestos. d) Es un hecho absolutamente imposible, puesto que el ser humano carece de receptores del subtipo H5N1 en las c\u00e9lulas del tracto respiratorio. e) Siempre requiere de la coinfecci\u00f3n de las c\u00e9lulas por un subtipo humano (H1N1 o H3N2) y el subtipo aviar H5N1.Las variantes virulentas del subtipo H5N1 del virus de la gripe (HPAI):a) Son causantes de una enfermedad aguda con una tasa leve de mortalidad en aves. b) Son causantes de una enfermedad de las aves que puede incluso pasar desapercibida si no se realiza una vigilancia activa con regularidad. c) Se denominan as\u00ed por las tasas de mortalidad tan elevadas que ocasionan cuando infectan a los seres humanos. d) Siempre pertenecen a los subtipos H5, H7 o H9 del virus de la gripe. e) Se caracterizan por provocar una infecci\u00f3n sist\u00e9mica en las aves dom\u00e9sticas en la que pr\u00e1cticamente todos los \u00f3rganos se ven afectados.", [["HPAI", "DISEASE", 880, 884], ["H1N1 o H3N2) y el subtipo aviar H5N1", "ORGANISM", 778, 814], ["subtipos H5", "ORGANISM", 1249, 1260], ["H7 o H9 del virus", "ORGANISM", 1262, 1279], ["La transmisi\u00f3n", "TEST", 353, 367], ["efectiva", "PROBLEM", 371, 379], ["Las variantes virulentas del", "TREATMENT", 815, 843]]], ["Los pacientes con neumon\u00eda que son diagnosticados de gripe aviar: a) Responden bien al tratamiento con los inhibidores de la prote\u00edna M2, amantadina y rimantadina, utilizados cl\u00e1sicamente. b) Responden bien al tratamiento con oseltamivir, independientemente de cu\u00e1ndo se comience el tratamiento. c) Presentan una marcada linfopenia. d) Suelen ser ni\u00f1os y personas mayores de 65 a\u00f1os. e) Se sobreinfectan con bacterias oportunistas, que son las responsables del cuadro neum\u00f3nico.", [["al tratamiento con oseltamivir", "TREATMENT", 207, 237], ["Se sobreinfectan con bacterias oportunistas", "PROBLEM", 387, 430]]], ["\u00bfQu\u00e9 virus se deben investigar en ni\u00f1os menores de 2 a\u00f1os con bronquiolitis, que acuden a urgencias en un hospital? a) Gripe y virus respiratorio sincitial. b) Gripe y parainfluenzavirus. c) Gripe y rinovirus. d) Cualquier virus respiratorio. e) En principio descartar virus respiratorio sincitial y metapneumovirus humano.", [["metapneumovirus humano", "DISEASE", 300, 322], ["Cualquier virus", "ORGANISM", 213, 228], ["En principio descartar virus", "ORGANISM", 246, 274], ["metapneumovirus", "ORGANISM", 300, 315], ["Cualquier virus respiratorio", "SPECIES", 213, 241], ["metapneumovirus", "SPECIES", 300, 315], ["Qu\u00e9 virus", "PROBLEM", 1, 10], ["Gripe y rinovirus", "PROBLEM", 191, 208], ["En principio descartar virus", "TREATMENT", 246, 274]]], ["\u00bfSe deben tomar medidas de actuaci\u00f3n especiales ante un diagn\u00f3stico positivo para metapneumovirus humano en un ni\u00f1o con un cuadro respiratorio grave? a) S\u00ed, aislamiento total del paciente para evitar contagio de la infecci\u00f3n de tipo nosocomial. b) S\u00ed, tratamiento con el antiviral espec\u00edfico correspondiente. c) S\u00ed, ingreso en la unidad de cuidados intensivos del hospital y estrecha vigilancia m\u00e9dica. d) No, se deber\u00eda de tratar exactamente igual que un caso de infecci\u00f3n por el virus respiratorio sincitial. e) No, se podr\u00eda dar el alta ya que no se puede tratar espec\u00edficamente.", [["metapneumovirus humano", "DISEASE", 82, 104], ["nosocomial", "DISEASE", 233, 243], ["metapneumovirus", "ORGANISM", 82, 97], ["aislamiento total del paciente para", "TREATMENT", 157, 192], ["tratamiento con el antiviral espec\u00edfico correspondiente", "TREATMENT", 252, 307]]]], "1f963c7242d618001a9a75635b52f66e69ff5d9a": [["I. INTRODUCTIONReports of prolific and successful research in the areas of biotechnology and genetic engineering have unleashed potential ideas that were previously inconceivable in the subject of dairying.", [["prolific", "OBSERVATION_MODIFIER", 26, 34]]], ["It is now firmly established that novel value-added products can be derived from milk and milk products with nutritional and biotechnological interventions.", [["milk", "ANATOMY", 81, 85], ["milk", "ANATOMY", 90, 94], ["milk", "ORGANISM_SUBSTANCE", 81, 85], ["milk", "ORGANISM_SUBSTANCE", 90, 94], ["novel value-added products", "TREATMENT", 34, 60], ["milk and milk products", "TREATMENT", 81, 103], ["nutritional and biotechnological interventions", "TREATMENT", 109, 155]]], ["While until recently, breeding policies have aimed at producing more milk, attempts are now directed toward enhancing the value of milk and studying its health implications.", [["milk", "ANATOMY", 69, 73], ["milk", "ANATOMY", 131, 135], ["milk", "ORGANISM_SUBSTANCE", 69, 73], ["milk", "ORGANISM_SUBSTANCE", 131, 135]]], ["This has found more support with clinically established epidemiological linkages between diet and chronic diseases that encourage search for new links between food and disease.I. INTRODUCTIONThe extranutritional therapeutic attributes of milk and milk products have also been brought into this broad network of research.", [["milk", "ANATOMY", 238, 242], ["milk", "ANATOMY", 247, 251], ["chronic diseases", "DISEASE", 98, 114], ["food and disease", "DISEASE", 159, 175], ["milk", "ORGANISM_SUBSTANCE", 238, 242], ["milk", "ORGANISM_SUBSTANCE", 247, 251], ["chronic diseases", "PROBLEM", 98, 114], ["disease", "PROBLEM", 168, 175], ["milk and milk products", "TREATMENT", 238, 260], ["chronic", "OBSERVATION_MODIFIER", 98, 105], ["diseases", "OBSERVATION", 106, 114]]], ["Milk composition can be altered by nutritional management or through the manipulation of naturally occurring genetic variation among cattle.", [["Milk", "ORGANISM_SUBSTANCE", 0, 4], ["cattle", "ORGANISM", 133, 139], ["cattle", "SPECIES", 133, 139], ["cattle", "SPECIES", 133, 139], ["Milk composition", "TREATMENT", 0, 16], ["nutritional management", "TREATMENT", 35, 57]]], ["The possible channels of influencing milk composition to suit specific needs can be investigated with the help of a thorough comprehension of the biochemistry, genetic traits, and factors in the animal diet that affect milk synthesis and composition.", [["milk", "ANATOMY", 37, 41], ["milk", "ANATOMY", 219, 223], ["milk", "ORGANISM_SUBSTANCE", 37, 41], ["milk", "ORGANISM_SUBSTANCE", 219, 223], ["influencing milk composition", "TREATMENT", 25, 53], ["milk synthesis", "TREATMENT", 219, 233], ["possible", "UNCERTAINTY", 4, 12]]], ["By an intelligent combination of the two approachesnutritional and genetic-a milk designed to suit consumer preferences can be developed.", [["milk", "ORGANISM_SUBSTANCE", 77, 81]]], ["This ''designer milk'' may be rich in specific milk components that may have influence on well-being or on processing.", [["milk", "ANATOMY", 47, 51], ["milk", "ORGANISM_SUBSTANCE", 16, 20], ["milk", "ORGANISM_SUBSTANCE", 47, 51]]], ["This chapter examines the potential that exists in altering milk composition by nutritional and genetic approaches in order to achieve specific health benefits and/or processing opportunities.II. MILK ''DESIGNING'': THE PROSPECTSMan has been taming and manipulating other species for his own benefits for thousands of years.", [["milk", "ANATOMY", 60, 64], ["milk", "ORGANISM_SUBSTANCE", 60, 64]]], ["Several breeds of cattle that produce large quantities of milk exist today as a result of selective breeding adopted by farmers over centuries.", [["milk", "ANATOMY", 58, 62], ["cattle", "ORGANISM", 18, 24], ["milk", "ORGANISM_SUBSTANCE", 58, 62], ["cattle", "SPECIES", 18, 24], ["cattle", "SPECIES", 18, 24], ["selective breeding", "TREATMENT", 90, 108], ["large", "OBSERVATION_MODIFIER", 38, 43], ["quantities", "OBSERVATION_MODIFIER", 44, 54]]], ["The global appeal of milk as a healthy beverage that is good for adults as well as infants has prompted much investigation on the commodity.II. MILK ''DESIGNING'': THE PROSPECTSResearch on animal breeding, husbandry, and feeding conditions has always had a profound impact on the quality of milk, its constituents, and the subsequently manufactured products.", [["milk", "ANATOMY", 21, 25], ["milk", "ANATOMY", 291, 295], ["milk", "ORGANISM_SUBSTANCE", 21, 25], ["infants", "ORGANISM", 83, 90], ["milk", "ORGANISM_SUBSTANCE", 291, 295], ["infants", "SPECIES", 83, 90], ["global", "OBSERVATION_MODIFIER", 4, 10]]], ["Altering the composition of milk in a manner that suits health and processing needs forms the basis of the current research interests in the area.", [["milk", "ANATOMY", 28, 32], ["milk", "ORGANISM_SUBSTANCE", 28, 32]]], ["For example, a greater proportion of unsaturated fatty acids in milk fat, reduced lactose content in milk for lactose-intolerant people, and/or milk free from b-lactoglobulin (b-LG) would benefit human diet and health.", [["milk fat", "ANATOMY", 64, 72], ["milk", "ANATOMY", 101, 105], ["milk", "ANATOMY", 144, 148], ["unsaturated fatty acids", "CHEMICAL", 37, 60], ["lactose", "CHEMICAL", 82, 89], ["lactose", "CHEMICAL", 110, 117], ["b-LG", "CHEMICAL", 176, 180], ["unsaturated fatty acids", "CHEMICAL", 37, 60], ["lactose", "CHEMICAL", 82, 89], ["lactose", "CHEMICAL", 110, 117], ["unsaturated fatty acids", "SIMPLE_CHEMICAL", 37, 60], ["milk", "ORGANISM_SUBSTANCE", 64, 68], ["fat", "TISSUE", 69, 72], ["lactose", "SIMPLE_CHEMICAL", 82, 89], ["milk", "ORGANISM_SUBSTANCE", 101, 105], ["lactose", "SIMPLE_CHEMICAL", 110, 117], ["people", "ORGANISM", 129, 135], ["milk", "ORGANISM_SUBSTANCE", 144, 148], ["b-lactoglobulin", "SIMPLE_CHEMICAL", 159, 174], ["b-LG", "SIMPLE_CHEMICAL", 176, 180], ["human", "ORGANISM", 196, 201], ["people", "SPECIES", 129, 135], ["human", "SPECIES", 196, 201], ["human", "SPECIES", 196, 201], ["unsaturated fatty acids in milk fat", "PROBLEM", 37, 72], ["reduced lactose content", "PROBLEM", 74, 97], ["lactose", "TEST", 110, 117], ["greater", "OBSERVATION_MODIFIER", 15, 22], ["unsaturated", "OBSERVATION_MODIFIER", 37, 48], ["fatty acids", "OBSERVATION", 49, 60], ["lactose content", "OBSERVATION_MODIFIER", 82, 97]]], ["From a technological point of view, there exist vast opportunities in altering the primary structure of casein to improve the technological properties of milk and producing milk high in protein content.", [["milk", "ANATOMY", 154, 158], ["milk", "ANATOMY", 173, 177], ["casein", "GENE_OR_GENE_PRODUCT", 104, 110], ["milk", "ORGANISM_SUBSTANCE", 154, 158], ["milk", "ORGANISM_SUBSTANCE", 173, 177], ["casein", "PROTEIN", 104, 110]]], ["Engineering milk that clots in less time leads to increased yield and/or more protein recovery during cheese manufacture.", [["milk", "ANATOMY", 12, 16], ["clots", "ANATOMY", 22, 27], ["milk", "ORGANISM_SUBSTANCE", 12, 16], ["clots", "ORGANISM_SUBSTANCE", 22, 27], ["cheese", "SPECIES", 102, 108], ["clots", "PROBLEM", 22, 27], ["increased yield", "PROBLEM", 50, 65], ["clots", "OBSERVATION", 22, 27], ["less time", "OBSERVATION_MODIFIER", 31, 40], ["cheese manufacture", "OBSERVATION", 102, 120]]], ["Milk that contains nutraceuticals and replacement ingredients for infant formula are other interesting avenues.II. MILK ''DESIGNING'': THE PROSPECTSGenetic manipulation (GM) also offers the prospect of healthier animals with improved resistance to diseases such as mastitis or to the ticks that can infest cattle, thus reducing the need for antibiotics and pesticides.", [["GM", "CHEMICAL", 170, 172], ["mastitis", "DISEASE", 265, 273], ["Milk", "ORGANISM_SUBSTANCE", 0, 4], ["cattle", "ORGANISM", 306, 312], ["infant", "SPECIES", 66, 72], ["cattle", "SPECIES", 306, 312], ["cattle", "SPECIES", 306, 312], ["Milk", "TREATMENT", 0, 4], ["nutraceuticals", "TREATMENT", 19, 33], ["replacement ingredients", "TREATMENT", 38, 61], ["infant formula", "TREATMENT", 66, 80], ["THE PROSPECTSGenetic manipulation", "TREATMENT", 135, 168], ["diseases", "PROBLEM", 248, 256], ["mastitis", "PROBLEM", 265, 273], ["antibiotics", "TREATMENT", 341, 352], ["pesticides", "TREATMENT", 357, 367], ["nutraceuticals", "OBSERVATION_MODIFIER", 19, 33]]], ["Medicines may be produced in the milk of cows.", [["milk", "ANATOMY", 33, 37], ["milk", "ORGANISM_SUBSTANCE", 33, 37], ["cows", "ORGANISM", 41, 45], ["cows", "SPECIES", 41, 45], ["Medicines", "TREATMENT", 0, 9]]], ["For example, GM cows could produce milk with a clotting factor for hemophiliacs, milk containing human serum albumin for blood transfusions, or milk with a hepatitis vaccine.", [["milk", "ANATOMY", 35, 39], ["milk", "ANATOMY", 81, 85], ["serum", "ANATOMY", 103, 108], ["blood", "ANATOMY", 121, 126], ["milk", "ANATOMY", 144, 148], ["GM", "CHEMICAL", 13, 15], ["hemophiliacs", "DISEASE", 67, 79], ["hepatitis", "DISEASE", 156, 165], ["cows", "ORGANISM", 16, 20], ["milk", "ORGANISM_SUBSTANCE", 35, 39], ["hemophiliacs", "ORGANISM", 67, 79], ["milk", "ORGANISM_SUBSTANCE", 81, 85], ["human", "ORGANISM", 97, 102], ["serum", "ORGANISM_SUBSTANCE", 103, 108], ["albumin", "GENE_OR_GENE_PRODUCT", 109, 116], ["blood", "ORGANISM_SUBSTANCE", 121, 126], ["milk", "ORGANISM_SUBSTANCE", 144, 148], ["clotting factor", "PROTEIN", 47, 62], ["cows", "SPECIES", 16, 20], ["human", "SPECIES", 97, 102], ["human", "SPECIES", 97, 102], ["GM cows", "PROBLEM", 13, 20], ["a clotting factor", "PROBLEM", 45, 62], ["hemophiliacs", "PROBLEM", 67, 79], ["milk", "TREATMENT", 81, 85], ["human serum albumin", "TREATMENT", 97, 116], ["blood transfusions", "TREATMENT", 121, 139], ["a hepatitis vaccine", "TREATMENT", 154, 173]]], ["Several of these medicines could be produced much more efficiently than with the technologies currently used.", [["these medicines", "TREATMENT", 11, 26], ["the technologies", "TREATMENT", 77, 93]]], ["Some of the potential changes that can be brought about in milk are listed in Table 1 .", [["milk", "ANATOMY", 59, 63], ["milk", "ORGANISM_SUBSTANCE", 59, 63]]], ["Better infant health, less mortality, less problems due to milk allergy Lonnerdal, 1996; Maga et al., 2006 C.4 Introduce human therapeutic proteins AgResearch Now, 2005; Morgan, 2006; Pettus, 2006III.", [["milk allergy", "DISEASE", 59, 71], ["milk", "ORGANISM_SUBSTANCE", 59, 63], ["human", "ORGANISM", 121, 126], ["human", "SPECIES", 121, 126], ["human", "SPECIES", 121, 126]]], ["MILK FAT MODIFICATIONThe quantity of milk fat is a determinant of its value and hence a major indicator of the revenue accrued from milk.", [["milk fat", "ANATOMY", 37, 45], ["milk", "ANATOMY", 132, 136], ["milk", "ORGANISM", 37, 41], ["fat", "TISSUE", 42, 45], ["milk", "ORGANISM_SUBSTANCE", 132, 136], ["MILK FAT MODIFICATION", "TREATMENT", 0, 21], ["quantity", "OBSERVATION_MODIFIER", 25, 33], ["milk fat", "OBSERVATION", 37, 45]]], ["As a recent trend, advanced knowledge about the chemistry of milk fat and human physiology encourages product developers to modify the milk fat to counter the changing functional and nutritional challenges.", [["milk fat", "ANATOMY", 61, 69], ["milk fat", "ANATOMY", 135, 143], ["milk", "ORGANISM", 61, 65], ["fat", "TISSUE", 66, 69], ["human", "ORGANISM", 74, 79], ["milk", "ORGANISM", 135, 139], ["fat", "TISSUE", 140, 143], ["human", "SPECIES", 74, 79], ["human", "SPECIES", 74, 79], ["the milk fat", "TREATMENT", 131, 143], ["nutritional challenges", "TREATMENT", 183, 205]]], ["Dairy products provide less than 15% of the total fat available in the diet (O'Donnell, 1993) .", [["fat", "ANATOMY", 50, 53], ["fat", "TISSUE", 50, 53], ["Dairy products", "TREATMENT", 0, 14]]], ["Milk fat provides 25% of the saturated fat, which is still not as high as that in the two groups of fats and oils (29%) and meat, poultry, and fish (39%).", [["Milk fat", "ANATOMY", 0, 8], ["fat", "ANATOMY", 39, 42], ["fats", "ANATOMY", 100, 104], ["oils", "ANATOMY", 109, 113], ["meat", "ANATOMY", 124, 128], ["Milk fat", "TISSUE", 0, 8], ["fat", "TISSUE", 39, 42], ["fats", "SIMPLE_CHEMICAL", 100, 104], ["oils", "TISSUE", 109, 113], ["meat", "ORGANISM_SUBDIVISION", 124, 128], ["fish", "ORGANISM_SUBDIVISION", 143, 147], ["meat", "SPECIES", 124, 128], ["Milk fat", "TREATMENT", 0, 8]]], ["The contribution of dairy products to the total cholesterol is 16%, much less than that in eggs (39%) and meat, poultry, and fish (43%).", [["meat", "ANATOMY", 106, 110], ["cholesterol", "CHEMICAL", 48, 59], ["cholesterol", "CHEMICAL", 48, 59], ["cholesterol", "SIMPLE_CHEMICAL", 48, 59], ["meat", "ORGANISM_SUBDIVISION", 106, 110], ["fish", "ORGANISM_SUBDIVISION", 125, 129], ["meat", "SPECIES", 106, 110], ["dairy products", "TREATMENT", 20, 34], ["the total cholesterol", "TEST", 38, 59], ["fish", "TEST", 125, 129], ["dairy products", "OBSERVATION", 20, 34]]], ["Modifications of the composition and quality of fodder result in different milk fat compositions and influence the nutritional and technological value of fats.", [["milk fat", "ANATOMY", 75, 83], ["milk", "ORGANISM_SUBDIVISION", 75, 79], ["fat", "TISSUE", 80, 83], ["fats", "ORGANISM_SUBDIVISION", 154, 158], ["different milk fat compositions", "TREATMENT", 65, 96]]], ["A sophisticated trend in the ''health market'' today is to modify the milk fat composition by either adopting suitable feeding strategies or by genetic modes.", [["milk fat", "ANATOMY", 70, 78], ["milk fat", "TISSUE", 70, 78], ["the milk fat composition", "TREATMENT", 66, 90], ["adopting suitable feeding strategies", "TREATMENT", 101, 137]]], ["It is now almost possible to achieve the ideal composition of milk fat for human health and well-being recommended by O'Donnell (1989) , after the Wisconsin Milk Board 1988 Milk Fat Roundtable.", [["milk fat", "ANATOMY", 62, 70], ["milk", "ORGANISM", 62, 66], ["fat", "TISSUE", 67, 70], ["human", "ORGANISM", 75, 80], ["human", "SPECIES", 75, 80], ["human", "SPECIES", 75, 80]]], ["The combination suggested at the meeting was less than 10% polyunsaturated fatty acids (PUFA), less than 8% saturated fatty acids (SFA), and more than 82% monounsaturated fatty acids (MUFA).A. Altering the fatty acid chain length and level of saturation in milk fatThe long-chain fatty acids of milk fat are derived from the diet via blood.", [["milk fat", "ANATOMY", 257, 265], ["milk fat", "ANATOMY", 295, 303], ["blood", "ANATOMY", 334, 339], ["polyunsaturated fatty acids", "CHEMICAL", 59, 86], ["PUFA", "CHEMICAL", 88, 92], ["fatty acids", "CHEMICAL", 118, 129], ["SFA", "CHEMICAL", 131, 134], ["monounsaturated fatty acids", "CHEMICAL", 155, 182], ["MUFA", "CHEMICAL", 184, 188], ["fatty acid", "CHEMICAL", 206, 216], ["fatty acids", "CHEMICAL", 280, 291], ["polyunsaturated fatty acids", "CHEMICAL", 59, 86], ["PUFA", "CHEMICAL", 88, 92], ["saturated fatty acids", "CHEMICAL", 108, 129], ["SFA", "CHEMICAL", 131, 134], ["monounsaturated fatty acids", "CHEMICAL", 155, 182], ["MUFA", "CHEMICAL", 184, 188], ["fatty acid", "CHEMICAL", 206, 216], ["fatty acids", "CHEMICAL", 280, 291], ["polyunsaturated fatty acids", "SIMPLE_CHEMICAL", 59, 86], ["PUFA", "SIMPLE_CHEMICAL", 88, 92], ["saturated fatty acids", "SIMPLE_CHEMICAL", 108, 129], ["SFA", "SIMPLE_CHEMICAL", 131, 134], ["monounsaturated fatty acids", "SIMPLE_CHEMICAL", 155, 182], ["MUFA", "SIMPLE_CHEMICAL", 184, 188], ["milk", "ORGANISM_SUBSTANCE", 257, 261], ["fat", "ORGANISM_SUBDIVISION", 262, 265], ["long-chain fatty acids", "SIMPLE_CHEMICAL", 269, 291], ["milk fat", "ORGANISM_SUBSTANCE", 295, 303], ["blood", "ORGANISM_SUBSTANCE", 334, 339], ["milk", "SPECIES", 295, 299], ["A.", "SPECIES", 190, 192], ["polyunsaturated fatty acids", "TEST", 59, 86], ["PUFA", "TEST", 88, 92], ["saturated fatty acids", "TEST", 108, 129], ["SFA", "TEST", 131, 134], ["Altering the fatty acid chain length", "PROBLEM", 193, 229], ["level of saturation", "TEST", 234, 253], ["The long-chain fatty acids of milk fat", "TREATMENT", 265, 303], ["SFA", "ANATOMY", 131, 134], ["fatty acid chain", "OBSERVATION_MODIFIER", 206, 222], ["length", "OBSERVATION_MODIFIER", 223, 229]]], ["The short-chain fatty acids (C10 and below) of milk fat are first synthesized in the mammary gland and then elongated to C12-C16.", [["milk fat", "ANATOMY", 47, 55], ["mammary gland", "ANATOMY", 85, 98], ["fatty acids", "CHEMICAL", 16, 27], ["C12-C16", "CHEMICAL", 121, 128], ["short-chain fatty acids", "CHEMICAL", 4, 27], ["C12-C16", "CHEMICAL", 121, 128], ["short-chain fatty acids", "SIMPLE_CHEMICAL", 4, 27], ["C10", "SIMPLE_CHEMICAL", 29, 32], ["milk fat", "ORGANISM_SUBSTANCE", 47, 55], ["mammary gland", "ORGAN", 85, 98], ["C12-C16", "SIMPLE_CHEMICAL", 121, 128], ["milk", "SPECIES", 47, 51], ["The short-chain fatty acids", "TEST", 0, 27], ["short", "OBSERVATION_MODIFIER", 4, 9], ["milk fat", "ANATOMY", 47, 55], ["mammary gland", "ANATOMY", 85, 98], ["elongated", "OBSERVATION_MODIFIER", 108, 117], ["C12", "ANATOMY_MODIFIER", 121, 124], ["C16", "ANATOMY_MODIFIER", 125, 128]]], ["If the Designer Milk mechanism for elongation is blocked by genetic technology, the ratio of medium-chain fatty acids (C12-C16) to short-chain fatty acids in milk fat should reduce.", [["milk fat", "ANATOMY", 158, 166], ["fatty acids", "CHEMICAL", 106, 117], ["C12-C16", "CHEMICAL", 119, 126], ["fatty acids", "CHEMICAL", 143, 154], ["fatty acids", "CHEMICAL", 106, 117], ["C12-C16", "CHEMICAL", 119, 126], ["short-chain fatty acids", "CHEMICAL", 131, 154], ["medium-chain fatty acids", "SIMPLE_CHEMICAL", 93, 117], ["C12-C16", "SIMPLE_CHEMICAL", 119, 126], ["short-chain fatty acids", "SIMPLE_CHEMICAL", 131, 154], ["milk fat", "ORGANISM_SUBSTANCE", 158, 166], ["the ratio of medium-chain fatty acids", "TEST", 80, 117], ["short-chain fatty acids in milk fat", "PROBLEM", 131, 166]]], ["Since the C12-C16 fatty acids are generally regarded by nutritionists as less desirable, milk fat with reduced content of mediumlength fatty acid chains would garner more value due to greater consumer demand.A. Altering the fatty acid chain length and level of saturation in milk fatThere is ample experimental evidence to suggest that nutritional modifications can cause significant changes in milk fat composition.", [["milk fat", "ANATOMY", 89, 97], ["milk fat", "ANATOMY", 275, 283], ["milk fat", "ANATOMY", 395, 403], ["C12-C16 fatty acids", "CHEMICAL", 10, 29], ["fatty acid", "CHEMICAL", 135, 145], ["fatty acid", "CHEMICAL", 224, 234], ["C12-C16 fatty acids", "CHEMICAL", 10, 29], ["fatty acid", "CHEMICAL", 135, 145], ["fatty acid", "CHEMICAL", 224, 234], ["C12-C16 fatty acids", "SIMPLE_CHEMICAL", 10, 29], ["milk", "ORGANISM", 89, 93], ["fat", "ORGANISM_SUBDIVISION", 94, 97], ["mediumlength fatty acid", "SIMPLE_CHEMICAL", 122, 145], ["milk", "ORGANISM_SUBSTANCE", 275, 279], ["fat", "TISSUE", 280, 283], ["milk fat", "TISSUE", 395, 403], ["mediumlength fatty acid chains", "TREATMENT", 122, 152], ["Altering the fatty acid chain length", "PROBLEM", 211, 247], ["nutritional modifications", "TREATMENT", 336, 361], ["significant changes in milk fat composition", "PROBLEM", 372, 415], ["fatty acid chain length", "OBSERVATION_MODIFIER", 224, 247], ["milk fat", "OBSERVATION", 395, 403]]], ["The degree of unsaturation of the serum lipids, tissue fat, and milk fat may be increased promptly by feeding unsaturated fats in an encapsulated or protected form to lactating animals (Ashes et al., 1997) .", [["serum", "ANATOMY", 34, 39], ["tissue fat", "ANATOMY", 48, 58], ["milk fat", "ANATOMY", 64, 72], ["serum", "ORGANISM_SUBSTANCE", 34, 39], ["lipids", "ORGANISM_SUBSTANCE", 40, 46], ["tissue fat", "TISSUE", 48, 58], ["milk fat", "TISSUE", 64, 72], ["the serum lipids", "TEST", 30, 46], ["milk fat", "TREATMENT", 64, 72], ["degree", "OBSERVATION_MODIFIER", 4, 10], ["unsaturation", "OBSERVATION_MODIFIER", 14, 26], ["increased", "OBSERVATION_MODIFIER", 80, 89]]], ["It is established that MUFA (C18:1) content can be increased by 50-80% and may approach 50% of milk fatty acids by feeding lipids rich in 18-carbon fatty acids (Grummer, 1991) .", [["MUFA", "CHEMICAL", 23, 27], ["C18:1", "CHEMICAL", 29, 34], ["fatty acids", "CHEMICAL", 100, 111], ["18-carbon fatty acids", "CHEMICAL", 138, 159], ["MUFA", "CHEMICAL", 23, 27], ["fatty acids", "CHEMICAL", 100, 111], ["18-carbon fatty acids", "CHEMICAL", 138, 159], ["MUFA", "SIMPLE_CHEMICAL", 23, 27], ["C18:1", "SIMPLE_CHEMICAL", 29, 34], ["milk fatty acids", "SIMPLE_CHEMICAL", 95, 111], ["lipids", "SIMPLE_CHEMICAL", 123, 129], ["18-carbon fatty acids", "SIMPLE_CHEMICAL", 138, 159], ["MUFA", "TEST", 23, 27], ["milk fatty acids", "TEST", 95, 111], ["increased", "OBSERVATION_MODIFIER", 51, 60]]], ["Feeding low-roughage diets increases the proportion of MUFA in milk fat, the effects of feeding low-roughage diets and lipid being additive.", [["milk fat", "ANATOMY", 63, 71], ["MUFA", "CHEMICAL", 55, 59], ["MUFA", "CHEMICAL", 55, 59], ["MUFA", "SIMPLE_CHEMICAL", 55, 59], ["milk fat", "TISSUE", 63, 71], ["lipid", "SIMPLE_CHEMICAL", 119, 124], ["MUFA in milk fat", "TREATMENT", 55, 71], ["feeding low-roughage diets", "TREATMENT", 88, 114], ["lipid being additive", "TREATMENT", 119, 139]]], ["The SFA content (palmitic acid, C16:0) of milk fat can also be reduced by 20-40% unless the supplemented lipid is rich in palmitic acid.", [["milk fat", "ANATOMY", 42, 50], ["SFA", "CHEMICAL", 4, 7], ["palmitic acid", "CHEMICAL", 17, 30], ["C16:0", "CHEMICAL", 32, 37], ["palmitic acid", "CHEMICAL", 122, 135], ["SFA", "CHEMICAL", 4, 7], ["palmitic acid", "CHEMICAL", 17, 30], ["palmitic acid", "CHEMICAL", 122, 135], ["SFA", "SIMPLE_CHEMICAL", 4, 7], ["palmitic acid", "SIMPLE_CHEMICAL", 17, 30], ["C16:0", "SIMPLE_CHEMICAL", 32, 37], ["milk", "ORGANISM", 42, 46], ["fat", "TISSUE", 47, 50], ["lipid", "SIMPLE_CHEMICAL", 105, 110], ["palmitic acid", "SIMPLE_CHEMICAL", 122, 135], ["The SFA content", "TEST", 0, 15], ["palmitic acid", "TEST", 17, 30], ["milk fat", "TREATMENT", 42, 50], ["palmitic acid", "TEST", 122, 135], ["SFA", "ANATOMY", 4, 7], ["palmitic", "OBSERVATION_MODIFIER", 17, 25], ["reduced", "OBSERVATION_MODIFIER", 63, 70], ["palmitic acid", "OBSERVATION", 122, 135]]], ["SFA particularly palmitic and other medium-chain fatty acids tend to increase levels of blood cholesterol (O'Donnell, 1993) .A. Altering the fatty acid chain length and level of saturation in milk fatFeeding highly unsaturated oils (e.g., soybean oil) caused depression in milk fat, but increased the proportion of unsaturated fatty acids to SFA in milk (www.extension.iastate.edu).", [["blood", "ANATOMY", 88, 93], ["milk fat", "ANATOMY", 192, 200], ["unsaturated oils", "ANATOMY", 215, 231], ["oil", "ANATOMY", 247, 250], ["milk fat", "ANATOMY", 273, 281], ["milk", "ANATOMY", 349, 353], ["SFA", "CHEMICAL", 0, 3], ["palmitic", "CHEMICAL", 17, 25], ["fatty acids", "CHEMICAL", 49, 60], ["cholesterol", "CHEMICAL", 94, 105], ["fatty acid", "CHEMICAL", 141, 151], ["unsaturated oils", "CHEMICAL", 215, 231], ["depression", "DISEASE", 259, 269], ["unsaturated fatty acids", "CHEMICAL", 315, 338], ["SFA", "CHEMICAL", 342, 345], ["SFA", "CHEMICAL", 0, 3], ["palmitic", "CHEMICAL", 17, 25], ["fatty acids", "CHEMICAL", 49, 60], ["cholesterol", "CHEMICAL", 94, 105], ["fatty acid", "CHEMICAL", 141, 151], ["unsaturated fatty acids", "CHEMICAL", 315, 338], ["SFA", "CHEMICAL", 342, 345], ["SFA", "SIMPLE_CHEMICAL", 0, 3], ["palmitic", "SIMPLE_CHEMICAL", 17, 25], ["medium-chain fatty acids", "SIMPLE_CHEMICAL", 36, 60], ["blood", "ORGANISM_SUBSTANCE", 88, 93], ["cholesterol", "SIMPLE_CHEMICAL", 94, 105], ["milk", "ORGANISM", 192, 196], ["fat", "ORGANISM_SUBDIVISION", 197, 200], ["milk", "ORGANISM", 273, 277], ["fat", "TISSUE", 278, 281], ["unsaturated fatty acids", "SIMPLE_CHEMICAL", 315, 338], ["SFA", "SIMPLE_CHEMICAL", 342, 345], ["milk", "ORGANISM_SUBSTANCE", 349, 353], ["soybean", "SPECIES", 239, 246], ["SFA", "TEST", 0, 3], ["palmitic", "TEST", 17, 25], ["other medium-chain fatty acids", "TEST", 30, 60], ["blood cholesterol", "TEST", 88, 105], ["Altering the fatty acid chain length", "PROBLEM", 128, 164], ["depression in milk fat", "PROBLEM", 259, 281], ["palmitic", "OBSERVATION_MODIFIER", 17, 25], ["milk fat", "OBSERVATION", 273, 281], ["SFA", "ANATOMY", 342, 345]]], ["A study at the University of Alberta (Mason, 2001) revealed that feeding canola oil in the encapsulated form (to protect it from biohydrogenation by the rumen microorganisms) led to higher increases in linoleic (18:2) and linolenic (18:3) acids than while feeding unprotected oil seeds.", [["canola oil", "ANATOMY", 73, 83], ["oil seeds", "ANATOMY", 276, 285], ["canola oil", "CHEMICAL", 73, 83], ["linoleic (18:2) and linolenic (18:3) acids", "CHEMICAL", 202, 244], ["linoleic (18:2) and linolenic (18:3) acids", "CHEMICAL", 202, 244], ["oil", "ORGANISM_SUBSTANCE", 80, 83], ["linoleic", "SIMPLE_CHEMICAL", 202, 210], ["18:2", "SIMPLE_CHEMICAL", 212, 216], ["linolenic (18:3) acids", "SIMPLE_CHEMICAL", 222, 244], ["oil", "ORGANISM_SUBSTANCE", 276, 279], ["canola", "SPECIES", 73, 79], ["A study", "TEST", 0, 7], ["feeding canola oil", "TREATMENT", 65, 83], ["linolenic (18:3) acids", "TREATMENT", 222, 244], ["higher", "OBSERVATION_MODIFIER", 182, 188], ["increases", "OBSERVATION_MODIFIER", 189, 198], ["linoleic", "OBSERVATION_MODIFIER", 202, 210]]], ["As the melting point of milk fat containing unsaturated fatty acids is more, the spreadability of butter made from this milk improved tremendously.", [["milk fat", "ANATOMY", 24, 32], ["milk", "ANATOMY", 120, 124], ["unsaturated fatty acids", "CHEMICAL", 44, 67], ["unsaturated fatty acids", "CHEMICAL", 44, 67], ["milk", "ORGANISM", 24, 28], ["fat", "TISSUE", 29, 32], ["unsaturated fatty acids", "SIMPLE_CHEMICAL", 44, 67], ["butter", "ORGANISM_SUBDIVISION", 98, 104], ["milk", "ORGANISM_SUBSTANCE", 120, 124], ["butter", "SPECIES", 98, 104], ["unsaturated fatty acids", "TREATMENT", 44, 67], ["fatty acids", "OBSERVATION", 56, 67]]], ["An Australian study involving the feeding of a special blend of canola and soybean meal in the protected form resulted in doubling the spreadability of butter (CSIRO, 1999) .", [["canola", "ORGANISM_SUBDIVISION", 64, 70], ["soybean", "ORGANISM", 75, 82], ["butter", "ORGANISM_SUBDIVISION", 152, 158], ["canola", "SPECIES", 64, 70], ["soybean", "SPECIES", 75, 82], ["canola", "SPECIES", 64, 70], ["soybean", "SPECIES", 75, 82], ["An Australian study", "TEST", 0, 19], ["a special blend of canola and soybean meal", "TREATMENT", 45, 87]]], ["When taken out of a refrigerator at 5 C, the butter was nearly as spreadable as margarine, without losing its special eating qualities.", [["margarine", "CHEMICAL", 80, 89], ["butter", "ORGANISM_SUBDIVISION", 45, 51], ["margarine", "SIMPLE_CHEMICAL", 80, 89]]], ["Clinical trials revealed that consumption of dairy products made from this milk led to decrease in lowdensity lipoprotein (LDL) levels in the blood of the consumers.", [["milk", "ANATOMY", 75, 79], ["blood", "ANATOMY", 142, 147], ["milk", "ORGANISM_SUBSTANCE", 75, 79], ["lowdensity", "SIMPLE_CHEMICAL", 99, 109], ["lipoprotein", "SIMPLE_CHEMICAL", 110, 121], ["LDL", "SIMPLE_CHEMICAL", 123, 126], ["blood", "ORGANISM_SUBSTANCE", 142, 147], ["lowdensity lipoprotein", "PROTEIN", 99, 121], ["LDL", "PROTEIN", 123, 126], ["Clinical trials", "TEST", 0, 15], ["dairy products", "TREATMENT", 45, 59], ["decrease in lowdensity lipoprotein (LDL) levels", "PROBLEM", 87, 134], ["decrease", "OBSERVATION_MODIFIER", 87, 95]]], ["Chouinard et al. (1998) compared the results of feeding to Holstein cows, a control total mixed ration (TMR) with TMR supplemented with calcium salts of three fatty acids from oils with progressive degree of unsaturationcanola oil, soybean oil, or linseed oil.", [["oils", "ANATOMY", 176, 180], ["unsaturationcanola oil", "ANATOMY", 208, 230], ["oil", "ANATOMY", 240, 243], ["oil", "ANATOMY", 256, 259], ["calcium salts", "CHEMICAL", 136, 149], ["fatty acids", "CHEMICAL", 159, 170], ["calcium salts", "CHEMICAL", 136, 149], ["fatty acids", "CHEMICAL", 159, 170], ["calcium salts", "SIMPLE_CHEMICAL", 136, 149], ["fatty acids", "SIMPLE_CHEMICAL", 159, 170], ["oil", "ORGANISM_SUBSTANCE", 227, 230], ["oil", "ORGANISM_SUBSTANCE", 256, 259], ["cows", "SPECIES", 68, 72], ["soybean", "SPECIES", 232, 239], ["Holstein", "SPECIES", 59, 67], ["soybean", "SPECIES", 232, 239], ["feeding to Holstein cows", "TREATMENT", 48, 72], ["a control total mixed ration", "TREATMENT", 74, 102], ["TMR", "TEST", 114, 117], ["calcium salts", "TREATMENT", 136, 149], ["three fatty acids", "TREATMENT", 153, 170], ["unsaturationcanola oil", "TREATMENT", 208, 230], ["soybean oil", "TREATMENT", 232, 243]]], ["The digestibility of nutrients was higher for rations containing calcium salts than for the control ration.", [["calcium", "CHEMICAL", 65, 72], ["calcium", "CHEMICAL", 65, 72], ["calcium salts", "SIMPLE_CHEMICAL", 65, 78], ["calcium salts", "TREATMENT", 65, 78], ["the control ration", "TREATMENT", 88, 106]]], ["The milk yield increased in proportion to the degree of unsaturation in the feed supplement.", [["milk", "ANATOMY", 4, 8], ["milk", "ORGANISM_SUBSTANCE", 4, 8], ["unsaturation in the feed supplement", "TREATMENT", 56, 91], ["milk yield", "OBSERVATION_MODIFIER", 4, 14], ["increased", "OBSERVATION_MODIFIER", 15, 24], ["unsaturation", "OBSERVATION_MODIFIER", 56, 68]]], ["The fat content in milk reduced in all the experimental diets as compared to the control.", [["fat", "ANATOMY", 4, 7], ["milk", "ANATOMY", 19, 23], ["fat", "TISSUE", 4, 7], ["milk", "ORGANISM_SUBSTANCE", 19, 23], ["fat content", "OBSERVATION", 4, 15], ["milk", "OBSERVATION_MODIFIER", 19, 23], ["reduced", "OBSERVATION_MODIFIER", 24, 31]]], ["The addition of calcium salts to the ration decreased the proportions of SFA that contained C6-C16 and increased the proportions of C18:0, cis-9-C18:1, and trans-11-C18:1 in milk fat.", [["milk fat", "ANATOMY", 174, 182], ["calcium salts", "CHEMICAL", 16, 29], ["SFA", "CHEMICAL", 73, 76], ["C6-C16", "CHEMICAL", 92, 98], ["C18:0, cis-9-C18:1, and trans-11-C18:1", "CHEMICAL", 132, 170], ["calcium salts", "CHEMICAL", 16, 29], ["SFA", "CHEMICAL", 73, 76], ["C6-C16", "CHEMICAL", 92, 98], ["C18:0", "CHEMICAL", 132, 137], ["cis-9-C18:1", "CHEMICAL", 139, 150], ["trans-11-C18:1", "CHEMICAL", 156, 170], ["calcium salts", "SIMPLE_CHEMICAL", 16, 29], ["SFA", "SIMPLE_CHEMICAL", 73, 76], ["C6-C16", "SIMPLE_CHEMICAL", 92, 98], ["C18:0", "SIMPLE_CHEMICAL", 132, 137], ["cis-9-C18:1", "SIMPLE_CHEMICAL", 139, 150], ["trans-11-C18:1", "SIMPLE_CHEMICAL", 156, 170], ["milk", "ORGANISM", 174, 178], ["fat", "TISSUE", 179, 182], ["calcium salts", "TREATMENT", 16, 29], ["C18:0", "TEST", 132, 137], ["cis", "TEST", 139, 142], ["trans", "TEST", 156, 161], ["SFA", "ANATOMY", 73, 76], ["C6", "ANATOMY_MODIFIER", 92, 94], ["increased", "OBSERVATION_MODIFIER", 103, 112], ["proportions", "OBSERVATION_MODIFIER", 117, 128]]], ["These findings were confirmed later by Aigster et al. (2000) who reported that feeding calcium salts of high-oleic sunflower oil (HOSO) containing more than 86% oleic acid at the rate of 7.5% of diet dry matter weight to Holstein cows increased the oleic acid content of milk fat from 26% to over 40% and decreased the cholesterol-raising saturates from 41% to 33%.A. Altering the fatty acid chain length and level of saturation in milk fatReports by Lee et al. (2004) elucidated the feeding of goats with different kinds of protein-oil supplements to alter the milk fat composition.", [["milk fat", "ANATOMY", 271, 279], ["oil", "ANATOMY", 533, 536], ["milk fat", "ANATOMY", 562, 570], ["calcium", "CHEMICAL", 87, 94], ["oleic sunflower oil", "CHEMICAL", 109, 128], ["HOSO", "CHEMICAL", 130, 134], ["oleic acid", "CHEMICAL", 161, 171], ["oleic acid", "CHEMICAL", 249, 259], ["cholesterol", "CHEMICAL", 319, 330], ["fatty acid", "CHEMICAL", 381, 391], ["calcium salts", "CHEMICAL", 87, 100], ["oleic acid", "CHEMICAL", 161, 171], ["oleic acid", "CHEMICAL", 249, 259], ["cholesterol", "CHEMICAL", 319, 330], ["fatty acid", "CHEMICAL", 381, 391], ["calcium", "SIMPLE_CHEMICAL", 87, 94], ["high-oleic sunflower oil", "SIMPLE_CHEMICAL", 104, 128], ["HOSO", "SIMPLE_CHEMICAL", 130, 134], ["oleic acid", "SIMPLE_CHEMICAL", 161, 171], ["oleic acid", "SIMPLE_CHEMICAL", 249, 259], ["milk", "ORGANISM", 271, 275], ["fat", "TISSUE", 276, 279], ["cholesterol", "SIMPLE_CHEMICAL", 319, 330], ["milk", "ORGANISM_SUBSTANCE", 432, 436], ["goats", "ORGANISM", 495, 500], ["oil", "ORGANISM_SUBSTANCE", 533, 536], ["milk", "MULTI-TISSUE_STRUCTURE", 562, 566], ["fat", "TISSUE", 567, 570], ["goats", "SPECIES", 495, 500], ["goats", "SPECIES", 495, 500], ["feeding calcium salts", "TREATMENT", 79, 100], ["high-oleic sunflower oil", "TREATMENT", 104, 128], ["oleic acid", "TEST", 161, 171], ["Holstein cows", "TEST", 221, 234], ["the oleic acid content of milk fat", "TREATMENT", 245, 279], ["the cholesterol", "TEST", 315, 330], ["Altering the fatty acid chain length", "PROBLEM", 368, 404], ["protein-oil supplements", "TREATMENT", 525, 548], ["the milk fat composition", "TREATMENT", 558, 582]]], ["Combinations of HOSO with keratin (KN), casein (CN), and dry casein (DCN) were fed to lactating goats.", [["HOSO", "CHEMICAL", 16, 20], ["HOSO", "SIMPLE_CHEMICAL", 16, 20], ["keratin", "GENE_OR_GENE_PRODUCT", 26, 33], ["KN", "SIMPLE_CHEMICAL", 35, 37], ["casein", "SIMPLE_CHEMICAL", 40, 46], ["CN", "SIMPLE_CHEMICAL", 48, 50], ["dry casein", "SIMPLE_CHEMICAL", 57, 67], ["DCN", "SIMPLE_CHEMICAL", 69, 72], ["goats", "ORGANISM", 96, 101], ["HOSO", "PROTEIN", 16, 20], ["keratin", "PROTEIN", 26, 33], ["casein", "PROTEIN", 40, 46], ["CN", "PROTEIN", 48, 50], ["goats", "SPECIES", 96, 101], ["goats", "SPECIES", 96, 101], ["keratin (KN)", "TREATMENT", 26, 38], ["casein (CN)", "TREATMENT", 40, 51], ["dry casein (DCN)", "TREATMENT", 57, 73]]], ["Oleic acid levels increased to 19.0% on the KN-oil supplement diet, 19.2% on the CN-oil supplement diet, and 25.2% on DCN-oil supplements diet compared to 12.5% in milk fat from goats on normal diet.", [["CN-oil", "ANATOMY", 81, 87], ["DCN-oil", "ANATOMY", 118, 125], ["milk fat", "ANATOMY", 164, 172], ["Oleic acid", "CHEMICAL", 0, 10], ["Oleic acid", "CHEMICAL", 0, 10], ["Oleic acid", "SIMPLE_CHEMICAL", 0, 10], ["oil", "ORGANISM_SUBSTANCE", 47, 50], ["oil", "ORGANISM_SUBSTANCE", 84, 87], ["DCN-oil", "SIMPLE_CHEMICAL", 118, 125], ["milk", "ORGANISM", 164, 168], ["fat", "TISSUE", 169, 172], ["goats", "ORGANISM", 178, 183], ["goats", "SPECIES", 178, 183], ["goats", "SPECIES", 178, 183], ["Oleic acid levels", "TEST", 0, 17], ["the KN-oil supplement diet", "TREATMENT", 40, 66], ["the CN-oil supplement diet", "TREATMENT", 77, 103], ["DCN-oil supplements diet", "TREATMENT", 118, 142]]], ["Feeding the protein-oil supplements also decreased solid content in milk fat at 10 C from 34.8% to 23.0% for DCN, to 26.5% for CN, and to 29.6% for KN.", [["oil", "ANATOMY", 20, 23], ["milk fat", "ANATOMY", 68, 76], ["oil", "ORGANISM_SUBSTANCE", 20, 23], ["solid", "SIMPLE_CHEMICAL", 51, 56], ["milk", "ORGANISM_SUBSTANCE", 68, 72], ["fat", "TISSUE", 73, 76], ["Feeding the protein-oil supplements", "TREATMENT", 0, 35], ["decreased solid content in milk fat", "TREATMENT", 41, 76], ["CN", "TEST", 127, 129]]], ["It was suggested that the DCN-oil supplement diet might increase the spreadability of butter at refrigerated temperatures.A. Altering the fatty acid chain length and level of saturation in milk fatStudies at the University of California (Davis) are focused on the desaturase gene to produce milk with decreased levels of SFA (CDRF, 2004) .", [["DCN-oil", "ANATOMY", 26, 33], ["milk", "ANATOMY", 291, 295], ["fatty acid", "CHEMICAL", 138, 148], ["SFA", "CHEMICAL", 321, 324], ["fatty acid", "CHEMICAL", 138, 148], ["SFA", "CHEMICAL", 321, 324], ["DCN", "SIMPLE_CHEMICAL", 26, 29], ["oil", "ORGANISM_SUBSTANCE", 30, 33], ["butter", "ORGANISM_SUBDIVISION", 86, 92], ["milk", "ORGANISM_SUBSTANCE", 189, 193], ["milk", "ORGANISM_SUBSTANCE", 291, 295], ["SFA", "SIMPLE_CHEMICAL", 321, 324], ["desaturase gene", "DNA", 264, 279], ["the DCN-oil supplement diet", "TREATMENT", 22, 49], ["Altering the fatty acid chain length", "PROBLEM", 125, 161], ["level of saturation in milk fatStudies", "PROBLEM", 166, 204], ["fatty acid chain length", "OBSERVATION_MODIFIER", 138, 161], ["SFA", "ANATOMY", 321, 324]]], ["The researchers targeted the stearoyl-CoA desaturase enzyme that converts specific medium-and long-chain SFA to their monounsaturated forms.", [["stearoyl-CoA", "CHEMICAL", 29, 41], ["SFA", "CHEMICAL", 105, 108], ["stearoyl-CoA", "CHEMICAL", 29, 41], ["SFA", "CHEMICAL", 105, 108], ["stearoyl-CoA desaturase", "GENE_OR_GENE_PRODUCT", 29, 52], ["SFA", "SIMPLE_CHEMICAL", 105, 108], ["stearoyl-CoA desaturase enzyme", "PROTEIN", 29, 59], ["the stearoyl-CoA desaturase enzyme", "TEST", 25, 59], ["SFA", "ANATOMY", 105, 108]]], ["The overall fatty acid composition of the milk of a transgenic line of goats that expressed a bovine b-LG promoter-rat stearoyl-CoA desaturase gene tilted in favor of a less saturated and more MUFA profile at the seventh day of lactation (Reh et al., 2004) .", [["milk", "ANATOMY", 42, 46], ["fatty acid", "CHEMICAL", 12, 22], ["stearoyl", "CHEMICAL", 119, 127], ["MUFA", "CHEMICAL", 193, 197], ["fatty acid", "CHEMICAL", 12, 22], ["stearoyl-CoA", "CHEMICAL", 119, 131], ["MUFA", "CHEMICAL", 193, 197], ["fatty acid", "SIMPLE_CHEMICAL", 12, 22], ["milk", "ORGANISM_SUBSTANCE", 42, 46], ["goats", "ORGANISM", 71, 76], ["bovine", "ORGANISM", 94, 100], ["b-LG", "GENE_OR_GENE_PRODUCT", 101, 105], ["rat", "ORGANISM", 115, 118], ["stearoyl-CoA desaturase", "GENE_OR_GENE_PRODUCT", 119, 142], ["MUFA", "SIMPLE_CHEMICAL", 193, 197], ["bovine b-LG promoter", "DNA", 94, 114], ["rat stearoyl-CoA desaturase gene", "DNA", 115, 147], ["goats", "SPECIES", 71, 76], ["bovine", "SPECIES", 94, 100], ["rat", "SPECIES", 115, 118], ["goats", "SPECIES", 71, 76], ["a transgenic line of goats", "TREATMENT", 50, 76], ["a bovine b-LG promoter-rat stearoyl-CoA desaturase gene", "TREATMENT", 92, 147], ["overall", "OBSERVATION_MODIFIER", 4, 11], ["fatty acid", "OBSERVATION", 12, 22]]], ["Efforts are under way to determine if genetic differences among breeds and individual animals are translated into ratios of SFA and unsaturated fatty acids.B. Increasing CLA levels in milk fatMilk fat is a good source of the putative anticancer agent, conjugated linoleic acid (CLA), a product synthesized in the rumen during the biohydrogenation of linoleic acid (LA).", [["milk fat", "ANATOMY", 184, 192], ["anticancer", "ANATOMY", 234, 244], ["rumen", "ANATOMY", 313, 318], ["SFA", "CHEMICAL", 124, 127], ["unsaturated fatty acids", "CHEMICAL", 132, 155], ["CLA", "CHEMICAL", 170, 173], ["linoleic acid", "CHEMICAL", 263, 276], ["CLA", "CHEMICAL", 278, 281], ["linoleic acid", "CHEMICAL", 350, 363], ["LA", "CHEMICAL", 365, 367], ["SFA", "CHEMICAL", 124, 127], ["unsaturated fatty acids", "CHEMICAL", 132, 155], ["linoleic acid", "CHEMICAL", 263, 276], ["CLA", "CHEMICAL", 278, 281], ["linoleic acid", "CHEMICAL", 350, 363], ["SFA", "SIMPLE_CHEMICAL", 124, 127], ["unsaturated fatty acids", "SIMPLE_CHEMICAL", 132, 155], ["CLA", "SIMPLE_CHEMICAL", 170, 173], ["milk fatMilk fat", "TISSUE", 184, 200], ["anticancer", "CANCER", 234, 244], ["conjugated linoleic acid", "SIMPLE_CHEMICAL", 252, 276], ["CLA", "SIMPLE_CHEMICAL", 278, 281], ["linoleic acid", "SIMPLE_CHEMICAL", 350, 363], ["LA", "SIMPLE_CHEMICAL", 365, 367], ["milk", "SPECIES", 184, 188], ["genetic differences among breeds", "PROBLEM", 38, 70], ["Increasing CLA levels", "PROBLEM", 159, 180], ["the putative anticancer agent", "TREATMENT", 221, 250], ["conjugated linoleic acid (CLA", "TREATMENT", 252, 281], ["the biohydrogenation of linoleic acid (LA", "TREATMENT", 326, 367], ["SFA", "ANATOMY", 124, 127], ["fatty acids", "OBSERVATION", 144, 155], ["Increasing", "OBSERVATION_MODIFIER", 159, 169], ["CLA", "OBSERVATION", 170, 173]]], ["Table 2 lists the CLA content in selected dairy products.", [["CLA", "CHEMICAL", 18, 21], ["CLA", "SIMPLE_CHEMICAL", 18, 21], ["selected dairy products", "TREATMENT", 33, 56]]], ["Research has shown that it is possible to influence the extent of ruminal biohydrogenation and the concentration of CLA absorbed and incorporated into milk fat.", [["milk fat", "ANATOMY", 151, 159], ["CLA", "CHEMICAL", 116, 119], ["CLA", "CHEMICAL", 116, 119], ["CLA", "SIMPLE_CHEMICAL", 116, 119], ["milk", "ORGANISM", 151, 155], ["fat", "TISSUE", 156, 159], ["ruminal biohydrogenation", "TREATMENT", 66, 90], ["ruminal biohydrogenation", "OBSERVATION", 66, 90]]], ["There is evidence that the concentration of CLA in milk influences its pharmaceutical properties (Kelly and Bauman, 1996) .", [["milk", "ANATOMY", 51, 55], ["CLA", "CHEMICAL", 44, 47], ["CLA", "CHEMICAL", 44, 47], ["CLA", "SIMPLE_CHEMICAL", 44, 47], ["milk", "ORGANISM_SUBSTANCE", 51, 55], ["concentration", "OBSERVATION_MODIFIER", 27, 40], ["CLA", "OBSERVATION_MODIFIER", 44, 47]]], ["The level of CLA could, therefore, influence the value of the milk as a commodity, although it is not at present a criterion for deciding the price of milk.B. Increasing CLA levels in milk fatCLAs reportedly suppress carcinogens, inhibiting proliferation of leukemia and cancers of the colon, prostate, ovaries, and breast.", [["milk", "ANATOMY", 62, 66], ["milk", "ANATOMY", 151, 155], ["milk", "ANATOMY", 184, 188], ["leukemia", "ANATOMY", 258, 266], ["cancers", "ANATOMY", 271, 278], ["colon", "ANATOMY", 286, 291], ["prostate", "ANATOMY", 293, 301], ["ovaries", "ANATOMY", 303, 310], ["breast", "ANATOMY", 316, 322], ["CLA", "CHEMICAL", 13, 16], ["CLA", "CHEMICAL", 170, 173], ["fatCLAs", "CHEMICAL", 189, 196], ["leukemia and cancers of the colon, prostate, ovaries", "DISEASE", 258, 310], ["CLA", "SIMPLE_CHEMICAL", 13, 16], ["milk", "ORGANISM_SUBSTANCE", 62, 66], ["milk", "ORGANISM_SUBSTANCE", 151, 155], ["CLA", "SIMPLE_CHEMICAL", 170, 173], ["milk", "ORGANISM_SUBSTANCE", 184, 188], ["fatCLAs", "SIMPLE_CHEMICAL", 189, 196], ["leukemia", "CANCER", 258, 266], ["cancers", "CANCER", 271, 278], ["colon", "ORGAN", 286, 291], ["prostate", "ORGAN", 293, 301], ["ovaries", "ORGAN", 303, 310], ["breast", "ORGAN", 316, 322], ["Increasing CLA levels", "PROBLEM", 159, 180], ["leukemia", "PROBLEM", 258, 266], ["cancers of the colon, prostate, ovaries, and breast", "PROBLEM", 271, 322], ["CLA", "OBSERVATION", 13, 16], ["Increasing", "OBSERVATION_MODIFIER", 159, 169], ["CLA", "OBSERVATION", 170, 173], ["proliferation", "OBSERVATION_MODIFIER", 241, 254], ["leukemia", "OBSERVATION", 258, 266], ["cancers", "OBSERVATION", 271, 278], ["colon", "ANATOMY", 286, 291], ["prostate", "ANATOMY", 293, 301], ["ovaries", "ANATOMY", 303, 310], ["breast", "ANATOMY", 316, 322]]], ["They are the only natural fatty acids accepted by the National Academy of Sciences of United States as exhibiting consistent antitumor properties at levels as low as 0.25-1.0% of total fats (Eynard and Lopez, 2003) .", [["antitumor", "ANATOMY", 125, 134], ["fatty acids", "CHEMICAL", 26, 37], ["fatty acids", "CHEMICAL", 26, 37], ["antitumor", "CANCER", 125, 134], ["fats", "ORGANISM_SUBDIVISION", 185, 189]]], ["The other reported beneficial health effects of CLA as supported by biomedical studies with animal models are antiatherogenic effect, altered nutrient partitioning, improved lipid metabolism, antidiabetic action (type II diabetes), immunity enhancement, and improved bone mineralization (Bauman et al., 2001; Bell and Kennelly, 2001) .B. Increasing CLA levels in milk fatReports suggest that feeding lipid sources rich in linoleic and linolenic acids either as seeds or free oil increases the CLA content of milk when oil is accessible to the rumen microorganisms for biohydrogenation (Dhiman et al., 2000) .", [["bone", "ANATOMY", 267, 271], ["oil", "ANATOMY", 475, 478], ["milk", "ANATOMY", 508, 512], ["oil", "ANATOMY", 518, 521], ["CLA", "CHEMICAL", 48, 51], ["type II diabetes", "DISEASE", 213, 229], ["CLA", "CHEMICAL", 349, 352], ["linoleic and linolenic acids", "CHEMICAL", 422, 450], ["CLA", "CHEMICAL", 493, 496], ["CLA", "CHEMICAL", 48, 51], ["linoleic and linolenic acids", "CHEMICAL", 422, 450], ["CLA", "SIMPLE_CHEMICAL", 48, 51], ["lipid", "SIMPLE_CHEMICAL", 174, 179], ["bone", "TISSUE", 267, 271], ["CLA", "SIMPLE_CHEMICAL", 349, 352], ["milk", "ORGANISM_SUBSTANCE", 363, 367], ["linoleic", "SIMPLE_CHEMICAL", 422, 430], ["linolenic acids", "SIMPLE_CHEMICAL", 435, 450], ["oil", "ORGANISM_SUBSTANCE", 475, 478], ["CLA", "SIMPLE_CHEMICAL", 493, 496], ["milk", "ORGANISM_SUBSTANCE", 508, 512], ["oil", "ORGANISM_SUBSTANCE", 518, 521], ["biomedical studies", "TEST", 68, 86], ["antiatherogenic effect", "PROBLEM", 110, 132], ["altered nutrient partitioning", "PROBLEM", 134, 163], ["improved lipid metabolism", "PROBLEM", 165, 190], ["type II diabetes)", "PROBLEM", 213, 230], ["immunity enhancement", "PROBLEM", 232, 252], ["improved bone mineralization", "PROBLEM", 258, 286], ["Increasing CLA levels in milk fatReports", "PROBLEM", 338, 378], ["linoleic and linolenic acids", "TREATMENT", 422, 450], ["nutrient partitioning", "OBSERVATION", 142, 163], ["lipid metabolism", "OBSERVATION", 174, 190], ["immunity enhancement", "OBSERVATION_MODIFIER", 232, 252], ["improved", "OBSERVATION_MODIFIER", 258, 266], ["bone", "ANATOMY", 267, 271], ["mineralization", "OBSERVATION", 272, 286]]], ["The scientists found that supplementing the dietary dry matter with 2% or 4% soybean resulted in a 237% or 314% increase in CLA content of milk compared with the control.", [["milk", "ANATOMY", 139, 143], ["CLA", "CHEMICAL", 124, 127], ["soybean", "ORGANISM", 77, 84], ["CLA", "SIMPLE_CHEMICAL", 124, 127], ["milk", "ORGANISM_SUBSTANCE", 139, 143], ["soybean", "SPECIES", 77, 84], ["4% soybean", "TREATMENT", 74, 84]]], ["Stanton (2000) and her team worked on the supplementation of cow's diet with ingredients such as full fat rapeseed, full fat soybean, and pulp-n-brew (by-product of brewers' grains rich in LA) to study their effect on the CLA levels in milk.", [["fat", "ANATOMY", 102, 105], ["fat", "ANATOMY", 121, 124], ["pulp", "ANATOMY", 138, 142], ["milk", "ANATOMY", 236, 240], ["LA", "CHEMICAL", 189, 191], ["CLA", "CHEMICAL", 222, 225], ["cow", "ORGANISM", 61, 64], ["fat", "TISSUE", 102, 105], ["pulp", "TISSUE", 138, 142], ["grains", "ORGANISM_SUBDIVISION", 174, 180], ["LA", "SIMPLE_CHEMICAL", 189, 191], ["CLA", "SIMPLE_CHEMICAL", 222, 225], ["milk", "ORGANISM_SUBSTANCE", 236, 240], ["cow", "SPECIES", 61, 64], ["soybean", "SPECIES", 125, 132], ["cow", "SPECIES", 61, 64], ["soybean", "SPECIES", 125, 132], ["the supplementation of cow's diet", "TREATMENT", 38, 71], ["full fat rapeseed", "TREATMENT", 97, 114], ["full fat soybean", "TREATMENT", 116, 132], ["pulp", "ANATOMY", 138, 142]]], ["When diets of pasture-fed cows were supplemented with full fat rapeseed and full fat soybean, the CLA levels in milk fat increased by 53% and 34%, respectively, after 18 days of feeding when compared to the unsupplemented group of cows on pasture which served as control.", [["milk fat", "ANATOMY", 112, 120], ["CLA", "CHEMICAL", 98, 101], ["cows", "ORGANISM", 26, 30], ["fat rapeseed", "TISSUE", 59, 71], ["fat", "ORGANISM_SUBDIVISION", 81, 84], ["soybean", "ORGANISM_SUBSTANCE", 85, 92], ["CLA", "SIMPLE_CHEMICAL", 98, 101], ["milk", "ORGANISM", 112, 116], ["fat", "TISSUE", 117, 120], ["cows", "ORGANISM", 231, 235], ["cows", "SPECIES", 26, 30], ["soybean", "SPECIES", 85, 92], ["cows", "SPECIES", 231, 235], ["soybean", "SPECIES", 85, 92], ["full fat rapeseed", "TREATMENT", 54, 71], ["full fat soybean", "TREATMENT", 76, 92], ["the CLA levels", "TEST", 94, 108]]], ["The yield and proximate composition of milk were unaffected by the supplementation.", [["milk", "ANATOMY", 39, 43], ["milk", "ORGANISM_SUBSTANCE", 39, 43], ["The yield and proximate composition of milk", "TREATMENT", 0, 43]]], ["Milk from a grass-fed cow can have five times as much CLA as milk from a grain-fed animal (Robinson, 2003) .", [["milk", "ANATOMY", 61, 65], ["CLA", "CHEMICAL", 54, 57], ["Milk", "ORGANISM_SUBSTANCE", 0, 4], ["cow", "ORGANISM", 22, 25], ["CLA", "SIMPLE_CHEMICAL", 54, 57], ["milk", "ORGANISM_SUBSTANCE", 61, 65], ["cow", "SPECIES", 22, 25], ["cow", "SPECIES", 22, 25]]], ["An experiment supplementing either silage, autumn grass, or spring grass over three periods with pulp-n-brew revealed that the CLA levels increased in case of supplementation of silage and autumn grass, but was less effective in the case of spring grass (Stanton, 2000) .", [["pulp", "ANATOMY", 97, 101], ["CLA", "CHEMICAL", 127, 130], ["pulp", "TISSUE", 97, 101], ["CLA", "SIMPLE_CHEMICAL", 127, 130], ["the CLA levels", "TEST", 123, 137], ["silage and autumn grass", "PROBLEM", 178, 201]]], ["Spring grass feeding led to a 2.1-fold increase in CLA content of milk.", [["milk", "ANATOMY", 66, 70], ["CLA", "CHEMICAL", 51, 54], ["CLA", "SIMPLE_CHEMICAL", 51, 54], ["milk", "ORGANISM_SUBSTANCE", 66, 70], ["a 2.1-fold increase in CLA content of milk", "TREATMENT", 28, 70]]], ["The CLA-enriched milk fat exhibited cytotoxicity toward mammary and colon cancer cells.B. Increasing CLA levels in milk fatIncorporating CLA along with soy oil in the diet of cows increased the CLA levels, simultaneously decreasing the SFA in milk fat (Pszczola et al., 2000) .", [["milk fat", "ANATOMY", 17, 25], ["mammary", "ANATOMY", 56, 63], ["colon cancer cells", "ANATOMY", 68, 86], ["milk fat", "ANATOMY", 115, 123], ["soy oil", "ANATOMY", 152, 159], ["milk fat", "ANATOMY", 243, 251], ["CLA", "CHEMICAL", 4, 7], ["mammary and colon cancer", "DISEASE", 56, 80], ["CLA", "CHEMICAL", 101, 104], ["CLA", "CHEMICAL", 137, 140], ["CLA", "CHEMICAL", 194, 197], ["SFA", "CHEMICAL", 236, 239], ["SFA", "CHEMICAL", 236, 239], ["CLA", "SIMPLE_CHEMICAL", 4, 7], ["milk", "ORGANISM", 17, 21], ["fat", "ORGANISM_SUBSTANCE", 22, 25], ["mammary", "CELL", 56, 63], ["colon cancer cells", "CELL", 68, 86], ["CLA", "SIMPLE_CHEMICAL", 101, 104], ["milk", "ORGANISM", 115, 119], ["fat", "ORGANISM_SUBDIVISION", 120, 123], ["CLA", "SIMPLE_CHEMICAL", 137, 140], ["oil", "ORGANISM_SUBSTANCE", 156, 159], ["cows", "ORGANISM", 175, 179], ["CLA", "SIMPLE_CHEMICAL", 194, 197], ["SFA", "SIMPLE_CHEMICAL", 236, 239], ["milk fat", "TISSUE", 243, 251], ["mammary and colon cancer cells", "CELL_TYPE", 56, 86], ["milk", "SPECIES", 17, 21], ["cows", "SPECIES", 175, 179], ["The CLA", "TEST", 0, 7], ["cytotoxicity toward mammary and colon cancer cells", "PROBLEM", 36, 86], ["soy oil", "TREATMENT", 152, 159], ["CLA", "ANATOMY", 4, 7], ["milk fat", "OBSERVATION", 17, 25], ["mammary", "ANATOMY", 56, 63], ["colon", "ANATOMY", 68, 73], ["cancer cells", "OBSERVATION", 74, 86], ["Increasing", "OBSERVATION_MODIFIER", 90, 100], ["CLA", "OBSERVATION", 101, 104], ["SFA", "ANATOMY", 236, 239], ["milk fat", "ANATOMY", 243, 251]]], ["In an attempt to increase the CLA content in milk via the cow's diet, Bell and Kennelly (2001) divided 28 Holstein cows into 4 groups and fed them different diets-control diet (CTD), low-fat diet (LFD), high-fat diet 1 (HF1), and high-fat diet 2 (HF2).", [["milk", "ANATOMY", 45, 49], ["CLA", "CHEMICAL", 30, 33], ["CLA", "SIMPLE_CHEMICAL", 30, 33], ["milk", "ORGANISM_SUBSTANCE", 45, 49], ["cow", "SPECIES", 58, 61], ["cows", "SPECIES", 115, 119], ["cow", "SPECIES", 58, 61], ["the cow's diet", "TREATMENT", 54, 68], ["low-fat diet (LFD)", "TREATMENT", 183, 201], ["high-fat diet", "TREATMENT", 203, 216], ["high-fat diet", "TREATMENT", 230, 243]]], ["The animals were kept on CTD for 8 days before starting the different diet regimen.", [["animals", "ORGANISM", 4, 11], ["CTD", "TREATMENT", 25, 28], ["the different diet regimen", "TREATMENT", 56, 82]]], ["All experimental diets resulted in lower fat percentage in the milk when compared to CTD, whereas other parameters such as milk yield, protein, and lactose were unaffected.", [["fat", "ANATOMY", 41, 44], ["milk", "ANATOMY", 63, 67], ["milk", "ANATOMY", 123, 127], ["lactose", "CHEMICAL", 148, 155], ["lactose", "CHEMICAL", 148, 155], ["fat", "TISSUE", 41, 44], ["milk", "ORGANISM_SUBSTANCE", 63, 67], ["milk", "ORGANISM_SUBSTANCE", 123, 127], ["lactose", "SIMPLE_CHEMICAL", 148, 155], ["All experimental diets", "TREATMENT", 0, 22], ["CTD", "PROBLEM", 85, 88], ["protein", "TEST", 135, 142], ["lactose", "TEST", 148, 155]]], ["The CLA concentration in milk fat was 0.49%, 0.56%, 3.7%, and 5.63% in the group fed CTD, LFD, HF1, and HF2, respectively.", [["milk fat", "ANATOMY", 25, 33], ["CLA", "CHEMICAL", 4, 7], ["CLA", "SIMPLE_CHEMICAL", 4, 7], ["milk fat", "ORGANISM_SUBSTANCE", 25, 33], ["The CLA concentration in milk fat", "TEST", 0, 33], ["LFD", "TEST", 90, 93], ["HF1", "TEST", 95, 98], ["HF2", "TEST", 104, 107], ["CLA", "OBSERVATION_MODIFIER", 4, 7], ["concentration", "OBSERVATION_MODIFIER", 8, 21]]], ["Thus, increasing the fat content in the diet increased the CLA content up to 9-12 times, despite lower total fat content.", [["fat", "ANATOMY", 21, 24], ["fat", "ANATOMY", 109, 112], ["CLA", "CHEMICAL", 59, 62], ["fat", "TISSUE", 21, 24], ["CLA", "SIMPLE_CHEMICAL", 59, 62], ["fat", "TISSUE", 109, 112], ["fat content", "OBSERVATION", 21, 32], ["fat content", "OBSERVATION", 109, 120]]], ["AbuGhazaleh et al. (2003) found that feeding lactating dairy cows a blend of fish oil and MUFA and PUFA resulted in an increase in the concentrations and yields of CLA in milk, the greatest increase being with a blend of a high LA source (e.g., regular sunflower seeds).", [["fish oil", "ANATOMY", 77, 85], ["milk", "ANATOMY", 171, 175], ["MUFA", "CHEMICAL", 90, 94], ["PUFA", "CHEMICAL", 99, 103], ["CLA", "CHEMICAL", 164, 167], ["LA", "CHEMICAL", 228, 230], ["MUFA", "CHEMICAL", 90, 94], ["PUFA", "CHEMICAL", 99, 103], ["CLA", "CHEMICAL", 164, 167], ["fish", "ORGANISM", 77, 81], ["oil", "ORGANISM_SUBSTANCE", 82, 85], ["MUFA", "SIMPLE_CHEMICAL", 90, 94], ["PUFA", "SIMPLE_CHEMICAL", 99, 103], ["CLA", "SIMPLE_CHEMICAL", 164, 167], ["milk", "ORGANISM_SUBSTANCE", 171, 175], ["LA", "SIMPLE_CHEMICAL", 228, 230], ["fish oil", "TREATMENT", 77, 85], ["MUFA", "TREATMENT", 90, 94], ["PUFA", "TREATMENT", 99, 103], ["CLA in milk", "PROBLEM", 164, 175], ["a high LA source", "PROBLEM", 221, 237], ["regular sunflower seeds", "TREATMENT", 245, 268], ["increase", "OBSERVATION_MODIFIER", 119, 127], ["greatest", "OBSERVATION_MODIFIER", 181, 189], ["increase", "OBSERVATION_MODIFIER", 190, 198]]], ["Beaulieu and Drackley (2004) reported similar results where a diet rich in LA led to increasing the CLA levels in milk fat twofold.", [["milk fat", "ANATOMY", 114, 122], ["LA", "CHEMICAL", 75, 77], ["CLA", "CHEMICAL", 100, 103], ["LA", "SIMPLE_CHEMICAL", 75, 77], ["CLA", "SIMPLE_CHEMICAL", 100, 103], ["milk fat", "ORGANISM_SUBSTANCE", 114, 122]]], ["Supplementing nonluminous green fodder with mustard cake in the feed of buffaloes resulted in 6.18-mg CLA per gram of fat as compared to 6.05 mg/g when the supplement was groundnut cake (Tyagi et al., 2004) .", [["fat", "ANATOMY", 118, 121], ["green fodder", "CHEMICAL", 26, 38], ["mustard cake", "CHEMICAL", 44, 56], ["CLA", "CHEMICAL", 102, 105], ["buffaloes", "ORGANISM", 72, 81], ["CLA", "SIMPLE_CHEMICAL", 102, 105], ["fat", "TISSUE", 118, 121], ["groundnut", "SPECIES", 171, 180], ["mustard cake", "TREATMENT", 44, 56], ["green fodder", "OBSERVATION", 26, 38], ["mustard cake", "OBSERVATION", 44, 56]]], ["The total CLA in buffalo milk and milk products increased significantly when the animals were fed berseem and wheat straw in the ratio 87:13.", [["milk", "ANATOMY", 25, 29], ["milk", "ANATOMY", 34, 38], ["CLA", "CHEMICAL", 10, 13], ["CLA", "SIMPLE_CHEMICAL", 10, 13], ["buffalo", "ORGANISM", 17, 24], ["milk", "ORGANISM_SUBSTANCE", 25, 29], ["milk products", "ORGANISM_SUBSTANCE", 34, 47], ["animals", "ORGANISM", 81, 88], ["buffalo", "SPECIES", 17, 24], ["wheat", "SPECIES", 110, 115], ["buffalo", "SPECIES", 17, 24], ["wheat", "SPECIES", 110, 115], ["The total CLA in buffalo milk", "TREATMENT", 0, 29], ["milk products", "TREATMENT", 34, 47], ["total", "OBSERVATION_MODIFIER", 4, 9], ["CLA", "OBSERVATION_MODIFIER", 10, 13], ["increased", "OBSERVATION_MODIFIER", 48, 57]]], ["Tsiplakou et al. (2006) examined the CLA content in the milk fat of sheep and goat milk segregated into two groups.", [["milk fat", "ANATOMY", 56, 64], ["milk", "ANATOMY", 83, 87], ["CLA", "CHEMICAL", 37, 40], ["CLA", "CHEMICAL", 37, 40], ["CLA", "SIMPLE_CHEMICAL", 37, 40], ["milk fat", "ORGANISM_SUBSTANCE", 56, 64], ["sheep", "ORGANISM", 68, 73], ["goat", "ORGANISM", 78, 82], ["milk", "ORGANISM_SUBSTANCE", 83, 87], ["milk", "SPECIES", 56, 60], ["sheep", "SPECIES", 68, 73], ["goat", "SPECIES", 78, 82], ["sheep", "SPECIES", 68, 73], ["goat", "SPECIES", 78, 82]]], ["The study revealed that the CLA content in milk fat of Group 1 increased in April and May, during the availability of early grass and declined thereafter, whereas that in Group 2 remained more or less constant.", [["milk fat", "ANATOMY", 43, 51], ["CLA", "CHEMICAL", 28, 31], ["CLA", "CHEMICAL", 28, 31], ["CLA", "SIMPLE_CHEMICAL", 28, 31], ["milk", "ORGANISM_SUBSTANCE", 43, 47], ["fat", "TISSUE", 48, 51], ["The study", "TEST", 0, 9], ["less constant", "OBSERVATION_MODIFIER", 196, 209]]], ["The CLA content (cis-9, trans-11) in sheep milk was 2% of the total fatty acids fat content and was much higher than that in goat milk (0.62%).B. Increasing CLA levels in milk fatAnimal variation is also a major source of differences in the CLA content of milk fat.", [["milk", "ANATOMY", 43, 47], ["milk", "ANATOMY", 130, 134], ["milk fat", "ANATOMY", 171, 179], ["milk fat", "ANATOMY", 256, 264], ["CLA", "CHEMICAL", 4, 7], ["cis-9, trans-11", "CHEMICAL", 17, 32], ["fatty acids", "CHEMICAL", 68, 79], ["CLA", "CHEMICAL", 157, 160], ["CLA", "CHEMICAL", 241, 244], ["CLA", "CHEMICAL", 4, 7], ["fatty acids", "CHEMICAL", 68, 79], ["CLA", "SIMPLE_CHEMICAL", 4, 7], ["cis-9", "SIMPLE_CHEMICAL", 17, 22], ["trans-11", "SIMPLE_CHEMICAL", 24, 32], ["sheep", "ORGANISM", 37, 42], ["milk", "ORGANISM_SUBSTANCE", 43, 47], ["fat", "TISSUE", 80, 83], ["goat", "ORGANISM", 125, 129], ["milk", "ORGANISM_SUBSTANCE", 130, 134], ["CLA", "SIMPLE_CHEMICAL", 157, 160], ["milk", "ORGANISM", 171, 175], ["CLA", "SIMPLE_CHEMICAL", 241, 244], ["milk", "ORGANISM_SUBSTANCE", 256, 260], ["fat", "TISSUE", 261, 264], ["sheep", "SPECIES", 37, 42], ["goat", "SPECIES", 125, 129], ["sheep", "SPECIES", 37, 42], ["goat", "SPECIES", 125, 129], ["The CLA content", "TEST", 0, 15], ["cis", "TEST", 17, 20], ["the total fatty acids fat content", "TEST", 58, 91], ["Increasing CLA levels", "PROBLEM", 146, 167], ["CLA", "ANATOMY", 4, 7], ["Increasing", "OBSERVATION_MODIFIER", 146, 156], ["CLA", "OBSERVATION_MODIFIER", 157, 160], ["levels", "OBSERVATION_MODIFIER", 161, 167], ["milk fat", "OBSERVATION_MODIFIER", 171, 179], ["milk fat", "OBSERVATION", 256, 264]]], ["Bauman and Perfield (2002) discovered that the 9,11 isomer of CLA in milk fat is synthesized by the cow and not rumen bacteria as had earlier been reported.", [["milk fat", "ANATOMY", 69, 77], ["CLA", "CHEMICAL", 62, 65], ["CLA", "CHEMICAL", 62, 65], ["9,11 isomer", "SIMPLE_CHEMICAL", 47, 58], ["CLA", "SIMPLE_CHEMICAL", 62, 65], ["milk fat", "ORGANISM_SUBSTANCE", 69, 77], ["cow", "ORGANISM", 100, 103], ["cow", "SPECIES", 100, 103], ["cow", "SPECIES", 100, 103], ["rumen bacteria", "PROBLEM", 112, 126]]], ["Synthesis involves a mammary enzyme, delta-9 desaturase, which acts on a trans-fatty (vaccenic) acid produced by rumen bacteria.", [["delta-9", "CHEMICAL", 37, 44], ["trans-fatty (vaccenic) acid", "CHEMICAL", 73, 100], ["mammary", "ORGAN", 21, 28], ["delta-9 desaturase", "GENE_OR_GENE_PRODUCT", 37, 55], ["trans-fatty (vaccenic) acid", "SIMPLE_CHEMICAL", 73, 100], ["mammary enzyme", "PROTEIN", 21, 35], ["delta-9 desaturase", "PROTEIN", 37, 55], ["a mammary enzyme", "TEST", 19, 35], ["delta", "TEST", 37, 42], ["rumen bacteria", "PROBLEM", 113, 127], ["mammary", "ANATOMY", 21, 28]]], ["Several genetic factors that regulate the expression of the delta-9 desaturase gene have been identified.", [["delta-9 desaturase", "GENE_OR_GENE_PRODUCT", 60, 78], ["delta-9 desaturase gene", "DNA", 60, 83], ["Several genetic factors", "PROBLEM", 0, 23], ["the delta", "TEST", 56, 65]]], ["In a line of transgenic goats that contained a rat stearoyl-CoA desaturase gene targeted at converting medium-and long-chain SFA to their monounsaturated forms, Reh et al. (2004) found that the desaturase enzyme also converted the rumen-derived MUFA C18:1 trans-11 to the C18:2 cis-9 trans-11 isomer (CLA) in the milk fat of one of these animals.C. The omega fatty acidsOmega-6 and omega-3 are essential fatty acids, but the body requires them in a ratio that is not normally achieved by the typical diet of today's developed nations.", [["milk fat", "ANATOMY", 313, 321], ["body", "ANATOMY", 425, 429], ["stearoyl-CoA", "CHEMICAL", 51, 63], ["SFA", "CHEMICAL", 125, 128], ["MUFA", "CHEMICAL", 245, 249], ["C18:1 trans-11", "CHEMICAL", 250, 264], ["C18:2 cis-9 trans-11 isomer", "CHEMICAL", 272, 299], ["CLA", "CHEMICAL", 301, 304], ["fatty acids", "CHEMICAL", 404, 415], ["stearoyl-CoA", "CHEMICAL", 51, 63], ["SFA", "CHEMICAL", 125, 128], ["MUFA C18:1 trans-11", "CHEMICAL", 245, 264], ["CLA", "CHEMICAL", 301, 304], ["omega fatty acidsOmega-6", "CHEMICAL", 353, 377], ["fatty acids", "CHEMICAL", 404, 415], ["goats", "ORGANISM", 24, 29], ["rat", "ORGANISM", 47, 50], ["stearoyl-CoA desaturase", "GENE_OR_GENE_PRODUCT", 51, 74], ["SFA", "SIMPLE_CHEMICAL", 125, 128], ["desaturase enzyme", "GENE_OR_GENE_PRODUCT", 194, 211], ["MUFA", "SIMPLE_CHEMICAL", 245, 249], ["C18:2 cis-9 trans-11 isomer", "SIMPLE_CHEMICAL", 272, 299], ["CLA", "SIMPLE_CHEMICAL", 301, 304], ["milk fat", "MULTI-TISSUE_STRUCTURE", 313, 321], ["C", "GENE_OR_GENE_PRODUCT", 346, 347], ["omega fatty acidsOmega-6", "SIMPLE_CHEMICAL", 353, 377], ["omega-3", "GENE_OR_GENE_PRODUCT", 382, 389], ["fatty acids", "SIMPLE_CHEMICAL", 404, 415], ["body", "ORGANISM_SUBDIVISION", 425, 429], ["rat stearoyl-CoA desaturase gene", "DNA", 47, 79], ["desaturase enzyme", "PROTEIN", 194, 211], ["goats", "SPECIES", 24, 29], ["rat", "SPECIES", 47, 50], ["goats", "SPECIES", 24, 29], ["rat", "SPECIES", 47, 50], ["a line of transgenic goats", "TREATMENT", 3, 29], ["a rat stearoyl-CoA desaturase gene", "TREATMENT", 45, 79], ["the desaturase enzyme", "TEST", 190, 211], ["the C18:2 cis", "TEST", 268, 281], ["The omega fatty acidsOmega", "TEST", 349, 375], ["essential fatty acids", "PROBLEM", 394, 415], ["SFA", "ANATOMY", 125, 128], ["fatty acids", "OBSERVATION", 404, 415]]], ["It is reported that the current average intakes of essential fatty acids expressed as ratios of o-6 to o-3 fatty acids are 8:1 in United Kingdom, 10:1 in United States, and 12:1 in Australia (www. omega-3info.com).", [["fatty acids", "CHEMICAL", 61, 72], ["o-3 fatty acids", "CHEMICAL", 103, 118], ["fatty acids", "CHEMICAL", 61, 72], ["o-6 to o-3 fatty acids", "CHEMICAL", 96, 118], ["o-3 fatty acids", "SIMPLE_CHEMICAL", 103, 118], ["essential fatty acids", "PROBLEM", 51, 72], ["fatty acids", "OBSERVATION", 61, 72]]], ["Health bulletins indicate that the proportion of o-6 to o-3 fatty acids should be equal or close to 5 for cardiovascular health (Simopoulos, 1999) .C. The omega fatty acidsAt present, the average PUFA content in modern diets (nearly 30% of calories) is too high.", [["cardiovascular", "ANATOMY", 106, 120], ["o-3 fatty acids", "CHEMICAL", 56, 71], ["fatty acids", "CHEMICAL", 161, 172], ["PUFA", "CHEMICAL", 196, 200], ["o-6 to o-3 fatty acids", "CHEMICAL", 49, 71], ["omega fatty acids", "CHEMICAL", 155, 172], ["PUFA", "CHEMICAL", 196, 200], ["o-3 fatty acids", "SIMPLE_CHEMICAL", 56, 71], ["omega fatty acids", "AMINO_ACID", 155, 172], ["PUFA", "SIMPLE_CHEMICAL", 196, 200], ["omega fatty acids", "PROTEIN", 155, 172], ["The omega fatty acids", "TREATMENT", 151, 172], ["the average PUFA content in modern diets", "TREATMENT", 184, 224]]], ["It is suggested that our PUFA intake should not be much greater than 4% of the caloric total, in approximate proportions of 2% o-3 linolenic acid and 2% o-6 linoleic acid (Fallon and Enig, 2000) .", [["PUFA", "CHEMICAL", 25, 29], ["o-3 linolenic acid", "CHEMICAL", 127, 145], ["o-6 linoleic acid", "CHEMICAL", 153, 170], ["PUFA", "CHEMICAL", 25, 29], ["o-3 linolenic acid", "CHEMICAL", 127, 145], ["o-6 linoleic acid", "CHEMICAL", 153, 170], ["Fallon", "CHEMICAL", 172, 178], ["PUFA", "SIMPLE_CHEMICAL", 25, 29], ["o-3 linolenic acid", "SIMPLE_CHEMICAL", 127, 145], ["o-6 linoleic acid", "SIMPLE_CHEMICAL", 153, 170], ["our PUFA intake", "TREATMENT", 21, 36], ["3 linolenic acid", "TREATMENT", 129, 145]]], ["The intake of total o-3 fatty acids in the United States is 1.6 g/day (Kris-Etherton et al., 2002) .", [["o-3 fatty acids", "CHEMICAL", 20, 35], ["o-3 fatty acids", "CHEMICAL", 20, 35], ["o-3 fatty acids", "SIMPLE_CHEMICAL", 20, 35], ["total o-3 fatty acids", "TREATMENT", 14, 35]]], ["Of this, a-linolenic acid (ALA) accounts for 1.4 g/ day, whereas eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) together account only for 0.1-0.2 g/day.", [["a-linolenic acid", "CHEMICAL", 9, 25], ["ALA", "CHEMICAL", 27, 30], ["eicosapentaenoic acid", "CHEMICAL", 65, 86], ["EPA", "CHEMICAL", 88, 91], ["docosahexaenoic acid", "CHEMICAL", 97, 117], ["DHA", "CHEMICAL", 119, 122], ["a-linolenic acid", "CHEMICAL", 9, 25], ["ALA", "CHEMICAL", 27, 30], ["eicosapentaenoic acid", "CHEMICAL", 65, 86], ["EPA", "CHEMICAL", 88, 91], ["docosahexaenoic acid", "CHEMICAL", 97, 117], ["DHA", "CHEMICAL", 119, 122], ["a-linolenic acid", "SIMPLE_CHEMICAL", 9, 25], ["ALA", "SIMPLE_CHEMICAL", 27, 30], ["eicosapentaenoic acid", "SIMPLE_CHEMICAL", 65, 86], ["EPA", "SIMPLE_CHEMICAL", 88, 91], ["docosahexaenoic acid", "SIMPLE_CHEMICAL", 97, 117], ["DHA", "SIMPLE_CHEMICAL", 119, 122], ["a-linolenic acid (ALA)", "TREATMENT", 9, 31], ["eicosapentaenoic acid (EPA", "TREATMENT", 65, 91], ["docosahexaenoic acid (DHA)", "TREATMENT", 97, 123]]], ["DHA is required by the brain and nerve cells and is essential for normal visual and neurological development in infants (Tomlinson, 2003) .", [["brain", "ANATOMY", 23, 28], ["nerve cells", "ANATOMY", 33, 44], ["neurological", "ANATOMY", 84, 96], ["DHA", "CHEMICAL", 0, 3], ["DHA", "CHEMICAL", 0, 3], ["DHA", "SIMPLE_CHEMICAL", 0, 3], ["brain", "ORGAN", 23, 28], ["nerve cells", "CELL", 33, 44], ["infants", "ORGANISM", 112, 119], ["nerve cells", "CELL_TYPE", 33, 44], ["infants", "SPECIES", 112, 119], ["DHA", "PROBLEM", 0, 3], ["brain", "ANATOMY", 23, 28], ["nerve", "ANATOMY", 33, 38]]], ["The major food sources of ALA are vegetable oils, principally canola and soybean oils.", [["vegetable oils", "ANATOMY", 34, 48], ["oils", "ANATOMY", 81, 85], ["ALA", "CHEMICAL", 26, 29], ["ALA", "CHEMICAL", 26, 29], ["ALA", "SIMPLE_CHEMICAL", 26, 29], ["vegetable oils", "ORGANISM_SUBSTANCE", 34, 48], ["canola", "ORGANISM_SUBDIVISION", 62, 68], ["soybean oils", "ORGANISM_SUBSTANCE", 73, 85], ["canola", "SPECIES", 62, 68], ["soybean", "SPECIES", 73, 80], ["canola", "SPECIES", 62, 68], ["soybean", "SPECIES", 73, 80], ["ALA", "OBSERVATION_MODIFIER", 26, 29]]], ["Oily fish are the richest source of EPA and DHA.", [["EPA", "CHEMICAL", 36, 39], ["DHA", "CHEMICAL", 44, 47], ["EPA", "CHEMICAL", 36, 39], ["DHA", "CHEMICAL", 44, 47], ["EPA", "SIMPLE_CHEMICAL", 36, 39], ["DHA", "SIMPLE_CHEMICAL", 44, 47]]], ["EPA and DHA can be made by the body from ALA, but sometimes this capacity is impaired, so oily fish remains the best source.", [["body", "ANATOMY", 31, 35], ["EPA", "CHEMICAL", 0, 3], ["DHA", "CHEMICAL", 8, 11], ["ALA", "CHEMICAL", 41, 44], ["EPA", "CHEMICAL", 0, 3], ["DHA", "CHEMICAL", 8, 11], ["ALA", "CHEMICAL", 41, 44], ["EPA", "SIMPLE_CHEMICAL", 0, 3], ["DHA", "SIMPLE_CHEMICAL", 8, 11], ["body", "ORGANISM_SUBDIVISION", 31, 35], ["ALA", "SIMPLE_CHEMICAL", 41, 44], ["EPA", "TREATMENT", 0, 3], ["DHA", "TREATMENT", 8, 11], ["this capacity", "PROBLEM", 60, 73], ["impaired", "OBSERVATION", 77, 85]]], ["The recommendations for intake of o-3 fatty acids range from 0.5 to 2 g/day.", [["o-3 fatty acids", "CHEMICAL", 34, 49], ["o-3 fatty acids", "CHEMICAL", 34, 49], ["o-3 fatty acids", "SIMPLE_CHEMICAL", 34, 49], ["intake of o-3 fatty acids", "TREATMENT", 24, 49]]], ["ISSFAL (International Society for the Study of Fatty Acids and Lipids) recommend 0.65-g EPA and DHA per day (Willumsen, 2006) .", [["EPA", "CHEMICAL", 88, 91], ["DHA", "CHEMICAL", 96, 99], ["Fatty Acids", "CHEMICAL", 47, 58], ["EPA", "CHEMICAL", 88, 91], ["DHA", "CHEMICAL", 96, 99], ["Fatty Acids", "SIMPLE_CHEMICAL", 47, 58], ["EPA", "SIMPLE_CHEMICAL", 88, 91], ["DHA", "SIMPLE_CHEMICAL", 96, 99], ["Fatty Acids", "TREATMENT", 47, 58], ["Lipids", "TREATMENT", 63, 69]]], ["Omega-6 is the essential fatty acid that is in ample supply in oils, nuts, and seeds.", [["oils", "ANATOMY", 63, 67], ["nuts", "ANATOMY", 69, 73], ["seeds", "ANATOMY", 79, 84], ["Omega-6", "CHEMICAL", 0, 7], ["fatty acid", "CHEMICAL", 25, 35], ["fatty acid", "CHEMICAL", 25, 35], ["Omega-6", "GENE_OR_GENE_PRODUCT", 0, 7], ["fatty acid", "SIMPLE_CHEMICAL", 25, 35], ["oils", "TISSUE", 63, 67], ["nuts", "ORGANISM_SUBDIVISION", 69, 73], ["seeds", "ORGANISM_SUBDIVISION", 79, 84], ["the essential fatty acid", "TREATMENT", 11, 35], ["fatty acid", "OBSERVATION", 25, 35]]], ["Table 3 lists the o-6 and o-3 fatty acid contents in commonly available food ingredients.C. The omega fatty acidsToo much o-6 in the diet creates an imbalance that can disrupt the production of prostaglandins leading to increased tendency to form blood clots, inflammation, high blood pressure, irritation of the digestive tract, Meat and fish (EPA \u00fe DHA g/100g edible portion) Poultry 0.05 -Oily fish 1.8-1.9 -Bacon and ham 0.008-0.009 -depressed immune function, sterility, cell proliferation, cancer, water retention, and weight gain.", [["blood clots", "ANATOMY", 247, 258], ["blood", "ANATOMY", 279, 284], ["digestive tract", "ANATOMY", 313, 328], ["cell", "ANATOMY", 476, 480], ["cancer", "ANATOMY", 496, 502], ["fatty acid", "CHEMICAL", 30, 40], ["o-6", "CHEMICAL", 122, 125], ["prostaglandins", "CHEMICAL", 194, 208], ["inflammation", "DISEASE", 260, 272], ["irritation of the digestive tract", "DISEASE", 295, 328], ["DHA", "CHEMICAL", 351, 354], ["depressed", "DISEASE", 438, 447], ["cancer", "DISEASE", 496, 502], ["weight gain", "DISEASE", 525, 536], ["o-6 and o-3 fatty acid", "CHEMICAL", 18, 40], ["omega fatty acids", "CHEMICAL", 96, 113], ["prostaglandins", "CHEMICAL", 194, 208], ["DHA", "CHEMICAL", 351, 354], ["o-3 fatty acid", "SIMPLE_CHEMICAL", 26, 40], ["C", "GENE_OR_GENE_PRODUCT", 89, 90], ["omega fatty acids", "SIMPLE_CHEMICAL", 96, 113], ["prostaglandins", "SIMPLE_CHEMICAL", 194, 208], ["blood", "ORGANISM_SUBSTANCE", 247, 252], ["clots", "ORGANISM_SUBSTANCE", 253, 258], ["blood", "ORGANISM_SUBSTANCE", 279, 284], ["digestive tract", "ORGANISM_SUBDIVISION", 313, 328], ["Meat", "ORGANISM_SUBDIVISION", 330, 334], ["fish", "ORGANISM_SUBDIVISION", 339, 343], ["EPA", "SIMPLE_CHEMICAL", 345, 348], ["cell", "CELL", 476, 480], ["cancer", "CANCER", 496, 502], ["The omega fatty acids", "TREATMENT", 92, 113], ["an imbalance", "PROBLEM", 146, 158], ["prostaglandins", "TREATMENT", 194, 208], ["increased tendency", "PROBLEM", 220, 238], ["blood clots", "PROBLEM", 247, 258], ["inflammation", "PROBLEM", 260, 272], ["high blood pressure", "PROBLEM", 274, 293], ["irritation of the digestive tract", "PROBLEM", 295, 328], ["fish (EPA \u00fe DHA g/100g edible portion", "TREATMENT", 339, 376], ["Poultry", "TEST", 378, 385], ["Oily fish", "TEST", 392, 401], ["depressed immune function", "PROBLEM", 438, 463], ["sterility", "PROBLEM", 465, 474], ["cell proliferation", "PROBLEM", 476, 494], ["cancer", "PROBLEM", 496, 502], ["water retention", "PROBLEM", 504, 519], ["weight gain", "PROBLEM", 525, 536], ["imbalance", "OBSERVATION", 149, 158], ["clots", "OBSERVATION", 253, 258], ["pressure", "OBSERVATION_MODIFIER", 285, 293], ["digestive tract", "ANATOMY", 313, 328], ["cell proliferation", "OBSERVATION", 476, 494], ["cancer", "OBSERVATION", 496, 502], ["water retention", "OBSERVATION", 504, 519]]], ["On the other hand, deficiency in o-3 is associated with asthma, heart disease, and learning deficiencies.", [["heart", "ANATOMY", 64, 69], ["asthma", "DISEASE", 56, 62], ["heart disease", "DISEASE", 64, 77], ["learning deficiencies", "DISEASE", 83, 104], ["o-3", "GENE_OR_GENE_PRODUCT", 33, 36], ["heart", "ORGAN", 64, 69], ["deficiency in o", "PROBLEM", 19, 34], ["asthma", "PROBLEM", 56, 62], ["heart disease", "PROBLEM", 64, 77], ["learning deficiencies", "PROBLEM", 83, 104], ["deficiency", "OBSERVATION", 19, 29], ["associated with", "UNCERTAINTY", 40, 55], ["asthma", "OBSERVATION", 56, 62], ["heart", "ANATOMY", 64, 69], ["disease", "OBSERVATION", 70, 77]]], ["It is established that o-3 fatty acids have a hypolipidaemic action in human, reducing harmful cholesterol levels, particularly plasma triglycerides (Tomlinson, 2003) .", [["plasma", "ANATOMY", 128, 134], ["o-3 fatty acids", "CHEMICAL", 23, 38], ["cholesterol", "CHEMICAL", 95, 106], ["o-3 fatty acids", "CHEMICAL", 23, 38], ["cholesterol", "CHEMICAL", 95, 106], ["triglycerides", "CHEMICAL", 135, 148], ["o-3 fatty acids", "SIMPLE_CHEMICAL", 23, 38], ["human", "ORGANISM", 71, 76], ["cholesterol", "SIMPLE_CHEMICAL", 95, 106], ["plasma", "ORGANISM_SUBSTANCE", 128, 134], ["triglycerides", "SIMPLE_CHEMICAL", 135, 148], ["human", "SPECIES", 71, 76], ["human", "SPECIES", 71, 76], ["harmful cholesterol levels", "TEST", 87, 113], ["plasma triglycerides", "TEST", 128, 148]]], ["It also has an anti-inflammatory action and helps to reduce platelet aggregation.", [["platelet", "ANATOMY", 60, 68], ["platelet aggregation", "DISEASE", 60, 80], ["platelet", "CELL", 60, 68], ["an anti-inflammatory action", "TREATMENT", 12, 39], ["platelet aggregation", "PROBLEM", 60, 80], ["anti-inflammatory", "OBSERVATION", 15, 32], ["platelet aggregation", "OBSERVATION", 60, 80]]], ["Essential fatty acids have proven to be effective in the treatment of several other ailments including eczema, rheumatoid arthritis, asthma, Alzheimer's disease, and Attention Deficit Hyperactivity Disorder (ADHD).", [["fatty acids", "CHEMICAL", 10, 21], ["eczema", "DISEASE", 103, 109], ["rheumatoid arthritis", "DISEASE", 111, 131], ["asthma", "DISEASE", 133, 139], ["Alzheimer's disease", "DISEASE", 141, 160], ["Attention Deficit Hyperactivity Disorder", "DISEASE", 166, 206], ["ADHD", "DISEASE", 208, 212], ["fatty acids", "CHEMICAL", 10, 21], ["Essential fatty acids", "SIMPLE_CHEMICAL", 0, 21], ["Essential fatty acids", "PROBLEM", 0, 21], ["several other ailments", "PROBLEM", 70, 92], ["eczema", "PROBLEM", 103, 109], ["rheumatoid arthritis", "PROBLEM", 111, 131], ["asthma", "PROBLEM", 133, 139], ["Alzheimer's disease", "PROBLEM", 141, 160], ["Attention Deficit Hyperactivity Disorder", "PROBLEM", 166, 206], ["fatty acids", "OBSERVATION", 10, 21], ["effective", "OBSERVATION_MODIFIER", 40, 49], ["ailments", "OBSERVATION", 84, 92], ["eczema", "OBSERVATION", 103, 109], ["rheumatoid arthritis", "OBSERVATION", 111, 131], ["asthma", "OBSERVATION", 133, 139], ["Alzheimer's disease", "OBSERVATION", 141, 160]]], ["There are reports that approximately equal amounts of these two fats in the diet will result in lower risk of cancer, cardiovascular disease, autoimmune disorders, allergies, obesity, diabetes, dementia, and some mental disorders (www.flax.com/newlibrary/ESSENT.html).", [["cancer", "ANATOMY", 110, 116], ["cardiovascular", "ANATOMY", 118, 132], ["cancer", "DISEASE", 110, 116], ["cardiovascular disease", "DISEASE", 118, 140], ["autoimmune disorders", "DISEASE", 142, 162], ["allergies", "DISEASE", 164, 173], ["obesity", "DISEASE", 175, 182], ["diabetes", "DISEASE", 184, 192], ["dementia", "DISEASE", 194, 202], ["cancer", "CANCER", 110, 116], ["cardiovascular", "ANATOMICAL_SYSTEM", 118, 132], ["cancer", "PROBLEM", 110, 116], ["cardiovascular disease", "PROBLEM", 118, 140], ["autoimmune disorders", "PROBLEM", 142, 162], ["allergies", "PROBLEM", 164, 173], ["obesity", "PROBLEM", 175, 182], ["diabetes", "PROBLEM", 184, 192], ["dementia", "PROBLEM", 194, 202], ["some mental disorders", "PROBLEM", 208, 229], ["cancer", "OBSERVATION", 110, 116], ["cardiovascular disease", "OBSERVATION", 118, 140], ["autoimmune disorders", "OBSERVATION", 142, 162], ["obesity", "OBSERVATION", 175, 182], ["diabetes", "OBSERVATION", 184, 192], ["dementia", "OBSERVATION", 194, 202], ["mental disorders", "OBSERVATION", 213, 229]]], ["Dietary manipulation in cows is a practical way to maintain a desired ratio of o-6 to o-3 fatty acids in milk.", [["milk", "ANATOMY", 105, 109], ["o-3 fatty acids", "CHEMICAL", 86, 101], ["o-6 to o-3 fatty acids", "CHEMICAL", 79, 101], ["cows", "ORGANISM", 24, 28], ["o-3 fatty acids", "SIMPLE_CHEMICAL", 86, 101], ["milk", "ORGANISM_SUBSTANCE", 105, 109], ["cows", "SPECIES", 24, 28], ["Dietary manipulation", "TREATMENT", 0, 20]]], ["Milk from pastured cows contains an ideal ratio of essential fatty acids.", [["fatty acids", "CHEMICAL", 61, 72], ["fatty acids", "CHEMICAL", 61, 72], ["Milk", "ORGANISM_SUBSTANCE", 0, 4], ["cows", "ORGANISM", 19, 23], ["fatty acids", "SIMPLE_CHEMICAL", 61, 72], ["cows", "SPECIES", 19, 23], ["essential fatty acids", "TREATMENT", 51, 72], ["fatty acids", "OBSERVATION", 61, 72]]], ["Dhiman et al. (1999) reported equal quantities of the omega fatty acids (16.5 mg/g fat) in the milk of cows entirely on pasture.", [["milk", "ANATOMY", 95, 99], ["fatty acids", "CHEMICAL", 60, 71], ["omega fatty acids", "CHEMICAL", 54, 71], ["omega fatty acids", "SIMPLE_CHEMICAL", 54, 71], ["fat", "TISSUE", 83, 86], ["milk", "ORGANISM_SUBSTANCE", 95, 99], ["cows", "ORGANISM", 103, 107], ["cows", "SPECIES", 103, 107], ["the omega fatty acids", "TREATMENT", 50, 71]]], ["Reducing the proportion of grass to two-third of the ration increased the o-6 fatty acids to 31.4 and decreased o-3 fatty acids to 13.5 mg/g milk fat.", [["milk fat", "ANATOMY", 141, 149], ["o-6 fatty acids", "CHEMICAL", 74, 89], ["o-3 fatty acids", "CHEMICAL", 112, 127], ["o-6 fatty acids", "CHEMICAL", 74, 89], ["o-3 fatty acids", "CHEMICAL", 112, 127], ["o-6 fatty acids", "SIMPLE_CHEMICAL", 74, 89], ["o-3 fatty acids", "SIMPLE_CHEMICAL", 112, 127], ["milk", "ORGANISM", 141, 145], ["fat", "TISSUE", 146, 149], ["the o", "TEST", 70, 75], ["fatty acids", "TEST", 78, 89]]], ["Further reduction in the dietary proportion of grass to one-third resulted in 42.7 and 8.2 mg/g fat of o-6 and o-3 fatty acids, respectively.", [["o-6 and o-3 fatty acids", "CHEMICAL", 103, 126], ["o-6 and o-3 fatty acids", "CHEMICAL", 103, 126], ["fat", "TISSUE", 96, 99], ["o-6", "SIMPLE_CHEMICAL", 103, 106], ["o-3 fatty acids", "SIMPLE_CHEMICAL", 111, 126], ["Further reduction", "TREATMENT", 0, 17], ["reduction", "OBSERVATION_MODIFIER", 8, 17]]], ["There are reports that organic milk contains almost 70% more o-3 fatty acid than nonorganic milk (Cheek, 2006) .C. The omega fatty acidsMammals are dependent on dietary sources of essential fatty acids as they lack the desaturase enzymes necessary to synthesize them.", [["o-3 fatty acid", "CHEMICAL", 61, 75], ["o-3 fatty acid", "CHEMICAL", 61, 75], ["omega fatty acidsMammals", "CHEMICAL", 119, 143], ["fatty acids", "CHEMICAL", 190, 201], ["milk", "ORGANISM_SUBSTANCE", 31, 35], ["o-3 fatty acid", "SIMPLE_CHEMICAL", 61, 75], ["milk", "ORGANISM_SUBSTANCE", 92, 96], ["omega fatty acidsMammals", "SIMPLE_CHEMICAL", 119, 143], ["fatty acids", "AMINO_ACID", 190, 201], ["desaturase enzymes", "PROTEIN", 219, 237], ["organic milk", "PROBLEM", 23, 35], ["The omega fatty acidsMammals", "PROBLEM", 115, 143], ["essential fatty acids", "PROBLEM", 180, 201], ["the desaturase enzymes", "TEST", 215, 237], ["Cheek", "ANATOMY", 98, 103], ["omega", "OBSERVATION_MODIFIER", 119, 124], ["fatty acidsMammals", "OBSERVATION", 125, 143], ["dependent", "OBSERVATION_MODIFIER", 148, 157], ["fatty acids", "OBSERVATION", 190, 201]]], ["Kao et al. (2006) engineered transgenic mice expressing the o-3 fatty acid desaturase enzyme from the nematode Caenorhabditis elegans, which synthesizes a wide range of PUFA and possesses the only known example of an o-3 desaturase enzyme in the animal kingdom.", [["PUFA", "CHEMICAL", 169, 173], ["o-3 fatty acid", "CHEMICAL", 60, 74], ["PUFA", "CHEMICAL", 169, 173], ["mice", "ORGANISM", 40, 44], ["o-3", "GENE_OR_GENE_PRODUCT", 60, 63], ["fatty acid desaturase", "GENE_OR_GENE_PRODUCT", 64, 85], ["nematode", "ORGANISM", 102, 110], ["Caenorhabditis elegans", "ORGANISM", 111, 133], ["PUFA", "SIMPLE_CHEMICAL", 169, 173], ["o-3 desaturase", "GENE_OR_GENE_PRODUCT", 217, 231], ["fatty acid desaturase enzyme", "PROTEIN", 64, 92], ["o-3 desaturase enzyme", "PROTEIN", 217, 238], ["mice", "SPECIES", 40, 44], ["Caenorhabditis elegans", "SPECIES", 111, 133], ["mice", "SPECIES", 40, 44], ["Caenorhabditis elegans", "SPECIES", 111, 133], ["3 fatty acid desaturase enzyme", "PROBLEM", 62, 92], ["the nematode Caenorhabditis elegans", "PROBLEM", 98, 133], ["desaturase enzyme", "TEST", 221, 238], ["nematode Caenorhabditis elegans", "OBSERVATION", 102, 133]]], ["The milk from these mice had more o-3 and less o-6 PUFA, and hence had showed an overall decrease in the o-6:o-3 PUFA ratio in the milk.", [["milk", "ANATOMY", 4, 8], ["milk", "ANATOMY", 131, 135], ["o-6 PUFA", "CHEMICAL", 47, 55], ["o-6:o-3 PUFA", "CHEMICAL", 105, 117], ["PUFA", "CHEMICAL", 51, 55], ["o-6:o-3 PUFA", "CHEMICAL", 105, 117], ["milk", "ORGANISM_SUBSTANCE", 4, 8], ["mice", "ORGANISM", 20, 24], ["o-6 PUFA", "SIMPLE_CHEMICAL", 47, 55], [":o-3 PUFA", "SIMPLE_CHEMICAL", 108, 117], ["milk", "ORGANISM_SUBSTANCE", 131, 135], ["mice", "SPECIES", 20, 24], ["mice", "SPECIES", 20, 24], ["an overall decrease", "PROBLEM", 78, 97], ["the o", "TEST", 101, 106], ["decrease", "OBSERVATION_MODIFIER", 89, 97]]], ["The milk phospholipids from the transgenic mice had an o-6:o-3 ratio of 1.78 as compared to 9.82 in the control animals.", [["milk", "ANATOMY", 4, 8], ["milk phospholipids", "ORGANISM_SUBSTANCE", 4, 22], ["mice", "ORGANISM", 43, 47], [":o-3", "GENE_OR_GENE_PRODUCT", 58, 62], ["mice", "SPECIES", 43, 47], ["mice", "SPECIES", 43, 47], ["The milk phospholipids", "TEST", 0, 22]]], ["The authors anticipate that this may be a suitable method to improve the nutritional profile of dairy-based diets.D. Reducing fat content in milkIt has long been recognized that the yield of milk fat can be altered through nutritional interventions.", [["fat", "ANATOMY", 126, 129], ["milk fat", "ANATOMY", 191, 199], ["fat", "TISSUE", 126, 129], ["milk", "ORGANISM_SUBSTANCE", 141, 145], ["milk", "ORGANISM", 191, 195], ["fat", "TISSUE", 196, 199], ["milk", "SPECIES", 141, 145], ["a suitable method", "TREATMENT", 40, 57], ["nutritional interventions", "TREATMENT", 223, 248], ["fat content", "OBSERVATION", 126, 137]]], ["Several workers have reported that supplementing normal diet with fats in different forms and concentrations decreases the yield of fat in milk (Baumgard et al., 2000; Bell and Kennelly, 2001; Chouinard et al., 1999; Peterson et al., 2002) .", [["fat", "ANATOMY", 132, 135], ["milk", "ANATOMY", 139, 143], ["fats", "SIMPLE_CHEMICAL", 66, 70], ["fat", "TISSUE", 132, 135], ["milk", "ORGANISM_SUBSTANCE", 139, 143]]], ["Genetic studies also pointed to the power of hereditary traits in influencing the quality of milk.", [["milk", "ANATOMY", 93, 97], ["milk", "ORGANISM_SUBSTANCE", 93, 97], ["Genetic studies", "TEST", 0, 15], ["hereditary traits", "PROBLEM", 45, 62]]], ["Genetic markers for milk quality of dairy cattle were discovered and reported by the Iowa State University in the United States in 1996 (www.biotech.iastate.edu/biotech_update).", [["milk", "ANATOMY", 20, 24], ["milk", "ORGANISM_SUBSTANCE", 20, 24], ["cattle", "SPECIES", 42, 48], ["cattle", "SPECIES", 42, 48], ["Genetic markers", "TEST", 0, 15]]], ["Laboratory experiments with the marker revealed that animals with the ability to produce low-fat milk could be accurately identified.", [["fat milk", "ANATOMY", 93, 101], ["fat milk", "ORGANISM_SUBSTANCE", 93, 101], ["Laboratory experiments", "TEST", 0, 22], ["the marker", "TEST", 28, 38]]], ["Such genetic testing was aimed at improving dairy herd performance by identifying animals with the potential to produce low-fat milk.", [["fat milk", "ANATOMY", 124, 132], ["dairy", "ORGANISM_SUBDIVISION", 44, 49], ["herd", "ORGANISM_SUBDIVISION", 50, 54], ["fat milk", "ORGANISM_SUBSTANCE", 124, 132], ["Such genetic testing", "TEST", 0, 20]]], ["A herd producing low-fat milk was seen as a means to reduce milk-processing costs as the low-fat milk eliminated the necessity to separate fat from milk.D. Reducing fat content in milkAs a variation to altering the fat composition, Wall et al. (1997) suggested that modifying the cow's genetic makeup to enable it to produce milk with 2% fat would reduce the cost of feed per kilogram milk by 22%.D. Reducing fat content in milkIn changing the fat composition, targeting enzymes that influence the synthesis of fat is important.", [["fat milk", "ANATOMY", 21, 29], ["milk", "ANATOMY", 60, 64], ["fat milk", "ANATOMY", 93, 101], ["fat", "ANATOMY", 139, 142], ["milk", "ANATOMY", 148, 152], ["fat", "ANATOMY", 165, 168], ["fat", "ANATOMY", 215, 218], ["milk", "ANATOMY", 325, 329], ["fat", "ANATOMY", 338, 341], ["fat", "ANATOMY", 409, 412], ["fat", "ANATOMY", 444, 447], ["fat", "ANATOMY", 511, 514], ["fat milk", "ORGANISM_SUBSTANCE", 21, 29], ["milk", "ORGANISM_SUBDIVISION", 60, 64], ["fat milk", "ORGANISM_SUBSTANCE", 93, 101], ["fat", "TISSUE", 139, 142], ["milk", "ORGANISM_SUBSTANCE", 148, 152], ["fat", "TISSUE", 165, 168], ["milk", "ORGANISM_SUBSTANCE", 180, 184], ["fat", "TISSUE", 215, 218], ["cow", "ORGANISM", 280, 283], ["milk", "ORGANISM_SUBSTANCE", 325, 329], ["fat", "TISSUE", 338, 341], ["milk", "ORGANISM_SUBSTANCE", 385, 389], ["fat", "TISSUE", 409, 412], ["fat", "TISSUE", 444, 447], ["fat", "TISSUE", 511, 514], ["milk", "SPECIES", 180, 184], ["cow", "SPECIES", 280, 283], ["A herd producing low-fat milk", "TREATMENT", 0, 29], ["milk-processing costs", "TREATMENT", 60, 81], ["the low-fat milk", "TREATMENT", 85, 101], ["the cow's genetic makeup", "TREATMENT", 276, 300], ["milkIn changing the fat composition", "TREATMENT", 424, 459], ["targeting enzymes", "TEST", 461, 478], ["fat content", "OBSERVATION", 165, 176], ["fat content", "OBSERVATION", 409, 420]]], ["As an example, reduction of acetyl-CoA carboxylase that regulates the rate of fat synthesis within the mammary gland would translate to a drastic reduction in the fat content of milk and reduce the energy required by the animal to produce milk (Ntambi et al., 1999) .E. Type of fatty acids versus product qualityThe type of fatty acids present in milk fat can influence the flavor and physical properties of dairy products.", [["fat", "ANATOMY", 78, 81], ["mammary gland", "ANATOMY", 103, 116], ["fat", "ANATOMY", 163, 166], ["milk", "ANATOMY", 178, 182], ["milk fat", "ANATOMY", 347, 355], ["acetyl-CoA", "CHEMICAL", 28, 38], ["fatty acids", "CHEMICAL", 278, 289], ["fatty acids", "CHEMICAL", 324, 335], ["acetyl-CoA", "CHEMICAL", 28, 38], ["fatty acids", "CHEMICAL", 278, 289], ["fatty acids", "CHEMICAL", 324, 335], ["acetyl-CoA carboxylase", "GENE_OR_GENE_PRODUCT", 28, 50], ["fat", "TISSUE", 78, 81], ["mammary gland", "ORGAN", 103, 116], ["fat", "TISSUE", 163, 166], ["milk", "ORGANISM_SUBSTANCE", 178, 182], ["milk", "ORGANISM_SUBSTANCE", 239, 243], ["fatty acids", "SIMPLE_CHEMICAL", 278, 289], ["fatty acids", "SIMPLE_CHEMICAL", 324, 335], ["milk fat", "ORGANISM_SUBSTANCE", 347, 355], ["acetyl-CoA carboxylase", "PROTEIN", 28, 50], ["acetyl-CoA carboxylase", "TREATMENT", 28, 50], ["fat synthesis", "PROBLEM", 78, 91], ["a drastic reduction in the fat content of milk", "TREATMENT", 136, 182], ["Type of fatty acids", "PROBLEM", 270, 289], ["fatty acids", "PROBLEM", 324, 335], ["dairy products", "TREATMENT", 408, 422], ["mammary gland", "ANATOMY", 103, 116], ["drastic", "OBSERVATION_MODIFIER", 138, 145], ["reduction", "OBSERVATION_MODIFIER", 146, 155], ["fatty acids", "OBSERVATION", 278, 289], ["fatty acids", "OBSERVATION", 324, 335]]], ["There are reports that butter produced from cows fed high-oleic sunflower seeds and regular sunflower seeds were equal or superior in flavors to the control butter (Middaugh et al., 1988) .", [["butter", "ORGANISM_SUBDIVISION", 23, 29], ["cows", "ORGANISM", 44, 48], ["cows", "SPECIES", 44, 48], ["high-oleic sunflower seeds", "TREATMENT", 53, 79]]], ["The experimental butter was softer, more unsaturated and exhibited acceptable flavor, manufacturing, and storage characteristics.", [["butter", "OBSERVATION_MODIFIER", 17, 23], ["softer", "OBSERVATION_MODIFIER", 28, 34], ["more unsaturated", "OBSERVATION_MODIFIER", 36, 52], ["acceptable flavor", "OBSERVATION", 67, 84]]], ["Other workers (CSIRO, 1999; Mason, 2001) have also reported the increase in the unsaturated fatty acids content in milk fat, leading to an improvement in the spreadability of butter even at refrigerated temperatures (Section III.A).E. Type of fatty acids versus product qualityExtruded soybean and sunflower diets yielded a Cheddar cheese that had higher concentrations of unsaturated fatty acids while maintaining flavor, manufacturing, and storage characteristics similar to that of control cheese (Lightfield et al., 1993) .", [["milk fat", "ANATOMY", 115, 123], ["fatty acids", "CHEMICAL", 92, 103], ["fatty acids", "CHEMICAL", 243, 254], ["unsaturated fatty acids", "CHEMICAL", 373, 396], ["unsaturated fatty acids", "CHEMICAL", 80, 103], ["fatty acids", "CHEMICAL", 243, 254], ["unsaturated fatty acids", "CHEMICAL", 373, 396], ["unsaturated fatty acids", "SIMPLE_CHEMICAL", 80, 103], ["milk", "ORGANISM_SUBSTANCE", 115, 119], ["fat", "TISSUE", 120, 123], ["butter", "ORGANISM_SUBDIVISION", 175, 181], ["fatty acids", "SIMPLE_CHEMICAL", 243, 254], ["soybean", "ORGANISM", 286, 293], ["unsaturated fatty acids", "SIMPLE_CHEMICAL", 373, 396], ["soybean", "SPECIES", 286, 293], ["soybean", "SPECIES", 286, 293], ["Cheddar", "SPECIES", 324, 331], ["the unsaturated fatty acids content in milk fat", "PROBLEM", 76, 123], ["fatty acids", "PROBLEM", 243, 254], ["Extruded soybean and sunflower diets", "TREATMENT", 277, 313], ["unsaturated fatty acids", "TREATMENT", 373, 396], ["increase", "OBSERVATION_MODIFIER", 64, 72], ["milk fat", "OBSERVATION", 115, 123], ["improvement", "OBSERVATION_MODIFIER", 139, 150], ["fatty acids", "OBSERVATION", 243, 254]]], ["It is also beneficial from a safety point of view as the accumulation of fatty acids, namely C12, C14, C18:1, and C18:2, enhanced the safety of cheeses against Listeria monocytogenes and Salmonella typhimurium (Schaffer et al., 1995) .E. Type of fatty acids versus product qualityIncreasing the oleic acid content of milk fat from 26% to over 40% by feeding calcium salts of HOSO containing more than 86% oleic acid at the rate of 7.5% of diet dry matter weight to Holstein cows did not affect the sensory and physicochemical properties of Latin American white cheese (Queso Blanco).", [["milk fat", "ANATOMY", 317, 325], ["fatty acids", "CHEMICAL", 73, 84], ["C12, C14, C18:1, and C18:2", "CHEMICAL", 93, 119], ["fatty acids", "CHEMICAL", 246, 257], ["oleic acid", "CHEMICAL", 295, 305], ["calcium salts", "CHEMICAL", 358, 371], ["HOSO", "CHEMICAL", 375, 379], ["oleic acid", "CHEMICAL", 405, 415], ["fatty acids", "CHEMICAL", 73, 84], ["C12, C14, C18:1, and C18:2", "CHEMICAL", 93, 119], ["fatty acids", "CHEMICAL", 246, 257], ["oleic acid", "CHEMICAL", 295, 305], ["calcium", "CHEMICAL", 358, 365], ["oleic acid", "CHEMICAL", 405, 415], ["fatty acids", "SIMPLE_CHEMICAL", 73, 84], ["C12", "SIMPLE_CHEMICAL", 93, 96], ["C14", "SIMPLE_CHEMICAL", 98, 101], ["C18:1", "SIMPLE_CHEMICAL", 103, 108], ["C18:2", "SIMPLE_CHEMICAL", 114, 119], ["Listeria monocytogenes", "ORGANISM", 160, 182], ["Salmonella typhimurium", "ORGANISM", 187, 209], ["fatty acids", "SIMPLE_CHEMICAL", 246, 257], ["oleic acid", "SIMPLE_CHEMICAL", 295, 305], ["milk fat", "TISSUE", 317, 325], ["calcium", "SIMPLE_CHEMICAL", 358, 365], ["HOSO", "SIMPLE_CHEMICAL", 375, 379], ["oleic acid", "SIMPLE_CHEMICAL", 405, 415], ["Listeria monocytogenes", "SPECIES", 160, 182], ["Salmonella typhimurium", "SPECIES", 187, 209], ["cows", "SPECIES", 474, 478], ["Listeria monocytogenes", "SPECIES", 160, 182], ["Salmonella typhimurium", "SPECIES", 187, 209], ["Latin American white cheese", "SPECIES", 540, 567], ["the accumulation of fatty acids", "TEST", 53, 84], ["C12", "TEST", 93, 96], ["C18", "TEST", 103, 106], ["C18", "TEST", 114, 117], ["Listeria monocytogenes", "PROBLEM", 160, 182], ["Salmonella typhimurium", "PROBLEM", 187, 209], ["Type of fatty acids", "PROBLEM", 238, 257], ["Increasing the oleic acid content of milk fat", "PROBLEM", 280, 325], ["feeding calcium salts of HOSO", "TREATMENT", 350, 379], ["oleic acid", "TREATMENT", 405, 415], ["fatty acids", "OBSERVATION", 73, 84], ["fatty acids", "OBSERVATION", 246, 257], ["oleic", "OBSERVATION_MODIFIER", 295, 300], ["acid content", "OBSERVATION", 301, 313], ["milk fat", "OBSERVATION", 317, 325]]], ["There was also no difference (as a result of the modified and improved fatty acid profile) between the firmness of the product from modified milk and that made from normal milk (Aigster et al., 2000) .IV. MILK SUGAR (LACTOSE) MODIFICATIONLactose, the major milk sugar, is also responsible for the osmotic regulation of lactation, thus causing the movement of water into milk.", [["milk", "ANATOMY", 141, 145], ["milk", "ANATOMY", 172, 176], ["milk", "ANATOMY", 257, 261], ["milk", "ANATOMY", 370, 374], ["fatty acid", "CHEMICAL", 71, 81], ["MODIFICATIONLactose", "CHEMICAL", 226, 245], ["fatty acid", "CHEMICAL", 71, 81], ["sugar", "CHEMICAL", 262, 267], ["fatty acid", "SIMPLE_CHEMICAL", 71, 81], ["milk", "ORGANISM_SUBSTANCE", 141, 145], ["milk", "ORGANISM_SUBSTANCE", 172, 176], ["milk", "ORGANISM_SUBSTANCE", 257, 261], ["sugar", "SIMPLE_CHEMICAL", 262, 267], ["milk", "ORGANISM_SUBSTANCE", 370, 374], ["improved fatty acid profile", "PROBLEM", 62, 89], ["IV", "TREATMENT", 201, 203], ["MODIFICATIONLactose", "TREATMENT", 226, 245], ["no", "UNCERTAINTY", 15, 17], ["difference", "OBSERVATION_MODIFIER", 18, 28]]], ["This carbohydrate is synthesized in the secretory vesicles of the mammary glands by the lactose synthase complex.", [["secretory vesicles", "ANATOMY", 40, 58], ["mammary glands", "ANATOMY", 66, 80], ["lactose", "CHEMICAL", 88, 95], ["carbohydrate", "CHEMICAL", 5, 17], ["lactose", "CHEMICAL", 88, 95], ["secretory vesicles", "CELLULAR_COMPONENT", 40, 58], ["mammary glands", "ORGAN", 66, 80], ["lactose synthase", "GENE_OR_GENE_PRODUCT", 88, 104], ["lactose synthase complex", "PROTEIN", 88, 112], ["the lactose synthase complex", "TREATMENT", 84, 112], ["secretory", "ANATOMY_MODIFIER", 40, 49], ["vesicles", "ANATOMY_MODIFIER", 50, 58], ["mammary glands", "ANATOMY", 66, 80], ["lactose synthase", "OBSERVATION", 88, 104]]], ["As lactose cannot diffuse out of the vesicles, it draws water into the vesicles by osmosis.", [["vesicles", "ANATOMY", 37, 45], ["vesicles", "ANATOMY", 71, 79], ["lactose", "CHEMICAL", 3, 10], ["lactose", "CHEMICAL", 3, 10], ["lactose", "SIMPLE_CHEMICAL", 3, 10], ["vesicles", "CELLULAR_COMPONENT", 37, 45], ["vesicles", "CELLULAR_COMPONENT", 71, 79], ["diffuse", "OBSERVATION_MODIFIER", 18, 25], ["vesicles", "ANATOMY", 37, 45], ["vesicles", "ANATOMY", 71, 79], ["osmosis", "OBSERVATION", 83, 90]]], ["Thus, the volume of milk produced is directly dependent on the amount of lactose synthesized.IV. MILK SUGAR (LACTOSE) MODIFICATIONLactose cannot be transported to the bloodstream directly.", [["milk", "ANATOMY", 20, 24], ["bloodstream", "ANATOMY", 167, 178], ["lactose", "CHEMICAL", 73, 80], ["lactose", "CHEMICAL", 73, 80], ["milk", "ORGANISM_SUBSTANCE", 20, 24], ["lactose", "SIMPLE_CHEMICAL", 73, 80], ["lactose synthesized", "TREATMENT", 73, 92], ["IV", "TREATMENT", 93, 95], ["MILK SUGAR (LACTOSE) MODIFICATIONLactose", "TREATMENT", 97, 137]]], ["It can be absorbed only after its enzymatic hydrolysis to the monosaccharides glucose and galactose by intestinal lactase (b-galactosidase).", [["intestinal", "ANATOMY", 103, 113], ["glucose", "CHEMICAL", 78, 85], ["galactose", "CHEMICAL", 90, 99], ["glucose", "CHEMICAL", 78, 85], ["galactose", "CHEMICAL", 90, 99], ["glucose", "SIMPLE_CHEMICAL", 78, 85], ["galactose", "SIMPLE_CHEMICAL", 90, 99], ["intestinal", "ORGAN", 103, 113], ["lactase", "GENE_OR_GENE_PRODUCT", 114, 121], ["b-galactosidase", "GENE_OR_GENE_PRODUCT", 123, 138], ["intestinal lactase (b-galactosidase", "PROTEIN", 103, 138], ["its enzymatic hydrolysis", "PROBLEM", 30, 54], ["the monosaccharides glucose", "TEST", 58, 85], ["galactose", "TEST", 90, 99], ["intestinal lactase", "TEST", 103, 121], ["intestinal", "ANATOMY", 103, 113]]], ["For many human beings, the level of b-galactosidase declines early in life to the point of virtual absence in adulthood, making them lactose intolerant.", [["lactose", "CHEMICAL", 133, 140], ["lactose", "CHEMICAL", 133, 140], ["human", "ORGANISM", 9, 14], ["b-galactosidase", "GENE_OR_GENE_PRODUCT", 36, 51], ["lactose", "SIMPLE_CHEMICAL", 133, 140], ["b-galactosidase", "PROTEIN", 36, 51], ["human", "SPECIES", 9, 14], ["human", "SPECIES", 9, 14], ["them lactose intolerant", "PROBLEM", 128, 151], ["lactose intolerant", "OBSERVATION", 133, 151]]], ["It is reported that more than 75% of the human adult population suffers from deficiency of b-galactosidase (Vilotte, 2002) .", [["human", "ORGANISM", 41, 46], ["b-galactosidase", "GENE_OR_GENE_PRODUCT", 91, 106], ["human", "SPECIES", 41, 46], ["human", "SPECIES", 41, 46], ["deficiency of b-galactosidase", "PROBLEM", 77, 106]]], ["When such individuals ingest milk or milk products, the lactose remains undigested and malabsorbed in the gut, where it causes retention of water by its osmotic action.", [["milk", "ANATOMY", 29, 33], ["milk", "ANATOMY", 37, 41], ["gut", "ANATOMY", 106, 109], ["lactose", "CHEMICAL", 56, 63], ["lactose", "CHEMICAL", 56, 63], ["milk", "ORGANISM_SUBSTANCE", 29, 33], ["milk", "ORGANISM_SUBSTANCE", 37, 41], ["lactose", "SIMPLE_CHEMICAL", 56, 63], ["gut", "ORGANISM_SUBDIVISION", 106, 109], ["water", "SIMPLE_CHEMICAL", 140, 145], ["milk products", "TREATMENT", 37, 50], ["the lactose", "TREATMENT", 52, 63], ["gut", "ANATOMY", 106, 109], ["retention", "OBSERVATION", 127, 136]]], ["This water retention coupled with the bacterial production of large volumes of carbon dioxide leads to intestinal upset and dehydration (Vesa, 1999) .IV. MILK SUGAR (LACTOSE) MODIFICATIONOne management tactic suggested for such patients is the avoidance of dairy products.", [["intestinal", "ANATOMY", 103, 113], ["carbon dioxide", "CHEMICAL", 79, 93], ["intestinal upset and dehydration", "DISEASE", 103, 135], ["carbon dioxide", "CHEMICAL", 79, 93], ["water", "SIMPLE_CHEMICAL", 5, 10], ["carbon dioxide", "SIMPLE_CHEMICAL", 79, 93], ["intestinal", "ORGAN", 103, 113], ["patients", "ORGANISM", 228, 236], ["patients", "SPECIES", 228, 236], ["This water retention", "PROBLEM", 0, 20], ["the bacterial production", "TREATMENT", 34, 58], ["carbon dioxide", "TREATMENT", 79, 93], ["intestinal upset", "PROBLEM", 103, 119], ["dehydration", "PROBLEM", 124, 135], ["IV", "TREATMENT", 150, 152], ["MILK SUGAR (LACTOSE) MODIFICATIONOne management", "TREATMENT", 154, 201], ["dairy products", "TREATMENT", 257, 271], ["water retention", "OBSERVATION", 5, 20], ["bacterial", "OBSERVATION_MODIFIER", 38, 47], ["production", "OBSERVATION_MODIFIER", 48, 58], ["large", "OBSERVATION_MODIFIER", 62, 67], ["volumes", "OBSERVATION_MODIFIER", 68, 75], ["carbon dioxide", "OBSERVATION", 79, 93], ["intestinal", "ANATOMY", 103, 113], ["upset", "OBSERVATION", 114, 119], ["dehydration", "OBSERVATION_MODIFIER", 124, 135]]], ["However, as milk is a major component in the human diet, this deprives them from the use of a valuable nutritional source.", [["milk", "ANATOMY", 12, 16], ["milk", "ORGANISM_SUBSTANCE", 12, 16], ["human", "ORGANISM", 45, 50], ["human", "SPECIES", 45, 50], ["human", "SPECIES", 45, 50]]], ["In addition, since milk can provide much of the required calcium for maintaining bone health, lactose intolerance can also be associated with osteopaenia in old people (Corazza et al., 1995) .", [["milk", "ANATOMY", 19, 23], ["bone", "ANATOMY", 81, 85], ["calcium", "CHEMICAL", 57, 64], ["lactose", "CHEMICAL", 94, 101], ["osteopaenia", "DISEASE", 142, 153], ["calcium", "CHEMICAL", 57, 64], ["lactose", "CHEMICAL", 94, 101], ["milk", "ORGANISM_SUBSTANCE", 19, 23], ["calcium", "SIMPLE_CHEMICAL", 57, 64], ["bone", "TISSUE", 81, 85], ["lactose", "SIMPLE_CHEMICAL", 94, 101], ["people", "ORGANISM", 161, 167], ["people", "SPECIES", 161, 167], ["calcium", "TREATMENT", 57, 64], ["lactose intolerance", "PROBLEM", 94, 113], ["osteopaenia", "PROBLEM", 142, 153], ["bone", "ANATOMY", 81, 85]]], ["A report suggests that by 2020, half of all American citizens older than 50 will have low bone mass and be at risk for fractures from osteoporosis if appropriate dietary and other precautions are not followed (Carmona, 2006) .", [["bone", "ANATOMY", 90, 94], ["low bone mass", "DISEASE", 86, 99], ["fractures", "DISEASE", 119, 128], ["osteoporosis", "DISEASE", 134, 146], ["bone", "TISSUE", 90, 94], ["low bone mass", "PROBLEM", 86, 99], ["fractures", "PROBLEM", 119, 128], ["osteoporosis", "PROBLEM", 134, 146], ["other precautions", "TREATMENT", 174, 191], ["bone", "ANATOMY", 90, 94], ["mass", "OBSERVATION", 95, 99], ["fractures", "OBSERVATION", 119, 128], ["osteoporosis", "OBSERVATION", 134, 146]]], ["Therefore, excluding milk from diet has adverse effects on health.IV. MILK SUGAR (LACTOSE) MODIFICATIONThe consequences of lactose intolerance can also be limited through the use of b-galactosidase-replacement (preharvest) or hydrolyzed lowlactose (postharvest) products.", [["milk", "ANATOMY", 21, 25], ["lactose", "CHEMICAL", 123, 130], ["b-galactosidase", "CHEMICAL", 182, 197], ["lowlactose", "CHEMICAL", 237, 247], ["lactose", "CHEMICAL", 123, 130], ["lowlactose", "CHEMICAL", 237, 247], ["milk", "ORGANISM_SUBSTANCE", 21, 25], ["lactose", "SIMPLE_CHEMICAL", 123, 130], ["b-galactosidase", "SIMPLE_CHEMICAL", 182, 197], ["lowlactose", "SIMPLE_CHEMICAL", 237, 247], ["IV", "TREATMENT", 66, 68], ["MILK SUGAR (LACTOSE)", "TREATMENT", 70, 90], ["lactose intolerance", "PROBLEM", 123, 142], ["b-galactosidase", "TREATMENT", 182, 197], ["replacement (preharvest)", "TREATMENT", 198, 222], ["hydrolyzed lowlactose (postharvest) products", "TREATMENT", 226, 270], ["lactose intolerance", "OBSERVATION", 123, 142]]], ["Besides the obvious nutritional advantage, a reduction in milk lactose content could also benefit agricultural and industrial purposes with less volume to transport, better milk coagulation, and less effluent production.", [["milk", "ANATOMY", 58, 62], ["milk", "ANATOMY", 173, 177], ["lactose", "CHEMICAL", 63, 70], ["milk coagulation", "DISEASE", 173, 189], ["lactose", "CHEMICAL", 63, 70], ["milk", "ORGANISM_SUBSTANCE", 58, 62], ["lactose", "SIMPLE_CHEMICAL", 63, 70], ["milk", "ORGANISM_SUBSTANCE", 173, 177], ["a reduction in milk lactose content", "TREATMENT", 43, 78], ["less", "OBSERVATION_MODIFIER", 195, 199], ["effluent production", "OBSERVATION", 200, 219]]], ["The complete removal of lactose from milk creates milk that is extremely viscous, containing very little water.", [["milk", "ANATOMY", 37, 41], ["milk", "ANATOMY", 50, 54], ["lactose", "CHEMICAL", 24, 31], ["lactose", "CHEMICAL", 24, 31], ["lactose", "SIMPLE_CHEMICAL", 24, 31], ["milk", "ORGANISM_SUBSTANCE", 37, 41], ["milk", "ORGANISM_SUBSTANCE", 50, 54], ["The complete removal of lactose from milk creates milk", "TREATMENT", 0, 54], ["complete", "OBSERVATION_MODIFIER", 4, 12], ["removal", "OBSERVATION", 13, 20], ["extremely viscous", "OBSERVATION_MODIFIER", 63, 80]]], ["It is extremely difficult to extract this milk from the mammary gland, making the milking process difficult and painful for the animal.", [["milk", "ANATOMY", 42, 46], ["mammary gland", "ANATOMY", 56, 69], ["milk", "ORGANISM_SUBSTANCE", 42, 46], ["mammary gland", "ORGAN", 56, 69], ["painful", "PROBLEM", 112, 119], ["mammary gland", "ANATOMY", 56, 69]]], ["However, research has shown that with controlled reduction in the lactose content of milk, it is possible to decrease the water, increase the percentage of total solids, and reduce the lactose yield of the milk while keeping fluidity intact.A. Preharvest methods of lactose reductiona-Lactalbumin (a-LA) is one of the major milk proteins present in almost all mammalian milks.", [["milk", "ANATOMY", 85, 89], ["milk", "ANATOMY", 206, 210], ["milk", "ANATOMY", 324, 328], ["milks", "ANATOMY", 370, 375], ["lactose", "CHEMICAL", 66, 73], ["lactose", "CHEMICAL", 185, 192], ["lactose reductiona-Lactalbumin", "CHEMICAL", 266, 296], ["LA", "CHEMICAL", 300, 302], ["lactose", "CHEMICAL", 66, 73], ["lactose", "CHEMICAL", 185, 192], ["lactose", "CHEMICAL", 266, 273], ["Lactalbumin", "CHEMICAL", 285, 296], ["a-LA", "CHEMICAL", 298, 302], ["lactose", "SIMPLE_CHEMICAL", 66, 73], ["milk", "ORGANISM_SUBSTANCE", 85, 89], ["lactose", "SIMPLE_CHEMICAL", 185, 192], ["milk", "ORGANISM_SUBSTANCE", 206, 210], ["lactose reductiona-Lactalbumin", "SIMPLE_CHEMICAL", 266, 296], ["a-LA", "SIMPLE_CHEMICAL", 298, 302], ["milk", "ORGANISM_SUBSTANCE", 324, 328], ["milks", "ORGANISM_SUBDIVISION", 370, 375], ["A.", "SPECIES", 241, 243], ["the lactose content of milk", "TREATMENT", 62, 89], ["total solids", "TREATMENT", 156, 168], ["the lactose yield of the milk", "TREATMENT", 181, 210], ["lactose reductiona", "TEST", 266, 284], ["Lactalbumin (a-LA", "TREATMENT", 285, 302], ["the major milk proteins", "TREATMENT", 314, 337], ["reduction", "OBSERVATION_MODIFIER", 49, 58], ["lactose content", "OBSERVATION_MODIFIER", 66, 81], ["lactose reductiona", "OBSERVATION", 266, 284], ["mammalian milks", "OBSERVATION", 360, 375]]], ["It interacts with b-1,4-UDP-galactosyl transferase (UDPgal) to modify substrate specificity of this enzyme, virtually creating a unique binding site for glucose and leading to the synthesis of lactose (Vilotte, 2002) .", [["b-1,4-UDP-galactosyl", "CHEMICAL", 18, 38], ["UDPgal", "CHEMICAL", 52, 58], ["glucose", "CHEMICAL", 153, 160], ["lactose", "CHEMICAL", 193, 200], ["b-1,4-UDP", "CHEMICAL", 18, 27], ["galactosyl", "CHEMICAL", 28, 38], ["glucose", "CHEMICAL", 153, 160], ["lactose", "CHEMICAL", 193, 200], ["b-1,4-UDP-galactosyl transferase", "GENE_OR_GENE_PRODUCT", 18, 50], ["UDPgal", "SIMPLE_CHEMICAL", 52, 58], ["glucose", "SIMPLE_CHEMICAL", 153, 160], ["lactose", "SIMPLE_CHEMICAL", 193, 200], ["b-1,4-UDP-galactosyl transferase", "PROTEIN", 18, 50], ["UDPgal", "PROTEIN", 52, 58], ["enzyme", "PROTEIN", 100, 106], ["this enzyme", "TEST", 95, 106], ["glucose", "TEST", 153, 160], ["the synthesis of lactose", "TREATMENT", 176, 200]]], ["The preharvest methodologies of reducing lactose involve either the introduction of b-galactosidase enzyme into milk via mammary gland-specific expression or the removal of a-LA and gene ''knockout'' methodologies.", [["milk", "ANATOMY", 112, 116], ["mammary gland", "ANATOMY", 121, 134], ["lactose", "CHEMICAL", 41, 48], ["lactose", "CHEMICAL", 41, 48], ["lactose", "SIMPLE_CHEMICAL", 41, 48], ["b-galactosidase enzyme", "GENE_OR_GENE_PRODUCT", 84, 106], ["milk", "ORGANISM_SUBSTANCE", 112, 116], ["mammary gland", "ORGAN", 121, 134], ["-LA", "GENE_OR_GENE_PRODUCT", 174, 177], ["b-galactosidase enzyme", "PROTEIN", 84, 106], ["reducing lactose", "TREATMENT", 32, 48], ["b-galactosidase enzyme", "TREATMENT", 84, 106], ["the removal", "TREATMENT", 158, 169], ["a-LA and gene ''knockout'' methodologies", "TREATMENT", 173, 213], ["mammary gland", "ANATOMY", 121, 134]]], ["Although these successful approaches provide valuable tools to address milk physiology, they reduce the overall sugar content of the milk, resulting in highly viscous milk.", [["milk", "ANATOMY", 71, 75], ["milk", "ANATOMY", 133, 137], ["milk", "ANATOMY", 167, 171], ["sugar", "CHEMICAL", 112, 117], ["milk", "ORGANISM_SUBSTANCE", 71, 75], ["sugar", "SIMPLE_CHEMICAL", 112, 117], ["milk", "ORGANISM_SUBSTANCE", 133, 137], ["milk", "ORGANISM_SUBSTANCE", 167, 171]]], ["Studies on mice have revealed that reduction of lactose via a-LA deletion was inappropriate because it impaired milk volume regulation.", [["milk", "ANATOMY", 112, 116], ["lactose", "CHEMICAL", 48, 55], ["lactose", "CHEMICAL", 48, 55], ["mice", "ORGANISM", 11, 15], ["lactose", "SIMPLE_CHEMICAL", 48, 55], ["-LA", "GENE_OR_GENE_PRODUCT", 61, 64], ["milk", "ORGANISM_SUBSTANCE", 112, 116], ["-LA deletion", "DNA", 61, 73], ["mice", "SPECIES", 11, 15], ["mice", "SPECIES", 11, 15], ["lactose", "TREATMENT", 48, 55], ["a-LA deletion", "PROBLEM", 60, 73], ["impaired milk volume regulation", "PROBLEM", 103, 134], ["milk volume", "OBSERVATION", 112, 123]]], ["The milk of such mice was highly viscous with very high protein (88%) and fat (60%), no a-LA and no lactose (Karatzas and Turner, 1997) .", [["milk", "ANATOMY", 4, 8], ["fat", "ANATOMY", 74, 77], ["lactose", "CHEMICAL", 100, 107], ["lactose", "CHEMICAL", 100, 107], ["milk", "ORGANISM_SUBSTANCE", 4, 8], ["mice", "ORGANISM", 17, 21], ["fat", "TISSUE", 74, 77], ["a-LA", "SIMPLE_CHEMICAL", 88, 92], ["lactose", "SIMPLE_CHEMICAL", 100, 107], ["mice", "SPECIES", 17, 21], ["mice", "SPECIES", 17, 21], ["fat", "TEST", 74, 77], ["a-LA", "PROBLEM", 88, 92]]], ["Knocking out the UDP-gal gene in mice also produced milk with no lactose but very high viscosity (Vilotte, 2002) .A. Preharvest methods of lactose reductionAn alternative to produce low-lactose milk is overexpression of b-galactosidase in milk.", [["milk", "ANATOMY", 52, 56], ["milk", "ANATOMY", 239, 243], ["UDP", "CHEMICAL", 17, 20], ["lactose", "CHEMICAL", 65, 72], ["lactose", "CHEMICAL", 139, 146], ["UDP", "CHEMICAL", 17, 20], ["lactose", "CHEMICAL", 65, 72], ["lactose", "CHEMICAL", 139, 146], ["lactose", "CHEMICAL", 186, 193], ["UDP-gal", "GENE_OR_GENE_PRODUCT", 17, 24], ["mice", "ORGANISM", 33, 37], ["milk", "ORGANISM_SUBSTANCE", 52, 56], ["lactose", "SIMPLE_CHEMICAL", 65, 72], ["lactose", "SIMPLE_CHEMICAL", 139, 146], ["milk", "ORGANISM_SUBSTANCE", 194, 198], ["b-galactosidase", "SIMPLE_CHEMICAL", 220, 235], ["milk", "ORGANISM_SUBSTANCE", 239, 243], ["UDP-gal gene", "DNA", 17, 29], ["b-galactosidase", "PROTEIN", 220, 235], ["mice", "SPECIES", 33, 37], ["mice", "SPECIES", 33, 37], ["the UDP", "TEST", 13, 20], ["lactose", "TREATMENT", 65, 72], ["very high viscosity", "PROBLEM", 77, 96], ["lactose reduction", "TREATMENT", 139, 156], ["low-lactose milk", "TREATMENT", 182, 198], ["b-galactosidase in milk", "TREATMENT", 220, 243], ["lactose reduction", "OBSERVATION", 139, 156]]], ["However, the monosachharides produced within the formed milk increases the osmotic pressure within the alveolar lumen, thereby drawing more water and resulting in further dilution of other milk components (Bremel et al., 1989) .", [["milk", "ANATOMY", 56, 60], ["alveolar lumen", "ANATOMY", 103, 117], ["milk", "ANATOMY", 189, 193], ["monosachharides", "CHEMICAL", 13, 28], ["monosachharides", "CHEMICAL", 13, 28], ["monosachharides", "SIMPLE_CHEMICAL", 13, 28], ["milk", "ORGANISM_SUBSTANCE", 56, 60], ["alveolar lumen", "MULTI-TISSUE_STRUCTURE", 103, 117], ["milk", "ORGANISM_SUBSTANCE", 189, 193], ["further dilution of other milk components", "TREATMENT", 163, 204], ["formed", "OBSERVATION_MODIFIER", 49, 55], ["milk", "OBSERVATION", 56, 60], ["osmotic pressure", "OBSERVATION", 75, 91], ["alveolar lumen", "OBSERVATION", 103, 117]]], ["Jost et al. (1999) explained an in vivo technique for low-lactose milk production.", [["milk", "ANATOMY", 66, 70], ["lactose", "CHEMICAL", 58, 65], ["milk", "ORGANISM_SUBSTANCE", 66, 70], ["an in vivo technique", "TREATMENT", 29, 49], ["low-lactose milk production", "TREATMENT", 54, 81]]], ["They generated transgenic mice that selectively produced a biologically active b-galactosidase in their milk.", [["milk", "ANATOMY", 104, 108], ["mice", "ORGANISM", 26, 30], ["b-galactosidase", "SIMPLE_CHEMICAL", 79, 94], ["milk", "ORGANISM_SUBSTANCE", 104, 108], ["mice", "SPECIES", 26, 30], ["mice", "SPECIES", 26, 30]]], ["In these transgenic mice, the lactose content of the milk is at least halved, even though the b-galactosidase expression levels were relatively low.", [["milk", "ANATOMY", 53, 57], ["lactose", "CHEMICAL", 30, 37], ["lactose", "CHEMICAL", 30, 37], ["mice", "ORGANISM", 20, 24], ["lactose", "SIMPLE_CHEMICAL", 30, 37], ["milk", "ORGANISM_SUBSTANCE", 53, 57], ["b-galactosidase", "GENE_OR_GENE_PRODUCT", 94, 109], ["b-galactosidase", "PROTEIN", 94, 109], ["mice", "SPECIES", 20, 24], ["mice", "SPECIES", 20, 24], ["the b-galactosidase expression levels", "TEST", 90, 127], ["transgenic mice", "OBSERVATION", 9, 24], ["lactose content", "OBSERVATION", 30, 45], ["low", "OBSERVATION_MODIFIER", 144, 147]]], ["The authors claim that it is likely that at least twofold greater levels of lactose reduction could be achieved.", [["lactose", "CHEMICAL", 76, 83], ["lactose", "CHEMICAL", 76, 83], ["lactose", "SIMPLE_CHEMICAL", 76, 83], ["lactose reduction", "TREATMENT", 76, 93], ["is likely", "UNCERTAINTY", 26, 35], ["lactose reduction", "OBSERVATION", 76, 93]]], ["In contrast to the previous studies by Bremel et al. (1989) and Karatzas and Turner (1997) , these experiments led to reduction in the lactose content while retaining most of the monosaccharide content of the milk. b-galactosidase synthesis in the mammary gland caused a significant decrease in milk lactose (50-85%) without obvious changes in fat and protein concentrations.", [["milk", "ANATOMY", 209, 213], ["mammary gland", "ANATOMY", 248, 261], ["milk", "ANATOMY", 295, 299], ["fat", "ANATOMY", 344, 347], ["lactose", "CHEMICAL", 135, 142], ["b-galactosidase", "CHEMICAL", 215, 230], ["lactose", "CHEMICAL", 300, 307], ["lactose", "CHEMICAL", 135, 142], ["monosaccharide", "CHEMICAL", 179, 193], ["lactose", "CHEMICAL", 300, 307], ["lactose", "SIMPLE_CHEMICAL", 135, 142], ["monosaccharide", "SIMPLE_CHEMICAL", 179, 193], ["milk", "ORGANISM_SUBSTANCE", 209, 213], ["b-galactosidase", "SIMPLE_CHEMICAL", 215, 230], ["mammary gland", "ORGAN", 248, 261], ["milk", "ORGANISM_SUBSTANCE", 295, 299], ["lactose", "SIMPLE_CHEMICAL", 300, 307], ["fat", "TISSUE", 344, 347], ["the previous studies", "TEST", 15, 35], ["the lactose content", "PROBLEM", 131, 150], ["b-galactosidase synthesis in the mammary gland", "PROBLEM", 215, 261], ["a significant decrease in milk lactose", "PROBLEM", 269, 307], ["obvious changes in fat and protein concentrations", "PROBLEM", 325, 374], ["reduction", "OBSERVATION_MODIFIER", 118, 127], ["lactose content", "OBSERVATION", 135, 150], ["mammary gland", "ANATOMY", 248, 261], ["significant", "OBSERVATION_MODIFIER", 271, 282], ["decrease", "OBSERVATION_MODIFIER", 283, 291], ["protein concentrations", "OBSERVATION", 352, 374]]], ["It thus helped to maintain a balanced nutrient supply as reflected in the similar growth curve reared on transgenic or control milk.", [["milk", "ANATOMY", 127, 131], ["milk", "ORGANISM_SUBSTANCE", 127, 131], ["a balanced nutrient supply", "TREATMENT", 27, 53], ["transgenic or control milk", "TREATMENT", 105, 131]]], ["It is likely that transgenic low-lactose milk production could offer a more balanced approach to managing lactose intolerance than postharvest or lactose-replacement products.", [["lactose", "CHEMICAL", 106, 113], ["lactose", "CHEMICAL", 146, 153], ["lactose", "CHEMICAL", 33, 40], ["lactose", "CHEMICAL", 106, 113], ["lactose", "CHEMICAL", 146, 153], ["milk", "ORGANISM_SUBSTANCE", 41, 45], ["lactose", "SIMPLE_CHEMICAL", 106, 113], ["lactose", "SIMPLE_CHEMICAL", 146, 153], ["transgenic low-lactose milk production", "PROBLEM", 18, 56], ["lactose intolerance", "PROBLEM", 106, 125], ["lactose-replacement products", "TREATMENT", 146, 174], ["is likely", "UNCERTAINTY", 3, 12], ["transgenic", "OBSERVATION_MODIFIER", 18, 28], ["low", "OBSERVATION_MODIFIER", 29, 32]]], ["However, more detailed analysis on several aspects such as the effect of splitting the lactose into glucose and galactose on the osmotic balance in the milk in the gut after ingestion and also the economic viability of the technology need to be investigated (Whitelaw, 1999) .V. MILK PROTEIN MODIFICATIONOne of the major products of the mammary glands being protein, exciting opportunities in research and technology extend the benefits of better protein supplementation.", [["milk", "ANATOMY", 152, 156], ["gut", "ANATOMY", 164, 167], ["mammary glands", "ANATOMY", 337, 351], ["lactose", "CHEMICAL", 87, 94], ["glucose", "CHEMICAL", 100, 107], ["galactose", "CHEMICAL", 112, 121], ["lactose", "CHEMICAL", 87, 94], ["glucose", "CHEMICAL", 100, 107], ["galactose", "CHEMICAL", 112, 121], ["lactose", "SIMPLE_CHEMICAL", 87, 94], ["glucose", "SIMPLE_CHEMICAL", 100, 107], ["galactose", "SIMPLE_CHEMICAL", 112, 121], ["milk", "ORGANISM_SUBSTANCE", 152, 156], ["gut", "ORGANISM_SUBDIVISION", 164, 167], ["mammary glands", "ORGAN", 337, 351], ["detailed analysis", "TEST", 14, 31], ["the lactose into glucose", "TEST", 83, 107], ["the osmotic balance", "TEST", 125, 144], ["better protein supplementation", "TREATMENT", 440, 470], ["gut", "ANATOMY", 164, 167], ["mammary glands", "ANATOMY", 337, 351]]], ["One of the most obvious changes in milk is the selective increase of a component that is already present.", [["milk", "ANATOMY", 35, 39], ["milk", "ORGANISM_SUBSTANCE", 35, 39], ["most", "OBSERVATION_MODIFIER", 11, 15], ["obvious", "OBSERVATION_MODIFIER", 16, 23], ["changes", "OBSERVATION", 24, 31], ["milk", "OBSERVATION", 35, 39], ["selective", "OBSERVATION_MODIFIER", 47, 56], ["increase", "OBSERVATION_MODIFIER", 57, 65], ["component", "OBSERVATION_MODIFIER", 71, 80]]], ["For example, an increase in one of the casein components in milk might provide a method of increasing the value of milk for the production of cheese.", [["milk", "ANATOMY", 60, 64], ["milk", "ANATOMY", 115, 119], ["casein", "GENE_OR_GENE_PRODUCT", 39, 45], ["milk", "ORGANISM_SUBSTANCE", 60, 64], ["milk", "ORGANISM_SUBSTANCE", 115, 119], ["cheese", "ORGANISM_SUBDIVISION", 142, 148], ["an increase", "PROBLEM", 13, 24], ["the casein components", "TREATMENT", 35, 56], ["increase", "OBSERVATION_MODIFIER", 16, 24], ["one", "OBSERVATION_MODIFIER", 28, 31]]], ["It was estimated that an increase of 20% in the as1-casein (as1-CN) would increase the revenue of the cheese industry by almost , respectively (Karatzas and Turner, 1997) .", [["as1-casein", "CHEMICAL", 48, 58], ["as1-CN", "CHEMICAL", 60, 66], ["as1-casein", "SIMPLE_CHEMICAL", 48, 58], ["as1-CN", "SIMPLE_CHEMICAL", 60, 66], ["CN", "PROTEIN", 64, 66], ["increase", "OBSERVATION_MODIFIER", 25, 33]]], ["Shani et al. (1992) tested the feasibility of producing large quantities of human serum albumin, which is used in blood transfusions, in the milk of transgenic livestock by generating transgenic mice as a model system.", [["serum", "ANATOMY", 82, 87], ["blood", "ANATOMY", 114, 119], ["milk", "ANATOMY", 141, 145], ["human", "ORGANISM", 76, 81], ["serum", "ORGANISM_SUBSTANCE", 82, 87], ["albumin", "GENE_OR_GENE_PRODUCT", 88, 95], ["blood", "ORGANISM_SUBSTANCE", 114, 119], ["milk", "ORGANISM_SUBDIVISION", 141, 145], ["mice", "ORGANISM", 195, 199], ["human", "SPECIES", 76, 81], ["mice", "SPECIES", 195, 199], ["human", "SPECIES", 76, 81], ["mice", "SPECIES", 195, 199], ["human serum albumin", "TEST", 76, 95], ["blood transfusions", "TREATMENT", 114, 132], ["large", "OBSERVATION_MODIFIER", 56, 61]]], ["Charlie and George were two calves created from fetal cells in the US in 1998 to produce the human serum albumin in their milk (Johnston, 2006) .VII. MILK WITH HUMAN THERAPEUTIC PROTEINSThe first report on expression of recombinant human fibrinogen (rHF) to the mammary gland of transgenic mice appeared a decade ago (Prunkard et al., 1996) .", [["fetal cells", "ANATOMY", 48, 59], ["serum", "ANATOMY", 99, 104], ["milk", "ANATOMY", 122, 126], ["mammary gland", "ANATOMY", 262, 275], ["calves", "ORGANISM", 28, 34], ["fetal cells", "CELL", 48, 59], ["human", "ORGANISM", 93, 98], ["serum", "ORGANISM_SUBSTANCE", 99, 104], ["albumin", "GENE_OR_GENE_PRODUCT", 105, 112], ["milk", "ORGANISM_SUBSTANCE", 122, 126], ["VII", "GENE_OR_GENE_PRODUCT", 145, 148], ["human", "ORGANISM", 232, 237], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 238, 248], ["rHF", "GENE_OR_GENE_PRODUCT", 250, 253], ["mammary gland", "ORGAN", 262, 275], ["mice", "ORGANISM", 290, 294], ["fetal cells", "CELL_TYPE", 48, 59], ["VII", "PROTEIN", 145, 148], ["recombinant human fibrinogen", "PROTEIN", 220, 248], ["rHF", "PROTEIN", 250, 253], ["calves", "SPECIES", 28, 34], ["human", "SPECIES", 93, 98], ["human", "SPECIES", 232, 237], ["mice", "SPECIES", 290, 294], ["human", "SPECIES", 93, 98], ["human", "SPECIES", 232, 237], ["mice", "SPECIES", 290, 294], ["the human serum albumin", "TEST", 89, 112], ["recombinant human fibrinogen (rHF", "TREATMENT", 220, 253], ["mammary gland", "ANATOMY", 262, 275]]], ["Fibrinogen is a complex plasma protein composed of two each of three different polypeptide chains.", [["plasma", "ANATOMY", 24, 30], ["Fibrinogen", "GENE_OR_GENE_PRODUCT", 0, 10], ["plasma", "ORGANISM_SUBSTANCE", 24, 30], ["Fibrinogen", "PROTEIN", 0, 10], ["complex plasma protein", "PROTEIN", 16, 38], ["polypeptide chains", "PROTEIN", 79, 97], ["Fibrinogen", "TEST", 0, 10], ["a complex plasma protein", "TEST", 14, 38], ["three different polypeptide chains", "TREATMENT", 63, 97], ["polypeptide chains", "OBSERVATION", 79, 97]]], ["The workers coinjected three expression cassettes, each containing the genomic sequence for one of the three human fibrinogen chains controlled by sheep whey protein b-LG promoter sequences into fertile mouse eggs.", [["eggs", "ANATOMY", 209, 213], ["human", "ORGANISM", 109, 114], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 115, 125], ["b-LG", "GENE_OR_GENE_PRODUCT", 166, 170], ["mouse", "ORGANISM", 203, 208], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 209, 213], ["expression cassettes", "DNA", 29, 49], ["genomic sequence", "DNA", 71, 87], ["human fibrinogen chains", "PROTEIN", 109, 132], ["sheep whey protein b-LG promoter sequences", "DNA", 147, 189], ["human", "SPECIES", 109, 114], ["sheep", "SPECIES", 147, 152], ["mouse", "SPECIES", 203, 208], ["human", "SPECIES", 109, 114], ["sheep", "SPECIES", 147, 152], ["mouse", "SPECIES", 203, 208], ["the three human fibrinogen chains", "TREATMENT", 99, 132], ["sheep whey protein b-LG promoter sequences", "TREATMENT", 147, 189]]], ["Analysis by PAGE revealed that the milk from the highest producing founder animal contained human fibrinogen subunits at concentrations of 2000 mg/ml.", [["milk", "ANATOMY", 35, 39], ["milk", "ORGANISM_SUBSTANCE", 35, 39], ["animal", "ORGANISM", 75, 81], ["human", "ORGANISM", 92, 97], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 98, 108], ["human fibrinogen subunits", "PROTEIN", 92, 117], ["human", "SPECIES", 92, 97], ["human", "SPECIES", 92, 97], ["Analysis", "TEST", 0, 8], ["human fibrinogen subunits", "TREATMENT", 92, 117]]], ["Incubation of the transgenic milk with thrombin and factor XIII produced a cross-linked fibrin clot, demonstrating that a major portion of the secreted fibrinogen was functional.", [["milk", "ANATOMY", 29, 33], ["fibrin clot", "ANATOMY", 88, 99], ["milk", "ORGANISM_SUBSTANCE", 29, 33], ["thrombin", "GENE_OR_GENE_PRODUCT", 39, 47], ["factor XIII", "GENE_OR_GENE_PRODUCT", 52, 63], ["fibrin", "GENE_OR_GENE_PRODUCT", 88, 94], ["clot", "ORGANISM_SUBSTANCE", 95, 99], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 152, 162], ["thrombin", "PROTEIN", 39, 47], ["factor XIII", "PROTEIN", 52, 63], ["secreted fibrinogen", "PROTEIN", 143, 162], ["milk", "SPECIES", 29, 33], ["the transgenic milk", "TREATMENT", 14, 33], ["thrombin", "TREATMENT", 39, 47], ["factor XIII", "TREATMENT", 52, 63], ["a cross-linked fibrin clot", "PROBLEM", 73, 99], ["the secreted fibrinogen", "TEST", 139, 162], ["fibrin clot", "OBSERVATION", 88, 99], ["fibrinogen", "OBSERVATION", 152, 162]]], ["Coleman (1996) reported that the concentration of rHF produced in mouse milk was more than 2 g/liter, whereas the amount generated by the cell culture method was only 0.002 g/liter.VII. MILK WITH HUMAN THERAPEUTIC PROTEINSBecause a-LA has a well-balanced amino acid composition, increasing the amount of a-LA in milk at the expense of b-LG may, besides lowering the risk of cow milk allergies, improve the nutritional quality of the milk.", [["milk", "ANATOMY", 72, 76], ["cell", "ANATOMY", 138, 142], ["milk", "ANATOMY", 312, 316], ["milk", "ANATOMY", 378, 382], ["milk", "ANATOMY", 433, 437], ["rHF", "CHEMICAL", 50, 53], ["LA", "CHEMICAL", 232, 234], ["amino acid", "CHEMICAL", 255, 265], ["-LA", "CHEMICAL", 305, 308], ["b-", "CHEMICAL", 335, 337], ["milk allergies", "DISEASE", 378, 392], ["rHF", "CHEMICAL", 50, 53], ["amino acid", "CHEMICAL", 255, 265], ["rHF", "SIMPLE_CHEMICAL", 50, 53], ["mouse", "ORGANISM", 66, 71], ["milk", "ORGANISM_SUBSTANCE", 72, 76], ["cell", "CELL", 138, 142], ["VII", "GENE_OR_GENE_PRODUCT", 181, 184], ["amino acid", "AMINO_ACID", 255, 265], ["-LA", "SIMPLE_CHEMICAL", 305, 308], ["milk", "ORGANISM_SUBSTANCE", 312, 316], ["b-LG", "SIMPLE_CHEMICAL", 335, 339], ["cow", "ORGANISM", 374, 377], ["milk", "ORGANISM_SUBDIVISION", 378, 382], ["milk", "ORGANISM_SUBSTANCE", 433, 437], ["rHF", "PROTEIN", 50, 53], ["VII", "PROTEIN", 181, 184], ["mouse", "SPECIES", 66, 71], ["cow", "SPECIES", 374, 377], ["mouse", "SPECIES", 66, 71], ["cow", "SPECIES", 374, 377], ["rHF", "PROBLEM", 50, 53], ["the cell culture method", "TEST", 134, 157], ["a well-balanced amino acid composition", "TREATMENT", 239, 277], ["a-LA in milk", "TREATMENT", 304, 316], ["cow milk allergies", "PROBLEM", 374, 392], ["rHF", "OBSERVATION", 50, 53]]], ["The technique of custom-designing amino acids in a protein to obtain special foods with therapeutic properties offers a ray of hope for patients of phenylketonuria (PKU).", [["amino acids", "CHEMICAL", 34, 45], ["phenylketonuria", "DISEASE", 148, 163], ["PKU", "DISEASE", 165, 168], ["amino acids", "CHEMICAL", 34, 45], ["phenylketonuria", "CHEMICAL", 148, 163], ["amino acids", "AMINO_ACID", 34, 45], ["patients", "ORGANISM", 136, 144], ["phenylketonuria", "SIMPLE_CHEMICAL", 148, 163], ["patients", "SPECIES", 136, 144], ["amino acids", "TREATMENT", 34, 45], ["therapeutic properties", "TREATMENT", 88, 110], ["phenylketonuria", "PROBLEM", 148, 163]]], ["This is a congenital disease occurring in those without the enzyme that metabolizes phenylalanine.", [["congenital disease", "DISEASE", 10, 28], ["phenylalanine", "CHEMICAL", 84, 97], ["phenylalanine", "CHEMICAL", 84, 97], ["phenylalanine", "SIMPLE_CHEMICAL", 84, 97], ["a congenital disease", "PROBLEM", 8, 28], ["the enzyme", "TEST", 56, 66], ["metabolizes phenylalanine", "TREATMENT", 72, 97], ["congenital", "OBSERVATION_MODIFIER", 10, 20], ["disease", "OBSERVATION", 21, 28]]], ["Although products are now available with no or low phenylalanine content, they are unappetizing.", [["phenylalanine", "CHEMICAL", 51, 64], ["phenylalanine", "CHEMICAL", 51, 64], ["phenylalanine", "AMINO_ACID", 51, 64], ["low phenylalanine content", "PROBLEM", 47, 72]]], ["The knowledge that a-LA contains only four phenylalanine residues in its amino acid makeup and their position can be determined easily makes this whey protein a possible target for treatment of PKU (Coleman, 1996) .", [["phenylalanine", "CHEMICAL", 43, 56], ["amino acid", "CHEMICAL", 73, 83], ["PKU", "DISEASE", 194, 197], ["phenylalanine", "CHEMICAL", 43, 56], ["amino acid", "CHEMICAL", 73, 83], ["a-LA", "SIMPLE_CHEMICAL", 19, 23], ["phenylalanine", "AMINO_ACID", 43, 56], ["amino acid", "AMINO_ACID", 73, 83], ["a-LA", "PROTEIN", 19, 23], ["whey protein", "PROTEIN", 146, 158], ["four phenylalanine residues", "TREATMENT", 38, 65], ["its amino acid makeup", "TREATMENT", 69, 90], ["phenylalanine residues", "OBSERVATION", 43, 65]]], ["Replacing these four phenylalanine residues with other amino acids by site-directed mutagenesis followed by the subsequent expression of the modified protein in milk and its purification would offer a logical sequence to the preparation of an improved dietary formula for PKU patients.VII. MILK WITH HUMAN THERAPEUTIC PROTEINSTransgenic animals can also secrete proteins such as blood clotting factors needed by human hemophilia sufferers in their milk (Suraokar and Bradley, 2000) .", [["milk", "ANATOMY", 161, 165], ["blood", "ANATOMY", 379, 384], ["milk", "ANATOMY", 448, 452], ["phenylalanine", "CHEMICAL", 21, 34], ["amino acids", "CHEMICAL", 55, 66], ["PKU", "DISEASE", 272, 275], ["hemophilia", "DISEASE", 418, 428], ["phenylalanine", "CHEMICAL", 21, 34], ["amino acids", "CHEMICAL", 55, 66], ["phenylalanine", "AMINO_ACID", 21, 34], ["amino acids", "AMINO_ACID", 55, 66], ["milk", "ORGANISM_SUBSTANCE", 161, 165], ["patients", "ORGANISM", 276, 284], ["VII", "GENE_OR_GENE_PRODUCT", 285, 288], ["blood", "ORGANISM_SUBSTANCE", 379, 384], ["clotting factors", "GENE_OR_GENE_PRODUCT", 385, 401], ["human", "ORGANISM", 412, 417], ["milk", "ORGANISM_SUBSTANCE", 448, 452], ["modified protein", "PROTEIN", 141, 157], ["VII", "PROTEIN", 285, 288], ["blood clotting factors", "PROTEIN", 379, 401], ["patients", "SPECIES", 276, 284], ["human", "SPECIES", 412, 417], ["human", "SPECIES", 412, 417], ["these four phenylalanine residues", "TREATMENT", 10, 43], ["other amino acids", "TREATMENT", 49, 66], ["directed mutagenesis", "TREATMENT", 75, 95], ["the modified protein in milk", "TREATMENT", 137, 165], ["its purification", "TREATMENT", 170, 186], ["a logical sequence", "TREATMENT", 199, 217], ["HUMAN THERAPEUTIC PROTEINSTransgenic animals", "TREATMENT", 300, 344], ["secrete proteins", "PROBLEM", 354, 370], ["blood clotting factors", "PROBLEM", 379, 401], ["phenylalanine residues", "OBSERVATION", 21, 43]]], ["On these lines, Polly, a genetically altered sheep was created at the Roslin Institute in Scotland to produce milk that contained the protein used to treat human hemophilia (Pettus, 2006) .", [["milk", "ANATOMY", 110, 114], ["hemophilia", "DISEASE", 162, 172], ["lines", "CELL", 9, 14], ["sheep", "ORGANISM", 45, 50], ["milk", "ORGANISM_SUBSTANCE", 110, 114], ["human", "ORGANISM", 156, 161], ["sheep", "SPECIES", 45, 50], ["human", "SPECIES", 156, 161], ["sheep", "SPECIES", 45, 50], ["human", "SPECIES", 156, 161], ["the protein", "TREATMENT", 130, 141], ["human hemophilia", "PROBLEM", 156, 172], ["lines", "OBSERVATION", 9, 14], ["hemophilia", "OBSERVATION", 162, 172]]], ["Wright et al. (1991) described the generation of five transgenic sheep (four female and one male) for a fusion of the ovine b-LG gene promoter to the human a-1 antitrypsin (AAT) genomic sequences.", [["sheep", "ORGANISM", 65, 70], ["ovine", "ORGANISM", 118, 123], ["b-LG", "GENE_OR_GENE_PRODUCT", 124, 128], ["human", "ORGANISM", 150, 155], ["a-1 antitrypsin", "GENE_OR_GENE_PRODUCT", 156, 171], ["AAT", "GENE_OR_GENE_PRODUCT", 173, 176], ["ovine b-LG gene promoter", "DNA", 118, 142], ["human a-1 antitrypsin (AAT) genomic sequences", "DNA", 150, 195], ["sheep", "SPECIES", 65, 70], ["human", "SPECIES", 150, 155], ["sheep", "SPECIES", 65, 70], ["human", "SPECIES", 150, 155], ["a fusion of the ovine b-LG gene promoter", "TREATMENT", 102, 142]]], ["AAT is a singlechain glycoprotein secreted by the liver and its main function is the inhibition of the enzyme elastase.", [["liver", "ANATOMY", 50, 55], ["AAT", "CHEMICAL", 0, 3], ["AAT", "GENE_OR_GENE_PRODUCT", 0, 3], ["liver", "ORGAN", 50, 55], ["elastase", "GENE_OR_GENE_PRODUCT", 110, 118], ["AAT", "PROTEIN", 0, 3], ["singlechain glycoprotein", "PROTEIN", 9, 33], ["enzyme elastase", "PROTEIN", 103, 118], ["a singlechain glycoprotein", "TREATMENT", 7, 33], ["the enzyme elastase", "PROBLEM", 99, 118], ["liver", "ANATOMY", 50, 55], ["main", "OBSERVATION_MODIFIER", 64, 68], ["enzyme elastase", "OBSERVATION", 103, 118]]], ["The absence of active AAT in the system leads to emphysema (loss of elasticity of the lung tissue) and/or other lung-related ailments such as cystic fibrosis and adult respiratory distress syndrome.", [["lung tissue", "ANATOMY", 86, 97], ["lung", "ANATOMY", 112, 116], ["cystic", "ANATOMY", 142, 148], ["respiratory", "ANATOMY", 168, 179], ["emphysema", "DISEASE", 49, 58], ["cystic fibrosis", "DISEASE", 142, 157], ["respiratory distress syndrome", "DISEASE", 168, 197], ["AAT", "GENE_OR_GENE_PRODUCT", 22, 25], ["lung tissue", "TISSUE", 86, 97], ["lung", "ORGAN", 112, 116], ["AAT", "PROTEIN", 22, 25], ["active AAT in the system", "PROBLEM", 15, 39], ["emphysema", "PROBLEM", 49, 58], ["elasticity of the lung tissue", "PROBLEM", 68, 97], ["other lung-related ailments", "PROBLEM", 106, 133], ["cystic fibrosis", "PROBLEM", 142, 157], ["adult respiratory distress syndrome", "PROBLEM", 162, 197], ["active", "OBSERVATION_MODIFIER", 15, 21], ["AAT", "OBSERVATION", 22, 25], ["emphysema", "OBSERVATION", 49, 58], ["loss", "OBSERVATION_MODIFIER", 60, 64], ["elasticity", "OBSERVATION_MODIFIER", 68, 78], ["lung tissue", "ANATOMY", 86, 97], ["lung", "ANATOMY", 112, 116], ["ailments", "OBSERVATION", 125, 133], ["cystic", "OBSERVATION_MODIFIER", 142, 148], ["fibrosis", "OBSERVATION", 149, 157], ["adult", "OBSERVATION_MODIFIER", 162, 167], ["respiratory distress syndrome", "OBSERVATION", 168, 197]]], ["Milk of three of the ewes generated by Wright et al. (1991) expressed human AAT (hAAT) at levels greater than 1 g/liter.", [["Milk", "ORGANISM_SUBSTANCE", 0, 4], ["ewes", "ORGANISM", 21, 25], ["human", "ORGANISM", 70, 75], ["AAT", "GENE_OR_GENE_PRODUCT", 76, 79], ["hAAT", "GENE_OR_GENE_PRODUCT", 81, 85], ["human AAT", "PROTEIN", 70, 79], ["hAAT", "PROTEIN", 81, 85], ["human", "SPECIES", 70, 75], ["human", "SPECIES", 70, 75]]], ["In one case, initial levels of hAAT exceeded 60 g/liter and stabilized at 35 g/ liter as lactation progressed. hAAT purified from the milk of these animals was fully N-glycosylated and had a biological activity indistinguishable from human plasma-derived material.", [["milk", "ANATOMY", 134, 138], ["plasma", "ANATOMY", 240, 246], ["hAAT", "CHEMICAL", 31, 35], ["hAAT", "CHEMICAL", 111, 115], ["hAAT", "GENE_OR_GENE_PRODUCT", 31, 35], ["hAAT", "GENE_OR_GENE_PRODUCT", 111, 115], ["milk", "ORGANISM_SUBSTANCE", 134, 138], ["human", "ORGANISM", 234, 239], ["plasma", "ORGANISM_SUBSTANCE", 240, 246], ["material", "TISSUE", 255, 263], ["hAAT", "PROTEIN", 31, 35], ["hAAT", "PROTEIN", 111, 115], ["human", "SPECIES", 234, 239], ["human", "SPECIES", 234, 239], ["initial levels", "TEST", 13, 27], ["hAAT", "TEST", 31, 35]]], ["These animals and their progeny exhibited stable transmission of the transgene.", [["stable", "OBSERVATION_MODIFIER", 42, 48]]], ["The founder animals yielded very similar levels of hAAT protein in milk continuously over several lactations.", [["milk", "ANATOMY", 67, 71], ["hAAT", "GENE_OR_GENE_PRODUCT", 51, 55], ["milk", "ORGANISM_SUBSTANCE", 67, 71], ["hAAT protein", "PROTEIN", 51, 63], ["very", "OBSERVATION_MODIFIER", 28, 32]]], ["A flock of seven first generation ewes (derived from a founder male) yielded comparable levels of hAAT protein in first and second lactation milk.", [["milk", "ANATOMY", 141, 145], ["ewes", "ORGANISM", 34, 38], ["hAAT", "GENE_OR_GENE_PRODUCT", 98, 102], ["milk", "ORGANISM_SUBSTANCE", 141, 145], ["hAAT protein", "PROTEIN", 98, 110]]], ["Two second generation ewes of this line also produced equivalent quantities of the human protein (Carver et al., 1993) .", [["human", "ORGANISM", 83, 88], ["human protein", "PROTEIN", 83, 96], ["human", "SPECIES", 83, 88], ["human", "SPECIES", 83, 88], ["equivalent", "OBSERVATION_MODIFIER", 54, 64], ["quantities", "OBSERVATION_MODIFIER", 65, 75]]], ["Several animals from this group are reported to secrete milk containing 35-47 g/liter without affecting the production of other proteins in milk (Coleman, 1996) .VII. MILK WITH HUMAN THERAPEUTIC PROTEINSWith successful advances in research, several other recombinant proteins of pharmaceutical interest have been developed from the milk of transgenic animals.", [["milk", "ANATOMY", 56, 60], ["milk", "ANATOMY", 140, 144], ["milk", "ANATOMY", 332, 336], ["milk", "ORGANISM_SUBSTANCE", 56, 60], ["milk", "ORGANISM_SUBSTANCE", 140, 144], ["VII", "GENE_OR_GENE_PRODUCT", 162, 165], ["milk", "ORGANISM_SUBSTANCE", 332, 336], ["VII", "PROTEIN", 162, 165], ["recombinant proteins", "PROTEIN", 255, 275], ["HUMAN THERAPEUTIC PROTEINSWith successful advances", "TREATMENT", 177, 227]]], ["In this context, some human proteins have already been expressed with success.", [["human", "ORGANISM", 22, 27], ["human proteins", "PROTEIN", 22, 36], ["human", "SPECIES", 22, 27], ["human", "SPECIES", 22, 27], ["some human proteins", "PROBLEM", 17, 36]]], ["Products such as insulin and growth hormone have also been obtained from the milk of transgenic cows, sheep, or goats (Margawati, 2003) .VII. MILK WITH HUMAN THERAPEUTIC PROTEINSGTC Biotherapeutics (Framingham, MA) uses both goats and cows to produce more than 60 therapeutic proteins, including plasma proteins, monoclonal antibodies, and vaccines.", [["milk", "ANATOMY", 77, 81], ["plasma", "ANATOMY", 296, 302], ["insulin", "GENE_OR_GENE_PRODUCT", 17, 24], ["growth hormone", "GENE_OR_GENE_PRODUCT", 29, 43], ["milk", "ORGANISM_SUBSTANCE", 77, 81], ["cows", "DEVELOPING_ANATOMICAL_STRUCTURE", 96, 100], ["sheep", "ORGANISM", 102, 107], ["goats", "ORGANISM", 112, 117], ["VII", "GENE_OR_GENE_PRODUCT", 137, 140], ["goats", "ORGANISM", 225, 230], ["cows", "ORGANISM", 235, 239], ["plasma", "ORGANISM_SUBSTANCE", 296, 302], ["insulin", "PROTEIN", 17, 24], ["VII", "PROTEIN", 137, 140], ["plasma proteins", "PROTEIN", 296, 311], ["monoclonal antibodies", "PROTEIN", 313, 334], ["cows", "SPECIES", 96, 100], ["sheep", "SPECIES", 102, 107], ["goats", "SPECIES", 112, 117], ["goats", "SPECIES", 225, 230], ["cows", "SPECIES", 235, 239], ["cows", "SPECIES", 96, 100], ["sheep", "SPECIES", 102, 107], ["goats", "SPECIES", 112, 117], ["goats", "SPECIES", 225, 230], ["Products", "TREATMENT", 0, 8], ["insulin and growth hormone", "TREATMENT", 17, 43], ["HUMAN THERAPEUTIC PROTEINSGTC Biotherapeutics (Framingham, MA)", "TREATMENT", 152, 214], ["plasma proteins", "TEST", 296, 311], ["monoclonal antibodies", "TREATMENT", 313, 334], ["vaccines", "TREATMENT", 340, 348]]], ["A recombinant human antithrombin III-an anticoagulant protein found in blood-which was produced in goat milk and was in the last stage of testing a couple of years ago (Subramanian, 2004) is now almost ready to be marketed.", [["blood", "ANATOMY", 71, 76], ["milk", "ANATOMY", 104, 108], ["human", "ORGANISM", 14, 19], ["antithrombin III", "GENE_OR_GENE_PRODUCT", 20, 36], ["blood", "ORGANISM_SUBSTANCE", 71, 76], ["goat", "ORGANISM", 99, 103], ["milk", "ORGANISM_SUBSTANCE", 104, 108], ["recombinant human antithrombin III", "PROTEIN", 2, 36], ["anticoagulant protein", "PROTEIN", 40, 61], ["human", "SPECIES", 14, 19], ["goat", "SPECIES", 99, 103], ["human", "SPECIES", 14, 19], ["goat", "SPECIES", 99, 103], ["A recombinant human antithrombin III", "TREATMENT", 0, 36], ["an anticoagulant protein", "TREATMENT", 37, 61]]], ["The company claims that the antithrombin (ATryn ) has been recommended for market authorization for the prophylaxis of venous thromboembolism in surgery of patients with congenital antithrombin deficiency (www.transgenics. com/news.html).", [["venous", "ANATOMY", 119, 125], ["ATryn", "CHEMICAL", 42, 47], ["venous thromboembolism", "DISEASE", 119, 141], ["congenital antithrombin deficiency", "DISEASE", 170, 204], ["antithrombin", "GENE_OR_GENE_PRODUCT", 28, 40], ["ATryn", "SIMPLE_CHEMICAL", 42, 47], ["venous", "PATHOLOGICAL_FORMATION", 119, 125], ["patients", "ORGANISM", 156, 164], ["antithrombin", "GENE_OR_GENE_PRODUCT", 181, 193], ["html", "GENE_OR_GENE_PRODUCT", 232, 236], ["antithrombin", "PROTEIN", 28, 40], ["antithrombin", "PROTEIN", 181, 193], ["html", "PROTEIN", 232, 236], ["patients", "SPECIES", 156, 164], ["the antithrombin (ATryn )", "TREATMENT", 24, 49], ["venous thromboembolism", "PROBLEM", 119, 141], ["surgery", "TREATMENT", 145, 152], ["congenital antithrombin deficiency", "PROBLEM", 170, 204], ["venous", "ANATOMY", 119, 125], ["thromboembolism", "OBSERVATION", 126, 141], ["congenital", "OBSERVATION_MODIFIER", 170, 180], ["antithrombin deficiency", "OBSERVATION", 181, 204]]], ["Besides being the first antithrombin product approved by the European Medicines Agency for use in all 25 countries of the European Union, ATryn will also be the only available antithrombin product that is produced by recombinant biotechnology and is not derived from the human blood supply.", [["blood", "ANATOMY", 277, 282], ["ATryn", "CHEMICAL", 138, 143], ["antithrombin", "GENE_OR_GENE_PRODUCT", 24, 36], ["ATryn", "SIMPLE_CHEMICAL", 138, 143], ["antithrombin", "GENE_OR_GENE_PRODUCT", 176, 188], ["human", "ORGANISM", 271, 276], ["blood", "ORGANISM_SUBSTANCE", 277, 282], ["antithrombin product", "PROTEIN", 176, 196], ["human", "SPECIES", 271, 276], ["human", "SPECIES", 271, 276], ["the first antithrombin product", "TREATMENT", 14, 44], ["antithrombin product", "TREATMENT", 176, 196]]], ["This drug is envisaged to be a boon for those suffering from a deficiency in antithrombin, a condition which becomes dangerous during surgery or childbirth, when they cannot take conventional blood-thinning pills.VII. MILK WITH HUMAN THERAPEUTIC PROTEINSThe Scientific American (www.sciam.com, 2001) reported a study at the National Institute of Allergy and Infectious Disease (United States) in which two mouse strains were genetically engineered to produce large quantities of a malarial parasite surface protein from Plasmodium falciparum.", [["blood", "ANATOMY", 192, 197], ["surface", "ANATOMY", 499, 506], ["Allergy and Infectious Disease", "DISEASE", 346, 376], ["Plasmodium falciparum", "DISEASE", 520, 541], ["antithrombin", "GENE_OR_GENE_PRODUCT", 77, 89], ["blood", "ORGANISM_SUBSTANCE", 192, 197], ["VII", "GENE_OR_GENE_PRODUCT", 213, 216], ["mouse", "ORGANISM", 406, 411], ["Plasmodium falciparum", "ORGANISM", 520, 541], ["antithrombin", "PROTEIN", 77, 89], ["VII", "PROTEIN", 213, 216], ["malarial parasite surface protein", "PROTEIN", 481, 514], ["mouse", "SPECIES", 406, 411], ["Plasmodium falciparum", "SPECIES", 520, 541], ["mouse", "SPECIES", 406, 411], ["Plasmodium falciparum", "SPECIES", 520, 541], ["a deficiency in antithrombin", "PROBLEM", 61, 89], ["a condition", "PROBLEM", 91, 102], ["conventional blood-thinning pills", "TREATMENT", 179, 212], ["a study", "TEST", 309, 316], ["two mouse strains", "PROBLEM", 402, 419], ["a malarial parasite surface protein", "PROBLEM", 479, 514], ["Plasmodium falciparum", "PROBLEM", 520, 541], ["deficiency", "OBSERVATION", 63, 73], ["large", "OBSERVATION_MODIFIER", 459, 464], ["Plasmodium falciparum", "OBSERVATION", 520, 541]]], ["The malaria vaccine secreted in their milk was able to contain the disease in monkeys vaccinated with the same.", [["milk", "ANATOMY", 38, 42], ["malaria", "DISEASE", 4, 11], ["milk", "ORGANISM_SUBSTANCE", 38, 42], ["monkeys", "ORGANISM", 78, 85], ["monkeys", "SPECIES", 78, 85], ["The malaria vaccine", "TREATMENT", 0, 19], ["the disease in monkeys vaccinated", "PROBLEM", 63, 96], ["malaria", "OBSERVATION", 4, 11], ["disease", "OBSERVATION", 67, 74]]], ["This study has now been extrapolated to target livestock as the source animals.", [["This study", "TEST", 0, 10]]], ["GTC is currently working on a project to develop the malaria vaccine from goat milk.", [["milk", "ANATOMY", 79, 83], ["malaria", "DISEASE", 53, 60], ["goat", "ORGANISM", 74, 78], ["milk", "ORGANISM_SUBSTANCE", 79, 83], ["goat", "SPECIES", 74, 78], ["goat", "SPECIES", 74, 78], ["GTC", "PROBLEM", 0, 3], ["the malaria vaccine", "TREATMENT", 49, 68], ["malaria", "OBSERVATION", 53, 60]]], ["It is understood that a liter of goat milk can contain up to 9 g of the transgenic protein and that eight goats can produce enough vaccine to inoculate 20 million people.", [["milk", "ANATOMY", 38, 42], ["goat", "ORGANISM", 33, 37], ["milk", "ORGANISM_SUBSTANCE", 38, 42], ["goats", "ORGANISM", 106, 111], ["people", "ORGANISM", 163, 169], ["transgenic protein", "PROTEIN", 72, 90], ["goat", "SPECIES", 33, 37], ["goats", "SPECIES", 106, 111], ["people", "SPECIES", 163, 169], ["goat", "SPECIES", 33, 37], ["goats", "SPECIES", 106, 111], ["a liter of goat milk", "TREATMENT", 22, 42], ["the transgenic protein", "TREATMENT", 68, 90]]], ["The cost to produce a transgenic protein in goat milk can thus be 3-30 times cheaper than the current method using mammalian cell culture.", [["milk", "ANATOMY", 49, 53], ["cell", "ANATOMY", 125, 129], ["goat", "ORGANISM", 44, 48], ["milk", "ORGANISM_SUBSTANCE", 49, 53], ["mammalian cell culture", "CELL", 115, 137], ["transgenic protein", "PROTEIN", 22, 40], ["mammalian cell culture", "CELL_LINE", 115, 137], ["goat", "SPECIES", 44, 48], ["goat", "SPECIES", 44, 48], ["a transgenic protein in goat milk", "TREATMENT", 20, 53], ["the current method", "TREATMENT", 90, 108], ["mammalian cell culture", "TREATMENT", 115, 137]]], ["In addition to these, GTC is also working on the development of a recombinant hAAT, a recombinant human albumin, and a CD137 antibody to stimulate the immune system as a potential treatment for solid tumors.VII. MILK WITH HUMAN THERAPEUTIC PROTEINSPPL Therapeutics (Edinburgh, United Kingdom, and Blacksburg, VA) is working with rabbits and sheep to produce AAT, fibrinogen, and a lipase to treat pancreatic insufficiency in digesting dietary lipids.", [["immune system", "ANATOMY", 151, 164], ["solid tumors", "ANATOMY", 194, 206], ["pancreatic", "ANATOMY", 397, 407], ["tumors", "DISEASE", 200, 206], ["pancreatic insufficiency", "DISEASE", 397, 421], ["hAAT", "GENE_OR_GENE_PRODUCT", 78, 82], ["human", "ORGANISM", 98, 103], ["albumin", "GENE_OR_GENE_PRODUCT", 104, 111], ["CD137", "GENE_OR_GENE_PRODUCT", 119, 124], ["solid tumors", "CANCER", 194, 206], ["VII", "GENE_OR_GENE_PRODUCT", 207, 210], ["rabbits", "ORGANISM", 329, 336], ["sheep", "ORGANISM", 341, 346], ["AAT", "GENE_OR_GENE_PRODUCT", 358, 361], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 363, 373], ["lipase", "GENE_OR_GENE_PRODUCT", 381, 387], ["pancreatic", "ORGAN", 397, 407], ["recombinant hAAT", "PROTEIN", 66, 82], ["recombinant human albumin", "PROTEIN", 86, 111], ["CD137 antibody", "PROTEIN", 119, 133], ["VII", "PROTEIN", 207, 210], ["AAT", "PROTEIN", 358, 361], ["fibrinogen", "PROTEIN", 363, 373], ["lipase", "PROTEIN", 381, 387], ["human", "SPECIES", 98, 103], ["rabbits", "SPECIES", 329, 336], ["sheep", "SPECIES", 341, 346], ["human", "SPECIES", 98, 103], ["rabbits", "SPECIES", 329, 336], ["sheep", "SPECIES", 341, 346], ["a recombinant human albumin", "TREATMENT", 84, 111], ["a CD137 antibody", "TEST", 117, 133], ["a potential treatment", "TREATMENT", 168, 189], ["solid tumors", "PROBLEM", 194, 206], ["AAT", "TEST", 358, 361], ["fibrinogen", "TEST", 363, 373], ["a lipase", "TEST", 379, 387], ["pancreatic insufficiency", "PROBLEM", 397, 421], ["dietary lipids", "TREATMENT", 435, 449], ["tumors", "OBSERVATION", 200, 206], ["pancreatic", "ANATOMY", 397, 407], ["insufficiency", "OBSERVATION", 408, 421]]], ["They are also attempting to engineer sheep to produce in milk a protein that reduces lung damage, thus providing hope to cystic fibrosis sufferers (Morgan, 2006) .VII. MILK WITH HUMAN THERAPEUTIC PROTEINSThe Environment Risk Management Authority (ERMA) of New Zealand has admitted an application from AgResearch, New Zealand, for field testing of some cattle which are genetically modified with copies of genes or nucleic acids derived from humans or cattle (www.ermanz. govt.nz, 2001) .", [["lung", "ANATOMY", 85, 89], ["cystic", "ANATOMY", 121, 127], ["lung damage", "DISEASE", 85, 96], ["cystic fibrosis", "DISEASE", 121, 136], ["nucleic acids", "CHEMICAL", 414, 427], ["sheep", "ORGANISM", 37, 42], ["milk", "ORGANISM_SUBSTANCE", 57, 61], ["lung", "ORGAN", 85, 89], ["VII", "GENE_OR_GENE_PRODUCT", 163, 166], ["cattle", "ORGANISM", 352, 358], ["humans", "ORGANISM", 441, 447], ["VII", "PROTEIN", 163, 166], ["sheep", "SPECIES", 37, 42], ["cattle", "SPECIES", 352, 358], ["humans", "SPECIES", 441, 447], ["cattle", "SPECIES", 451, 457], ["sheep", "SPECIES", 37, 42], ["cattle", "SPECIES", 352, 358], ["humans", "SPECIES", 441, 447], ["cattle", "SPECIES", 451, 457], ["lung damage", "PROBLEM", 85, 96], ["cystic fibrosis sufferers", "PROBLEM", 121, 146], ["HUMAN THERAPEUTIC PROTEINSThe Environment", "TREATMENT", 178, 219], ["New Zealand", "TREATMENT", 313, 324], ["field testing", "TEST", 330, 343], ["nucleic acids", "TREATMENT", 414, 427], ["lung", "ANATOMY", 85, 89], ["damage", "OBSERVATION", 90, 96], ["cystic", "OBSERVATION_MODIFIER", 121, 127], ["fibrosis", "OBSERVATION", 128, 136]]], ["The first of these involves inserting additional copies of two cattle milk casein genes to increase the protein content of milk (www. agresearch.co.nz, 2001) .", [["milk", "ANATOMY", 123, 127], ["milk", "ORGANISM", 70, 74], ["casein", "GENE_OR_GENE_PRODUCT", 75, 81], ["milk", "ORGANISM_SUBSTANCE", 123, 127], ["cattle milk casein genes", "DNA", 63, 87], ["cattle", "SPECIES", 63, 69], ["cattle", "SPECIES", 63, 69], ["two cattle milk casein genes", "TREATMENT", 59, 87]]], ["The second one is to disrupt the b-LG in order to decrease causes of milk allergies.", [["milk", "ANATOMY", 69, 73], ["milk allergies", "DISEASE", 69, 83], ["b-LG", "GENE_OR_GENE_PRODUCT", 33, 37], ["milk", "ORGANISM_SUBSTANCE", 69, 73], ["milk allergies", "PROBLEM", 69, 83], ["LG", "ANATOMY", 35, 37], ["milk allergies", "OBSERVATION", 69, 83]]], ["The field tests also involve the insertion of a copy of the human myelin basic protein (MBP) gene in cattle.", [["human", "ORGANISM", 60, 65], ["myelin basic protein", "GENE_OR_GENE_PRODUCT", 66, 86], ["MBP", "GENE_OR_GENE_PRODUCT", 88, 91], ["human myelin basic protein (MBP) gene", "DNA", 60, 97], ["human", "SPECIES", 60, 65], ["cattle", "SPECIES", 101, 107], ["human", "SPECIES", 60, 65], ["cattle", "SPECIES", 101, 107], ["The field tests", "TEST", 0, 15], ["the human myelin basic protein (MBP", "TREATMENT", 56, 91]]], ["The protein, when secreted in their milk, may be purified and tested for its efficacy in the treatment of multiple sclerosis.", [["milk", "ANATOMY", 36, 40], ["multiple sclerosis", "DISEASE", 106, 124], ["milk", "ORGANISM_SUBSTANCE", 36, 40], ["multiple sclerosis", "PROBLEM", 106, 124], ["multiple", "OBSERVATION_MODIFIER", 106, 114], ["sclerosis", "OBSERVATION", 115, 124]]], ["Multiple sclerosis is a chronic demyelinating disease of the human central nervous system connected with clinical neurological signs of paralysis and histopathological changes.", [["central nervous system", "ANATOMY", 67, 89], ["neurological", "ANATOMY", 114, 126], ["Multiple sclerosis", "DISEASE", 0, 18], ["demyelinating disease of the human central nervous system", "DISEASE", 32, 89], ["paralysis", "DISEASE", 136, 145], ["human", "ORGANISM", 61, 66], ["central nervous system", "ANATOMICAL_SYSTEM", 67, 89], ["human", "SPECIES", 61, 66], ["human", "SPECIES", 61, 66], ["Multiple sclerosis", "PROBLEM", 0, 18], ["a chronic demyelinating disease of the human central nervous system", "PROBLEM", 22, 89], ["paralysis", "PROBLEM", 136, 145], ["histopathological changes", "PROBLEM", 150, 175], ["sclerosis", "OBSERVATION", 9, 18], ["chronic", "OBSERVATION_MODIFIER", 24, 31], ["demyelinating", "OBSERVATION", 32, 45], ["human", "ANATOMY_MODIFIER", 61, 66], ["central", "ANATOMY_MODIFIER", 67, 74], ["nervous system", "ANATOMY", 75, 89], ["paralysis", "OBSERVATION", 136, 145]]], ["It is expected that secretion of MBP in cattle milk will allow the generation of large amounts of human MBP and will ultimately facilitate as a drug for the treatment of multiple sclerosis.VII. MILK WITH HUMAN THERAPEUTIC PROTEINSScientists at AgResearch have also patented a technology to produce bovine milk with enhanced quantities of immunoglobulin (IgA) antibodies (AgResearch Now, 2005) .", [["milk", "ANATOMY", 47, 51], ["milk", "ANATOMY", 305, 309], ["multiple sclerosis", "DISEASE", 170, 188], ["MBP", "GENE_OR_GENE_PRODUCT", 33, 36], ["cattle", "ORGANISM", 40, 46], ["milk", "ORGANISM_SUBSTANCE", 47, 51], ["human", "ORGANISM", 98, 103], ["MBP", "GENE_OR_GENE_PRODUCT", 104, 107], ["VII", "GENE_OR_GENE_PRODUCT", 189, 192], ["bovine", "ORGANISM", 298, 304], ["milk", "ORGANISM_SUBSTANCE", 305, 309], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 338, 352], ["IgA", "GENE_OR_GENE_PRODUCT", 354, 357], ["MBP", "PROTEIN", 33, 36], ["human MBP", "PROTEIN", 98, 107], ["VII", "PROTEIN", 189, 192], ["immunoglobulin (IgA) antibodies", "PROTEIN", 338, 369], ["cattle", "SPECIES", 40, 46], ["human", "SPECIES", 98, 103], ["bovine", "SPECIES", 298, 304], ["cattle", "SPECIES", 40, 46], ["human", "SPECIES", 98, 103], ["bovine", "SPECIES", 298, 304], ["secretion of MBP in cattle milk", "PROBLEM", 20, 51], ["human MBP", "TREATMENT", 98, 107], ["a drug", "TREATMENT", 142, 148], ["multiple sclerosis", "PROBLEM", 170, 188], ["a technology", "TREATMENT", 274, 286], ["multiple", "OBSERVATION_MODIFIER", 170, 178], ["sclerosis", "OBSERVATION", 179, 188]]], ["IgA is the dominant immunoglobulin in human milk and provides infants with essential protection against pathogens.", [["milk", "ANATOMY", 44, 48], ["IgA", "GENE_OR_GENE_PRODUCT", 0, 3], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 20, 34], ["human", "ORGANISM", 38, 43], ["milk", "ORGANISM_SUBSTANCE", 44, 48], ["infants", "ORGANISM", 62, 69], ["IgA", "PROTEIN", 0, 3], ["dominant immunoglobulin", "PROTEIN", 11, 34], ["human", "SPECIES", 38, 43], ["milk", "SPECIES", 44, 48], ["infants", "SPECIES", 62, 69], ["human", "SPECIES", 38, 43], ["pathogens", "PROBLEM", 104, 113], ["dominant", "OBSERVATION_MODIFIER", 11, 19], ["immunoglobulin", "OBSERVATION", 20, 34]]], ["IgA also contributes to adult health by helping to protect human mucosal surfaces like the stomach, intestinal tract, lungs, nose, ears, and eyes.", [["mucosal surfaces", "ANATOMY", 65, 81], ["stomach", "ANATOMY", 91, 98], ["intestinal tract", "ANATOMY", 100, 116], ["lungs", "ANATOMY", 118, 123], ["nose", "ANATOMY", 125, 129], ["ears", "ANATOMY", 131, 135], ["eyes", "ANATOMY", 141, 145], ["IgA", "GENE_OR_GENE_PRODUCT", 0, 3], ["human", "ORGANISM", 59, 64], ["mucosal surfaces", "MULTI-TISSUE_STRUCTURE", 65, 81], ["stomach", "ORGAN", 91, 98], ["intestinal tract", "MULTI-TISSUE_STRUCTURE", 100, 116], ["lungs", "ORGAN", 118, 123], ["nose", "ORGANISM_SUBDIVISION", 125, 129], ["ears", "ORGAN", 131, 135], ["eyes", "ORGAN", 141, 145], ["IgA", "PROTEIN", 0, 3], ["human", "SPECIES", 59, 64], ["human", "SPECIES", 59, 64], ["intestinal tract, lungs, nose, ears, and eyes", "PROBLEM", 100, 145], ["stomach", "ANATOMY", 91, 98], ["intestinal tract", "ANATOMY", 100, 116], ["lungs", "ANATOMY", 118, 123], ["nose", "ANATOMY", 125, 129], ["ears", "ANATOMY", 131, 135], ["eyes", "ANATOMY", 141, 145]]], ["One application of the technology being pursued is the prevention of human fungal infections including thrush, caused mostly by Candida albicans.", [["fungal infections", "DISEASE", 75, 92], ["thrush", "DISEASE", 103, 109], ["Candida albicans", "DISEASE", 128, 144], ["human", "ORGANISM", 69, 74], ["Candida albicans", "ORGANISM", 128, 144], ["human", "SPECIES", 69, 74], ["Candida albicans", "SPECIES", 128, 144], ["human", "SPECIES", 69, 74], ["Candida albicans", "SPECIES", 128, 144], ["the technology", "TREATMENT", 19, 33], ["human fungal infections", "PROBLEM", 69, 92], ["thrush", "PROBLEM", 103, 109], ["Candida albicans", "PROBLEM", 128, 144], ["fungal", "OBSERVATION_MODIFIER", 75, 81], ["infections", "OBSERVATION", 82, 92], ["thrush", "OBSERVATION", 103, 109], ["Candida albicans", "OBSERVATION", 128, 144]]], ["These antibodies can also be tailored to protect against specific gut or oral diseases.VII. MILK WITH HUMAN THERAPEUTIC PROTEINSIn this context, the milk is undergoing trials at Otago's school of dentistry to assess its potential for protecting teeth against decay-causing bacteria (New Zealand Herald, 2006) .", [["gut", "ANATOMY", 66, 69], ["oral", "ANATOMY", 73, 77], ["milk", "ANATOMY", 149, 153], ["teeth", "ANATOMY", 245, 250], ["oral diseases", "DISEASE", 73, 86], ["gut", "ORGANISM_SUBDIVISION", 66, 69], ["oral", "ORGANISM_SUBDIVISION", 73, 77], ["VII", "GENE_OR_GENE_PRODUCT", 87, 90], ["milk", "ORGANISM_SUBSTANCE", 149, 153], ["teeth", "ORGAN", 245, 250], ["antibodies", "PROTEIN", 6, 16], ["VII", "PROTEIN", 87, 90], ["These antibodies", "TREATMENT", 0, 16], ["oral diseases", "PROBLEM", 73, 86], ["HUMAN THERAPEUTIC PROTEINSIn", "TREATMENT", 102, 130], ["protecting teeth", "PROBLEM", 234, 250], ["bacteria", "PROBLEM", 273, 281]]], ["It is reported that about 10,000 cows immunized to protect against fungal infections would be sufficient to provide a protein powder for a mouthwash or lozenge that would form a barrier on the teeth, tongue, and cells lining the mouth and hence repel oral thrush.VII. MILK WITH HUMAN THERAPEUTIC PROTEINSPharming, NV (Leiden, the Netherlands) has obtained a US Patent for the production and composition of pharmaceuticals containing human a-glucosidase (Biotech Patent News, 2000) .", [["teeth", "ANATOMY", 193, 198], ["tongue", "ANATOMY", 200, 206], ["cells", "ANATOMY", 212, 217], ["mouth", "ANATOMY", 229, 234], ["oral", "ANATOMY", 251, 255], ["fungal infections", "DISEASE", 67, 84], ["cows", "ORGANISM", 33, 37], ["teeth", "ORGAN", 193, 198], ["tongue", "ORGAN", 200, 206], ["cells", "CELL", 212, 217], ["mouth", "ORGAN", 229, 234], ["oral", "ORGANISM_SUBDIVISION", 251, 255], ["VII", "GENE_OR_GENE_PRODUCT", 263, 266], ["human", "ORGANISM", 433, 438], ["a-glucosidase", "SIMPLE_CHEMICAL", 439, 452], ["VII", "PROTEIN", 263, 266], ["cows", "SPECIES", 33, 37], ["human", "SPECIES", 433, 438], ["human", "SPECIES", 433, 438], ["fungal infections", "PROBLEM", 67, 84], ["a protein powder", "TREATMENT", 116, 132], ["a mouthwash", "TREATMENT", 137, 148], ["lozenge", "TREATMENT", 152, 159], ["a barrier on the teeth", "TREATMENT", 176, 198], ["repel oral thrush", "PROBLEM", 245, 262], ["a US", "TEST", 356, 360], ["composition of pharmaceuticals", "TREATMENT", 391, 421], ["teeth", "ANATOMY", 193, 198], ["tongue", "ANATOMY", 200, 206], ["mouth", "ANATOMY", 229, 234], ["thrush", "OBSERVATION", 256, 262], ["Patent", "OBSERVATION", 361, 367]]], ["They have developed transgenic cattle capable of producing this enzyme in their milk.", [["milk", "ANATOMY", 80, 84], ["cattle", "ORGANISM", 31, 37], ["milk", "ORGANISM_SUBSTANCE", 80, 84], ["cattle", "SPECIES", 31, 37], ["cattle", "SPECIES", 31, 37]]], ["The company claims that this can help in treating Pompe's disease, a hereditary, lethal muscle disorder that annually affects almost 5000-10,000 people living in the West.", [["muscle", "ANATOMY", 88, 94], ["Pompe's disease", "DISEASE", 50, 65], ["hereditary", "DISEASE", 69, 79], ["muscle disorder", "DISEASE", 88, 103], ["muscle", "ORGAN", 88, 94], ["people", "ORGANISM", 145, 151], ["people", "SPECIES", 145, 151], ["Pompe's disease", "PROBLEM", 50, 65], ["a hereditary, lethal muscle disorder", "PROBLEM", 67, 103], ["lethal muscle", "ANATOMY", 81, 94]]], ["Genzyme Transgenics (Framingham, MA) have also succeeded in producing human a-glucosidase from transgenic animals (Dove, 2000) .VII. MILK WITH HUMAN THERAPEUTIC PROTEINSThe Pharming Group maintains a transgenic dairy herd in the Dane County town of Vienna and claims that over the next decade their 13-strength herd will procreate 200 or more Holstein and Brown Swiss cows.", [["human", "ORGANISM", 70, 75], ["a-glucosidase", "GENE_OR_GENE_PRODUCT", 76, 89], ["VII", "GENE_OR_GENE_PRODUCT", 128, 131], ["human a-glucosidase", "PROTEIN", 70, 89], ["VII", "PROTEIN", 128, 131], ["human", "SPECIES", 70, 75], ["cows", "SPECIES", 368, 372], ["human", "SPECIES", 70, 75]]], ["The cattle will produce milk from which medicinal proteins can be turned into drugs that fight human illnesses such as hemophilia, hereditary angiodema, and gastrointestinal infections besides Pompe's disease (Millard, 2000) .VII. MILK WITH HUMAN THERAPEUTIC PROTEINSNexia, a US company, has engineered a herd of goats with milk containing an antidote for the nerve agents sarin and VX (Morgan, 2006) .", [["milk", "ANATOMY", 24, 28], ["angiodema", "ANATOMY", 142, 151], ["gastrointestinal", "ANATOMY", 157, 173], ["milk", "ANATOMY", 324, 328], ["nerve", "ANATOMY", 360, 365], ["hemophilia", "DISEASE", 119, 129], ["hereditary angiodema", "DISEASE", 131, 151], ["gastrointestinal infections", "DISEASE", 157, 184], ["Pompe's disease", "DISEASE", 193, 208], ["sarin", "CHEMICAL", 373, 378], ["VX", "CHEMICAL", 383, 385], ["cattle", "ORGANISM", 4, 10], ["milk", "ORGANISM_SUBSTANCE", 24, 28], ["human", "ORGANISM", 95, 100], ["gastrointestinal", "ORGAN", 157, 173], ["VII", "GENE_OR_GENE_PRODUCT", 226, 229], ["goats", "ORGANISM", 313, 318], ["milk", "ORGANISM_SUBSTANCE", 324, 328], ["sarin", "SIMPLE_CHEMICAL", 373, 378], ["VX", "SIMPLE_CHEMICAL", 383, 385], ["VII", "PROTEIN", 226, 229], ["cattle", "SPECIES", 4, 10], ["human", "SPECIES", 95, 100], ["goats", "SPECIES", 313, 318], ["cattle", "SPECIES", 4, 10], ["human", "SPECIES", 95, 100], ["goats", "SPECIES", 313, 318], ["medicinal proteins", "TREATMENT", 40, 58], ["human illnesses", "PROBLEM", 95, 110], ["hemophilia", "PROBLEM", 119, 129], ["hereditary angiodema", "PROBLEM", 131, 151], ["gastrointestinal infections", "PROBLEM", 157, 184], ["Pompe's disease", "PROBLEM", 193, 208], ["milk", "TREATMENT", 324, 328], ["an antidote", "TREATMENT", 340, 351], ["hemophilia", "OBSERVATION", 119, 129], ["gastrointestinal", "ANATOMY", 157, 173], ["infections", "OBSERVATION", 174, 184], ["nerve", "ANATOMY", 360, 365]]], ["Experiments are under way at Hematech, South Dakota to create a transgenic cow (Transchromic, Tc cow) that will have an immune system that is half human and half bovine.", [["cow", "ORGANISM", 75, 78], ["Tc cow", "ORGANISM", 94, 100], ["human", "ORGANISM", 147, 152], ["bovine", "ORGANISM", 162, 168], ["cow", "SPECIES", 75, 78], ["cow", "SPECIES", 97, 100], ["human", "SPECIES", 147, 152], ["bovine", "SPECIES", 162, 168], ["cow", "SPECIES", 75, 78], ["cow", "SPECIES", 97, 100], ["human", "SPECIES", 147, 152], ["a transgenic cow", "PROBLEM", 62, 78], ["an immune system", "TREATMENT", 117, 133]]], ["Its cells will contain an additional artificial chromosome, with the genes for human antibodies (Morgan, 2006) .", [["cells", "ANATOMY", 4, 9], ["chromosome", "ANATOMY", 48, 58], ["cells", "CELL", 4, 9], ["chromosome", "CELLULAR_COMPONENT", 48, 58], ["human", "ORGANISM", 79, 84], ["human antibodies", "PROTEIN", 79, 95], ["human", "SPECIES", 79, 84], ["human", "SPECIES", 79, 84], ["an additional artificial chromosome", "TREATMENT", 23, 58]]], ["The firm claims that when the Tc cow is immunized with an infectious agent, such as inactivated botulinum toxin, it will produce human polyclonal antibodies.", [["Tc cow", "ORGANISM", 30, 36], ["botulinum toxin", "SIMPLE_CHEMICAL", 96, 111], ["human", "ORGANISM", 129, 134], ["human polyclonal antibodies", "PROTEIN", 129, 156], ["cow", "SPECIES", 33, 36], ["human", "SPECIES", 129, 134], ["cow", "SPECIES", 33, 36], ["human", "SPECIES", 129, 134], ["the Tc cow", "TREATMENT", 26, 36], ["an infectious agent", "TREATMENT", 55, 74], ["inactivated botulinum toxin", "PROBLEM", 84, 111], ["human polyclonal antibodies", "PROBLEM", 129, 156], ["firm", "OBSERVATION_MODIFIER", 4, 8], ["infectious", "OBSERVATION", 58, 68]]], ["These can then be purified from the cow's blood and given to patients who cannot fight these infections owing to defects in their own immune systems.", [["blood", "ANATOMY", 42, 47], ["infections", "DISEASE", 93, 103], ["cow", "ORGANISM", 36, 39], ["blood", "ORGANISM_SUBSTANCE", 42, 47], ["patients", "ORGANISM", 61, 69], ["cow", "SPECIES", 36, 39], ["patients", "SPECIES", 61, 69], ["cow", "SPECIES", 36, 39], ["the cow's blood", "TEST", 32, 47], ["these infections", "PROBLEM", 87, 103], ["defects in their own immune systems", "PROBLEM", 113, 148], ["infections", "OBSERVATION", 93, 103]]], ["Hematech has already created Tc calves, which carry the human chromosome.", [["chromosome", "ANATOMY", 62, 72], ["Hematech", "CHEMICAL", 0, 8], ["Hematech", "GENE_OR_GENE_PRODUCT", 0, 8], ["Tc calves", "ORGANISM", 29, 38], ["human", "ORGANISM", 56, 61], ["chromosome", "CELLULAR_COMPONENT", 62, 72], ["human chromosome", "DNA", 56, 72], ["calves", "SPECIES", 32, 38], ["human", "SPECIES", 56, 61], ["human", "SPECIES", 56, 61]]], ["The remaining work is to knock out the equivalent bovine antibody genes, so the Tc cow produces purely human antibodies in its blood.", [["blood", "ANATOMY", 127, 132], ["bovine", "ORGANISM", 50, 56], ["antibody", "GENE_OR_GENE_PRODUCT", 57, 65], ["Tc cow", "ORGANISM", 80, 86], ["human", "ORGANISM", 103, 108], ["blood", "ORGANISM_SUBSTANCE", 127, 132], ["bovine antibody genes", "DNA", 50, 71], ["human antibodies", "PROTEIN", 103, 119], ["bovine", "SPECIES", 50, 56], ["cow", "SPECIES", 83, 86], ["human", "SPECIES", 103, 108], ["cow", "SPECIES", 83, 86], ["human", "SPECIES", 103, 108], ["the equivalent bovine antibody genes", "PROBLEM", 35, 71], ["purely human antibodies in its blood", "PROBLEM", 96, 132]]], ["The firm anticipates that the technology will be more efficient and less expensive than present methods for generating human antibodies-cell culture-which can make only monoclonal (single variant) antibodies.VIII. DESIGNER MILK FOR ANIMAL GROWTH AND HEALTHVaccines, antibiotics, and the natural immune system of the animal have been used to cure diseases in the cow till recently.", [["cell", "ANATOMY", 136, 140], ["human", "ORGANISM", 119, 124], ["cell", "CELL", 136, 140], ["VIII", "GENE_OR_GENE_PRODUCT", 208, 212], ["cow", "ORGANISM", 362, 365], ["human antibodies", "PROTEIN", 119, 135], ["monoclonal (single variant) antibodies", "PROTEIN", 169, 207], ["VIII", "PROTEIN", 208, 212], ["human", "SPECIES", 119, 124], ["cow", "SPECIES", 362, 365], ["human", "SPECIES", 119, 124], ["cow", "SPECIES", 362, 365], ["generating human antibodies", "TEST", 108, 135], ["cell culture", "TEST", 136, 148], ["monoclonal (single variant) antibodies", "PROBLEM", 169, 207], ["HEALTHVaccines", "TREATMENT", 250, 264], ["antibiotics", "TREATMENT", 266, 277], ["cure diseases", "PROBLEM", 341, 354], ["firm", "OBSERVATION", 4, 8]]], ["The use of gene transfer technologies to produce dairy cows that resist several infections and diseases is a novel development in biotechnology.VIII. DESIGNER MILK FOR ANIMAL GROWTH AND HEALTHThe volume of water drawn into milk by osmotic forces is related to lactose synthesis and therefore, a-LA is a deciding factor in the ultimate milk volume.", [["milk", "ANATOMY", 223, 227], ["milk", "ANATOMY", 335, 339], ["infections", "DISEASE", 80, 90], ["lactose", "CHEMICAL", 260, 267], ["lactose", "CHEMICAL", 260, 267], ["VIII", "GENE_OR_GENE_PRODUCT", 144, 148], ["milk", "ORGANISM_SUBSTANCE", 223, 227], ["lactose", "SIMPLE_CHEMICAL", 260, 267], ["a-LA", "SIMPLE_CHEMICAL", 293, 297], ["milk", "ORGANISM_SUBSTANCE", 335, 339], ["VIII", "PROTEIN", 144, 148], ["cows", "SPECIES", 55, 59], ["dairy", "SPECIES", 49, 54], ["gene transfer technologies", "TREATMENT", 11, 37], ["dairy cows", "PROBLEM", 49, 59], ["several infections", "PROBLEM", 72, 90], ["diseases", "PROBLEM", 95, 103], ["lactose synthesis", "TREATMENT", 260, 277], ["infections", "OBSERVATION", 80, 90], ["volume", "OBSERVATION_MODIFIER", 196, 202]]], ["Noble et al. (2002) used transgenic gilts expressing bovine a-LA in their milk to study whether the presence of the transgene influences lactation.", [["milk", "ANATOMY", 74, 78], ["gilts", "ORGANISM", 36, 41], ["bovine", "ORGANISM", 53, 59], ["-LA", "GENE_OR_GENE_PRODUCT", 61, 64], ["milk", "ORGANISM_SUBSTANCE", 74, 78], ["bovine", "SPECIES", 53, 59], ["bovine", "SPECIES", 53, 59], ["transgenic gilts", "TREATMENT", 25, 41]]], ["They reported that lactose concentrations and milk production increased in the experimental group and that the piglets reared on the transgenic animals exhibited enhanced growth rates.VIII. DESIGNER MILK FOR ANIMAL GROWTH AND HEALTHIn the area of pig husbandry, the trend of reduced lactation lengths increases the number of pigs born per sow annually, but also creates the need for sows that produce more milk in early lactation, to obtain maximal pig growth during the short lactation period.", [["milk", "ANATOMY", 46, 50], ["milk", "ANATOMY", 406, 410], ["lactose", "CHEMICAL", 19, 26], ["lactose", "CHEMICAL", 19, 26], ["lactose", "SIMPLE_CHEMICAL", 19, 26], ["milk", "ORGANISM_SUBSTANCE", 46, 50], ["piglets", "ORGANISM", 111, 118], ["VIII", "GENE_OR_GENE_PRODUCT", 184, 188], ["pig", "ORGANISM", 247, 250], ["pigs", "ORGANISM", 325, 329], ["sows", "ORGANISM", 383, 387], ["milk", "ORGANISM_SUBSTANCE", 406, 410], ["pig", "ORGANISM", 449, 452], ["VIII", "PROTEIN", 184, 188], ["piglets", "SPECIES", 111, 118], ["pig", "SPECIES", 247, 250], ["pigs", "SPECIES", 325, 329], ["piglets", "SPECIES", 111, 118], ["pig", "SPECIES", 247, 250], ["pigs", "SPECIES", 325, 329], ["pig", "SPECIES", 449, 452], ["lactose concentrations", "PROBLEM", 19, 41], ["milk production", "PROBLEM", 46, 61], ["enhanced growth rates", "PROBLEM", 162, 183], ["pig husbandry", "TREATMENT", 247, 260], ["reduced lactation lengths", "PROBLEM", 275, 300], ["maximal pig growth", "PROBLEM", 441, 459], ["lactose concentrations", "OBSERVATION", 19, 41], ["increased", "OBSERVATION_MODIFIER", 62, 71]]], ["This becomes difficult in pigs as the maximum milk production does not occur until between the 21st and 28th days of lactation.", [["milk", "ANATOMY", 46, 50], ["pigs", "ORGANISM", 26, 30], ["milk", "ORGANISM_SUBSTANCE", 46, 50], ["pigs", "SPECIES", 26, 30], ["pigs", "SPECIES", 26, 30]]], ["Also, the higher number of pigs born per litter increases the demand for milk production.", [["milk", "ANATOMY", 73, 77], ["pigs", "ORGANISM", 27, 31], ["milk", "ORGANISM_SUBSTANCE", 73, 77], ["pigs", "SPECIES", 27, 31], ["pigs", "SPECIES", 27, 31], ["higher", "OBSERVATION_MODIFIER", 10, 16], ["number", "OBSERVATION_MODIFIER", 17, 23]]], ["With a view to provide better energy intake through higher lactose levels in sow milk, Bleck et al. (1998b) attempted overexpression of bovine a-LA in porcine milk.", [["milk", "ANATOMY", 159, 163], ["lactose", "CHEMICAL", 59, 66], ["a-LA", "CHEMICAL", 143, 147], ["lactose", "CHEMICAL", 59, 66], ["lactose", "SIMPLE_CHEMICAL", 59, 66], ["milk", "ORGANISM_SUBSTANCE", 81, 85], ["bovine", "ORGANISM", 136, 142], ["a-LA", "GENE_OR_GENE_PRODUCT", 143, 147], ["porcine", "ORGANISM", 151, 158], ["milk", "ORGANISM_SUBSTANCE", 159, 163], ["bovine a-LA", "PROTEIN", 136, 147], ["bovine", "SPECIES", 136, 142], ["porcine", "SPECIES", 151, 158], ["bovine", "SPECIES", 136, 142], ["porcine", "SPECIES", 151, 158], ["higher lactose levels", "TREATMENT", 52, 73], ["overexpression of bovine a-LA in porcine milk", "TREATMENT", 118, 163]]], ["The two lines of transgenic pigs so produced had 3.8% lactose in their milk as compared to 2.6% in the milk of control animals.VIII. DESIGNER MILK FOR ANIMAL GROWTH AND HEALTHThe tracheal mucosa of the cow is the source of tracheal antimicrobial peptide (TAP), a member of the b-defensin family of antibiotic peptides.", [["milk", "ANATOMY", 71, 75], ["milk", "ANATOMY", 103, 107], ["tracheal mucosa", "ANATOMY", 179, 194], ["lactose", "CHEMICAL", 54, 61], ["lactose", "CHEMICAL", 54, 61], ["pigs", "ORGANISM", 28, 32], ["lactose", "SIMPLE_CHEMICAL", 54, 61], ["milk", "ORGANISM_SUBSTANCE", 71, 75], ["milk", "ORGANISM_SUBSTANCE", 103, 107], ["VIII", "GENE_OR_GENE_PRODUCT", 127, 131], ["tracheal mucosa", "MULTI-TISSUE_STRUCTURE", 179, 194], ["cow", "ORGANISM", 202, 205], ["tracheal", "ORGAN", 223, 231], ["TAP", "GENE_OR_GENE_PRODUCT", 255, 258], ["b-defensin", "GENE_OR_GENE_PRODUCT", 277, 287], ["VIII", "PROTEIN", 127, 131], ["TAP", "PROTEIN", 255, 258], ["b-defensin family", "PROTEIN", 277, 294], ["pigs", "SPECIES", 28, 32], ["cow", "SPECIES", 202, 205], ["pigs", "SPECIES", 28, 32], ["cow", "SPECIES", 202, 205], ["transgenic pigs", "TREATMENT", 17, 32], ["3.8% lactose in their milk", "TREATMENT", 49, 75], ["tracheal antimicrobial peptide", "TREATMENT", 223, 253], ["antibiotic peptides", "TREATMENT", 298, 317], ["two", "OBSERVATION_MODIFIER", 4, 7], ["lines", "OBSERVATION_MODIFIER", 8, 13], ["transgenic", "OBSERVATION_MODIFIER", 17, 27], ["pigs", "OBSERVATION_MODIFIER", 28, 32], ["tracheal mucosa", "ANATOMY", 179, 194], ["tracheal", "ANATOMY", 223, 231], ["antimicrobial peptide", "OBSERVATION", 232, 253]]], ["TAP protects the upper airway of bovines from infection.", [["upper airway", "ANATOMY", 17, 29], ["infection", "DISEASE", 46, 55], ["TAP", "GENE_OR_GENE_PRODUCT", 0, 3], ["upper airway", "ORGAN", 17, 29], ["bovines", "ORGANISM", 33, 40], ["TAP", "PROTEIN", 0, 3], ["bovines", "SPECIES", 33, 40], ["TAP", "TREATMENT", 0, 3], ["infection", "PROBLEM", 46, 55], ["upper", "ANATOMY_MODIFIER", 17, 22], ["airway", "ANATOMY", 23, 29], ["bovines", "OBSERVATION", 33, 40], ["infection", "OBSERVATION", 46, 55]]], ["The limited availability of bovine TAP (bTAP) prompted researchers to create transgenic mice expressing bTAP (Yarus et al., 1996) in their milk.", [["milk", "ANATOMY", 139, 143], ["bovine", "ORGANISM", 28, 34], ["TAP", "GENE_OR_GENE_PRODUCT", 35, 38], ["bTAP", "GENE_OR_GENE_PRODUCT", 40, 44], ["mice", "ORGANISM", 88, 92], ["bTAP", "GENE_OR_GENE_PRODUCT", 104, 108], ["milk", "ORGANISM_SUBSTANCE", 139, 143], ["bovine TAP", "PROTEIN", 28, 38], ["bTAP", "PROTEIN", 40, 44], ["bovine", "SPECIES", 28, 34], ["mice", "SPECIES", 88, 92], ["bovine", "SPECIES", 28, 34], ["mice", "SPECIES", 88, 92], ["bovine TAP (bTAP", "TREATMENT", 28, 44]]], ["They purified bTAP from milk by acid precipitation, reverse-phase HPLC, and ion-exchange chromatography.", [["milk", "ANATOMY", 24, 28], ["bTAP", "CHEMICAL", 14, 18], ["bTAP", "SIMPLE_CHEMICAL", 14, 18], ["milk", "ORGANISM_SUBSTANCE", 24, 28], ["bTAP", "PROTEIN", 14, 18], ["acid precipitation", "TREATMENT", 32, 50], ["ion-exchange chromatography", "TEST", 76, 103]]], ["This milk-derived bTAP had antimicrobial activity against E. coli.", [["milk", "ANATOMY", 5, 9], ["bTAP", "CHEMICAL", 18, 22], ["milk", "ORGANISM_SUBSTANCE", 5, 9], ["bTAP", "SIMPLE_CHEMICAL", 18, 22], ["E. coli", "ORGANISM", 58, 65], ["E. coli", "SPECIES", 58, 65], ["E. coli", "SPECIES", 58, 65], ["This milk", "TREATMENT", 0, 9], ["antimicrobial activity", "TREATMENT", 27, 49], ["E. coli", "PROBLEM", 58, 65], ["coli", "OBSERVATION", 61, 65]]], ["The work may herald the expression of the bTAP in bovine milk and its evaluation or use as an antibiotic in agriculture and medicine.VIII. DESIGNER MILK FOR ANIMAL GROWTH AND HEALTHMastitis, an inflammatory reaction of the mammary gland, usually resulting from a microbial infection, is a widespread disease seen in cattle throughout the world.", [["milk", "ANATOMY", 57, 61], ["mammary gland", "ANATOMY", 223, 236], ["microbial infection", "DISEASE", 263, 282], ["bTAP", "GENE_OR_GENE_PRODUCT", 42, 46], ["bovine", "ORGANISM", 50, 56], ["milk", "ORGANISM_SUBSTANCE", 57, 61], ["VIII", "GENE_OR_GENE_PRODUCT", 133, 137], ["mammary gland", "ORGAN", 223, 236], ["bTAP", "PROTEIN", 42, 46], ["VIII", "PROTEIN", 133, 137], ["bovine", "SPECIES", 50, 56], ["cattle", "SPECIES", 316, 322], ["bovine", "SPECIES", 50, 56], ["cattle", "SPECIES", 316, 322], ["the bTAP in bovine milk", "TREATMENT", 38, 61], ["its evaluation", "TEST", 66, 80], ["an antibiotic in agriculture", "TREATMENT", 91, 119], ["medicine", "TREATMENT", 124, 132], ["ANIMAL GROWTH", "PROBLEM", 157, 170], ["HEALTHMastitis", "PROBLEM", 175, 189], ["an inflammatory reaction of the mammary gland", "PROBLEM", 191, 236], ["a microbial infection", "PROBLEM", 261, 282], ["a widespread disease", "PROBLEM", 287, 307], ["inflammatory", "OBSERVATION", 194, 206], ["mammary gland", "ANATOMY", 223, 236], ["microbial", "OBSERVATION_MODIFIER", 263, 272], ["infection", "OBSERVATION", 273, 282], ["widespread", "OBSERVATION_MODIFIER", 289, 299], ["disease", "OBSERVATION", 300, 307]]], ["The major bacterial species that are responsible for bovine mastitis are Staphylococcus aureus, Streptococcus dysgalactiae, Streptococcus agalactiae, Streptococcus uberis, and E. coli.", [["bovine mastitis", "DISEASE", 53, 68], ["Staphylococcus aureus", "DISEASE", 73, 94], ["Streptococcus dysgalactiae", "DISEASE", 96, 122], ["bovine", "ORGANISM", 53, 59], ["Staphylococcus aureus", "ORGANISM", 73, 94], ["Streptococcus dysgalactiae", "ORGANISM", 96, 122], ["Streptococcus agalactiae", "ORGANISM", 124, 148], ["Streptococcus uberis", "ORGANISM", 150, 170], ["E. coli", "ORGANISM", 176, 183], ["bovine", "SPECIES", 53, 59], ["Staphylococcus aureus", "SPECIES", 73, 94], ["Streptococcus dysgalactiae", "SPECIES", 96, 122], ["Streptococcus agalactiae", "SPECIES", 124, 148], ["Streptococcus uberis", "SPECIES", 150, 170], ["E. coli", "SPECIES", 176, 183], ["bovine", "SPECIES", 53, 59], ["Staphylococcus aureus", "SPECIES", 73, 94], ["Streptococcus dysgalactiae", "SPECIES", 96, 122], ["Streptococcus agalactiae", "SPECIES", 124, 148], ["Streptococcus uberis", "SPECIES", 150, 170], ["E. coli", "SPECIES", 176, 183], ["The major bacterial species", "PROBLEM", 0, 27], ["bovine mastitis", "PROBLEM", 53, 68], ["Staphylococcus aureus", "PROBLEM", 73, 94], ["Streptococcus dysgalactiae", "PROBLEM", 96, 122], ["Streptococcus agalactiae", "PROBLEM", 124, 148], ["Streptococcus uberis", "PROBLEM", 150, 170], ["E. coli", "PROBLEM", 176, 183], ["major", "OBSERVATION_MODIFIER", 4, 9], ["bacterial species", "OBSERVATION", 10, 27], ["responsible for", "UNCERTAINTY", 37, 52], ["bovine mastitis", "OBSERVATION", 53, 68], ["Streptococcus dysgalactiae", "OBSERVATION", 96, 122], ["Streptococcus agalactiae", "OBSERVATION", 124, 148], ["Streptococcus uberis", "OBSERVATION", 150, 170], ["E. coli", "OBSERVATION", 176, 183]]], ["Of these, the first three cause a contagious route of transmission, whereas Streptococcus uberis and E. coli are considered to be environmental agents.", [["Streptococcus uberis", "ORGANISM", 76, 96], ["E. coli", "ORGANISM", 101, 108], ["Streptococcus uberis", "SPECIES", 76, 96], ["E. coli", "SPECIES", 101, 108], ["Streptococcus uberis", "SPECIES", 76, 96], ["E. coli", "SPECIES", 101, 108], ["Streptococcus uberis", "PROBLEM", 76, 96], ["E. coli", "PROBLEM", 101, 108]]], ["While stringent disease control plans have eradicated Streptococcus dysgalactiae and Streptococcus agalactiae from many herds (Kerr and Wellnitz, 2003) , controlling S. aureus has been difficult.VIII. DESIGNER MILK FOR ANIMAL GROWTH AND HEALTHTransgenic technology to control mastitis would involve the production of antibacterial enzymes by the mammary epithelial cells.", [["mammary epithelial cells", "ANATOMY", 346, 370], ["Streptococcus dysgalactiae", "DISEASE", 54, 80], ["S. aureus", "DISEASE", 166, 175], ["mastitis", "DISEASE", 276, 284], ["Streptococcus dysgalactiae", "ORGANISM", 54, 80], ["Streptococcus agalactiae", "ORGANISM", 85, 109], ["S. aureus", "ORGANISM", 166, 175], ["VIII", "GENE_OR_GENE_PRODUCT", 195, 199], ["mammary epithelial cells", "CELL", 346, 370], ["VIII", "PROTEIN", 195, 199], ["antibacterial enzymes", "PROTEIN", 317, 338], ["mammary epithelial cells", "CELL_TYPE", 346, 370], ["Streptococcus dysgalactiae", "SPECIES", 54, 80], ["Streptococcus agalactiae", "SPECIES", 85, 109], ["S. aureus", "SPECIES", 166, 175], ["Streptococcus dysgalactiae", "SPECIES", 54, 80], ["Streptococcus agalactiae", "SPECIES", 85, 109], ["S. aureus", "SPECIES", 166, 175], ["stringent disease control plans", "PROBLEM", 6, 37], ["Streptococcus dysgalactiae", "PROBLEM", 54, 80], ["Streptococcus agalactiae", "PROBLEM", 85, 109], ["S. aureus", "PROBLEM", 166, 175], ["ANIMAL GROWTH", "PROBLEM", 219, 232], ["HEALTHTransgenic technology", "TREATMENT", 237, 264], ["mastitis", "PROBLEM", 276, 284], ["antibacterial enzymes", "TEST", 317, 338], ["aureus", "OBSERVATION", 169, 175], ["mastitis", "OBSERVATION", 276, 284], ["mammary", "ANATOMY", 346, 353], ["epithelial cells", "OBSERVATION", 354, 370]]], ["These being degraded along with other milk proteins would not pose a health risk to the consumer like regular antibiotics.", [["milk", "ORGANISM_SUBSTANCE", 38, 42], ["milk proteins", "PROTEIN", 38, 51], ["other milk proteins", "TREATMENT", 32, 51], ["regular antibiotics", "TREATMENT", 102, 121]]], ["Initial studies on the application of transgenic technology involved the generation of mice that produced milk containing hLZ (Maga et al., 1994) and human lactoferrin (Platenburg et al., 1994) .", [["milk", "ANATOMY", 106, 110], ["mice", "ORGANISM", 87, 91], ["milk", "ORGANISM_SUBSTANCE", 106, 110], ["hLZ", "SIMPLE_CHEMICAL", 122, 125], ["human", "ORGANISM", 150, 155], ["lactoferrin", "GENE_OR_GENE_PRODUCT", 156, 167], ["human lactoferrin", "PROTEIN", 150, 167], ["mice", "SPECIES", 87, 91], ["milk", "SPECIES", 106, 110], ["human", "SPECIES", 150, 155], ["mice", "SPECIES", 87, 91], ["human", "SPECIES", 150, 155], ["Initial studies", "TEST", 0, 15], ["transgenic technology", "TREATMENT", 38, 59], ["human lactoferrin", "TREATMENT", 150, 167]]], ["While the former has limited effect on mastitiscausing organisms, no conclusive study on the efficacy of the latter is reported.VIII. DESIGNER MILK FOR ANIMAL GROWTH AND HEALTHLysostaphin is a potent peptidoglycan hydrolase naturally secreted by S. simulans.", [["HEALTHLysostaphin", "CHEMICAL", 170, 187], ["VIII", "GENE_OR_GENE_PRODUCT", 128, 132], ["S. simulans", "ORGANISM", 246, 257], ["VIII", "PROTEIN", 128, 132], ["peptidoglycan hydrolase", "PROTEIN", 200, 223], ["S. simulans", "SPECIES", 246, 257], ["S. simulans", "SPECIES", 246, 257], ["mastitiscausing organisms", "PROBLEM", 39, 64], ["conclusive study", "TEST", 69, 85], ["ANIMAL GROWTH", "PROBLEM", 152, 165], ["HEALTHLysostaphin", "TREATMENT", 170, 187], ["a potent peptidoglycan hydrolase", "TREATMENT", 191, 223]]], ["This antimicrobial protein has a potent antistaphylococcal activity and its secretion into milk offers considerable resistance to infection caused by S. aureus.", [["antistaphylococcal", "ANATOMY", 40, 58], ["milk", "ANATOMY", 91, 95], ["infection", "DISEASE", 130, 139], ["antistaphylococcal", "CANCER", 40, 58], ["milk", "ORGANISM_SUBSTANCE", 91, 95], ["S. aureus", "ORGANISM", 150, 159], ["antimicrobial protein", "PROTEIN", 5, 26], ["S. aureus", "SPECIES", 150, 159], ["S. aureus", "SPECIES", 150, 159], ["This antimicrobial protein", "TREATMENT", 0, 26], ["a potent antistaphylococcal activity", "TREATMENT", 31, 67], ["infection", "PROBLEM", 130, 139], ["S. aureus", "PROBLEM", 150, 159], ["infection", "OBSERVATION", 130, 139], ["aureus", "OBSERVATION", 153, 159]]], ["Kerr et al. (2001) developed three lines of transgenic mice that produced varying levels of lysostaphin (100 mg/ml in two and 1 mg/ml in the third) in their milk.", [["milk", "ANATOMY", 157, 161], ["lysostaphin", "CHEMICAL", 92, 103], ["mice", "ORGANISM", 55, 59], ["lysostaphin", "SIMPLE_CHEMICAL", 92, 103], ["milk", "ORGANISM_SUBSTANCE", 157, 161], ["mice", "SPECIES", 55, 59], ["mice", "SPECIES", 55, 59], ["transgenic mice", "TREATMENT", 44, 59], ["lysostaphin", "TREATMENT", 92, 103]]], ["Transgenic as well as control mice were challenged with intramammary infusion of a strain of S. aureus.", [["mice", "ORGANISM", 30, 34], ["intramammary", "IMMATERIAL_ANATOMICAL_ENTITY", 56, 68], ["S. aureus", "ORGANISM", 93, 102], ["mice", "SPECIES", 30, 34], ["S. aureus", "SPECIES", 93, 102], ["mice", "SPECIES", 30, 34], ["S. aureus", "SPECIES", 93, 102], ["intramammary infusion", "TREATMENT", 56, 77], ["S. aureus", "PROBLEM", 93, 102], ["aureus", "OBSERVATION", 96, 102]]], ["None of these glands from the transgenic animals were visibly infected.", [["glands", "ANATOMY", 14, 20], ["glands", "ORGAN", 14, 20], ["animals", "ORGANISM", 41, 48], ["glands", "ANATOMY", 14, 20], ["visibly", "OBSERVATION_MODIFIER", 54, 61], ["infected", "OBSERVATION", 62, 70]]], ["These glands contained less than 10% of the bacterial load observed in the heavily infected controls.", [["glands", "ANATOMY", 6, 12], ["glands", "ORGAN", 6, 12], ["the bacterial load", "PROBLEM", 40, 58], ["glands", "ANATOMY", 6, 12], ["less", "OBSERVATION_MODIFIER", 23, 27], ["bacterial load", "OBSERVATION", 44, 58], ["heavily", "OBSERVATION_MODIFIER", 75, 82], ["infected", "OBSERVATION", 83, 91]]], ["Wall et al. (2005) engineered and introduced into Jersey cows, a transgene that includes the genetic code for producing lysostaphin.", [["lysostaphin", "CHEMICAL", 120, 131], ["lysostaphin", "GENE_OR_GENE_PRODUCT", 120, 131], ["cows", "SPECIES", 57, 61], ["a transgene", "TREATMENT", 63, 74], ["lysostaphin", "TREATMENT", 120, 131]]], ["The gene for secreting lysostaphin was introduced from a nonpathogenic species of Staphylococcus that uses the protein to deter the pathogenic counterpart, S. aureus.", [["lysostaphin", "CHEMICAL", 23, 34], ["lysostaphin", "GENE_OR_GENE_PRODUCT", 23, 34], ["S. aureus", "ORGANISM", 156, 165], ["S. aureus", "SPECIES", 156, 165], ["S. aureus", "SPECIES", 156, 165], ["secreting lysostaphin", "TREATMENT", 13, 34], ["a nonpathogenic species", "PROBLEM", 55, 78], ["Staphylococcus", "PROBLEM", 82, 96], ["the protein", "TREATMENT", 107, 118], ["S. aureus", "PROBLEM", 156, 165], ["Staphylococcus", "OBSERVATION", 82, 96], ["aureus", "OBSERVATION", 159, 165]]], ["The lysostaphin was secreted into milk of the modified animals to the order of 0.9-14 mg/ml.", [["milk", "ANATOMY", 34, 38], ["lysostaphin", "CHEMICAL", 4, 15], ["lysostaphin", "GENE_OR_GENE_PRODUCT", 4, 15], ["milk", "ORGANISM_SUBSTANCE", 34, 38], ["The lysostaphin", "TREATMENT", 0, 15], ["lysostaphin", "OBSERVATION_MODIFIER", 4, 15]]], ["The milk destroyed the causative organisms in vitro.", [["milk", "ANATOMY", 4, 8], ["milk", "ORGANISM_SUBSTANCE", 4, 8]]], ["Ten nontransgenic cows that were given intramammary infusions of S. aureus showed positive signs of mastitis infection, whereas three transgenic cows under the same treatment remained unaffected.", [["mastitis infection", "DISEASE", 100, 118], ["cows", "ORGANISM", 18, 22], ["S. aureus", "ORGANISM", 65, 74], ["cows", "ORGANISM", 145, 149], ["cows", "SPECIES", 18, 22], ["S. aureus", "SPECIES", 65, 74], ["cows", "SPECIES", 145, 149], ["S. aureus", "SPECIES", 65, 74], ["Ten nontransgenic cows", "PROBLEM", 0, 22], ["intramammary infusions", "TREATMENT", 39, 61], ["S. aureus", "PROBLEM", 65, 74], ["mastitis infection", "PROBLEM", 100, 118], ["aureus", "OBSERVATION", 68, 74], ["positive signs of", "UNCERTAINTY", 82, 99], ["mastitis", "OBSERVATION", 100, 108]]], ["A small dose of 3 mg/ml of lysostaphin in milk was sufficient to provide protection against S. aureus.", [["milk", "ANATOMY", 42, 46], ["lysostaphin", "CHEMICAL", 27, 38], ["lysostaphin", "SIMPLE_CHEMICAL", 27, 38], ["milk", "ORGANISM_SUBSTANCE", 42, 46], ["S. aureus", "ORGANISM", 92, 101], ["S. aureus", "SPECIES", 92, 101], ["S. aureus", "SPECIES", 92, 101], ["lysostaphin in milk", "TREATMENT", 27, 46], ["S. aureus", "PROBLEM", 92, 101], ["small", "OBSERVATION_MODIFIER", 2, 7], ["aureus", "OBSERVATION", 95, 101]]], ["Although milk containing other natural antimicrobial proteins such as lactoferrin and LZ has been approved for human consumption, milk containing lysostaphin would need permission from regulatory agencies (Bliss, 2005) .VIII. DESIGNER MILK FOR ANIMAL GROWTH AND HEALTHColiforms account for about 40-50% of mastitis cases in the United States.", [["milk", "ANATOMY", 9, 13], ["LZ", "CHEMICAL", 86, 88], ["lysostaphin", "CHEMICAL", 146, 157], ["mastitis", "DISEASE", 306, 314], ["milk", "ORGANISM_SUBSTANCE", 9, 13], ["lactoferrin", "GENE_OR_GENE_PRODUCT", 70, 81], ["LZ", "GENE_OR_GENE_PRODUCT", 86, 88], ["human", "ORGANISM", 111, 116], ["milk", "ORGANISM_SUBSTANCE", 130, 134], ["lysostaphin", "SIMPLE_CHEMICAL", 146, 157], ["VIII", "GENE_OR_GENE_PRODUCT", 220, 224], ["lactoferrin", "PROTEIN", 70, 81], ["LZ", "PROTEIN", 86, 88], ["VIII", "PROTEIN", 220, 224], ["human", "SPECIES", 111, 116], ["human", "SPECIES", 111, 116], ["natural antimicrobial proteins", "TREATMENT", 31, 61], ["lactoferrin and LZ", "TREATMENT", 70, 88], ["human consumption", "TREATMENT", 111, 128], ["milk containing lysostaphin", "TREATMENT", 130, 157], ["mastitis", "PROBLEM", 306, 314], ["mastitis", "OBSERVATION", 306, 314]]], ["One-tenth of the affected animals become useless for milk production and several die from shock induced by the bacterial toxin, or endotoxin, causing an estimated loss of $1.4 billion annually for farmers in terms of medical expenses and cost of milk that cannot be sold (McBride, 2002) .", [["milk", "ANATOMY", 53, 57], ["shock", "DISEASE", 90, 95], ["endotoxin", "CHEMICAL", 131, 140], ["milk", "ORGANISM_SUBSTANCE", 53, 57], ["milk", "ORGANISM_SUBSTANCE", 246, 250], ["milk production", "PROBLEM", 53, 68], ["shock", "PROBLEM", 90, 95], ["the bacterial toxin", "PROBLEM", 107, 126], ["endotoxin", "PROBLEM", 131, 140], ["cost of milk", "TREATMENT", 238, 250]]], ["Vaccines, while having limited success in reducing clinical symptoms, do not remove the organisms.", [["Vaccines", "TREATMENT", 0, 8], ["reducing clinical symptoms", "PROBLEM", 42, 68]]], ["Wang et al. (2002) report the identification and characterization of the gene for soluble CD14, which binds and neutralizes endotoxins responsible for mastitis.", [["mastitis", "DISEASE", 151, 159], ["CD14", "GENE_OR_GENE_PRODUCT", 90, 94], ["CD14", "PROTEIN", 90, 94], ["the identification", "TEST", 26, 44], ["soluble CD14", "TREATMENT", 82, 94], ["neutralizes endotoxins", "TREATMENT", 112, 134], ["mastitis", "PROBLEM", 151, 159], ["mastitis", "OBSERVATION", 151, 159]]], ["This soluble protein which can be found set in the membranes of white blood cells in cows was also discovered in cow milk.", [["membranes", "ANATOMY", 51, 60], ["white blood cells", "ANATOMY", 64, 81], ["milk", "ANATOMY", 117, 121], ["membranes", "CELLULAR_COMPONENT", 51, 60], ["white blood cells", "CELL", 64, 81], ["cows", "ORGANISM", 85, 89], ["cow", "ORGANISM", 113, 116], ["milk", "ORGANISM_SUBSTANCE", 117, 121], ["white blood cells", "CELL_TYPE", 64, 81], ["cows", "SPECIES", 85, 89], ["cow", "SPECIES", 113, 116], ["cow", "SPECIES", 113, 116], ["This soluble protein", "TEST", 0, 20], ["white blood cells", "TEST", 64, 81]]], ["Just as the protein increases during coliform infections in humans and laboratory animals, it was shown to tone down the severe reaction of the bovines to coliform endotoxin as well as initiate a suitable response to the infiltrating bacteria.", [["coliform infections", "DISEASE", 37, 56], ["humans", "ORGANISM", 60, 66], ["bovines", "ORGANISM", 144, 151], ["coliform endotoxin", "PROTEIN", 155, 173], ["humans", "SPECIES", 60, 66], ["humans", "SPECIES", 60, 66], ["bovines", "SPECIES", 144, 151], ["coliform infections", "PROBLEM", 37, 56], ["the severe reaction", "PROBLEM", 117, 136], ["coliform endotoxin", "TREATMENT", 155, 173], ["the infiltrating bacteria", "PROBLEM", 217, 242], ["increases", "OBSERVATION_MODIFIER", 20, 29], ["coliform", "OBSERVATION_MODIFIER", 37, 45], ["infections", "OBSERVATION", 46, 56], ["severe", "OBSERVATION_MODIFIER", 121, 127], ["infiltrating", "OBSERVATION", 221, 233]]], ["The gene was cloned and the recombinant bovine CD14 protein (rb-CD14) produced was evaluated.", [["bovine", "ORGANISM", 40, 46], ["CD14", "GENE_OR_GENE_PRODUCT", 47, 51], ["rb-CD14", "GENE_OR_GENE_PRODUCT", 61, 68], ["recombinant bovine CD14 protein", "PROTEIN", 28, 59], ["rb", "PROTEIN", 61, 63], ["CD14", "PROTEIN", 64, 68], ["bovine", "SPECIES", 40, 46], ["the recombinant bovine CD14 protein", "TEST", 24, 59]]], ["Intraperitoneal injection of rb-CD14 together with endotoxin reduced fatality in mice.", [["Intraperitoneal", "ANATOMY", 0, 15], ["endotoxin", "CHEMICAL", 51, 60], ["Intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 0, 15], ["rb-CD14", "GENE_OR_GENE_PRODUCT", 29, 36], ["endotoxin", "SIMPLE_CHEMICAL", 51, 60], ["mice", "ORGANISM", 81, 85], ["rb-CD14", "PROTEIN", 29, 36], ["endotoxin", "PROTEIN", 51, 60], ["mice", "SPECIES", 81, 85], ["mice", "SPECIES", 81, 85], ["Intraperitoneal injection of rb-CD14", "TREATMENT", 0, 36], ["endotoxin reduced fatality", "PROBLEM", 51, 77]]], ["Preliminary trials showed that intramammary injection of soluble rb-CD14 is 100% effective in preventing mastitis by E. coli in lactating dairy cows.", [["intramammary", "ANATOMY", 31, 43], ["mastitis", "DISEASE", 105, 113], ["intramammary", "IMMATERIAL_ANATOMICAL_ENTITY", 31, 43], ["rb-CD14", "GENE_OR_GENE_PRODUCT", 65, 72], ["E. coli", "ORGANISM", 117, 124], ["rb", "PROTEIN", 65, 67], ["CD14", "PROTEIN", 68, 72], ["E. coli", "SPECIES", 117, 124], ["cows", "SPECIES", 144, 148], ["E. coli", "SPECIES", 117, 124], ["Preliminary trials", "TEST", 0, 18], ["intramammary injection of soluble rb", "TREATMENT", 31, 67], ["CD14", "TREATMENT", 68, 72], ["mastitis", "PROBLEM", 105, 113], ["E. coli", "PROBLEM", 117, 124], ["intramammary", "ANATOMY", 31, 43], ["mastitis", "OBSERVATION", 105, 113], ["E. coli", "OBSERVATION", 117, 124]]], ["The workers have filed a patent application on rb-CD14 which promises both effective treatment for infected cows and prevention in future cows genetically engineered with the gene.", [["rb-CD14", "GENE_OR_GENE_PRODUCT", 47, 54], ["cows", "ORGANISM", 108, 112], ["cows", "ORGANISM", 138, 142], ["rb", "PROTEIN", 47, 49], ["CD14", "PROTEIN", 50, 54], ["cows", "SPECIES", 108, 112], ["cows", "SPECIES", 138, 142], ["rb-CD14", "TREATMENT", 47, 54], ["infected cows", "PROBLEM", 99, 112], ["patent", "OBSERVATION", 25, 31]]], ["They claim that the gene for CD14 can be designed and inserted into the modified animals so that they can produce the protein only in their mammary cells.IX. ASSORTED ADVANTAGESThe use of molecular biology to reduce the presence of pathogenic organisms in milk is a potentially advantageous prospect and has been reviewed in the previous section (Section VIII).", [["mammary cells", "ANATOMY", 140, 153], ["milk", "ANATOMY", 256, 260], ["CD14", "GENE_OR_GENE_PRODUCT", 29, 33], ["mammary cells", "CELL", 140, 153], ["IX", "GENE_OR_GENE_PRODUCT", 154, 156], ["milk", "ORGANISM_SUBSTANCE", 256, 260], ["CD14", "PROTEIN", 29, 33], ["mammary cells", "CELL_TYPE", 140, 153], ["IX", "PROTEIN", 154, 156], ["CD14", "PROBLEM", 29, 33], ["pathogenic organisms in milk", "PROBLEM", 232, 260], ["mammary", "ANATOMY", 140, 147], ["pathogenic", "OBSERVATION_MODIFIER", 232, 242], ["organisms", "OBSERVATION", 243, 252]]], ["It is clear that it might now be possible to produce specific antibodies in the mammary gland that are capable of preventing mastitis infection or those that aid in preventing human diseases.", [["mammary gland", "ANATOMY", 80, 93], ["mastitis infection", "DISEASE", 125, 143], ["mammary gland", "ORGAN", 80, 93], ["human", "ORGANISM", 176, 181], ["antibodies", "PROTEIN", 62, 72], ["human", "SPECIES", 176, 181], ["human", "SPECIES", 176, 181], ["specific antibodies in the mammary gland", "PROBLEM", 53, 93], ["mastitis infection", "PROBLEM", 125, 143], ["human diseases", "PROBLEM", 176, 190], ["clear", "OBSERVATION", 6, 11], ["antibodies", "OBSERVATION", 62, 72], ["mammary gland", "ANATOMY", 80, 93], ["mastitis", "OBSERVATION", 125, 133]]], ["Thus, one can foresee antibodies against Salmonella, Listeria, or other pathogens that will produce safer milk products.", [["milk", "ANATOMY", 106, 110], ["milk", "ORGANISM", 106, 110], ["antibodies", "PROTEIN", 22, 32], ["Salmonella", "SPECIES", 41, 51], ["antibodies", "PROBLEM", 22, 32], ["Salmonella", "PROBLEM", 41, 51], ["Listeria", "PROBLEM", 53, 61], ["other pathogens", "PROBLEM", 66, 81], ["safer milk products", "TREATMENT", 100, 119]]], ["Active recombinant immunoglobulin capable of neutralizing Coronavirus was produced in mouse milk (Castilla et al., 1998) .", [["milk", "ANATOMY", 92, 96], ["Coronavirus", "CHEMICAL", 58, 69], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 19, 33], ["Coronavirus", "ORGANISM", 58, 69], ["mouse", "ORGANISM", 86, 91], ["milk", "ORGANISM_SUBSTANCE", 92, 96], ["recombinant immunoglobulin", "PROTEIN", 7, 33], ["mouse", "SPECIES", 86, 91], ["milk", "SPECIES", 92, 96], ["Coronavirus", "SPECIES", 58, 69], ["mouse", "SPECIES", 86, 91], ["Active recombinant immunoglobulin", "TREATMENT", 0, 33], ["neutralizing Coronavirus", "PROBLEM", 45, 69], ["neutralizing Coronavirus", "OBSERVATION", 45, 69]]], ["Increasing the concentration of IgA receptors in mammary cell may potentially lead to the accumulation of the protective antibodies in milk (De Groot et al., 1999) .", [["mammary cell", "ANATOMY", 49, 61], ["milk", "ANATOMY", 135, 139], ["IgA", "GENE_OR_GENE_PRODUCT", 32, 35], ["mammary cell", "CELL", 49, 61], ["milk", "ORGANISM_SUBSTANCE", 135, 139], ["IgA receptors", "PROTEIN", 32, 45], ["mammary cell", "CELL_TYPE", 49, 61], ["protective antibodies", "PROTEIN", 110, 131], ["IgA receptors in mammary cell", "PROBLEM", 32, 61], ["concentration", "OBSERVATION_MODIFIER", 15, 28], ["mammary", "ANATOMY", 49, 56], ["cell", "OBSERVATION", 57, 61], ["protective", "OBSERVATION_MODIFIER", 110, 120], ["antibodies", "OBSERVATION", 121, 131]]], ["While recombinant immunoglobulins have been expressed in mammalian transgenic milk (Gavilondo et al., 2000) , a calf with a gene that promotes the growth of red cells in humans has been produced by transgenesis (www.publicscan.fi).", [["milk", "ANATOMY", 78, 82], ["red cells", "ANATOMY", 157, 166], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 18, 33], ["milk", "ORGANISM_SUBSTANCE", 78, 82], ["calf", "ORGANISM_SUBDIVISION", 112, 116], ["red cells", "CELL", 157, 166], ["humans", "ORGANISM", 170, 176], ["recombinant immunoglobulins", "PROTEIN", 6, 33], ["red cells", "CELL_TYPE", 157, 166], ["milk", "SPECIES", 78, 82], ["calf", "SPECIES", 112, 116], ["humans", "SPECIES", 170, 176], ["humans", "SPECIES", 170, 176], ["recombinant immunoglobulins", "TREATMENT", 6, 33], ["red cells", "PROBLEM", 157, 166], ["calf", "ANATOMY", 112, 116], ["red cells", "OBSERVATION", 157, 166]]], ["Research is also under way to manufacture milk through transgenesis for treatment of diseases such as PKU, hereditary emphysema, and cystic fibrosis (Margawati, 2003) .IX. ASSORTED ADVANTAGESIn an interesting application of transgenic technology combining sericulture and dairying, goats that produce spider silk in milk have been engineered (Dove, 2000) .", [["milk", "ANATOMY", 42, 46], ["cystic", "ANATOMY", 133, 139], ["milk", "ANATOMY", 316, 320], ["PKU", "DISEASE", 102, 105], ["hereditary emphysema", "DISEASE", 107, 127], ["cystic fibrosis", "DISEASE", 133, 148], ["milk", "ORGANISM_SUBSTANCE", 42, 46], ["goats", "ORGANISM", 282, 287], ["spider silk", "ORGANISM", 301, 312], ["milk", "ORGANISM_SUBSTANCE", 316, 320], ["goats", "SPECIES", 282, 287], ["milk", "SPECIES", 316, 320], ["goats", "SPECIES", 282, 287], ["transgenesis", "TREATMENT", 55, 67], ["treatment", "TREATMENT", 72, 81], ["diseases", "PROBLEM", 85, 93], ["PKU", "PROBLEM", 102, 105], ["hereditary emphysema", "PROBLEM", 107, 127], ["cystic fibrosis", "PROBLEM", 133, 148], ["transgenic technology", "TREATMENT", 224, 245], ["diseases", "OBSERVATION", 85, 93], ["hereditary", "OBSERVATION_MODIFIER", 107, 117], ["emphysema", "OBSERVATION", 118, 127], ["cystic", "OBSERVATION_MODIFIER", 133, 139], ["fibrosis", "OBSERVATION", 140, 148]]], ["Spider silk is made of protein-based polymer filaments or threads secreted by specialized epithelial cells.", [["filaments", "ANATOMY", 45, 54], ["epithelial cells", "ANATOMY", 90, 106], ["epithelial cells", "CELL", 90, 106], ["specialized epithelial cells", "CELL_TYPE", 78, 106], ["Spider silk", "TREATMENT", 0, 11], ["protein", "TEST", 23, 30], ["specialized epithelial cells", "OBSERVATION", 78, 106]]], ["These fibers are flexible and lightweight and have extraordinary strength and toughness comparable to those of synthetic high-performance fibers.", [["fibers", "ANATOMY", 6, 12], ["fibers", "CELLULAR_COMPONENT", 6, 12], ["fibers", "CELL", 138, 144], ["flexible", "OBSERVATION_MODIFIER", 17, 25]]], ["Although it appears delicate and is one-tenth the width of a human hair, it is stronger than steel and stretches more than nylon (www.sciam.com, 2002) .", [["hair", "ANATOMY", 67, 71], ["human", "ORGANISM", 61, 66], ["hair", "ORGAN", 67, 71], ["human", "SPECIES", 61, 66], ["human", "SPECIES", 61, 66], ["delicate", "OBSERVATION", 20, 28]]], ["Several attempts have been made to synthesize spider silk for industrial and medical applications.", [["synthesize spider silk", "TREATMENT", 35, 57], ["medical applications", "TREATMENT", 77, 97]]], ["Unfortunately, the high shearing forces in conventional fermentations cause the spidroin protein to aggregate, making it useless for manufacturing fibers.", [["fibers", "ANATOMY", 147, 153], ["fibers", "CELLULAR_COMPONENT", 147, 153], ["spidroin protein", "PROTEIN", 80, 96], ["the high shearing forces", "TREATMENT", 15, 39], ["conventional fermentations", "TREATMENT", 43, 69], ["the spidroin protein", "PROBLEM", 76, 96], ["high", "OBSERVATION_MODIFIER", 19, 23], ["shearing", "OBSERVATION_MODIFIER", 24, 32], ["forces", "OBSERVATION_MODIFIER", 33, 39]]], ["So, these spider genes were introduced into the cells of lactating goats and they secreted silk in tiny strands along with their milk.", [["cells", "ANATOMY", 48, 53], ["silk", "ANATOMY", 91, 95], ["milk", "ANATOMY", 129, 133], ["cells", "CELL", 48, 53], ["goats", "ORGANISM", 67, 72], ["silk", "TISSUE", 91, 95], ["milk", "ORGANISM_SUBSTANCE", 129, 133], ["spider genes", "DNA", 10, 22], ["goats", "SPECIES", 67, 72], ["goats", "SPECIES", 67, 72], ["these spider genes", "TREATMENT", 4, 22], ["spider genes", "OBSERVATION", 10, 22], ["tiny", "OBSERVATION_MODIFIER", 99, 103], ["strands", "OBSERVATION", 104, 111]]], ["These polymer strands could be woven into threads after extracting them from the milk and used for applications such as military uniforms, medical microsutures, and tennis racket strings (Anonymous, 2002) .", [["milk", "ANATOMY", 81, 85], ["milk", "ORGANISM_SUBSTANCE", 81, 85], ["These polymer strands", "TREATMENT", 0, 21], ["applications", "TREATMENT", 99, 111], ["polymer strands", "OBSERVATION", 6, 21]]], ["Nexia, a US company, has developed a strain of fast-maturing Breed Early Lactate Early (BELE) transgenic goats that secretes the spider silk in milk (Dove, 2000) .IX. ASSORTED ADVANTAGESNexia is already working with the US army to develop bulletproof vests and surgical suture material from spider silk.", [["milk", "ANATOMY", 144, 148], ["Nexia", "CHEMICAL", 0, 5], ["Lactate", "CHEMICAL", 73, 80], ["Lactate", "CHEMICAL", 73, 80], ["Lactate", "SIMPLE_CHEMICAL", 73, 80], ["goats", "ORGANISM", 105, 110], ["milk", "ORGANISM_SUBSTANCE", 144, 148], ["suture material", "TISSUE", 270, 285], ["goats", "SPECIES", 105, 110], ["goats", "SPECIES", 105, 110], ["a strain of fast-maturing Breed", "PROBLEM", 35, 66], ["Early Lactate Early (BELE) transgenic goats", "PROBLEM", 67, 110], ["bulletproof vests", "TREATMENT", 239, 256], ["surgical suture material from spider silk", "TREATMENT", 261, 302], ["spider silk", "OBSERVATION_MODIFIER", 129, 140], ["surgical suture", "OBSERVATION", 261, 276], ["spider silk", "OBSERVATION", 291, 302]]], ["The team produced soluble recombinant spider silk proteins with molecular masses of 60-140 kDa (Lazaris et al., 2002) .", [["soluble recombinant spider silk proteins", "PROTEIN", 18, 58], ["soluble recombinant spider silk proteins", "TREATMENT", 18, 58], ["molecular masses", "PROBLEM", 64, 80], ["masses", "OBSERVATION", 74, 80]]], ["They were able to wet spin the silk monofilaments derived from a concentrated aqueous solution of soluble recombinant spider silk protein under conditions of low shear and coagulation.", [["soluble recombinant spider silk protein", "PROTEIN", 98, 137], ["a concentrated aqueous solution of soluble recombinant spider silk protein", "TREATMENT", 63, 137], ["low shear", "OBSERVATION_MODIFIER", 158, 167]]], ["The spun fibers were water-insoluble with diameters ranging from 10 to 40 mm and exhibited toughness and modulus values comparable to those of native dragline silks but had lower tenacity.", [["fibers", "ANATOMY", 9, 15], ["The spun fibers", "TEST", 0, 15], ["diameters", "TEST", 42, 51], ["toughness and modulus values", "PROBLEM", 91, 119], ["lower tenacity", "PROBLEM", 173, 187], ["spun", "OBSERVATION_MODIFIER", 4, 8], ["fibers", "OBSERVATION_MODIFIER", 9, 15], ["water-insoluble", "OBSERVATION_MODIFIER", 21, 36], ["diameters", "OBSERVATION_MODIFIER", 42, 51], ["ranging", "OBSERVATION_MODIFIER", 52, 59], ["10 to 40 mm", "OBSERVATION_MODIFIER", 65, 76], ["toughness", "OBSERVATION_MODIFIER", 91, 100], ["modulus values", "OBSERVATION", 105, 119], ["dragline silks", "OBSERVATION", 150, 164], ["lower", "OBSERVATION_MODIFIER", 173, 178], ["tenacity", "OBSERVATION", 179, 187]]], ["They anticipate that the manufacturing processes for these products would be more environmental friendly than the production of conventional plastics.X. THE FUTURENovel research in genetic engineering attempts to alter and control the genetic makeup of animals in several ways.", [["X.", "SPECIES", 150, 152], ["these products", "TREATMENT", 53, 67], ["conventional plastics", "TREATMENT", 128, 149]]], ["One example is that of somatic cell therapy, wherein specific cells of an individual animal are modified to produce desired characteristics without changing its genetic characters.", [["somatic cell", "ANATOMY", 23, 35], ["cells", "ANATOMY", 62, 67], ["somatic cell", "CELL", 23, 35], ["cells", "CELL", 62, 67], ["somatic cell therapy", "TREATMENT", 23, 43], ["somatic cell therapy", "OBSERVATION", 23, 43]]], ["On the other hand, transgenesis involves the modification of the genetic line wherein the altered traits can be inherited by the progeny.", [["transgenesis", "TREATMENT", 19, 31], ["genetic line", "OBSERVATION", 65, 77]]], ["Both techniques are useful in the enhancement of animal productivity, faster growth, improved feed conversion, better quality of animal products, and improved resistance to diseases.X. THE FUTUREHowever, the technology presents several hurdles to its ultimate development.", [["animal products", "TREATMENT", 129, 144], ["improved resistance to diseases", "PROBLEM", 150, 181], ["improved resistance", "OBSERVATION", 150, 169]]], ["Cattle, for example, often suffer at birth from immature respiratory systems.", [["Cattle", "SPECIES", 0, 6], ["immature respiratory systems", "PROBLEM", 48, 76], ["respiratory systems", "ANATOMY", 57, 76]]], ["They are also frequently born late, leading to problems with delivery.", [["delivery", "TREATMENT", 61, 69]]], ["The survival rate in cloning attempts also is low.", [["The survival rate", "TREATMENT", 0, 17], ["survival", "OBSERVATION_MODIFIER", 4, 12], ["low", "OBSERVATION_MODIFIER", 46, 49]]], ["Generally only 1-5% of embryos typically survive to term (Kling, 2001) .", [["embryos", "ANATOMY", 23, 30], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 23, 30]]], ["Dolly, the sheep and the first animal to be cloned from an adult cell in 1996, was the lone success out of the 277 attempts (Taylor, 2006) .X. THE FUTURESuccessful transgenic studies have generated mice that produce milk with 33% more total solids (40-50% TS) and 17% less lactose than normal mouse milk.", [["cell", "ANATOMY", 65, 69], ["milk", "ANATOMY", 216, 220], ["milk", "ANATOMY", 299, 303], ["lactose", "CHEMICAL", 273, 280], ["lactose", "CHEMICAL", 273, 280], ["sheep", "ORGANISM", 11, 16], ["adult cell", "CELL", 59, 69], ["mice", "ORGANISM", 198, 202], ["milk", "ORGANISM_SUBSTANCE", 216, 220], ["lactose", "SIMPLE_CHEMICAL", 273, 280], ["mouse", "ORGANISM", 293, 298], ["milk", "ORGANISM_SUBSTANCE", 299, 303], ["sheep", "SPECIES", 11, 16], ["mice", "SPECIES", 198, 202], ["mouse", "SPECIES", 293, 298], ["milk", "SPECIES", 299, 303], ["sheep", "SPECIES", 11, 16], ["mice", "SPECIES", 198, 202], ["mouse", "SPECIES", 293, 298], ["total solids", "TREATMENT", 235, 247]]], ["As the increase in the total solids is associated with a decrease in total milk volume, the net result is the same quantity of fat and protein being produced in a lesser total milk volume.", [["milk", "ANATOMY", 75, 79], ["milk", "ANATOMY", 176, 180], ["milk", "ORGANISM_SUBSTANCE", 75, 79], ["fat", "TISSUE", 127, 130], ["milk", "ORGANISM_SUBSTANCE", 176, 180], ["the total solids", "TREATMENT", 19, 35], ["a decrease in total milk volume", "PROBLEM", 55, 86], ["a lesser total milk volume", "TREATMENT", 161, 187], ["increase", "OBSERVATION_MODIFIER", 7, 15], ["decrease", "OBSERVATION_MODIFIER", 57, 65]]], ["If this technology could be extrapolated in dairy animals, milk that contains 6.5% protein, 7% fat, 2.5% lactose, and 50% less water is not an improbable accomplishment.", [["milk", "ANATOMY", 59, 63], ["lactose", "CHEMICAL", 105, 112], ["lactose", "CHEMICAL", 105, 112], ["milk", "ORGANISM_SUBSTANCE", 59, 63], ["fat", "TISSUE", 95, 98], ["lactose", "SIMPLE_CHEMICAL", 105, 112], ["lactose", "TREATMENT", 105, 112]]], ["The advantages in terms of animal health would include less stress on the cow and on her udder since she would be producing onehalf her normal volume of milk and decrease in mastitis owing to less lactose availability for the causative organisms.", [["milk", "ANATOMY", 153, 157], ["mastitis", "DISEASE", 174, 182], ["lactose", "CHEMICAL", 197, 204], ["lactose", "CHEMICAL", 197, 204], ["cow", "ORGANISM_SUBDIVISION", 74, 77], ["udder", "ORGANISM_SUBDIVISION", 89, 94], ["milk", "ORGANISM_SUBSTANCE", 153, 157], ["lactose", "SIMPLE_CHEMICAL", 197, 204], ["cow", "SPECIES", 74, 77], ["cow", "SPECIES", 74, 77], ["mastitis", "PROBLEM", 174, 182], ["the causative organisms", "PROBLEM", 222, 245], ["mastitis", "OBSERVATION", 174, 182]]], ["The processing industry would gain in terms of (1) skim milk with twice protein content and half the lactose content of normal milk, (2) easier to produce low lactose or lactose-free dairy products, (3) better product yields due to concentration, (4) reduction in total whey output because of low milk volume and lactose content, and (5) direct economic benefits in terms of 50% reduction in the cost of milk transportation owing to reduced volumes.X. THE FUTUREThe future of biotechnologically derived foods is, however, uncertain even after three decades of positive results.", [["milk", "ANATOMY", 56, 60], ["milk", "ANATOMY", 127, 131], ["milk", "ANATOMY", 297, 301], ["milk", "ANATOMY", 404, 408], ["lactose", "CHEMICAL", 101, 108], ["lactose", "CHEMICAL", 159, 166], ["lactose", "CHEMICAL", 170, 177], ["lactose", "CHEMICAL", 313, 320], ["lactose", "CHEMICAL", 101, 108], ["lactose", "CHEMICAL", 159, 166], ["lactose", "CHEMICAL", 170, 177], ["lactose", "CHEMICAL", 313, 320], ["milk", "ORGANISM_SUBSTANCE", 56, 60], ["lactose", "SIMPLE_CHEMICAL", 101, 108], ["milk", "ORGANISM_SUBSTANCE", 127, 131], ["lactose", "SIMPLE_CHEMICAL", 159, 166], ["lactose", "SIMPLE_CHEMICAL", 170, 177], ["milk", "ORGANISM_SUBDIVISION", 297, 301], ["lactose", "SIMPLE_CHEMICAL", 313, 320], ["milk", "ORGANISM_SUBSTANCE", 404, 408], ["1) skim milk", "TREATMENT", 48, 60], ["low lactose", "TREATMENT", 155, 166], ["lactose-free dairy products", "TREATMENT", 170, 197], ["total whey output", "TEST", 264, 281], ["low milk volume", "PROBLEM", 293, 308], ["lactose content", "PROBLEM", 313, 328], ["50% reduction", "TREATMENT", 375, 388], ["the cost of milk transportation", "TREATMENT", 392, 423], ["reduced volumes", "PROBLEM", 433, 448], ["lactose content", "OBSERVATION_MODIFIER", 313, 328]]], ["Improved and sophisticated equipment for milk processing may be more acceptable to consumers than genetic and transgenic technology for altering milk composition.", [["milk", "ANATOMY", 41, 45], ["milk", "ANATOMY", 145, 149], ["milk", "ORGANISM_SUBSTANCE", 41, 45], ["milk", "ORGANISM_SUBSTANCE", 145, 149], ["milk processing", "TREATMENT", 41, 56], ["altering milk composition", "TREATMENT", 136, 161]]], ["Consumer acceptance will always contribute to and guide decisions about biotechnological manipulations aimed at increasing milk production or altering milk composition.", [["milk", "ANATOMY", 123, 127], ["milk", "ANATOMY", 151, 155], ["milk", "ORGANISM_SUBSTANCE", 123, 127], ["milk", "ORGANISM_SUBDIVISION", 151, 155], ["biotechnological manipulations", "TREATMENT", 72, 102], ["increasing milk production", "TREATMENT", 112, 138]]], ["Animal welfare, demonstrable and sustained safety of the product, improved health properties of the product, and enhanced profitability as compared with conventional practices would be the key factors that would eventually decide the future of designer foods.X. THE FUTUREThe natural human tendency to resist change, especially those that trouble their feeling and instincts, is an important point to consider.", [["human", "ORGANISM", 284, 289], ["human", "SPECIES", 284, 289], ["human", "SPECIES", 284, 289], ["natural human tendency", "OBSERVATION", 276, 298]]], ["As all consequences of biological research involving animal studies could be classified under this category, there is bound to be tremendous resistance to topics such as transgenic technology.", [["animal studies", "TEST", 53, 67], ["transgenic technology", "TREATMENT", 170, 191]]], ["The perception among various groups of human beings is also different.", [["human", "ORGANISM", 39, 44], ["human", "SPECIES", 39, 44], ["human", "SPECIES", 39, 44]]], ["That a human being controls these natural desires of animals itself is a reason for dissent.X. THE FUTUREThe topics of genetic engineering and transgenic technology have been under debate ever since the idea was first conceived.", [["human", "ORGANISM", 7, 12], ["animals", "ORGANISM", 53, 60], ["human", "SPECIES", 7, 12], ["human", "SPECIES", 7, 12], ["X.", "SPECIES", 92, 94], ["transgenic technology", "TREATMENT", 143, 164]]], ["The activists argue that the transformation of animals according to human needs smudges the clear demarcation between man and animal in ethical, moral, and biological perspectives.", [["human", "ORGANISM", 68, 73], ["man", "ORGANISM", 118, 121], ["human", "SPECIES", 68, 73], ["man", "SPECIES", 118, 121], ["human", "SPECIES", 68, 73]]], ["Thus, the moral principles, which were behind the treatment of animals in the past, are no more valid or adequate.", [["no more", "UNCERTAINTY", 88, 95]]], ["Researchers while considering human requirements also need to find new methods of dealing with animals with their interests, suffering, and welfare in mind.", [["human", "ORGANISM", 30, 35], ["human", "SPECIES", 30, 35], ["human", "SPECIES", 30, 35]]]], "PMC7476578": [["Author's contributionThe idea was generated by SC and PB.", [["SC", "CELL", 47, 49]]]], "9a57067e2e3de83a2425748c0419caff3f1205e1": [["IntroductionThe aetiological agent of the severe acute respiratory syndrome (SARS) is a coronavirus (SARS-CoV) which was responsible for causing a worldwide pandemic of lower respiratory tract infection between November 2002 and July 2003 Ksiazek et al., 2003; Marra et al., 2003; Rota et al., 2003) .", [["lower respiratory tract", "ANATOMY", 169, 192], ["acute respiratory syndrome", "DISEASE", 49, 75], ["SARS", "DISEASE", 77, 81], ["coronavirus", "DISEASE", 88, 99], ["SARS-CoV)", "DISEASE", 101, 110], ["lower respiratory tract infection", "DISEASE", 169, 202], ["SARS-CoV", "ORGANISM", 101, 109], ["tract", "ORGANISM_SUBDIVISION", 187, 192], ["SARS-CoV", "SPECIES", 101, 109], ["the severe acute respiratory syndrome", "PROBLEM", 38, 75], ["SARS", "PROBLEM", 77, 81], ["a coronavirus (SARS-CoV)", "PROBLEM", 86, 110], ["lower respiratory tract infection", "PROBLEM", 169, 202], ["severe", "OBSERVATION_MODIFIER", 42, 48], ["acute", "OBSERVATION_MODIFIER", 49, 54], ["respiratory syndrome", "OBSERVATION", 55, 75], ["lower", "ANATOMY_MODIFIER", 169, 174], ["respiratory tract", "ANATOMY", 175, 192]]], ["During this time, there were approximately 8100 probable SARS cases and approximately 800 recorded fatalities (http://www.wpro.who.int/sars/).", [["SARS", "DISEASE", 57, 61], ["SARS cases", "PROBLEM", 57, 67]]], ["Rapid identification of individuals presenting with the disease as well as appropriate nursing techniques and quarantine procedures allowed the outbreak to be controlled by July of 2003.", [["the disease", "PROBLEM", 52, 63], ["appropriate nursing techniques", "TREATMENT", 75, 105], ["quarantine procedures", "TREATMENT", 110, 131], ["disease", "OBSERVATION", 56, 63]]], ["There have since been smaller outbreaks of the disease, but these have been contained with minimal secondary transmission.", [["the disease", "PROBLEM", 43, 54], ["smaller", "OBSERVATION_MODIFIER", 22, 29], ["outbreaks", "OBSERVATION_MODIFIER", 30, 39], ["disease", "OBSERVATION", 47, 54], ["minimal", "OBSERVATION_MODIFIER", 91, 98], ["secondary transmission", "OBSERVATION", 99, 121]]], ["In the clinic, SARS-CoV infection presents as atypical pneumonia, with patients reporting symptoms of high fever (>38 \u00b0C), dry cough, shortness of breath (dyspnea) and/or more severe breathing difficulties, which may occasionally require mechanical ventilation.", [["SARS-CoV infection", "DISEASE", 15, 33], ["pneumonia", "DISEASE", 55, 64], ["fever", "DISEASE", 107, 112], ["dry cough", "DISEASE", 123, 132], ["shortness of breath", "DISEASE", 134, 153], ["dyspnea", "DISEASE", 155, 162], ["breathing difficulties", "DISEASE", 183, 205], ["SARS-CoV", "ORGANISM", 15, 23], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["SARS-CoV", "SPECIES", 15, 23], ["SARS", "PROBLEM", 15, 19], ["CoV infection", "PROBLEM", 20, 33], ["atypical pneumonia", "PROBLEM", 46, 64], ["symptoms", "PROBLEM", 90, 98], ["high fever", "PROBLEM", 102, 112], ["dry cough", "PROBLEM", 123, 132], ["shortness of breath", "PROBLEM", 134, 153], ["dyspnea", "PROBLEM", 155, 162], ["more severe breathing difficulties", "PROBLEM", 171, 205], ["mechanical ventilation", "TREATMENT", 238, 260], ["CoV", "ANATOMY", 20, 23], ["infection", "OBSERVATION", 24, 33], ["atypical", "OBSERVATION_MODIFIER", 46, 54], ["pneumonia", "OBSERVATION", 55, 64], ["cough", "OBSERVATION", 127, 132], ["severe", "OBSERVATION_MODIFIER", 176, 182], ["breathing", "OBSERVATION", 183, 192], ["mechanical ventilation", "OBSERVATION", 238, 260]]], ["The viral reservoirs are presumed to be bats (Wang and Eaton, 2007; Wang et al., 2006) and the palm civet cat has been implicated as a carrier of the virus, though there may also be other asymptomatic animal carriers (Shi and Hu, 2008) .IntroductionOf the several proteins found in the SARS coronavirus (Tan et al., 2006; Ying et al., 2004) , the large SARS-CoV spike glycoprotein (S) (Tripet et al., 2004 ) located on the virion surface is involved in both target cell attachment and fusion processes (Yang et al., 2004) .", [["virion surface", "ANATOMY", 423, 437], ["cell", "ANATOMY", 465, 469], ["SARS coronavirus", "DISEASE", 286, 302], ["palm civet cat", "ORGANISM", 95, 109], ["SARS coronavirus", "ORGANISM", 286, 302], ["cell", "CELL", 465, 469], ["SARS-CoV spike glycoprotein", "PROTEIN", 353, 380], ["cat", "SPECIES", 106, 109], ["palm civet cat", "SPECIES", 95, 109], ["SARS coronavirus", "SPECIES", 286, 302], ["SARS-CoV", "SPECIES", 353, 361], ["The viral reservoirs", "TREATMENT", 0, 20], ["the virus", "PROBLEM", 146, 155], ["the SARS coronavirus", "PROBLEM", 282, 302], ["the large SARS", "PROBLEM", 343, 357], ["viral reservoirs", "OBSERVATION", 4, 20], ["presumed to be", "UNCERTAINTY", 25, 39], ["may also be", "UNCERTAINTY", 170, 181], ["large", "OBSERVATION_MODIFIER", 347, 352], ["SARS", "OBSERVATION", 353, 357], ["both", "ANATOMY_MODIFIER", 453, 457], ["target cell attachment", "OBSERVATION", 458, 480]]], ["As with several coronaviruses, the spike glycoprotein can be proteolytically cleaved into two non-covalently associated glycoproteins: the virion-associated S1 (666 amino acid residues) containing the receptor attachment site and the transmembrane-anchored S2 (583 residues) responsible for fusion activity (Bergeron et al., 2005; Follis et al., 2006; Li et al., 2005) .IntroductionThe SARS-CoV S glycoprotein is a 1255-amino acid precursor polypeptide as deduced from the published genome sequence and has 23 potential N-linked glycosylation sites Marra et al., 2003; Rota et al., 2003; Xiao et al., 2003) .", [["transmembrane", "ANATOMY", 234, 247], ["amino acid", "CHEMICAL", 165, 175], ["1255-amino acid", "CHEMICAL", 415, 430], ["amino acid", "CHEMICAL", 165, 175], ["amino acid", "CHEMICAL", 420, 430], ["N", "CHEMICAL", 520, 521], ["virion", "CELLULAR_COMPONENT", 139, 145], ["amino acid", "AMINO_ACID", 165, 175], ["transmembrane", "CELLULAR_COMPONENT", 234, 247], ["SARS-CoV S glycoprotein", "GENE_OR_GENE_PRODUCT", 386, 409], ["amino acid", "AMINO_ACID", 420, 430], ["spike glycoprotein", "PROTEIN", 35, 53], ["non-covalently associated glycoproteins", "PROTEIN", 94, 133], ["S1", "PROTEIN", 157, 159], ["666 amino acid residues", "PROTEIN", 161, 184], ["receptor attachment site", "PROTEIN", 201, 225], ["transmembrane-anchored S2", "PROTEIN", 234, 259], ["583 residues", "PROTEIN", 261, 273], ["SARS-CoV S glycoprotein", "PROTEIN", 386, 409], ["SARS-CoV", "SPECIES", 386, 394], ["several coronaviruses", "PROBLEM", 8, 29], ["the spike glycoprotein", "TREATMENT", 31, 53], ["amino acid residues", "TREATMENT", 165, 184], ["fusion activity", "PROBLEM", 291, 306], ["CoV S glycoprotein", "TREATMENT", 391, 409], ["amino acid precursor polypeptide", "TREATMENT", 420, 452]]], ["Previous studies have demonstrated that several of these sites are occupied and possess both complex-type and high-mannose type N-glycans (Krokhin et al., 2003; Song et al., 2004; Ying et al., 2004) .IntroductionHowever, full glycan analysis has not yet been performed.IntroductionSARS-CoV uses the angiotensin converting enzyme 2 (ACE2) as the primary receptor (Chen and Subbarao, 2007; Li et al., 2003; Moore et al., 2004; Wang et al., 2004) suggesting that oligomannose-containing N-glycans on the SARS-CoV S glycoprotein surface may be involved in mediating virus attachment to cells expressing this cell surface lectin.", [["cells", "ANATOMY", 582, 587], ["cell surface", "ANATOMY", 604, 616], ["angiotensin", "CHEMICAL", 299, 310], ["oligomannose", "CHEMICAL", 460, 472], ["mannose", "CHEMICAL", 115, 122], ["oligomannose", "CHEMICAL", 460, 472], ["N", "CHEMICAL", 484, 485], ["IntroductionSARS-CoV", "GENE_OR_GENE_PRODUCT", 269, 289], ["angiotensin converting enzyme 2", "GENE_OR_GENE_PRODUCT", 299, 330], ["ACE2", "GENE_OR_GENE_PRODUCT", 332, 336], ["oligomannose", "SIMPLE_CHEMICAL", 460, 472], ["N-glycans", "SIMPLE_CHEMICAL", 484, 493], ["SARS-CoV", "ORGANISM", 501, 509], ["cells", "CELL", 582, 587], ["cell", "CELL", 604, 608], ["lectin", "GENE_OR_GENE_PRODUCT", 617, 623], ["angiotensin converting enzyme 2", "PROTEIN", 299, 330], ["ACE2", "PROTEIN", 332, 336], ["SARS-CoV S glycoprotein", "PROTEIN", 501, 524], ["cell surface lectin", "PROTEIN", 604, 623], ["Previous studies", "TEST", 0, 16], ["full glycan analysis", "TEST", 221, 241], ["IntroductionSARS", "TEST", 269, 285], ["the angiotensin converting enzyme", "TREATMENT", 295, 328], ["oligomannose", "TEST", 460, 472], ["the SARS", "PROBLEM", 497, 505], ["CoV S glycoprotein surface", "TREATMENT", 506, 532], ["several", "OBSERVATION_MODIFIER", 40, 47], ["both", "OBSERVATION_MODIFIER", 88, 92], ["complex", "OBSERVATION_MODIFIER", 93, 100], ["high", "OBSERVATION_MODIFIER", 110, 114]]], ["The Ctype lectins DC-SIGN and L-SIGN (DC/L-SIGN) can enhance viral entry (Marzi et al., 2004; Yang et al., 2004) .", [["DC-SIGN", "GENE_OR_GENE_PRODUCT", 18, 25], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 30, 36], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 41, 47], ["DC", "PROTEIN", 18, 20], ["SIGN", "PROTEIN", 21, 25], ["L", "PROTEIN", 30, 31], ["SIGN", "PROTEIN", 32, 36], ["DC", "PROTEIN", 38, 40], ["L", "PROTEIN", 41, 42], ["SIGN", "PROTEIN", 43, 47], ["The Ctype lectins DC", "TEST", 0, 20], ["SIGN", "TEST", 21, 25]]], ["Site-directed mutagenesis analyses have identified seven glycosylation sites on the S protein critical for DC/L-SIGN-mediated virus entry.", [["DC", "ANATOMY", 107, 109], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 110, 116], ["glycosylation sites", "PROTEIN", 57, 76], ["S protein", "PROTEIN", 84, 93], ["DC", "CELL_TYPE", 107, 109], ["SIGN", "PROTEIN", 112, 116], ["Site-directed mutagenesis analyses", "TEST", 0, 34], ["seven glycosylation sites", "PROBLEM", 51, 76], ["the S protein", "TEST", 80, 93], ["DC", "TEST", 107, 109]]], ["They include asparagine residues 109, 118, 119, 158, 227, 589, and 699 , which are distinct from residues of the ACE2-binding domain (amino acids 318-510) (Han et al., 2007) .", [["asparagine", "CHEMICAL", 13, 23], ["amino acids 318-510", "CHEMICAL", 134, 153], ["asparagine", "CHEMICAL", 13, 23], ["amino acids 318-510", "CHEMICAL", 134, 153], ["asparagine", "AMINO_ACID", 13, 23], ["ACE2", "GENE_OR_GENE_PRODUCT", 113, 117], ["amino acids", "AMINO_ACID", 134, 145], ["318-510", "AMINO_ACID", 146, 153], ["ACE2-binding domain", "PROTEIN", 113, 132], ["amino acids 318-510", "PROTEIN", 134, 153], ["asparagine residues", "TEST", 13, 32], ["the ACE2", "TEST", 109, 117], ["amino acids", "TEST", 134, 145]]], ["Recently, L-SIGN (DC-SIGNR) has been shown to act as an entry receptor for SARS-CoV infection (Jeffers et al., 2004) , and its expression in lung alveolar and liver cells correlates with the disease pathogenesis observed in these organs in many SARS patients.IntroductionGiven that oligomannose N-glycans may be involved in viral attachment to cells it is of interest to study the effects of modifications to the N-glycan profile with the object of possibly identifying therapeutic strategies.", [["lung alveolar", "ANATOMY", 141, 154], ["liver cells", "ANATOMY", 159, 170], ["organs", "ANATOMY", 230, 236], ["cells", "ANATOMY", 344, 349], ["SARS-CoV infection", "DISEASE", 75, 93], ["SARS", "DISEASE", 245, 249], ["oligomannose N-glycans", "CHEMICAL", 282, 304], ["oligomannose", "CHEMICAL", 282, 294], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 10, 16], ["DC-SIGNR", "GENE_OR_GENE_PRODUCT", 18, 26], ["SARS-CoV", "ORGANISM", 75, 83], ["lung alveolar", "CELL", 141, 154], ["liver cells", "CELL", 159, 170], ["organs", "ORGAN", 230, 236], ["patients", "ORGANISM", 250, 258], ["oligomannose N-glycans", "SIMPLE_CHEMICAL", 282, 304], ["cells", "CELL", 344, 349], ["L", "PROTEIN", 10, 11], ["SIGN", "PROTEIN", 12, 16], ["DC", "PROTEIN", 18, 20], ["SIGNR", "PROTEIN", 21, 26], ["lung alveolar and liver cells", "CELL_TYPE", 141, 170], ["patients", "SPECIES", 250, 258], ["SARS-CoV", "SPECIES", 75, 83], ["SARS", "PROBLEM", 75, 79], ["CoV infection", "PROBLEM", 80, 93], ["its expression in lung alveolar and liver cells", "PROBLEM", 123, 170], ["the disease pathogenesis", "PROBLEM", 187, 211], ["oligomannose N-glycans", "TREATMENT", 282, 304], ["therapeutic strategies", "TREATMENT", 470, 492], ["infection", "OBSERVATION", 84, 93], ["lung", "ANATOMY", 141, 145], ["alveolar", "ANATOMY_MODIFIER", 146, 154], ["liver", "ANATOMY", 159, 164], ["disease", "OBSERVATION", 191, 198]]], ["This report describes the first complete Nglycosylation analysis of SARS-CoV S glycoprotein produced in Vero E6 cells, a cell line derived from African green monkeys, and demonstrates the inhibitory effect of the \u03b1glucosidase inhibitor N-butyl-deoxynojirimycin (NB-DNJ) on virus replication in this cell line.Characterization of SARS-CoV spike proteinViral proteins from purified viral particles were separated on 9% SDS-PAGE gels and stained with Coomassie blue (Fig. 1) .", [["Vero E6 cells", "ANATOMY", 104, 117], ["cell line", "ANATOMY", 121, 130], ["cell line", "ANATOMY", 299, 308], ["N-butyl-deoxynojirimycin", "CHEMICAL", 236, 260], ["NB-DNJ", "CHEMICAL", 262, 268], ["Coomassie blue", "CHEMICAL", 448, 462], ["N-butyl-deoxynojirimycin", "CHEMICAL", 236, 260], ["NB-DNJ", "CHEMICAL", 262, 268], ["Coomassie blue", "CHEMICAL", 448, 462], ["SARS-CoV S glycoprotein", "GENE_OR_GENE_PRODUCT", 68, 91], ["Vero E6 cells", "CELL", 104, 117], ["cell line", "CELL", 121, 130], ["African green monkeys", "ORGANISM", 144, 165], ["\u03b1glucosidase", "SIMPLE_CHEMICAL", 213, 225], ["N-butyl-deoxynojirimycin", "SIMPLE_CHEMICAL", 236, 260], ["NB-DNJ", "SIMPLE_CHEMICAL", 262, 268], ["cell line", "CELL", 299, 308], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 329, 337], ["Coomassie blue", "SIMPLE_CHEMICAL", 448, 462], ["SARS-CoV S glycoprotein", "PROTEIN", 68, 91], ["Vero E6 cells", "CELL_LINE", 104, 117], ["cell line", "CELL_LINE", 121, 130], ["SARS-CoV spike proteinViral proteins", "PROTEIN", 329, 365], ["green monkeys", "SPECIES", 152, 165], ["Vero E6", "SPECIES", 104, 111], ["African green monkeys", "SPECIES", 144, 165], ["SARS-CoV", "SPECIES", 329, 337], ["Coomassie blue", "SPECIES", 448, 462], ["SARS-CoV S glycoprotein", "PROBLEM", 68, 91], ["Vero E6 cells", "TREATMENT", 104, 117], ["a cell line", "TREATMENT", 119, 130], ["the \u03b1glucosidase inhibitor", "TREATMENT", 209, 235], ["butyl", "TREATMENT", 238, 243], ["deoxynojirimycin (NB-DNJ)", "TREATMENT", 244, 269], ["virus replication", "TREATMENT", 273, 290], ["this cell line", "TREATMENT", 294, 308], ["SARS", "PROBLEM", 329, 333], ["CoV spike proteinViral proteins", "TEST", 334, 365], ["purified viral particles", "PROBLEM", 371, 395], ["cell line", "OBSERVATION", 121, 130], ["cell line", "OBSERVATION", 299, 308], ["SARS", "OBSERVATION", 329, 333], ["viral particles", "OBSERVATION", 380, 395]]], ["The proteins S, M and N were detected but the gel was not dense enough to detect the smaller (7 kDa) E protein.", [["E protein", "PROTEIN", 101, 110], ["The proteins S", "TEST", 0, 14]]], ["Western blotting using the SARS-CoV S glycoprotein antibody (Imgenex) confirmed the identity and molecular weight (180 kDa) of the S protein which was consistent with earlier reports (Krokhin et al., 2003; Song et al., 2004; Xiao et al., 2003) and indicated the presence of the fully modified glycoprotein.", [["SARS-CoV S glycoprotein antibody", "GENE_OR_GENE_PRODUCT", 27, 59], ["SARS-CoV S glycoprotein antibody", "PROTEIN", 27, 59], ["Imgenex", "PROTEIN", 61, 68], ["S protein", "PROTEIN", 131, 140], ["glycoprotein", "PROTEIN", 293, 305], ["SARS-CoV", "SPECIES", 27, 35], ["Western blotting", "TEST", 0, 16], ["the SARS", "TEST", 23, 31], ["CoV S glycoprotein antibody", "TEST", 32, 59], ["molecular weight", "TEST", 97, 113], ["the S protein", "TEST", 127, 140], ["consistent with", "UNCERTAINTY", 151, 166]]], ["There was no apparent difference in molecular weight between the glycoproteins produced with and without NB-DNJ.Identification of N-glycansThe spike glycoprotein-containing band was cut from the gel for N-glycan analysis by in-gel PNGase F digestion followed by HPLC (as 2AB derivatives), exoglycosidase digestion, MALDI-TOF and nanoelectrospray MS/MS as described below.", [["NB-DNJ", "ANATOMY", 105, 111], ["N-glycans", "CHEMICAL", 130, 139], ["N-glycans", "GENE_OR_GENE_PRODUCT", 130, 139], ["exoglycosidase", "SIMPLE_CHEMICAL", 289, 303], ["glycoproteins", "PROTEIN", 65, 78], ["N-glycans", "PROTEIN", 130, 139], ["spike glycoprotein", "PROTEIN", 143, 161], ["apparent difference", "PROBLEM", 13, 32], ["The spike glycoprotein-containing band", "TREATMENT", 139, 177], ["N-glycan analysis", "TREATMENT", 203, 220], ["HPLC", "TEST", 262, 266], ["2AB derivatives", "TREATMENT", 271, 286], ["exoglycosidase digestion", "TREATMENT", 289, 313], ["MALDI", "TEST", 315, 320], ["MS", "PROBLEM", 349, 351], ["no apparent", "UNCERTAINTY", 10, 21], ["difference", "OBSERVATION_MODIFIER", 22, 32]]], ["The HPLC trace of the SARS-CoV glycans obtained without NB-DNJ treatment is shown in Fig. 2a .", [["SARS", "DISEASE", 22, 26], ["NB-DNJ", "CHEMICAL", 56, 62], ["NB-DNJ", "SIMPLE_CHEMICAL", 56, 62], ["SARS-CoV", "SPECIES", 22, 30], ["The HPLC", "TEST", 0, 8], ["the SARS", "PROBLEM", 18, 26], ["CoV glycans", "TEST", 27, 38], ["NB", "PROBLEM", 56, 58], ["DNJ treatment", "TREATMENT", 59, 72]]], ["Traces obtained before and after digestion withArthrobacter ureafaciens sialidase (Fig. 2b) were virtually identical showing negligible incorporation of sialic acid in these glycans.", [["sialic acid", "CHEMICAL", 153, 164], ["sialic acid", "CHEMICAL", 153, 164], ["sialic acid", "SIMPLE_CHEMICAL", 153, 164], ["withArthrobacter ureafaciens sialidase", "SPECIES", 43, 81], ["withArthrobacter ureafaciens", "SPECIES", 43, 71], ["digestion withArthrobacter ureafaciens sialidase", "TREATMENT", 33, 81], ["sialic acid", "TREATMENT", 153, 164], ["sialic acid", "OBSERVATION", 153, 164]]], ["Previous work (Feldmann et al., 1994) has also shown a lack of sialylated N-glycans in Marburg virus grown in Vero E6 cells.", [["Vero E6 cells", "ANATOMY", 110, 123], ["N", "CHEMICAL", 74, 75], ["Marburg virus", "ORGANISM", 87, 100], ["Vero E6 cells", "CELL", 110, 123], ["Vero E6 cells", "CELL_LINE", 110, 123], ["Marburg virus", "SPECIES", 87, 100], ["Vero E6", "SPECIES", 110, 117], ["sialylated N-glycans", "PROBLEM", 63, 83], ["Marburg virus", "PROBLEM", 87, 100], ["Vero E6 cells", "OBSERVATION", 110, 123]]], ["The positive ion MALDI (Fig. 3) and negative ion nanoelectrospray spectra were similar to each other and to the HPLC trace although more glycans were resolved by mass spectrometry.", [["ion nanoelectrospray spectra", "TEST", 45, 73], ["the HPLC", "TEST", 108, 116], ["mass spectrometry", "PROBLEM", 162, 179], ["positive", "OBSERVATION_MODIFIER", 4, 12], ["ion MALDI", "OBSERVATION_MODIFIER", 13, 22]]], ["Table 1 lists the identified glycans and their percentage of the total glycan pool as measured by MALDI-TOF MS and Table 2 lists the percentage of various compound glycan types.", [["compound glycan types", "OBSERVATION", 155, 176]]], ["Because a few of the glycans with different structures had the same mass and were, thus, not separated by mass spectrometry, the figures should be taken as approximate.", [["the same mass", "PROBLEM", 59, 72], ["mass spectrometry", "TEST", 106, 123], ["few", "OBSERVATION_MODIFIER", 10, 13], ["same", "OBSERVATION_MODIFIER", 63, 67], ["mass", "OBSERVATION", 68, 72]]], ["Nevertheless, they reflect the composition of the mixture reasonably accurately.Identification of N-glycansThe glycans were identified by exoglycosidase digestion with monitoring by HPLC and by negative ion MS/MS of their [M+H 2 PO 4 ] \u2212 ions (Harvey, 2005a) using electrospray sample introduction (Harvey, 2005b,c; Harvey et al., 2008b) .", [["[M+H 2 PO 4 ] \u2212", "CHEMICAL", 222, 237], ["N-glycans", "GENE_OR_GENE_PRODUCT", 98, 107], ["exoglycosidase", "SIMPLE_CHEMICAL", 138, 152], ["[M+H 2 PO 4 ] \u2212 ions", "SIMPLE_CHEMICAL", 222, 242], ["N-glycans", "PROTEIN", 98, 107], ["N-glycansThe glycans", "PROBLEM", 98, 118], ["HPLC", "TEST", 182, 186]]], ["The HPLC traces obtained after ABS and bovine testis \u03b2-galactosidase (BTG) treatment ( Fig. 2c ) confirmed attachment of galactose at the non-reducing termini of the glycan antenna.", [["BTG", "CHEMICAL", 70, 73], ["galactose", "CHEMICAL", 121, 130], ["galactose", "CHEMICAL", 121, 130], ["bovine", "ORGANISM", 39, 45], ["testis \u03b2-galactosidase", "SIMPLE_CHEMICAL", 46, 68], ["BTG", "SIMPLE_CHEMICAL", 70, 73], ["galactose", "SIMPLE_CHEMICAL", 121, 130], ["non-reducing termini", "PROTEIN", 138, 158], ["bovine", "SPECIES", 39, 45], ["bovine", "SPECIES", 39, 45], ["The HPLC traces", "TEST", 0, 15], ["ABS", "TEST", 31, 34], ["bovine testis \u03b2-galactosidase", "TREATMENT", 39, 68], ["BTG) treatment", "TREATMENT", 70, 84], ["galactose", "TREATMENT", 121, 130]]], ["Further incubation with hexosaminidase ( Fig. 2d ) reduced the profile to Man 3 GlcNAc 2 , Man 3 GlcNAc 2 Fuc 1 and a series of unaffected high-mannose glycans.", [["Man 3 GlcNAc", "CHEMICAL", 74, 86], ["GlcNAc", "CHEMICAL", 97, 103], ["mannose", "CHEMICAL", 144, 151], ["hexosaminidase", "GENE_OR_GENE_PRODUCT", 24, 38], ["Man 3 GlcNAc 2", "GENE_OR_GENE_PRODUCT", 74, 88], ["Man 3 GlcNAc 2 Fuc 1", "GENE_OR_GENE_PRODUCT", 91, 111], ["high-mannose glycans", "SIMPLE_CHEMICAL", 139, 159], ["hexosaminidase", "PROTEIN", 24, 38], ["Further incubation", "TREATMENT", 0, 18], ["hexosaminidase ( Fig.", "TREATMENT", 24, 45], ["a series", "TEST", 116, 124]]], ["A few compounds were present at concentrations that were too weak to permit acquisition of informative MS/MS spectra.", [["too weak", "PROBLEM", 57, 65], ["few", "OBSERVATION_MODIFIER", 2, 5], ["compounds", "OBSERVATION", 6, 15]]], ["However, their structures could be deduced from the structures of related compounds, e.g., complex glycans with different numbers of galactose residues.", [["galactose", "CHEMICAL", 133, 142], ["galactose", "CHEMICAL", 133, 142], ["galactose", "SIMPLE_CHEMICAL", 133, 142], ["galactose residues", "TREATMENT", 133, 151], ["compounds", "OBSERVATION_MODIFIER", 74, 83], ["galactose residues", "OBSERVATION", 133, 151]]], ["Ion nomenclature in the following discussion follows that introduced by Domon and Costello (1988) as modified by Harvey et al. (2004) by the use of the subscript \"R\" to specify cleavages adjacent to the reducing-terminal GlcNAc residue and \"R-1\" to specify cleavages adjacent to the penultimate GlcNAc in order to avoid confusion by the subscript number changing as a function of antenna length.High-mannose glycansHigh-mannose glycans containing from four to nine mannose residues were present in the glycan mixture (Fig. 3) .", [["confusion", "DISEASE", 320, 329], ["mannose", "CHEMICAL", 465, 472], ["GlcNAc", "CHEMICAL", 221, 227], ["GlcNAc", "CHEMICAL", 295, 301], ["mannose", "CHEMICAL", 400, 407], ["mannose", "CHEMICAL", 420, 427], ["mannose", "CHEMICAL", 465, 472], ["R-1", "GENE_OR_GENE_PRODUCT", 241, 244], ["GlcNAc", "GENE_OR_GENE_PRODUCT", 295, 301], ["penultimate GlcNAc", "PROTEIN", 283, 301], ["terminal GlcNAc residue", "PROBLEM", 212, 235], ["the penultimate GlcNAc", "TREATMENT", 279, 301], ["confusion", "PROBLEM", 320, 329], ["High-mannose glycansHigh-mannose glycans", "TREATMENT", 395, 435], ["GlcNAc residue", "OBSERVATION", 221, 235]]], ["Incubation with Aspergillus saitoi a-mannosidase (data not shown) reduced the larger compounds to Man 5 GlcNAc 2 (compound 3, Table 1 ) confirming the \u03b1mannose linkages.", [["Man 5 GlcNAc 2", "CHEMICAL", 98, 112], ["\u03b1mannose", "CHEMICAL", 151, 159], ["Man 5 GlcNAc", "CHEMICAL", 98, 110], ["\u03b1mannose", "CHEMICAL", 151, 159], ["Aspergillus saitoi", "ORGANISM", 16, 34], ["a-mannosidase", "SIMPLE_CHEMICAL", 35, 48], ["Man 5 GlcNAc 2", "SIMPLE_CHEMICAL", 98, 112], ["\u03b1mannose", "SIMPLE_CHEMICAL", 151, 159], ["Aspergillus saitoi", "SPECIES", 16, 34], ["Aspergillus saitoi", "SPECIES", 16, 34], ["Aspergillus saitoi a-mannosidase", "TREATMENT", 16, 48], ["larger", "OBSERVATION_MODIFIER", 78, 84]]], ["The negative ion MS/MS spectra of the high-mannose glycans Man 5-9 GlcNAc 2 (phosphate adducts) are shown in Fig. 4 .", [["Man", "CHEMICAL", 59, 62], ["5-9 GlcNAc 2", "CHEMICAL", 63, 75], ["phosphate", "CHEMICAL", 77, 86], ["mannose", "CHEMICAL", 43, 50], ["GlcNAc", "CHEMICAL", 67, 73], ["phosphate", "CHEMICAL", 77, 86], ["Man 5-9 GlcNAc 2", "SIMPLE_CHEMICAL", 59, 75], ["phosphate adducts", "SIMPLE_CHEMICAL", 77, 94], ["MS spectra", "TEST", 20, 30], ["GlcNAc 2 (phosphate adducts", "TREATMENT", 67, 94], ["ion MS", "OBSERVATION_MODIFIER", 13, 19]]], ["The cross-ring 2,4 A R and 2,4 A R-1 fragments together with the B R-1 ion at the high-mass end of the spectra define the 1\u21924linked chitobiose core (Harvey, 2005b; Harvey et al., 2008b) and the single C 1 fragment at m/z 179 confirmed hexose (mannose) as the only non-reducing end residue.", [["hexose", "CHEMICAL", 235, 241], ["mannose", "CHEMICAL", 243, 250], ["chitobiose", "CHEMICAL", 132, 142], ["hexose", "CHEMICAL", 235, 241], ["mannose", "CHEMICAL", 243, 250], ["2,4 A R", "SIMPLE_CHEMICAL", 15, 22], ["2,4 A R-1 fragments", "SIMPLE_CHEMICAL", 27, 46], ["B R-1", "GENE_OR_GENE_PRODUCT", 65, 70], ["chitobiose", "SIMPLE_CHEMICAL", 132, 142], ["hexose", "SIMPLE_CHEMICAL", 235, 241], ["mannose", "SIMPLE_CHEMICAL", 243, 250], ["cross-ring 2,4 A R and 2,4 A R-1 fragments", "DNA", 4, 46], ["The cross-ring", "TEST", 0, 14], ["the B R", "TEST", 61, 68], ["the single C 1 fragment", "PROBLEM", 190, 213], ["hexose (mannose", "TREATMENT", 235, 250], ["non-reducing end residue", "PROBLEM", 264, 288], ["fragments", "OBSERVATION", 37, 46], ["mass", "OBSERVATION", 87, 91], ["end residue", "OBSERVATION", 277, 288]]], ["The ions towards the centre of the spectrum were mainly derived from the 6-antenna and allowed the distribution of the mannose residues between the two antennae to be determined.", [["mannose", "CHEMICAL", 119, 126], ["mannose", "SIMPLE_CHEMICAL", 119, 126], ["the mannose residues", "TREATMENT", 115, 135], ["ions", "OBSERVATION", 4, 8], ["mannose residues", "OBSERVATION", 119, 135]]], ["Predominant among these ions were the D-ion (formal loss of the 3-antenna from the C R-1 ion), the [D-18] \u2212 ion and the O,3 A R-2 cross-ring cleavage fragment (core mannose residue) (Harvey, 2005b) .", [["D-ion", "CHEMICAL", 38, 43], ["D-ion", "CHEMICAL", 38, 43], ["[D-18] \u2212", "CHEMICAL", 99, 107], ["O", "CHEMICAL", 120, 121], ["mannose", "CHEMICAL", 165, 172], ["D-ion", "SIMPLE_CHEMICAL", 38, 43], ["[D-18] \u2212 ion", "SIMPLE_CHEMICAL", 99, 111], ["C R", "PROTEIN", 83, 86], ["A R-2 cross-ring cleavage fragment", "TREATMENT", 124, 158], ["ions", "OBSERVATION", 24, 28], ["cleavage fragment", "OBSERVATION", 141, 158]]], ["Thus, Man 5 GlcNAc 2 (3) produced a spectrum with these ions at m/z 647, 629 and 575, respectively.", [["Man 5 GlcNAc 2", "CHEMICAL", 6, 20], ["GlcNAc", "CHEMICAL", 12, 18], ["Man 5 GlcNAc 2 (3)", "SIMPLE_CHEMICAL", 6, 24]]], ["Further confirmation of the substitution pattern was provided by the C 2 ion at m/z 503 (three mannose residues).", [["C 2", "CHEMICAL", 69, 72], ["mannose", "CHEMICAL", 95, 102], ["the substitution pattern", "TEST", 24, 48]]], ["In the spectrum of Man 6 GlcNAc 2 (7, Fig. 4b ) the D, [D-18] \u2212 and O,3 A R-2 ions were in the same position as in the spectrum of Man 5 GlcNAc 2 showing that the sixth mannose was attached to the 3-antenna.", [["Man 5 GlcNAc", "CHEMICAL", 131, 143], ["mannose", "CHEMICAL", 169, 176], ["GlcNAc", "CHEMICAL", 25, 31], ["O", "CHEMICAL", 68, 69], ["Man 5 GlcNAc", "CHEMICAL", 131, 143], ["mannose", "CHEMICAL", 169, 176], ["D", "SIMPLE_CHEMICAL", 52, 53], ["[D-18] \u2212", "SIMPLE_CHEMICAL", 55, 63], ["O,3 A R-2 ions", "SIMPLE_CHEMICAL", 68, 82], ["Man 5 GlcNAc 2", "SIMPLE_CHEMICAL", 131, 145], ["mannose", "SIMPLE_CHEMICAL", 169, 176], ["GlcNAc", "TEST", 25, 31], ["D", "TEST", 56, 57], ["A R-2 ions", "TREATMENT", 72, 82]]], ["These three diagnostic ions all shifted by 162 mass units to higher mass in the spectrum of Man 7 GlcNAc 2 (12, Fig. 4c) showing that the seventh mannose was attached to the 6antenna and the high abundance of the ion at m/z 485 was consistent with its location on the 6-branch of this antenna.", [["mannose", "CHEMICAL", 146, 153], ["Man 7 GlcNAc", "CHEMICAL", 92, 104], ["mannose", "CHEMICAL", 146, 153], ["mannose", "SIMPLE_CHEMICAL", 146, 153], ["6antenna", "PROTEIN", 174, 182], ["higher mass", "PROBLEM", 61, 72], ["Man 7 GlcNAc", "TREATMENT", 92, 104], ["this antenna", "TREATMENT", 280, 292], ["higher", "OBSERVATION_MODIFIER", 61, 67], ["mass", "OBSERVATION", 68, 72], ["high", "OBSERVATION_MODIFIER", 191, 195], ["abundance", "OBSERVATION_MODIFIER", 196, 205], ["consistent with", "UNCERTAINTY", 232, 247]]], ["This ion, termed D\u2032, is thought to be equivalent to ion D as the result of the same substitution pattern of the branched mannose of the 6-antenna to that at the mannose of the core.", [["mannose", "CHEMICAL", 121, 128], ["mannose", "CHEMICAL", 161, 168], ["ion D", "SIMPLE_CHEMICAL", 52, 57], ["mannose", "SIMPLE_CHEMICAL", 121, 128], ["mannose", "SIMPLE_CHEMICAL", 161, 168], ["thought to be", "UNCERTAINTY", 24, 37], ["branched", "ANATOMY_MODIFIER", 112, 120]]], ["This same pattern of D, [D-18] \u2212 , O,3 A R-2 and D\u2032 ions was present in the spectrum of Man 8 GlcNAc 2 (19, Fig. 4d ) confirming attachment of the 8 th mannose to the 3-antenna and indicating that this compound had the classical d1,d3-substitution pattern.", [["[D-18] \u2212 , O,3 A R-2 and D\u2032", "CHEMICAL", 24, 51], ["Man 8 GlcNAc", "CHEMICAL", 88, 100], ["mannose", "CHEMICAL", 152, 159], ["D", "SIMPLE_CHEMICAL", 21, 22], ["[D-18] \u2212", "SIMPLE_CHEMICAL", 24, 32], ["O,3 A R-2", "SIMPLE_CHEMICAL", 35, 44], ["D\u2032 ions", "SIMPLE_CHEMICAL", 49, 56], ["mannose", "SIMPLE_CHEMICAL", 152, 159], ["d3", "PROTEIN", 232, 234], ["D", "TEST", 25, 26], ["D\u2032 ions", "PROBLEM", 49, 56], ["GlcNAc", "TEST", 94, 100], ["this compound", "PROBLEM", 197, 210], ["substitution pattern", "OBSERVATION", 235, 255]]], ["Finally, in the spectrum of Man 9 GlcNAc 2 (25, Fig. 4e indicated the presence of a second isomer with three mannose residues in the 3-antenna.", [["Man 9 GlcNAc 2", "CHEMICAL", 28, 42], ["GlcNAc", "CHEMICAL", 34, 40], ["mannose", "CHEMICAL", 109, 116], ["three mannose residues", "TREATMENT", 103, 125], ["mannose residues", "OBSERVATION", 109, 125]]], ["A fragmentation spectrum was not obtained for Man 4 GlcNAc 2 (1).Hybrid glycansHybrid glycans (numbers 9, 13, 14 and 20, Table 1 ) were detected in the mass spectra but were not apparent in the HPLC trace of the total glycans.", [["Man 4 GlcNAc", "CHEMICAL", 46, 58], ["Man 4 GlcNAc 2 (1)", "GENE_OR_GENE_PRODUCT", 46, 64], ["A fragmentation spectrum", "TEST", 0, 24], ["Hybrid glycansHybrid glycans", "TREATMENT", 65, 93], ["the HPLC", "TEST", 190, 198], ["fragmentation", "OBSERVATION", 2, 15], ["Hybrid glycans", "OBSERVATION", 79, 93]]], ["However, they became visible by HPLC following incubation with Jack bean \u03b1-mannosidase which removed all of the mannose residues from the 6-antenna to leave the chitobiose core and 3-antenna which consisted of GlcNAc and Gal-GlcNAc (data not shown).", [["mannose", "CHEMICAL", 112, 119], ["chitobiose", "CHEMICAL", 161, 171], ["GlcNAc", "CHEMICAL", 210, 216], ["Gal-GlcNAc", "CHEMICAL", 221, 231], ["chitobiose", "SIMPLE_CHEMICAL", 161, 171], ["GlcNAc", "GENE_OR_GENE_PRODUCT", 210, 216], ["Gal-GlcNAc", "GENE_OR_GENE_PRODUCT", 221, 231], ["Jack bean", "SPECIES", 63, 72], ["Jack bean \u03b1-mannosidase", "TREATMENT", 63, 86], ["the mannose residues", "TREATMENT", 108, 128], ["GlcNAc and Gal-GlcNAc", "TREATMENT", 210, 231]]], ["Fig. 5 shows the negative ion MS/ MS spectra of the hybrid glycans 9 (Fig. 5a) and 14 (Fig. 5b) .", [["the hybrid glycans", "TEST", 48, 66]]], ["The pattern of mannose substitution on the 6-antenna was determined by the masses of the D, [D-18] \u2212 , O,3 A R-2 , D\u2032 and [D\u2032-18] \u2212 ions in the negative ion MS/MS spectra as described above.", [["mannose", "CHEMICAL", 15, 22], ["mannose", "CHEMICAL", 15, 22], ["O", "CHEMICAL", 103, 104], ["mannose", "SIMPLE_CHEMICAL", 15, 22], ["D", "SIMPLE_CHEMICAL", 89, 90], ["[D-18] \u2212", "SIMPLE_CHEMICAL", 92, 100], ["O,3 A R-2 , D\u2032", "SIMPLE_CHEMICAL", 103, 117], ["[D\u2032-18] \u2212 ions", "SIMPLE_CHEMICAL", 122, 136], ["mannose substitution", "TREATMENT", 15, 35], ["D\u2032", "TEST", 115, 117], ["D\u2032", "TEST", 123, 125], ["ions", "TEST", 132, 136], ["MS spectra", "PROBLEM", 160, 170], ["mannose substitution", "OBSERVATION", 15, 35], ["masses", "OBSERVATION", 75, 81]]], ["The spectrum of the glycan corresponding to Hex 5 GlcNAc 3 (9, Fig. 5a ) showed the presence of two compounds as evidenced by the appearance of two sets of D and [D-18] \u2212 ions (m/z 647/629 and 485/467) indicating three and two mannose residues respectively in the 6-antenna.", [["Hex 5 GlcNAc", "CHEMICAL", 44, 56], ["mannose", "CHEMICAL", 227, 234], ["Hex 5 GlcNAc 3", "GENE_OR_GENE_PRODUCT", 44, 58], ["D", "SIMPLE_CHEMICAL", 156, 157], ["[D-18] \u2212 ions", "SIMPLE_CHEMICAL", 162, 175], ["Hex 5 GlcNAc", "TREATMENT", 44, 56], ["mannose residues", "OBSERVATION", 227, 243]]], ["The linkage of the mannose residue in the compounds with two mannose residues in the 6antenna was not determined.", [["mannose", "CHEMICAL", 19, 26], ["mannose", "CHEMICAL", 61, 68], ["mannose", "CHEMICAL", 19, 26], ["mannose", "CHEMICAL", 61, 68], ["mannose", "SIMPLE_CHEMICAL", 19, 26], ["the mannose residue", "PROBLEM", 15, 34], ["two mannose residues", "TREATMENT", 57, 77], ["mannose residue", "OBSERVATION", 19, 34], ["compounds", "OBSERVATION_MODIFIER", 42, 51], ["mannose residues", "OBSERVATION", 61, 77]]], ["Location of the fucose at position 6 of the terminal GlcNAc residue, when present, was determined by the masses of the abundant 2,4 A R , 2,4 A R-1 and B R-1 ions in the MS/MS spectra (Harvey, 2005c; Harvey et al., 2008b) all of which were formed by loss of the fucose residue as the result of its attachment to the eliminated neutral fragment.", [["fucose", "CHEMICAL", 16, 22], ["fucose", "CHEMICAL", 16, 22], ["GlcNAc", "CHEMICAL", 53, 59], ["fucose", "CHEMICAL", 262, 268], ["fucose", "AMINO_ACID", 16, 22], ["2,4 A R-1", "SIMPLE_CHEMICAL", 138, 147], ["B R-1 ions", "SIMPLE_CHEMICAL", 152, 162], ["position 6", "PROTEIN", 26, 36], ["the terminal GlcNAc residue", "PROBLEM", 40, 67], ["A R", "TEST", 142, 145], ["the fucose residue", "PROBLEM", 258, 276], ["the eliminated neutral fragment", "PROBLEM", 312, 343], ["fucose", "OBSERVATION_MODIFIER", 16, 22], ["terminal", "OBSERVATION_MODIFIER", 44, 52], ["GlcNAc residue", "OBSERVATION", 53, 67], ["masses", "OBSERVATION", 105, 111], ["fucose residue", "OBSERVATION", 262, 276], ["neutral fragment", "OBSERVATION", 327, 343]]], ["No antenna-substituted fucose was detected in these or in the spectra of the complex glycans.", [["fucose", "CHEMICAL", 23, 29], ["fucose", "CHEMICAL", 23, 29], ["antenna-substituted fucose", "SIMPLE_CHEMICAL", 3, 29], ["antenna-substituted fucose", "PROBLEM", 3, 29], ["antenna", "ANATOMY_MODIFIER", 3, 10], ["substituted fucose", "OBSERVATION", 11, 29]]], ["The composition of the 3-antenna was specified by the mass of an E-type cross-ring fragment ion (substituents plus 101 mass units from the mannose residue (Harvey, 2005c; Harvey et al., 2008b) ).", [["mannose", "CHEMICAL", 139, 146], ["the mass", "PROBLEM", 50, 58], ["an E-type cross-ring fragment ion (substituents", "TREATMENT", 62, 109], ["mass", "OBSERVATION", 54, 58], ["ring fragment", "OBSERVATION", 78, 91], ["mannose residue", "OBSERVATION", 139, 154]]], ["These ions were of low abundance but were present at m/z 304 and 466 in the spectrum shown in Fig. 5a and at m/z 466 in Fig. 5b confirming the presence of GlcNAc and Gal-GlcNAc antennae respectively.", [["GlcNAc", "CHEMICAL", 155, 161], ["GlcNAc", "CHEMICAL", 170, 176], ["GlcNAc", "GENE_OR_GENE_PRODUCT", 155, 161], ["Gal-GlcNAc antennae", "GENE_OR_GENE_PRODUCT", 166, 185], ["low abundance", "PROBLEM", 19, 32], ["GlcNAc and Gal-GlcNAc antennae", "TREATMENT", 155, 185], ["low abundance", "OBSERVATION_MODIFIER", 19, 32], ["Fig", "OBSERVATION", 94, 97]]], ["The 3-antenna composition was further defined by an O,3 A cross-ring cleavage ion formed by fragmentation of the mannose residue and which appeared at 59 mass units above the mass of the substituents linked to the mannose (m/z 262 for a GlcNAc-containing antenna and m/z 424 for Gal-GlcNAc, see Fig. 5 ).Complex glycansRepresentative spectra are shown in Fig. 6 .", [["mannose", "CHEMICAL", 214, 221], ["O", "CHEMICAL", 52, 53], ["mannose", "CHEMICAL", 113, 120], ["mannose", "CHEMICAL", 214, 221], ["GlcNAc", "CHEMICAL", 237, 243], ["Gal-GlcNAc", "CHEMICAL", 279, 289], ["mannose", "SIMPLE_CHEMICAL", 214, 221], ["GlcNAc", "SIMPLE_CHEMICAL", 237, 243], ["Gal-GlcNAc", "GENE_OR_GENE_PRODUCT", 279, 289], ["The 3-antenna composition", "TREATMENT", 0, 25], ["A cross-ring cleavage", "TREATMENT", 56, 77], ["the mannose residue", "PROBLEM", 109, 128], ["a GlcNAc-containing antenna and m/z", "TREATMENT", 235, 270], ["Gal-GlcNAc", "TREATMENT", 279, 289], ["mannose residue", "OBSERVATION", 113, 128], ["mass", "OBSERVATION", 175, 179], ["glycans", "OBSERVATION", 312, 319]]], ["Bi-, tri-and tetra-antennary glycans were found, with and without core fucose and with and without a bisecting GlcNAc residue.", [["fucose", "CHEMICAL", 71, 77], ["GlcNAc", "CHEMICAL", 111, 117], ["Bi-", "SIMPLE_CHEMICAL", 0, 3], ["tri-and tetra-antennary glycans", "SIMPLE_CHEMICAL", 5, 36], ["fucose", "SIMPLE_CHEMICAL", 71, 77], ["Bi-, tri-and tetra-antennary glycans", "PROBLEM", 0, 36], ["core fucose", "TEST", 66, 77], ["a bisecting GlcNAc residue", "PROBLEM", 99, 125], ["GlcNAc residue", "OBSERVATION", 111, 125]]], ["Exoglycosidase digestion with ABS, BTG and GUH (Fig. 2) showed that the antennae consisted of galactose and GlcNAc only.", [["antennae", "ANATOMY", 72, 80], ["BTG", "CHEMICAL", 35, 38], ["galactose", "CHEMICAL", 94, 103], ["galactose", "CHEMICAL", 94, 103], ["GlcNAc", "CHEMICAL", 108, 114], ["Exoglycosidase", "SIMPLE_CHEMICAL", 0, 14], ["BTG", "SIMPLE_CHEMICAL", 35, 38], ["galactose", "SIMPLE_CHEMICAL", 94, 103], ["GlcNAc", "SIMPLE_CHEMICAL", 108, 114], ["Exoglycosidase digestion", "PROBLEM", 0, 24], ["ABS", "TEST", 30, 33], ["BTG", "TEST", 35, 38], ["galactose and GlcNAc", "TREATMENT", 94, 114]]], ["Their negative ion MS/MS spectra were identical to those from reference standards.", [["ion MS/MS spectra", "PROBLEM", 15, 32], ["ion MS", "OBSERVATION_MODIFIER", 15, 21]]], ["The branching structure of the triantennary glycan (29, Fig. 6c ) was revealed by the mass of the E 3 ion (m/z 831, the subscript \"3\" indicates its origin from the 3-antenna) (Harvey, 2005c; Harvey et al., 2008a) .", [["the triantennary glycan", "TEST", 27, 50], ["branching", "OBSERVATION_MODIFIER", 4, 13], ["triantennary", "ANATOMY_MODIFIER", 31, 43], ["glycan", "ANATOMY_MODIFIER", 44, 50], ["mass", "OBSERVATION", 86, 90]]], ["This ion was also present in the spectrum of the tetra-antennary glycan (34, Fig. 6d ) but, whereas the D and [D-18] \u2212 ions from the 6-antenna in the spectrum of the triantennary glycan were at the same m/z values (688 and 670 respectively) as in the spectrum of the biantennary glycan (Fig. 6a) , they moved to m/z 1053 and 1035 in the spectrum of the tetra-antennary glycan reflecting the presence of the additional Gal-GlcNAc moiety in the 6-antenna.", [["Gal-GlcNAc", "CHEMICAL", 418, 428], ["tetra", "CHEMICAL", 49, 54], ["tetra", "CHEMICAL", 353, 358], ["Gal-GlcNAc", "CHEMICAL", 418, 428], ["tetra-antennary glycan", "SIMPLE_CHEMICAL", 49, 71], ["D", "SIMPLE_CHEMICAL", 104, 105], ["[D-18] \u2212 ions", "SIMPLE_CHEMICAL", 110, 123], ["tetra-antennary glycan", "SIMPLE_CHEMICAL", 353, 375], ["Gal-GlcNAc moiety", "SIMPLE_CHEMICAL", 418, 435], ["the tetra-antennary glycan", "TEST", 45, 71], ["ions", "TREATMENT", 119, 123], ["the triantennary glycan", "TEST", 162, 185], ["the additional Gal-GlcNAc moiety", "TREATMENT", 403, 435]]], ["An additional [D-36] \u2212 ion at m/z 1017 was also characteristic of this branched structure on the 6-antenna.", [["[D-36] \u2212", "CHEMICAL", 14, 22], ["[D-36] \u2212", "SIMPLE_CHEMICAL", 14, 22]]], ["The fucose substitution pattern on the core GlcNAc residue was defined by the masses of the 2,4 A R , 2,4 A R-1 and B R-1 ions as described above.", [["fucose", "CHEMICAL", 4, 10], ["GlcNAc", "CHEMICAL", 44, 50], ["fucose", "SIMPLE_CHEMICAL", 4, 10], ["R-1", "GENE_OR_GENE_PRODUCT", 108, 111], ["B R-1 ions", "SIMPLE_CHEMICAL", 116, 126], ["The fucose substitution pattern", "PROBLEM", 0, 31], ["the core GlcNAc residue", "PROBLEM", 35, 58], ["the masses", "PROBLEM", 74, 84], ["fucose substitution", "OBSERVATION", 4, 23], ["GlcNAc residue", "OBSERVATION", 44, 58], ["masses", "OBSERVATION", 78, 84], ["1 ions", "ANATOMY_MODIFIER", 120, 126]]], ["The occurrence of a bisecting GlcNAc residue was determined by the presence of an abundant [D-221] \u2212 ion (e.g., m/z 670 in Fig. 6b ), equivalent in mass to the [M-18] \u2212 ion from the corresponding compound that did not contain a bisecting GlcNAc residue, as described earlier (Harvey et al., 2008b) .Complex glycansThese basic complex structures were accompanied by relatively large amounts of analogues with fewer numbers of galactose residues (Table 1) , confirmed by incubations with bovine testis \u03b2-galactosidase.", [["testis", "ANATOMY", 493, 499], ["galactose", "CHEMICAL", 425, 434], ["GlcNAc", "CHEMICAL", 30, 36], ["GlcNAc", "CHEMICAL", 238, 244], ["galactose", "CHEMICAL", 425, 434], ["[M-18] \u2212 ion", "SIMPLE_CHEMICAL", 160, 172], ["galactose", "SIMPLE_CHEMICAL", 425, 434], ["bovine", "ORGANISM", 486, 492], ["testis \u03b2-galactosidase", "GENE_OR_GENE_PRODUCT", 493, 515], ["bovine testis \u03b2-galactosidase", "PROTEIN", 486, 515], ["bovine", "SPECIES", 486, 492], ["a bisecting GlcNAc residue", "PROBLEM", 18, 44], ["equivalent in mass", "PROBLEM", 134, 152], ["a bisecting GlcNAc residue", "PROBLEM", 226, 252], ["relatively large amounts of analogues", "PROBLEM", 365, 402], ["galactose residues", "PROBLEM", 425, 443], ["bovine testis \u03b2-galactosidase", "TREATMENT", 486, 515], ["GlcNAc residue", "OBSERVATION", 30, 44], ["mass", "OBSERVATION", 148, 152], ["bisecting", "OBSERVATION_MODIFIER", 228, 237], ["GlcNAc residue", "OBSERVATION", 238, 252], ["glycans", "OBSERVATION", 307, 314], ["complex", "OBSERVATION_MODIFIER", 326, 333], ["relatively", "OBSERVATION_MODIFIER", 365, 375], ["large", "OBSERVATION_MODIFIER", 376, 381], ["amounts", "OBSERVATION_MODIFIER", 382, 389], ["analogues", "OBSERVATION_MODIFIER", 393, 402], ["galactose residues", "OBSERVATION", 425, 443], ["bovine testis", "OBSERVATION", 486, 499]]], ["Four representative spectra are shown in Fig. 7 .", [["Fig", "OBSERVATION_MODIFIER", 41, 44]]], ["All illustrated compounds contain a fucose residue attached to the core GlcNAc as shown by the masses of the 2,4 A R , 2,4 A R-1 and B R-1 ions as above.", [["fucose", "CHEMICAL", 36, 42], ["GlcNAc", "CHEMICAL", 72, 78], ["GlcNAc", "GENE_OR_GENE_PRODUCT", 72, 78], ["2,4 A R , 2,4 A R-1", "SIMPLE_CHEMICAL", 109, 128], ["B R-1 ions", "SIMPLE_CHEMICAL", 133, 143], ["a fucose residue", "PROBLEM", 34, 50], ["the core GlcNAc", "TREATMENT", 63, 78], ["the masses", "TEST", 91, 101], ["fucose residue", "OBSERVATION", 36, 50], ["masses", "OBSERVATION", 95, 101]]], ["The spectrum of the biantennary glycan lacking both galactose residues (10, Fig. 7a ) contained D and [D-18] \u2212 ions at m/z 526 and 508, respectively, consistent with the absence of galactose in the 6-antenna.", [["galactose", "CHEMICAL", 52, 61], ["galactose", "CHEMICAL", 181, 190], ["galactose", "CHEMICAL", 52, 61], ["galactose", "CHEMICAL", 181, 190], ["galactose", "SIMPLE_CHEMICAL", 52, 61], ["D", "SIMPLE_CHEMICAL", 96, 97], ["[D-18] \u2212 ions", "SIMPLE_CHEMICAL", 102, 115], ["galactose", "SIMPLE_CHEMICAL", 181, 190], ["the biantennary glycan", "TREATMENT", 16, 38], ["both galactose residues", "TREATMENT", 47, 70], ["galactose", "TREATMENT", 181, 190]]], ["The C 1 ion was at m/ z 220 showing GlcNAc at the non-reducing terminus.", [["GlcNAc", "CHEMICAL", 36, 42], ["C 1", "GENE_OR_GENE_PRODUCT", 4, 7], ["GlcNAc", "GENE_OR_GENE_PRODUCT", 36, 42], ["non-reducing terminus", "PROTEIN", 50, 71], ["GlcNAc", "PROBLEM", 36, 42], ["non-reducing terminus", "OBSERVATION", 50, 71]]], ["Addition of one galactose residue ( Fig. 7b ) produced a mixed spectrum of glycans with the galactose attached to either antenna (15) as shown by the two pairs of D and [D-18] \u2212 ions at m/z 526/508 (major isomer) and at m/z 688/670.", [["galactose", "CHEMICAL", 16, 25], ["galactose", "CHEMICAL", 92, 101], ["galactose", "CHEMICAL", 16, 25], ["galactose", "CHEMICAL", 92, 101], ["galactose", "SIMPLE_CHEMICAL", 16, 25], ["galactose", "SIMPLE_CHEMICAL", 92, 101], ["D", "SIMPLE_CHEMICAL", 163, 164], ["[D-18] \u2212 ions", "SIMPLE_CHEMICAL", 169, 182], ["one galactose residue", "TREATMENT", 12, 33], ["a mixed spectrum of glycans", "TREATMENT", 55, 82], ["the galactose", "TREATMENT", 88, 101], ["galactose residue", "OBSERVATION", 16, 33]]], ["Two C 1 ions at m/z 179 and 220 confirmed both hexose (galactose) and GlcNAc, respectively, at the non-reducing terminus.", [["hexose", "CHEMICAL", 47, 53], ["galactose", "CHEMICAL", 55, 64], ["hexose", "CHEMICAL", 47, 53], ["galactose", "CHEMICAL", 55, 64], ["GlcNAc", "CHEMICAL", 70, 76], ["hexose", "SIMPLE_CHEMICAL", 47, 53], ["galactose", "SIMPLE_CHEMICAL", 55, 64], ["GlcNAc", "SIMPLE_CHEMICAL", 70, 76], ["non-reducing terminus", "PROTEIN", 99, 120], ["GlcNAc", "TEST", 70, 76], ["terminus", "OBSERVATION_MODIFIER", 112, 120]]], ["The 1,3 A 3 ion at m/z 424 was consistent with the presence of a Gal-GlcNAc-containing antenna.Complex glycansMost of the other spectra from the glycans containing low galactose were of mixtures.", [["Gal-GlcNAc", "CHEMICAL", 65, 75], ["galactose", "CHEMICAL", 168, 177], ["Gal-GlcNAc", "CHEMICAL", 65, 75], ["galactose", "CHEMICAL", 168, 177], ["1,3 A 3 ion", "SIMPLE_CHEMICAL", 4, 15], ["Gal-GlcNAc", "SIMPLE_CHEMICAL", 65, 75], ["galactose", "SIMPLE_CHEMICAL", 168, 177], ["Gal-GlcNAc-containing antenna", "PROTEIN", 65, 94], ["a Gal-GlcNAc-containing antenna", "TREATMENT", 63, 94], ["consistent with", "UNCERTAINTY", 31, 46], ["glycans", "OBSERVATION", 103, 110]]], ["They were interpreted by postulation of the expected ions, based on the structures of the identified fully galactosylated compounds and finding the relevant diagnostic ions in the spectra.", [["fully galactosylated compounds", "PROBLEM", 101, 131], ["galactosylated compounds", "OBSERVATION", 107, 131]]], ["Thus, the spectrum of the compounds having the composition Man 3 GlcNAc 5 Fuc 1 (17, Fig. 7c ) would be expected to contain contributions from the bisected biantennary glycan and the triantennary glycan, both lacking galactose.", [["Man 3 GlcNAc 5 Fuc 1", "CHEMICAL", 59, 79], ["galactose", "CHEMICAL", 217, 226], ["GlcNAc", "CHEMICAL", 65, 71], ["galactose", "CHEMICAL", 217, 226], ["biantennary glycan", "GENE_OR_GENE_PRODUCT", 156, 174], ["galactose", "SIMPLE_CHEMICAL", 217, 226], ["the triantennary glycan", "TREATMENT", 179, 202]]], ["The spectrum contained a prominent ion at m/z 507 at the expected mass of the E ion from the triantennary glycan lacking galactose and D and [D-18] \u2212 ions at m/z 526/508 from the 6-antenna.", [["galactose", "CHEMICAL", 121, 130], ["galactose", "CHEMICAL", 121, 130], ["D", "CHEMICAL", 135, 136], ["galactose", "SIMPLE_CHEMICAL", 121, 130], ["D", "SIMPLE_CHEMICAL", 135, 136], ["[D-18] \u2212 ions", "SIMPLE_CHEMICAL", 141, 154], ["a prominent ion at m/z", "PROBLEM", 23, 45], ["prominent", "OBSERVATION_MODIFIER", 25, 34], ["mass", "OBSERVATION", 66, 70]]], ["The enhanced relative abundance of the ion at m/z 508 suggested the presence of a small amount of the bisected biantennary glycan, this ion corresponding to [D-221] \u2212 .", [["[D-221] \u2212", "CHEMICAL", 157, 166], ["[D-221] \u2212", "SIMPLE_CHEMICAL", 157, 166], ["a small amount of the bisected biantennary glycan", "PROBLEM", 80, 129], ["abundance", "OBSERVATION_MODIFIER", 22, 31], ["small", "OBSERVATION_MODIFIER", 82, 87], ["amount", "OBSERVATION_MODIFIER", 88, 94], ["biantennary glycan", "OBSERVATION", 111, 129]]], ["The two compounds (24) producing the spectrum in Fig. 7d were the degalactosylated tetra-antennary glycan and the bisected triantennary compound.", [["the degalactosylated tetra-antennary glycan", "TREATMENT", 62, 105], ["the bisected triantennary compound", "PROBLEM", 110, 144], ["two", "OBSERVATION_MODIFIER", 4, 7], ["compounds", "OBSERVATION_MODIFIER", 8, 17]]], ["The former compound produced the characteristic D, [D-18]Effect of NB-DNJ against SARS-CoV infection-Following infection with SARS-CoV (strain Tor2, MOI = 10 \u22124 ) and incubation with the iminosugar inhibitor NB-DNJ, the integrity of the Vero E6 cell monolayer was monitored daily by light microscopy.", [["cell monolayer", "ANATOMY", 245, 259], ["NB-DNJ", "CHEMICAL", 67, 73], ["SARS-CoV infection", "DISEASE", 82, 100], ["infection", "DISEASE", 111, 120], ["SARS", "DISEASE", 126, 130], ["iminosugar", "CHEMICAL", 187, 197], ["NB-DNJ", "CHEMICAL", 208, 214], ["iminosugar", "CHEMICAL", 187, 197], ["NB-DNJ", "CHEMICAL", 208, 214], ["D", "SIMPLE_CHEMICAL", 48, 49], ["[D-18]", "SIMPLE_CHEMICAL", 51, 57], ["NB-DNJ", "SIMPLE_CHEMICAL", 67, 73], ["SARS-CoV", "ORGANISM", 82, 90], ["SARS-CoV", "ORGANISM", 126, 134], ["iminosugar", "SIMPLE_CHEMICAL", 187, 197], ["NB-DNJ", "SIMPLE_CHEMICAL", 208, 214], ["Vero E6 cell monolayer", "CELL", 237, 259], ["Vero E6 cell monolayer", "CELL_LINE", 237, 259], ["SARS-CoV", "SPECIES", 82, 90], ["SARS-CoV", "SPECIES", 126, 134], ["Vero E6", "SPECIES", 237, 244], ["NB", "TREATMENT", 67, 69], ["DNJ", "TREATMENT", 70, 73], ["SARS", "PROBLEM", 82, 86], ["CoV infection", "PROBLEM", 87, 100], ["infection", "PROBLEM", 111, 120], ["SARS", "PROBLEM", 126, 130], ["CoV (strain Tor2", "TREATMENT", 131, 147], ["MOI", "TEST", 149, 152], ["the iminosugar inhibitor NB", "TREATMENT", 183, 210], ["the Vero E6 cell monolayer", "TEST", 233, 259], ["light microscopy", "TEST", 283, 299], ["CoV", "ANATOMY", 87, 90], ["infection", "OBSERVATION", 91, 100], ["Vero", "ANATOMY", 237, 241], ["E6 cell monolayer", "OBSERVATION", 242, 259]]], ["At NB-DNJ concentrations of 100 \u00b5g/mL and above, the cell monolayer remained intact and showed no signs of virally-induced cytopathic effects (CPE).", [["cell monolayer", "ANATOMY", 53, 67], ["NB-DNJ", "CHEMICAL", 3, 9], ["NB-DNJ", "SIMPLE_CHEMICAL", 3, 9], ["cell monolayer", "CELL", 53, 67], ["DNJ concentrations", "TREATMENT", 6, 24], ["the cell monolayer", "TEST", 49, 67], ["virally-induced cytopathic effects", "PROBLEM", 107, 141], ["cell monolayer", "OBSERVATION", 53, 67], ["intact", "OBSERVATION", 77, 83], ["no signs of", "UNCERTAINTY", 95, 106], ["cytopathic", "OBSERVATION_MODIFIER", 123, 133]]], ["However, no significant toxicity was seen at this drug concentration as shown by the XTT assay (data not shown).", [["toxicity", "DISEASE", 24, 32], ["XTT", "CHEMICAL", 85, 88], ["significant toxicity", "PROBLEM", 12, 32], ["the XTT assay", "TEST", 81, 94], ["no", "UNCERTAINTY", 9, 11], ["significant", "OBSERVATION_MODIFIER", 12, 23], ["toxicity", "OBSERVATION", 24, 32]]], ["Fig. 8b shows the NP-HPLC profile of the N-glycans from the spike protein that was obtained in the presence of NB-DNJ at 100 \u00b5g/mL, the concentration that protected the cells against CPE.", [["cells", "ANATOMY", 169, 174], ["NB-DNJ", "CHEMICAL", 111, 117], ["NB-DNJ", "CHEMICAL", 111, 117], ["NB-DNJ", "SIMPLE_CHEMICAL", 111, 117], ["cells", "CELL", 169, 174], ["spike protein", "PROTEIN", 60, 73], ["the NP", "TEST", 14, 20], ["the spike protein", "TEST", 56, 73], ["NB", "TREATMENT", 111, 113], ["DNJ", "TREATMENT", 114, 117], ["CPE", "PROBLEM", 183, 186]]], ["The glycans of higher molecular weight than were observed in the sample without NB-DNJ were identified by HPLC and exoglycosidase digestion (A. ureafaciens sialidase, bovine testis \u03b2-galactosidase S. pneumonia N-acetyl-hexosaminidase, Jack bean \u03b1-mannosidase and bovine kidney \u03b1fucosidase) as Glc 3 Man 7 GlcNAc 2 , Glc 3 Man 8 GlcNAc 2 and Glc 3 Man 9 GlcNAc 2 showing that NB-DNJ at the concentration used (100 \u00b5g/mL) was able to partially inhibit glycan processing by blocking the first stage, namely removal of the terminal glucose residues from the 3-antenna. \u03b1-Mannosidase was, however, still able to remove the outer mannose residues from the 6-antenna to give the observed compounds.", [["sample", "ANATOMY", 65, 71], ["kidney", "ANATOMY", 270, 276], ["Glc 3 Man 9 GlcNAc", "CHEMICAL", 341, 359], ["NB-DNJ", "CHEMICAL", 375, 381], ["glucose", "CHEMICAL", 528, 535], ["\u03b1-Mannosidase", "CHEMICAL", 565, 578], ["NB-DNJ", "CHEMICAL", 80, 86], ["N-acetyl", "CHEMICAL", 210, 218], ["Glc", "CHEMICAL", 293, 296], ["GlcNAc", "CHEMICAL", 305, 311], ["Glc", "CHEMICAL", 316, 319], ["GlcNAc", "CHEMICAL", 328, 334], ["Glc", "CHEMICAL", 341, 344], ["GlcNAc", "CHEMICAL", 353, 359], ["NB-DNJ", "CHEMICAL", 375, 381], ["glucose", "CHEMICAL", 528, 535], ["mannose", "CHEMICAL", 624, 631], ["NB-DNJ", "SIMPLE_CHEMICAL", 80, 86], ["exoglycosidase", "SIMPLE_CHEMICAL", 115, 129], ["A. ureafaciens sialidase", "ORGANISM", 141, 165], ["bovine", "ORGANISM", 167, 173], ["testis", "ORGAN", 174, 180], ["N-acetyl-hexosaminidase", "GENE_OR_GENE_PRODUCT", 210, 233], ["Jack bean", "ORGANISM", 235, 244], ["\u03b1-mannosidase", "SIMPLE_CHEMICAL", 245, 258], ["bovine", "ORGANISM", 263, 269], ["kidney", "ORGAN", 270, 276], ["Glc 3 Man 7 GlcNAc 2", "GENE_OR_GENE_PRODUCT", 293, 313], ["Glc 3 Man 8 GlcNAc 2", "GENE_OR_GENE_PRODUCT", 316, 336], ["Glc 3 Man 9 GlcNAc 2", "GENE_OR_GENE_PRODUCT", 341, 361], ["NB-DNJ", "SIMPLE_CHEMICAL", 375, 381], ["glucose", "SIMPLE_CHEMICAL", 528, 535], ["\u03b1-Mannosidase", "SIMPLE_CHEMICAL", 565, 578], ["bovine testis \u03b2-galactosidase S. pneumonia N-acetyl-hexosaminidase, Jack bean \u03b1-mannosidase", "PROTEIN", 167, 258], ["bovine kidney \u03b1fucosidase", "PROTEIN", 263, 288], ["A. ureafaciens", "SPECIES", 141, 155], ["bovine", "SPECIES", 167, 173], ["S. pneumonia", "SPECIES", 197, 209], ["bean", "SPECIES", 240, 244], ["bovine", "SPECIES", 263, 269], ["A. ureafaciens", "SPECIES", 141, 155], ["bovine", "SPECIES", 167, 173], ["Jack bean", "SPECIES", 235, 244], ["HPLC", "TEST", 106, 110], ["exoglycosidase digestion", "PROBLEM", 115, 139], ["sialidase", "TEST", 156, 165], ["bovine testis", "TEST", 167, 180], ["\u03b2-galactosidase", "TEST", 181, 196], ["pneumonia", "PROBLEM", 200, 209], ["acetyl", "TREATMENT", 212, 218], ["hexosaminidase", "TREATMENT", 219, 233], ["Jack bean \u03b1-mannosidase", "TREATMENT", 235, 258], ["bovine kidney \u03b1fucosidase", "TEST", 263, 288], ["Glc", "TEST", 293, 296], ["GlcNAc", "TEST", 305, 311], ["Glc", "TEST", 316, 319], ["GlcNAc", "TEST", 328, 334], ["Glc", "TEST", 341, 344], ["GlcNAc", "TEST", 353, 359], ["NB", "TEST", 375, 377], ["removal", "TREATMENT", 504, 511], ["the terminal glucose residues", "TREATMENT", 515, 544], ["Mannosidase", "TREATMENT", 567, 578], ["the outer mannose residues", "TREATMENT", 614, 640], ["pneumonia", "OBSERVATION", 200, 209], ["kidney", "ANATOMY", 270, 276], ["terminal", "OBSERVATION_MODIFIER", 519, 527], ["glucose residues", "OBSERVATION", 528, 544]]], ["Although processing of the 3antenna was blocked, complex glycans were still found in the profile.", [["3antenna", "DNA", 27, 35], ["complex glycans", "PROBLEM", 49, 64]]], ["The most likely reason would be the presence of an endo-mannosidase that was able to split off Glc 3 Man from the 3-antenna.", [["Glc", "CHEMICAL", 95, 98], ["Glc", "CHEMICAL", 95, 98], ["endo-mannosidase", "GENE_OR_GENE_PRODUCT", 51, 67], ["Glc 3 Man", "GENE_OR_GENE_PRODUCT", 95, 104], ["endo-mannosidase", "PROTEIN", 51, 67], ["Glc 3 Man", "PROTEIN", 95, 104], ["an endo-mannosidase", "TREATMENT", 48, 67], ["Glc", "TEST", 95, 98], ["most likely", "UNCERTAINTY", 4, 15]]], ["Such an enzyme has been reported from rats (Lubas and Spiro, 1987; Lubas and Spiro, 1988; Moore and Spiro, 1990 ) but there appears to be no information on its possible occurrence in the African green monkey.", [["rats", "ORGANISM", 38, 42], ["green monkey", "ORGANISM", 195, 207], ["rats", "SPECIES", 38, 42], ["green monkey", "SPECIES", 195, 207], ["African green monkey", "SPECIES", 187, 207], ["an enzyme", "TEST", 5, 14]]], ["However, the high abundance of the peak labelled as 29 in Fig. 8b is accounted for by the isomer of Man 8 GlcNAc 2 that has lost a mannose residue from the 3-antenna (same GU value as the fucosylated triantennary glycan) supporting this proposal.Effect of NB-DNJ treatment on N-glycan profiles-Although the postulated endomannosidase activity permits extensive N-glycan processing with the production of complex glycans and a nearly normal profile in the presence of NB-DNJ, the drug prevents formation of the mono-glucosylated N-glycans that are necessary for binding to the chaperones calnexin and calreticulin that are essential for correct protein folding.", [["Man 8 GlcNAc 2", "CHEMICAL", 100, 114], ["NB-DNJ", "CHEMICAL", 256, 262], ["NB-DNJ", "CHEMICAL", 467, 473], ["GlcNAc", "CHEMICAL", 106, 112], ["mannose", "CHEMICAL", 131, 138], ["NB-DNJ", "CHEMICAL", 256, 262], ["NB-DNJ", "CHEMICAL", 467, 473], ["N", "CHEMICAL", 528, 529], ["Man 8 GlcNAc 2", "GENE_OR_GENE_PRODUCT", 100, 114], ["NB-DNJ", "SIMPLE_CHEMICAL", 256, 262], ["endomannosidase", "GENE_OR_GENE_PRODUCT", 318, 333], ["NB-DNJ", "SIMPLE_CHEMICAL", 467, 473], ["calnexin", "GENE_OR_GENE_PRODUCT", 587, 595], ["calreticulin", "GENE_OR_GENE_PRODUCT", 600, 612], ["fucosylated triantennary glycan", "PROTEIN", 188, 219], ["endomannosidase", "PROTEIN", 318, 333], ["mono-glucosylated N-glycans", "PROTEIN", 510, 537], ["calnexin", "PROTEIN", 587, 595], ["calreticulin", "PROTEIN", 600, 612], ["a mannose residue", "PROBLEM", 129, 146], ["the fucosylated triantennary glycan", "TREATMENT", 184, 219], ["NB", "TREATMENT", 256, 258], ["DNJ treatment", "TREATMENT", 259, 272], ["N-glycan profiles", "TEST", 276, 293], ["the postulated endomannosidase activity", "PROBLEM", 303, 342], ["extensive N-glycan processing", "PROBLEM", 351, 380], ["complex glycans", "PROBLEM", 404, 419], ["DNJ", "TREATMENT", 470, 473], ["the mono-glucosylated N-glycans", "TREATMENT", 506, 537], ["the chaperones calnexin", "TREATMENT", 572, 595], ["correct protein folding", "PROBLEM", 636, 659], ["high", "OBSERVATION_MODIFIER", 13, 17], ["abundance", "OBSERVATION_MODIFIER", 18, 27], ["mannose residue", "OBSERVATION", 131, 146]]], ["Viral surface glycoproteins are dependent on such an interaction for correct folding (Vigerust and Shepherd, 2007) .", [["surface", "ANATOMY", 6, 13], ["Viral surface glycoproteins", "PROTEIN", 0, 27], ["Viral surface glycoproteins", "PROBLEM", 0, 27], ["surface glycoproteins", "OBSERVATION", 6, 27]]], ["Thus, \u03b1-glucosidase inhibition will prevent this interaction and potentially lead to regional or global glycoprotein misfolding.", [["\u03b1-glucosidase", "CHEMICAL", 6, 19], ["\u03b1-glucosidase", "GENE_OR_GENE_PRODUCT", 6, 19], ["\u03b1-glucosidase", "PROTEIN", 6, 19], ["\u03b1-glucosidase inhibition", "TREATMENT", 6, 30], ["regional or global glycoprotein misfolding", "PROBLEM", 85, 127], ["global", "OBSERVATION_MODIFIER", 97, 103], ["glycoprotein misfolding", "OBSERVATION", 104, 127]]], ["Therefore, the observation that the SARS-CoV S glycoprotein can undergo extensive N-glycan processing to complex structures in the presence of NB-DNJ does not necessarily correlate with proper glycoprotein folding.", [["NB-DNJ", "ANATOMY", 143, 149], ["SARS", "DISEASE", 36, 40], ["NB-DNJ", "CHEMICAL", 143, 149], ["SARS-CoV S glycoprotein", "GENE_OR_GENE_PRODUCT", 36, 59], ["NB-DNJ", "GENE_OR_GENE_PRODUCT", 143, 149], ["SARS-CoV S glycoprotein", "PROTEIN", 36, 59], ["DNJ", "PROTEIN", 146, 149], ["glycoprotein", "PROTEIN", 193, 205], ["SARS-CoV", "SPECIES", 36, 44], ["the observation", "TEST", 11, 26], ["the SARS", "PROBLEM", 32, 40], ["CoV S glycoprotein", "TREATMENT", 41, 59], ["extensive N-glycan processing", "TREATMENT", 72, 101], ["NB", "OBSERVATION", 143, 145], ["glycoprotein folding", "OBSERVATION", 193, 213]]], ["Unfortunately, the necessary conformationally sensitive anti-SARS-CoV S antibodies for testing this conclusion were not available at the time this study was performed.", [["S antibodies", "GENE_OR_GENE_PRODUCT", 70, 82], ["anti-SARS-CoV", "PROTEIN", 56, 69], ["S antibodies", "PROTEIN", 70, 82], ["S antibodies", "TEST", 70, 82], ["testing", "TEST", 87, 94], ["this study", "TEST", 142, 152]]], ["Improper folding induced by NB-DNJ could explain the protective effect of the drug towards viral infection but the ability to retain complex N-glycan processing could contribute to the drug's low cytotoxicity.ConclusionsThis study is the first to describe fully the range of N-glycans present on the SARS-CoV spike glycoprotein.", [["NB-DNJ", "CHEMICAL", 28, 34], ["viral infection", "DISEASE", 91, 106], ["NB-DNJ", "CHEMICAL", 28, 34], ["N", "CHEMICAL", 141, 142], ["NB-DNJ", "SIMPLE_CHEMICAL", 28, 34], ["SARS-CoV spike glycoprotein", "GENE_OR_GENE_PRODUCT", 300, 327], ["SARS-CoV spike glycoprotein", "PROTEIN", 300, 327], ["SARS-CoV", "SPECIES", 300, 308], ["Improper folding", "PROBLEM", 0, 16], ["the drug", "TREATMENT", 74, 82], ["viral infection", "PROBLEM", 91, 106], ["complex N-glycan processing", "PROBLEM", 133, 160], ["the drug's low cytotoxicity", "PROBLEM", 181, 208], ["This study", "TEST", 220, 230], ["the SARS", "TEST", 296, 304], ["infection", "OBSERVATION", 97, 106]]], ["They consisted mainly of high-mannose (Man 5-9 GlcNAc 2 , about 30% of the total glycans), hybrid (28%) and bi-, tri-and tetra-antennary complex glycans (42%) with and without both bisecting GlcNAc and core fucose.", [["Man 5-9 GlcNAc", "CHEMICAL", 39, 53], ["mannose", "CHEMICAL", 30, 37], ["GlcNAc", "CHEMICAL", 47, 53], ["GlcNAc", "CHEMICAL", 191, 197], ["fucose", "CHEMICAL", 207, 213], ["high-mannose", "SIMPLE_CHEMICAL", 25, 37], ["GlcNAc", "GENE_OR_GENE_PRODUCT", 191, 197], ["core fucose", "SIMPLE_CHEMICAL", 202, 213], ["GlcNAc", "TEST", 47, 53], ["hybrid", "TEST", 91, 97], ["bi-", "TEST", 108, 111], ["high", "OBSERVATION_MODIFIER", 25, 29]]], ["Complex glycans with fewer than the full complement of galactose residues were present in relatively high abundance with 49% of the complex glycans carrying no galactose.", [["galactose", "CHEMICAL", 55, 64], ["galactose", "CHEMICAL", 160, 169], ["galactose", "CHEMICAL", 55, 64], ["galactose", "CHEMICAL", 160, 169], ["galactose", "SIMPLE_CHEMICAL", 55, 64], ["galactose", "SIMPLE_CHEMICAL", 160, 169], ["Complex glycans", "PROBLEM", 0, 15], ["galactose residues", "PROBLEM", 55, 73], ["glycans", "OBSERVATION", 8, 15]]], ["Sialylation was negligible.", [["negligible", "OBSERVATION_MODIFIER", 16, 26]]], ["No evidence was found for glycans with N-acetyllactosamine extensions or with fucose attached to an antenna.", [["N-acetyllactosamine", "CHEMICAL", 39, 58], ["fucose", "CHEMICAL", 78, 84], ["N-acetyllactosamine", "CHEMICAL", 39, 58], ["fucose", "CHEMICAL", 78, 84], ["N-acetyllactosamine", "SIMPLE_CHEMICAL", 39, 58], ["fucose", "SIMPLE_CHEMICAL", 78, 84], ["glycans", "PROBLEM", 26, 33], ["N-acetyllactosamine extensions", "TREATMENT", 39, 69], ["fucose", "TREATMENT", 78, 84], ["an antenna", "TREATMENT", 97, 107]]], ["The relatively high abundance of complex glycans lacking one or more of the normal galactose residues might indicate the involvement of the lectin, LSECtin in viral binding, as recently found for Ebola virus (Powlesland et al., 2008) .ConclusionsTreatment with the glucosidase inhibitor NB-DNJ inhibited N-glycan processing as evidenced by the appearance in the profiles of glycans of composition Glc 3 Man 7-9 GlcNAc 2 .", [["galactose", "CHEMICAL", 83, 92], ["Ebola virus", "DISEASE", 196, 207], ["NB-DNJ", "CHEMICAL", 287, 293], ["N-glycan", "CHEMICAL", 304, 312], ["Glc 3 Man 7-9 GlcNAc", "CHEMICAL", 397, 417], ["galactose", "CHEMICAL", 83, 92], ["NB-DNJ", "CHEMICAL", 287, 293], ["Glc", "CHEMICAL", 397, 400], ["GlcNAc", "CHEMICAL", 411, 417], ["lectin", "GENE_OR_GENE_PRODUCT", 140, 146], ["LSECtin", "GENE_OR_GENE_PRODUCT", 148, 155], ["Ebola virus", "ORGANISM", 196, 207], ["glucosidase", "GENE_OR_GENE_PRODUCT", 265, 276], ["NB-DNJ", "SIMPLE_CHEMICAL", 287, 293], ["N-glycan", "SIMPLE_CHEMICAL", 304, 312], ["Glc 3", "GENE_OR_GENE_PRODUCT", 397, 402], ["GlcNAc 2", "GENE_OR_GENE_PRODUCT", 411, 419], ["complex glycans", "PROTEIN", 33, 48], ["lectin", "PROTEIN", 140, 146], ["LSECtin", "PROTEIN", 148, 155], ["Ebola virus", "SPECIES", 196, 207], ["Ebola virus", "SPECIES", 196, 207], ["the involvement of the lectin", "PROBLEM", 117, 146], ["viral binding", "PROBLEM", 159, 172], ["Ebola virus", "PROBLEM", 196, 207], ["the glucosidase inhibitor NB", "TREATMENT", 261, 289], ["glycan processing", "TREATMENT", 306, 323], ["Glc", "TEST", 397, 400], ["relatively", "OBSERVATION_MODIFIER", 4, 14], ["high", "OBSERVATION_MODIFIER", 15, 19], ["abundance", "OBSERVATION_MODIFIER", 20, 29], ["complex", "OBSERVATION_MODIFIER", 33, 40], ["glycans", "OBSERVATION", 41, 48], ["galactose residues", "OBSERVATION", 83, 101], ["viral binding", "OBSERVATION", 159, 172]]], ["However, some complex glycans still appeared in the glycan profile, suggesting the presence of an \u03b1-endomannosidase that was able to hydrolyse the Glc 3 -Man 3 chain of the 3antenna allowing attachment of GlcNAc in the first step towards complex glycan biosynthesis.", [["Glc", "CHEMICAL", 147, 150], ["Glc", "CHEMICAL", 147, 150], ["GlcNAc", "CHEMICAL", 205, 211], ["\u03b1-endomannosidase", "GENE_OR_GENE_PRODUCT", 98, 115], ["Glc 3", "GENE_OR_GENE_PRODUCT", 147, 152], ["GlcNAc", "GENE_OR_GENE_PRODUCT", 205, 211], ["\u03b1-endomannosidase", "PROTEIN", 98, 115], ["Glc 3 -Man 3 chain", "PROTEIN", 147, 165], ["GlcNAc", "PROTEIN", 205, 211], ["some complex glycans", "PROBLEM", 9, 29], ["the Glc", "TEST", 143, 150], ["GlcNAc", "TREATMENT", 205, 211], ["complex", "OBSERVATION_MODIFIER", 14, 21], ["glycans", "OBSERVATION", 22, 29], ["glycan biosynthesis", "OBSERVATION", 246, 265]]], ["Protection of cells against the cytopathic effects of the virus, possibly as the result of the inhibition of glycan processing, suggests a possible use of glucosidase inhibitors to treat SARS-CoV infections.MaterialsMethanol was obtained from BDH Ltd.", [["cells", "ANATOMY", 14, 19], ["SARS-CoV infections", "DISEASE", 187, 206], ["Methanol", "CHEMICAL", 216, 224], ["Methanol", "CHEMICAL", 216, 224], ["BDH", "CHEMICAL", 243, 246], ["cells", "CELL", 14, 19], ["glucosidase", "GENE_OR_GENE_PRODUCT", 155, 166], ["SARS-CoV", "ORGANISM", 187, 195], ["Methanol", "SIMPLE_CHEMICAL", 216, 224], ["BDH Ltd", "SIMPLE_CHEMICAL", 243, 250], ["SARS-CoV", "SPECIES", 187, 195], ["Protection of cells", "TREATMENT", 0, 19], ["the cytopathic effects", "PROBLEM", 28, 50], ["the virus", "PROBLEM", 54, 63], ["the inhibition of glycan processing", "PROBLEM", 91, 126], ["glucosidase inhibitors", "TREATMENT", 155, 177], ["SARS", "PROBLEM", 187, 191], ["CoV infections", "PROBLEM", 192, 206], ["MaterialsMethanol", "TREATMENT", 207, 224], ["cytopathic", "OBSERVATION_MODIFIER", 32, 42], ["virus", "OBSERVATION", 58, 63], ["CoV infections", "OBSERVATION", 192, 206]]], ["Ammonium phosphate and 2,5dihydroxybenzoic acid (DHB) were from Aldrich Chemical Co. Ltd.", [["Ammonium phosphate", "CHEMICAL", 0, 18], ["2,5dihydroxybenzoic acid", "CHEMICAL", 23, 47], ["DHB", "CHEMICAL", 49, 52], ["Ammonium phosphate", "CHEMICAL", 0, 18], ["2,5dihydroxybenzoic acid", "CHEMICAL", 23, 47], ["DHB", "CHEMICAL", 49, 52], ["Ammonium phosphate", "SIMPLE_CHEMICAL", 0, 18], ["2,5dihydroxybenzoic acid", "SIMPLE_CHEMICAL", 23, 47], ["DHB", "SIMPLE_CHEMICAL", 49, 52], ["Ammonium phosphate", "TREATMENT", 0, 18], ["2,5dihydroxybenzoic acid (DHB", "TREATMENT", 23, 52]]], ["(Poole); water was distilled before use in a quartz apparatus.", [["a quartz apparatus", "TREATMENT", 43, 61]]], ["NB-DNJ was a gift from Monsanto Searle (St Louis, USA).Preparation of SARS-CoVAll work with infectious SARS-CoV was performed in the high biocontainment laboratory of the National Microbiology Laboratory (NML) of the Public Health Agency of Canada (PHAC).", [["NB-DNJ", "ANATOMY", 0, 6], ["SARS", "DISEASE", 70, 74], ["SARS", "DISEASE", 103, 107], ["NB-DNJ", "CELL", 0, 6], ["SARS-CoV", "ORGANISM", 103, 111], ["SARS-CoV", "SPECIES", 103, 111], ["infectious SARS", "PROBLEM", 92, 107], ["CoV", "PROBLEM", 108, 111]]], ["Vero E6 cells (ATCC CRL-1586, kidney epithelial cells derived from African green monkeys (Cercopithecus aethiops)) were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS) and subsequently infected with the Tor2 strain of the SARS-CoV (Marra et al., 2003) at an MOI of 10 \u22124 with and without the presence of different concentrations (0, 100, 500 and 1000 mg/mL) of NB-DNJ.", [["Vero E6 cells", "ANATOMY", 0, 13], ["ATCC CRL-1586", "ANATOMY", 15, 28], ["kidney epithelial cells", "ANATOMY", 30, 53], ["fetal bovine serum", "ANATOMY", 189, 207], ["FBS", "ANATOMY", 209, 212], ["NB-DNJ", "ANATOMY", 407, 413], ["CRL-1586", "CHEMICAL", 20, 28], ["SARS", "DISEASE", 268, 272], ["Vero E6 cells", "CELL", 0, 13], ["ATCC CRL-1586", "CELL", 15, 28], ["kidney epithelial cells", "CELL", 30, 53], ["African green monkeys", "ORGANISM", 67, 88], ["Cercopithecus aethiops", "ORGANISM", 90, 112], ["bovine", "ORGANISM", 195, 201], ["serum", "ORGANISM_SUBSTANCE", 202, 207], ["FBS", "ORGANISM_SUBSTANCE", 209, 212], ["Tor2", "GENE_OR_GENE_PRODUCT", 249, 253], ["SARS-CoV", "ORGANISM", 268, 276], ["NB-DNJ", "CELL", 407, 413], ["Vero E6 cells", "CELL_LINE", 0, 13], ["ATCC CRL-1586", "CELL_LINE", 15, 28], ["kidney epithelial cells", "CELL_TYPE", 30, 53], ["Vero", "SPECIES", 0, 4], ["green monkeys", "SPECIES", 75, 88], ["Cercopithecus aethiops", "SPECIES", 90, 112], ["bovine", "SPECIES", 195, 201], ["Vero E6", "SPECIES", 0, 7], ["ATCC CRL-1586", "SPECIES", 15, 28], ["African green monkeys", "SPECIES", 67, 88], ["Cercopithecus aethiops", "SPECIES", 90, 112], ["bovine", "SPECIES", 195, 201], ["SARS-CoV", "SPECIES", 268, 276], ["Vero E6 cells", "TEST", 0, 13], ["ATCC CRL", "TEST", 15, 23], ["kidney epithelial cells", "PROBLEM", 30, 53], ["African green monkeys", "TREATMENT", 67, 88], ["10% fetal bovine serum (FBS", "TEST", 185, 212], ["the SARS", "TEST", 264, 272], ["E6 cells", "OBSERVATION", 5, 13], ["kidney", "ANATOMY", 30, 36], ["epithelial cells", "OBSERVATION", 37, 53]]], ["After 1 h of virus adsorption, cells were washed 3 times and DMEM supplemented with 2% FBS (with and without NB-DNJ) was added.", [["cells", "ANATOMY", 31, 36], ["FBS", "ANATOMY", 87, 90], ["cells", "CELL", 31, 36], ["FBS", "ORGANISM_SUBSTANCE", 87, 90], ["virus adsorption", "TREATMENT", 13, 29], ["cells", "TREATMENT", 31, 36], ["2% FBS", "TREATMENT", 84, 90], ["NB-DNJ)", "TREATMENT", 109, 116]]], ["Forty-eight hours post-infection, the cell supernatant was harvested and cells were cleared by low-speed centrifugation.", [["cell supernatant", "ANATOMY", 38, 54], ["cells", "ANATOMY", 73, 78], ["cell", "CELL", 38, 42], ["cells", "CELL", 73, 78], ["the cell supernatant", "TREATMENT", 34, 54]]], ["Virus particles were pelleted through a 20% sucrose cushion at 20,000 rpm for 2 h, washed with PBS and resuspended and inactivated in 1 \u00d7 sample loading buffer with 1.5% SDS.", [["sucrose", "CHEMICAL", 44, 51], ["sucrose", "CHEMICAL", 44, 51], ["Virus", "ORGANISM", 0, 5], ["Virus particles", "PROBLEM", 0, 15], ["a 20% sucrose cushion", "TREATMENT", 38, 59], ["PBS", "TREATMENT", 95, 98], ["1 \u00d7 sample loading buffer", "TREATMENT", 134, 159]]], ["Infectivity was further inactivated by heating the specimens at 100 \u00b0C for 15 min prior to removal from high biocontainment.Assay for cellular toxicityVero E6 cells were cultured in 96-well plates in DMEM supplemented with 10% FBS.", [["specimens", "ANATOMY", 51, 60], ["cellular", "ANATOMY", 134, 142], ["Vero E6 cells", "ANATOMY", 151, 164], ["FBS", "ANATOMY", 227, 230], ["toxicity", "DISEASE", 143, 151], ["cellular", "CELL", 134, 142], ["Vero E6 cells", "CELL", 151, 164], ["FBS", "ORGANISM_SUBSTANCE", 227, 230], ["Vero E6 cells", "CELL_LINE", 151, 164], ["Vero E6", "SPECIES", 151, 158], ["removal", "TREATMENT", 91, 98], ["high biocontainment", "TREATMENT", 104, 123], ["Assay", "TEST", 124, 129], ["cellular toxicity", "PROBLEM", 134, 151], ["Vero E6 cells", "TEST", 151, 164], ["10% FBS", "TREATMENT", 223, 230], ["cellular toxicity", "OBSERVATION", 134, 151], ["E6 cells", "OBSERVATION", 156, 164]]], ["At 80% confluency the medium was removed and replaced with DMEM/2% FBS containing various concentrations (10-1000 \u00b5g/mL) of NB-DNJ, 5 wells per each concentration.", [["FBS", "ANATOMY", 67, 70], ["NB-DNJ", "CHEMICAL", 124, 130], ["FBS", "ORGANISM_SUBSTANCE", 67, 70], ["NB-DNJ", "SIMPLE_CHEMICAL", 124, 130], ["DMEM", "TREATMENT", 59, 63], ["2% FBS", "TREATMENT", 64, 70], ["various concentrations", "TREATMENT", 82, 104]]], ["Drug cytotoxicity was assessed on days 1, 2 and 3 post-treatment using the XTT metabolic assay (Roche, Laval, Canada) according to the manufacturer's directions.SDS-PAGE analysis of SARS-CoV preparationThe SARS-CoV preparation was analysed by 9% polyacrylamide gel electrophoresis (SDS-PAGE) followed by Coomassie blue staining.", [["XTT", "CHEMICAL", 75, 78], ["polyacrylamide", "CHEMICAL", 246, 260], ["Coomassie blue", "CHEMICAL", 304, 318], ["SARS-CoV", "ORGANISM", 182, 190], ["CoV", "ORGANISM", 211, 214], ["Coomassie", "SIMPLE_CHEMICAL", 304, 313], ["SARS-CoV", "SPECIES", 182, 190], ["SARS-CoV", "SPECIES", 206, 214], ["Drug cytotoxicity", "PROBLEM", 0, 17], ["treatment", "TREATMENT", 55, 64], ["the XTT metabolic assay", "TEST", 71, 94], ["SDS", "TEST", 161, 164], ["SARS", "PROBLEM", 182, 186], ["CoV preparation", "TREATMENT", 187, 202], ["The SARS-CoV preparation", "TREATMENT", 202, 226], ["9% polyacrylamide gel electrophoresis", "TREATMENT", 243, 280]]], ["The stained protein band corresponding to the SARS-CoV S glycoprotein was cut from the gel for enzymatic digestion with peptide Nglycosidase F (PNGase F, Roche Diagnostics Ltd., Basel, Switzerland) and subsequent Nglycan analysis (see below).Western blotting analysis of the SARS-CoV S glycoproteinTo confirm that the band selected for N-glycan analysis was that corresponding to the SARS-CoV S glycoprotein, an anti-SARS-CoV S antibody was used in a western blotting protocol.", [["SARS-CoV S glycoprotein", "GENE_OR_GENE_PRODUCT", 46, 69], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 275, 283], ["SARS-CoV S glycoprotein", "GENE_OR_GENE_PRODUCT", 384, 407], ["anti-SARS-CoV S antibody", "GENE_OR_GENE_PRODUCT", 412, 436], ["SARS-CoV S glycoprotein", "PROTEIN", 46, 69], ["SARS-CoV S glycoproteinTo", "PROTEIN", 275, 300], ["SARS-CoV S glycoprotein", "PROTEIN", 384, 407], ["anti-SARS-CoV S antibody", "PROTEIN", 412, 436], ["SARS-CoV", "SPECIES", 46, 54], ["SARS-CoV", "SPECIES", 275, 283], ["SARS-CoV", "SPECIES", 384, 392], ["The stained protein band", "PROBLEM", 0, 24], ["the SARS", "PROBLEM", 42, 50], ["CoV S glycoprotein", "TREATMENT", 51, 69], ["the gel", "TREATMENT", 83, 90], ["enzymatic digestion", "TREATMENT", 95, 114], ["subsequent Nglycan analysis", "TEST", 202, 229], ["blotting analysis", "TEST", 250, 267], ["the SARS", "TEST", 271, 279], ["CoV S glycoproteinTo", "TEST", 280, 300], ["the band", "TEST", 314, 322], ["N-glycan analysis", "TEST", 336, 353], ["the SARS", "TEST", 380, 388], ["an anti-SARS-CoV S antibody", "TREATMENT", 409, 436], ["protein band", "OBSERVATION", 12, 24]]], ["Briefly, the SARS-CoV preparation was subjected to SDS-PAGE on a 9% gel and the proteins were transferred to PVDF membranes using the semi-dry transfer technique.", [["PVDF membranes", "ANATOMY", 109, 123], ["SARS", "DISEASE", 13, 17], ["PVDF", "CHEMICAL", 109, 113], ["membranes", "CELLULAR_COMPONENT", 114, 123], ["SARS-CoV", "SPECIES", 13, 21], ["the SARS", "PROBLEM", 9, 17], ["CoV preparation", "TREATMENT", 18, 33], ["a 9% gel", "TREATMENT", 63, 71], ["the proteins", "TREATMENT", 76, 88], ["PVDF membranes", "TREATMENT", 109, 123], ["the semi-dry transfer technique", "TREATMENT", 130, 161]]], ["The membranes were blocked in 5% milk solution in 1 \u00d7 phosphate-buffered saline (PBS) overnight then incubated with a mouse anti-SARS IgG1 (clone 16F1071, Imgenex, CA, USA) diluted 1:1000 in 3% milk solution at room temperature for at least 1 h.", [["membranes", "ANATOMY", 4, 13], ["milk", "ANATOMY", 33, 37], ["phosphate", "CHEMICAL", 54, 63], ["phosphate", "CHEMICAL", 54, 63], ["membranes", "CELLULAR_COMPONENT", 4, 13], ["milk", "ORGANISM_SUBSTANCE", 33, 37], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 54, 79], ["mouse", "ORGANISM", 118, 123], ["IgG1", "GENE_OR_GENE_PRODUCT", 134, 138], ["clone", "ORGANISM", 140, 145], ["milk", "ORGANISM_SUBSTANCE", 194, 198], ["mouse anti-SARS IgG1", "PROTEIN", 118, 138], ["mouse", "SPECIES", 118, 123], ["mouse", "SPECIES", 118, 123], ["5% milk solution", "TREATMENT", 30, 46], ["1 \u00d7 phosphate", "TREATMENT", 50, 63], ["buffered saline (PBS", "TREATMENT", 64, 84], ["a mouse anti-SARS IgG1", "TREATMENT", 116, 138]]], ["The membranes were washed three times in PBS-0.05% Tween-20 before 1 h incubation at room temperature with a horseradish peroxidase(HRP)-conjugated goat anti-mouse secondary antibody (Sigma Chemicals) diluted 1:1000 in 3% milk solution.", [["membranes", "ANATOMY", 4, 13], ["Tween-20", "CHEMICAL", 51, 59], ["Tween-20", "CHEMICAL", 51, 59], ["membranes", "CELLULAR_COMPONENT", 4, 13], ["Tween-20", "SIMPLE_CHEMICAL", 51, 59], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 109, 131], ["HRP", "SIMPLE_CHEMICAL", 132, 135], ["goat", "ORGANISM", 148, 152], ["Sigma Chemicals", "SIMPLE_CHEMICAL", 184, 199], ["milk", "ORGANISM_SUBSTANCE", 222, 226], ["horseradish peroxidase(HRP)-conjugated goat anti-mouse secondary antibody", "PROTEIN", 109, 182], ["horseradish", "SPECIES", 109, 120], ["goat", "SPECIES", 148, 152], ["anti-mouse", "SPECIES", 153, 163], ["goat", "SPECIES", 148, 152], ["The membranes", "TREATMENT", 0, 13], ["a horseradish peroxidase(HRP", "TREATMENT", 107, 135], ["conjugated goat anti-mouse secondary antibody (Sigma Chemicals)", "TREATMENT", 137, 200]]], ["The membranes were washed three times in PBS-0.05% Tween-20, then once with PBS.", [["membranes", "ANATOMY", 4, 13], ["Tween-20", "CHEMICAL", 51, 59], ["Tween-20", "CHEMICAL", 51, 59], ["membranes", "CELLULAR_COMPONENT", 4, 13], ["Tween-20", "SIMPLE_CHEMICAL", 51, 59], ["The membranes", "TREATMENT", 0, 13], ["PBS", "TREATMENT", 76, 79]]], ["The SARS-CoV glycoprotein band was detected by developing the membranes using the ECL Western blotting detection kit (Amersham Biosciences, Little Chalfont, UK) according to the manufacturers instructions and followed by exposure to X-ray film (CL-X Posure film, Pierce).N-glycan release using peptide N-glycosidase FThe procedure essentially followed that described by K\u00fcster et al. (1997) .", [["membranes", "ANATOMY", 62, 71], ["N-glycan", "CHEMICAL", 271, 279], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 4, 12], ["membranes", "CELLULAR_COMPONENT", 62, 71], ["SARS-CoV glycoprotein band", "PROTEIN", 4, 30], ["SARS-CoV", "SPECIES", 4, 12], ["The SARS-CoV glycoprotein band", "TREATMENT", 0, 30], ["X-ray film", "TEST", 233, 243], ["CL", "TEST", 245, 247], ["glycan release", "TREATMENT", 273, 287], ["peptide N", "TREATMENT", 294, 303], ["glycosidase FThe procedure", "TREATMENT", 304, 330]]], ["The glycoproteins were separated by SDS-PAGE with a BioRad Mini-Protean II apparatus with 80 \u00d7 80 \u00d7 0.75 mm plates and a 9% resolving gel.", [["The glycoproteins", "TREATMENT", 0, 17], ["mm plates", "TEST", 105, 114]]], ["Developed gels were stained with Coomassie Blue R-250.", [["Coomassie Blue R-250", "CHEMICAL", 33, 53], ["Coomassie Blue", "CHEMICAL", 33, 47], ["Coomassie Blue R-250", "SIMPLE_CHEMICAL", 33, 53], ["Coomassie Blue R-250", "SPECIES", 33, 53], ["Coomassie Blue", "TEST", 33, 47]]], ["The SARS-CoV S glycoprotein gel bands were excised from the gel and cut into pieces about 1 mm 2 , washed with 300 \u00b5L 20 mM NaHCO 3 (BDH Limited, Poole, UK) and soaked in the buffer for 30 min.", [["NaHCO 3", "CHEMICAL", 124, 131], ["NaHCO 3", "CHEMICAL", 124, 131], ["BDH", "CHEMICAL", 133, 136], ["SARS-CoV", "SPECIES", 4, 12], ["The SARS-CoV S glycoprotein gel bands", "TREATMENT", 0, 37], ["20 mM NaHCO", "TREATMENT", 118, 129]]], ["This procedure was repeated twice; on the third wash, 45 mM dithiothreitol (20 \u00b5L) was added and incubated for 30 min at 60 \u00b0C to reduce disulfide bonds.", [["dithiothreitol", "CHEMICAL", 60, 74], ["dithiothreitol", "CHEMICAL", 60, 74], ["disulfide", "CHEMICAL", 137, 146], ["dithiothreitol", "SIMPLE_CHEMICAL", 60, 74], ["This procedure", "TREATMENT", 0, 14], ["the third wash", "TREATMENT", 38, 52], ["45 mM dithiothreitol (20 \u00b5L)", "TREATMENT", 54, 82], ["disulfide bonds", "OBSERVATION", 137, 152]]], ["Iodoacetamide (100 mM; 20 \u00b5L) was added and the solution was incubated for 30 min in the dark.", [["Iodoacetamide", "CHEMICAL", 0, 13], ["Iodoacetamide", "CHEMICAL", 0, 13], ["Iodoacetamide", "SIMPLE_CHEMICAL", 0, 13], ["Iodoacetamide", "TREATMENT", 0, 13], ["the solution", "TREATMENT", 44, 56]]], ["Then a 1:1 (v/v) solution (300 \u00b5L) of aqueous acetonitrile:20 mM NaHCO 3 , pH 7.0, was added and incubated for 60 min followed by vacuum drying.", [["aqueous acetonitrile", "CHEMICAL", 38, 58], ["NaHCO", "CHEMICAL", 65, 70], ["acetonitrile", "CHEMICAL", 46, 58], ["NaHCO 3", "CHEMICAL", 65, 72], ["NaHCO 3", "SIMPLE_CHEMICAL", 65, 72], ["a 1:1 (v/v) solution", "TREATMENT", 5, 25], ["aqueous acetonitrile", "TREATMENT", 38, 58], ["20 mM NaHCO", "TREATMENT", 59, 70], ["pH", "TEST", 75, 77], ["vacuum drying", "TREATMENT", 130, 143]]], ["PNGase F (EC 3.2.2.18, 30 mL, 100 U/mL; Roche Diagnostics Ltd.) and NaHCO 3 buffer (enough to cover the gel, 70-100 \u00b5L) was added to the dried gel pieces which were incubated at 37 \u00b0C for 12-16 h (overnight).", [["NaHCO 3", "CHEMICAL", 68, 75], ["PNGase F", "GENE_OR_GENE_PRODUCT", 0, 8], ["NaHCO 3 buffer", "TREATMENT", 68, 82], ["the gel", "TREATMENT", 100, 107], ["the dried gel pieces", "TREATMENT", 133, 153]]], ["The supernatant was retained and the gel was washed twice with water (200 \u00b5L), and then with acetonitrile (200 \u00b5L, Riedel de H\u00e4en Laboratory, Seelze, Germany); the washes were collected and desalted by incubation with 50 \u00b5L H + -activated AG-50, then centrifuged.", [["supernatant", "ANATOMY", 4, 15], ["acetonitrile", "CHEMICAL", 93, 105], ["H", "CHEMICAL", 224, 225], ["AG-50", "CHEMICAL", 239, 244], ["acetonitrile", "CHEMICAL", 93, 105], ["acetonitrile", "SIMPLE_CHEMICAL", 93, 105], ["AG-50", "SIMPLE_CHEMICAL", 239, 244], ["The supernatant", "TREATMENT", 0, 15], ["the gel", "TREATMENT", 33, 40], ["acetonitrile", "TREATMENT", 93, 105], ["the washes", "TREATMENT", 160, 170], ["-activated AG", "TEST", 228, 241]]], ["The supernatant was filtered through 0.45 \u00b5m Millipore LH hydrophilic PTFE syringe-tip filter then vacuum dried in preparation for direct mass spectrometric analysis or 2-aminobenzamide (2AB) labelling followed by HPLC analysis.", [["supernatant", "ANATOMY", 4, 15], ["2-aminobenzamide", "CHEMICAL", 169, 185], ["2AB", "CHEMICAL", 187, 190], ["PTFE", "CHEMICAL", 70, 74], ["2-aminobenzamide", "CHEMICAL", 169, 185], ["2AB", "CHEMICAL", 187, 190], ["2-aminobenzamide", "SIMPLE_CHEMICAL", 169, 185], ["2AB", "SIMPLE_CHEMICAL", 187, 190], ["The supernatant", "TREATMENT", 0, 15], ["0.45 \u00b5m Millipore LH hydrophilic PTFE syringe", "TREATMENT", 37, 82], ["tip filter", "TREATMENT", 83, 93], ["vacuum dried", "TREATMENT", 99, 111], ["direct mass spectrometric analysis", "TEST", 131, 165], ["aminobenzamide (2AB) labelling", "TREATMENT", 171, 201], ["HPLC analysis", "TEST", 214, 227], ["tip filter", "OBSERVATION", 83, 93]]], ["Samples for mass spectrometric analysis were further cleaned by drop dialysis with a Nafion 117 membrane (B\u00f6rnsen et al., 1995) .Glycan derivatisation with 2-aminobenzamideGlycans were labelled with 2AB by reductive amination (Bigge et al., 1995) using a 2AB labelling kit from Glyko (now part of Prozyme at Hayward, CA, USA).", [["Nafion 117", "CHEMICAL", 85, 95], ["Glycan", "CHEMICAL", 129, 135], ["2-aminobenzamide", "CHEMICAL", 156, 172], ["2AB", "CHEMICAL", 199, 202], ["Nafion", "CHEMICAL", 85, 91], ["Glycan", "CHEMICAL", 129, 135], ["2-aminobenzamide", "CHEMICAL", 156, 172], ["2AB", "CHEMICAL", 199, 202], ["Glycan", "SIMPLE_CHEMICAL", 129, 135], ["2-aminobenzamide", "SIMPLE_CHEMICAL", 156, 172], ["Glycans", "SIMPLE_CHEMICAL", 172, 179], ["2AB", "SIMPLE_CHEMICAL", 199, 202], ["Samples", "TEST", 0, 7], ["mass spectrometric analysis", "TEST", 12, 39], ["drop dialysis", "TREATMENT", 64, 77], ["a Nafion 117 membrane", "TREATMENT", 83, 104], ["Glycan derivatisation", "TREATMENT", 129, 150], ["aminobenzamide", "TREATMENT", 158, 172], ["Glyko", "TEST", 278, 283]]], ["The 2AB labelling solution was prepared according to the manufacturer's instructions and stored at \u221220 \u00b0C. Five microliters of this solution was added to the dried sugars and incubated at 65 \u00b0C for 2 h.", [["sugars", "CHEMICAL", 164, 170], ["2AB", "SIMPLE_CHEMICAL", 4, 7], ["The 2AB labelling solution", "TREATMENT", 0, 26], ["this solution", "TREATMENT", 127, 140], ["the dried sugars", "TREATMENT", 154, 170]]], ["Residual 2AB reagent was removed by ascending paper chromatography on 3 MM chromatography paper (Millipore, Watford, UK) in 100% acetonitrile.", [["acetonitrile", "CHEMICAL", 129, 141], ["acetonitrile", "CHEMICAL", 129, 141], ["acetonitrile", "SIMPLE_CHEMICAL", 129, 141], ["Residual 2AB reagent", "TREATMENT", 0, 20], ["ascending paper chromatography", "TEST", 36, 66]]], ["After 2 h, the sample was viewed under a UV light and the spot corresponding to the labelled sugars was cut from the paper and the sugars were eluted using four sequential aliquots of water (0.5 mL) into a nitric acid-washed glass tube.", [["sample", "ANATOMY", 15, 21], ["nitric acid", "CHEMICAL", 206, 217], ["sugars", "CHEMICAL", 93, 99], ["sugars", "CHEMICAL", 131, 137], ["nitric acid", "CHEMICAL", 206, 217], ["sugars", "SIMPLE_CHEMICAL", 93, 99], ["sugars", "SIMPLE_CHEMICAL", 131, 137], ["water", "SIMPLE_CHEMICAL", 184, 189], ["nitric acid", "SIMPLE_CHEMICAL", 206, 217], ["a UV light", "TREATMENT", 39, 49], ["the spot", "TEST", 54, 62], ["the labelled sugars", "TEST", 80, 99], ["the sugars", "TEST", 127, 137], ["four sequential aliquots of water", "TREATMENT", 156, 189], ["a nitric acid-washed glass tube", "TREATMENT", 204, 235], ["glass tube", "OBSERVATION", 225, 235]]], ["The eluted N-glycans were vacuum dried and then redissolved in water (200 \u00b5L).Glycan sequencing using exoglycosidase digestionOne to two picomoles of 2AB-labelled N-glycans were vacuum dried and incubated at 37 \u00b0C for 10 h in 50 mM sodium citrate buffer (pH 5.2) with exoglycosidases (Glyko) as follows: Arthrobacter ureafaciens sialidase (ABS, EC 3.2.1.18), a mixture of ABS and bovine testis \u03b2-galactosidase (BTG, EC 3.2.1.23), and a mixture of ABS, BTG and Streptococcus pneumoniae N-acetyl-hexosaminidase (GUH, EC 3.2.1.30) at the manufacturer's recommended concentrations.", [["testis", "ANATOMY", 387, 393], ["2AB", "CHEMICAL", 150, 153], ["sodium citrate", "CHEMICAL", 232, 246], ["Glyko", "CHEMICAL", 285, 290], ["BTG", "CHEMICAL", 452, 455], ["N-acetyl-hexosaminidase", "CHEMICAL", 485, 508], ["2AB", "CHEMICAL", 150, 153], ["sodium citrate", "CHEMICAL", 232, 246], ["N-acetyl", "CHEMICAL", 485, 493], ["N-glycans", "SIMPLE_CHEMICAL", 11, 20], ["Glycan", "SIMPLE_CHEMICAL", 78, 84], ["exoglycosidase", "SIMPLE_CHEMICAL", 102, 116], ["picomoles", "SIMPLE_CHEMICAL", 137, 146], ["2AB", "SIMPLE_CHEMICAL", 150, 153], ["N-glycans", "SIMPLE_CHEMICAL", 163, 172], ["sodium citrate", "SIMPLE_CHEMICAL", 232, 246], ["exoglycosidases", "SIMPLE_CHEMICAL", 268, 283], ["Glyko", "SIMPLE_CHEMICAL", 285, 290], ["Arthrobacter ureafaciens", "ORGANISM", 304, 328], ["sialidase", "ORGANISM", 329, 338], ["EC", "CELL", 345, 347], ["bovine", "ORGANISM", 380, 386], ["testis", "ORGAN", 387, 393], ["\u03b2-galactosidase", "SIMPLE_CHEMICAL", 394, 409], ["EC", "CELL", 416, 418], ["ABS", "SIMPLE_CHEMICAL", 447, 450], ["BTG", "SIMPLE_CHEMICAL", 452, 455], ["Streptococcus pneumoniae", "ORGANISM", 460, 484], ["N-acetyl-hexosaminidase", "SIMPLE_CHEMICAL", 485, 508], ["GUH", "SIMPLE_CHEMICAL", 510, 513], ["hexosaminidase", "PROTEIN", 494, 508], ["Arthrobacter ureafaciens sialidase", "SPECIES", 304, 338], ["bovine", "SPECIES", 380, 386], ["Streptococcus pneumoniae", "SPECIES", 460, 484], ["Arthrobacter ureafaciens", "SPECIES", 304, 328], ["bovine", "SPECIES", 380, 386], ["Streptococcus pneumoniae", "SPECIES", 460, 484], ["The eluted N-glycans", "TREATMENT", 0, 20], ["vacuum", "TREATMENT", 26, 32], ["Glycan sequencing", "TEST", 78, 95], ["exoglycosidase digestionOne", "TREATMENT", 102, 129], ["2AB-labelled N-glycans", "TREATMENT", 150, 172], ["vacuum", "TREATMENT", 178, 184], ["50 mM sodium citrate buffer", "TREATMENT", 226, 253], ["pH", "TEST", 255, 257], ["exoglycosidases", "TEST", 268, 283], ["Arthrobacter ureafaciens sialidase", "TEST", 304, 338], ["EC", "TEST", 345, 347], ["ABS", "TEST", 372, 375], ["bovine testis \u03b2-galactosidase", "TEST", 380, 409], ["BTG", "TEST", 411, 414], ["EC", "TEST", 416, 418], ["ABS", "TEST", 447, 450], ["BTG", "TEST", 452, 455], ["Streptococcus pneumoniae", "PROBLEM", 460, 484], ["acetyl", "TREATMENT", 487, 493], ["hexosaminidase", "TEST", 494, 508], ["EC", "TEST", 515, 517], ["vacuum dried", "OBSERVATION", 26, 38], ["bovine testis", "ANATOMY", 380, 393], ["Streptococcus pneumoniae", "OBSERVATION", 460, 484]]], ["In a second experiment, glycans were incubated with Jack bean mannosidase (JBM, EC 3.2.1.24) 10 \u00b5L, 50 U/mL and Aspergillus saitoi \u03b11-2mannosidase (ASM), 2 \u00b5L, 1 mU/mL.", [["mannosidase", "GENE_OR_GENE_PRODUCT", 62, 73], ["\u03b11-2mannosidase", "SIMPLE_CHEMICAL", 131, 146], ["ASM", "CELL", 148, 151], ["Aspergillus saitoi", "SPECIES", 112, 130], ["Jack bean", "SPECIES", 52, 61], ["Aspergillus saitoi", "SPECIES", 112, 130], ["Jack bean mannosidase", "TEST", 52, 73], ["EC", "TEST", 80, 82], ["Aspergillus saitoi", "TEST", 112, 130]]], ["The enzymes were removed after exoglycosidase digestions using washed (200 \u00b5L water, centrifugation at 7000 rpm for 10 min) nitrocellulose 0.45 \u00b5m microspin filters (Radleys, Saffron Walden, UK).", [["nitrocellulose", "CHEMICAL", 124, 138], ["The enzymes", "TEST", 0, 11], ["exoglycosidase digestions", "TREATMENT", 31, 56], ["nitrocellulose", "TREATMENT", 124, 138], ["microspin filters", "TREATMENT", 147, 164]]], ["The sample (10 \u00b5L) was added to the filter and centrifuged at 13,000 rpm for 3 min.", [["sample", "ANATOMY", 4, 10], ["The sample (10 \u00b5L)", "TREATMENT", 0, 18], ["the filter", "TREATMENT", 32, 42], ["filter", "OBSERVATION", 36, 42]]], ["The digestion tube was washed with water (20 \u00b5L) which was transferred to the filter and centrifuged at 13,000 rpm for 3 min.", [["tube", "ANATOMY", 14, 18], ["tube", "TISSUE", 14, 18], ["The digestion tube", "TREATMENT", 0, 18], ["digestion tube", "OBSERVATION", 4, 18]]], ["The filter was rinsed with water (100 \u00b5L) and centrifuged at 13,000 rpm for a further 3 min.", [["The filter", "TREATMENT", 0, 10], ["filter", "OBSERVATION", 4, 10]]], ["The collected solution was vacuum dried and then redissolved in water (20 \u00b5L) for analysis by HPLC.Normal-phase HPLC analysisAcetonitrile (80 \u00b5L) was added to 10% of the sample (20 \u00b5L) and 95 \u00b5L was examined on a normal-phase (NP)-HPLC system (Waters Alliance 2690, Waters Corporation, Milford, MA, USA) fitted with a GlycoSep N column (Oxford GlycoSciences, Abingdon, UK) with a run time of 180 min (Guile et al., 1996) .", [["sample", "ANATOMY", 170, 176], ["analysisAcetonitrile", "CHEMICAL", 117, 137], ["analysisAcetonitrile", "SIMPLE_CHEMICAL", 117, 137], ["The collected solution", "TREATMENT", 0, 22], ["vacuum dried", "TREATMENT", 27, 39], ["a GlycoSep N column", "TREATMENT", 316, 335], ["vacuum dried", "OBSERVATION", 27, 39], ["-phase", "OBSERVATION_MODIFIER", 105, 111]]], ["The N-linked sugars eluted from the column with a retention time of between 40 and 120 min.", [["N-linked sugars", "CHEMICAL", 4, 19], ["N", "CHEMICAL", 4, 5], ["sugars", "CHEMICAL", 13, 19], ["The N-linked sugars", "TEST", 0, 19], ["column", "ANATOMY", 36, 42]]], ["Comparison with a dextran ladder allowed assignment of glucose unit (GU) values to each peak, which facilitated identification of the glycans present in the released pool.Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS)Positive ion MALDI-TOF mass spectra were obtained with a Waters-MS Technologies TofSpec 2E reflectron TOF mass spectrometer (Waters Ltd, Manchester).", [["dextran", "CHEMICAL", 18, 25], ["glucose", "CHEMICAL", 55, 62], ["glucose", "CHEMICAL", 55, 62], ["dextran", "SIMPLE_CHEMICAL", 18, 25], ["glucose", "SIMPLE_CHEMICAL", 55, 62], ["a dextran ladder", "TREATMENT", 16, 32], ["Matrix-assisted laser desorption", "TREATMENT", 171, 203], ["ionization time", "TEST", 204, 219], ["flight mass spectrometry", "TEST", 223, 247], ["MALDI", "TEST", 249, 254], ["ion MALDI", "TEST", 271, 280], ["TOF mass spectra", "PROBLEM", 281, 297], ["a Waters", "TEST", 317, 325], ["TofSpec", "TEST", 342, 349]]], ["The pulse and acceleration voltages were 3 and 20 kV, respectively.", [["The pulse", "TEST", 0, 9], ["acceleration voltages", "TEST", 14, 35]]], ["Data acquisition and processing were performed with MassLynx software version 3.3.", [["Data acquisition", "TEST", 0, 16], ["MassLynx software version", "TEST", 52, 77]]], ["Samples were prepared by mixing an aqueous solution of the sample (0.5 \u00b5L) with a saturated solution of DHB in acetonitrile (0.3 \u00b5L) on the stainless steel MALDI target and allowing the mixture to dry under ambient conditions.", [["Samples", "ANATOMY", 0, 7], ["sample", "ANATOMY", 59, 65], ["DHB", "CHEMICAL", 104, 107], ["acetonitrile", "CHEMICAL", 111, 123], ["DHB", "CHEMICAL", 104, 107], ["acetonitrile", "CHEMICAL", 111, 123], ["DHB", "SIMPLE_CHEMICAL", 104, 107], ["acetonitrile", "SIMPLE_CHEMICAL", 111, 123], ["Samples", "TEST", 0, 7], ["a saturated solution of DHB in acetonitrile", "TREATMENT", 80, 123], ["the stainless steel MALDI target", "TREATMENT", 136, 168]]], ["The dried sample spot was then re-dissolved in ethanol (0.2 \u00b5L) and again allowed to dry.Electrospray mass spectrometryElectrospray mass spectrometry was performed with a Waters quadrupole-time-of-flight (Q-TOF) Ultima Global instrument in negative ion mode.", [["ethanol", "CHEMICAL", 47, 54], ["ethanol", "CHEMICAL", 47, 54], ["ethanol", "SIMPLE_CHEMICAL", 47, 54], ["The dried sample spot", "TEST", 0, 21], ["ethanol", "TREATMENT", 47, 54], ["Electrospray mass spectrometry", "PROBLEM", 89, 119], ["Electrospray mass spectrometry", "TEST", 119, 149], ["a Waters quadrupole", "TREATMENT", 169, 188], ["negative", "OBSERVATION", 240, 248], ["ion mode", "OBSERVATION_MODIFIER", 249, 257]]], ["Samples in 1:1 (v:v) methanol:water were infused through Proxeon nanospray capillaries (Proxeon Biosystems, Odense, Denmark).", [["Samples", "ANATOMY", 0, 7], ["methanol", "CHEMICAL", 21, 29], ["v:v) methanol", "SIMPLE_CHEMICAL", 16, 29], ["water", "SIMPLE_CHEMICAL", 30, 35], ["capillaries", "TISSUE", 75, 86], ["Samples", "TEST", 0, 7], ["methanol:water", "TREATMENT", 21, 35], ["Proxeon nanospray capillaries (Proxeon Biosystems", "TREATMENT", 57, 106]]], ["The ion source conditions were as follows: temperature, 120 \u00b0C; nitrogen flow, 50 L/h; infusion needle potential, 1.2 kV; cone voltage, 100 V; RF-1 voltage, 150 V. Spectra (2 s scans) were acquired with a digitization rate of 4 GHz and accumulated until a satisfactory signal:noise ratio had been obtained.", [["nitrogen", "CHEMICAL", 64, 72], ["RF", "PROTEIN", 143, 145], ["temperature", "TEST", 43, 54], ["nitrogen flow", "TEST", 64, 77], ["infusion needle potential", "TEST", 87, 112], ["cone voltage", "TEST", 122, 134], ["RF", "TEST", 143, 145], ["voltage", "TEST", 148, 155], ["Spectra (2 s scans", "TEST", 164, 182], ["a digitization rate", "TEST", 203, 222], ["noise ratio", "TEST", 276, 287]]], ["The major ions were [M+H 2 PO 4 ] \u2212 , the phosphate apparently arising from residual phosphate in the original sample, as observed previously from all glycan samples released as above.", [["sample", "ANATOMY", 111, 117], ["phosphate", "CHEMICAL", 42, 51], ["phosphate", "CHEMICAL", 85, 94], ["[M+H 2 PO 4 ] \u2212", "CHEMICAL", 20, 35], ["phosphate", "CHEMICAL", 42, 51], ["phosphate", "CHEMICAL", 85, 94], ["[M+H 2 PO 4 ] \u2212", "SIMPLE_CHEMICAL", 20, 35], ["phosphate", "SIMPLE_CHEMICAL", 42, 51], ["phosphate", "SIMPLE_CHEMICAL", 85, 94], ["M+H", "TEST", 21, 24], ["the phosphate", "TEST", 38, 51], ["residual phosphate", "PROBLEM", 76, 94], ["all glycan samples", "TEST", 147, 165]]], ["For MS/MS data acquisition, the parent ion was selected at low resolution (about 5 m/z mass window) to allow transmission of isotope peaks and fragmented with argon at a pressure (recorded on the instrument's pressure gauge) of 0.5 mBar.", [["MS/MS data acquisition", "TEST", 4, 26], ["z mass window", "TREATMENT", 85, 98], ["isotope peaks", "PROBLEM", 125, 138], ["argon", "TREATMENT", 159, 164], ["a pressure", "TEST", 168, 178], ["the instrument's pressure gauge", "TEST", 192, 223], ["isotope peaks", "OBSERVATION", 125, 138], ["fragmented", "OBSERVATION_MODIFIER", 143, 153]]], ["The voltage on the collision cell was adjusted with mass and charge to give an even distribution of fragment ions across the mass scale.", [["cell", "ANATOMY", 29, 33], ["cell", "CELL", 29, 33], ["mass", "PROBLEM", 52, 56], ["fragment ions", "PROBLEM", 100, 113], ["voltage", "OBSERVATION_MODIFIER", 4, 11], ["collision cell", "OBSERVATION", 19, 33], ["fragment", "OBSERVATION", 100, 108], ["mass", "OBSERVATION", 125, 129]]], ["Typical values were 80-120 V. Other voltages were as recommended by the manufacturer.", [["Typical values", "TEST", 0, 14], ["Other voltages", "TEST", 30, 44]]], ["Instrument control, data acquisition and processing were performed with MassLynx software version 4.0.", [["data acquisition", "TEST", 20, 36], ["MassLynx software version", "TEST", 72, 97]]], ["Displayed spectra have been smoother using the Savitzky Golay algorithm (5 \u00d7 2) and abundant background ions at m/z 195, 291 and 344 have been removed for clarity.AcknowledgmentsWe thank the Wellcome Trust and the Biotechnology and Biological Sciences Research Council for equipment grants to purchase the Q-TOF and TofSpec mass spectrometers, respectively.", [["the Savitzky Golay algorithm", "TEST", 43, 71], ["TofSpec mass spectrometers", "TREATMENT", 316, 342]]], ["We thank the Public Health Agency of Canada (PHAC) for financial support.", [["financial support", "TREATMENT", 55, 72]]], ["Table 1 and the key to the structural symbols is in the legend to Fig. 2 with the addition of \u25a1 = glucose.", [["glucose", "CHEMICAL", 98, 105], ["glucose", "CHEMICAL", 98, 105], ["\u25a1 = glucose", "SIMPLE_CHEMICAL", 94, 105], ["\u25a1 = glucose", "TREATMENT", 94, 105]]], ["Glycan types are coloured: blue = high mannose, orange = hybrid, purple = monoantennary, red = biantennary, green = triantennary, pink = tetra-antennary.", [["mannose", "CHEMICAL", 39, 46], ["Glycan", "SIMPLE_CHEMICAL", 0, 6], ["mannose", "SIMPLE_CHEMICAL", 39, 46], ["green = triantennary", "SIMPLE_CHEMICAL", 108, 128], ["purple", "OBSERVATION_MODIFIER", 65, 71], ["pink", "OBSERVATION_MODIFIER", 130, 134]]], ["The three glycans with residual glucose residues are highlighted.", [["glucose", "CHEMICAL", 32, 39], ["glucose", "CHEMICAL", 32, 39], ["glucose", "SIMPLE_CHEMICAL", 32, 39], ["residual glucose residues", "PROBLEM", 23, 48], ["glucose residues", "OBSERVATION", 32, 48]]]], "PMC7328253": [], "393370b4ecc8a512cd673b64b3040d12ce30eb0a": [["IntroductionAn adverse drug reaction (ADR) is considered to be one of the significant causes of morbidity and mortality, estimated to be the fourth to sixth highest cause of death in the United States [8] .", [["adverse drug reaction", "DISEASE", 15, 36], ["death", "DISEASE", 174, 179], ["IntroductionAn adverse drug reaction", "PROBLEM", 0, 36], ["morbidity", "PROBLEM", 96, 105], ["morbidity", "OBSERVATION", 96, 105]]], ["Most ADR detection research has been aimed to predict ADRs in pre-marketing phases, using biomedical information sources such as chemical structures, protein targets, and therapeutic indications.", [["ADR", "CHEMICAL", 5, 8], ["ADRs", "DISEASE", 54, 58], ["protein targets", "TEST", 150, 165]]], ["Especially, studies using graph-structured data have demonstrated the superiority of modeling biomedical interactions as graphs.", [["graph-structured data", "TEST", 26, 47]]], ["Nevertheless, capturing potential ADRs from the entire population in post-marketing phases is also essential to fully establish the ADR profiles [5] .", [["ADRs", "DISEASE", 34, 38], ["potential ADRs", "PROBLEM", 24, 38]]], ["The potential causal relationship between an adverse event and a drug is called a 'signal' when the relation is previously unknown or incompletely documented.", [["an adverse event", "PROBLEM", 42, 58]]], ["Traditional ADR signal detection research in post-marketing phases mainly counts on a spontaneous and voluntary reporting system that collects spontaneous reports of suspected drug-related events, such as the WHO Uppsala Monitoring Center [1, 2, 4] .", [["ADR", "CHEMICAL", 12, 15], ["Traditional ADR signal detection", "TEST", 0, 32], ["post-marketing phases", "TEST", 45, 66]]], ["Therefore, recent studies have attempted algorithmic approaches to detect ADR signals on large clinical databases such as electronic health records (EHR) and healthcare claims data [5, 14] .", [["recent studies", "TEST", 11, 25], ["algorithmic approaches", "TEST", 41, 63], ["ADR signals", "PROBLEM", 74, 85]]], ["Many of these studies apply basic machine learning techniques such as random forest, support vector machines, and neural networks.", [["neural networks", "ANATOMY", 114, 129], ["neural networks", "MULTI-TISSUE_STRUCTURE", 114, 129], ["these studies", "TEST", 8, 21], ["basic machine learning techniques", "TREATMENT", 28, 61], ["random forest", "TREATMENT", 70, 83], ["support vector machines", "TREATMENT", 85, 108]]], ["However, fewer studies are using graph-based approaches on the clinical databases in the field of post-marketing ADR signal detection.", [["ADR", "CHEMICAL", 113, 116], ["fewer studies", "TEST", 9, 22], ["the clinical databases", "TEST", 59, 81], ["post-marketing ADR signal detection", "TEST", 98, 133]]], ["Due to the complex polypharmacy and multiple relations among drugs and diseases, we expect that graph structure can provide insights to potential ADRs, which may not otherwise be apparent using disconnected structures.IntroductionIn this study, we develop a novel graph-based framework for ADR signal detection using healthcare claims data to construct a Drug-disease graph.", [["ADRs", "DISEASE", 146, 150], ["ADR", "CHEMICAL", 290, 293], ["the complex polypharmacy", "PROBLEM", 7, 31], ["diseases", "PROBLEM", 71, 79], ["potential ADRs", "PROBLEM", 136, 150], ["this study", "TEST", 233, 243], ["ADR signal detection", "TEST", 290, 310], ["a Drug-disease graph", "PROBLEM", 353, 373], ["complex", "OBSERVATION_MODIFIER", 11, 18], ["polypharmacy", "OBSERVATION", 19, 31]]], ["The constructed graph is a heterogeneous graph with drug and disease nodes, as it is depicted in Fig. 1 .", [["disease nodes", "MULTI-TISSUE_STRUCTURE", 61, 74], ["drug and disease nodes", "PROBLEM", 52, 74], ["heterogeneous", "OBSERVATION_MODIFIER", 27, 40], ["disease nodes", "OBSERVATION", 61, 74]]], ["The nodes represent the medicine prescription codes and disease diagnosis codes derived from the healthcare claims data.", [["nodes", "ANATOMY", 4, 9], ["nodes", "MULTI-TISSUE_STRUCTURE", 4, 9], ["nodes", "OBSERVATION", 4, 9]]], ["For example, l2 -distance between two node embeddings, which are learned from the data, is used to define the drugdrug and disease-disease edge weights.", [["node", "ANATOMY", 38, 42], ["node", "MULTI-TISSUE_STRUCTURE", 38, 42], ["l2", "DNA", 13, 15], ["l2 -distance between two node embeddings", "PROBLEM", 13, 53], ["the drugdrug and disease-disease edge weights", "PROBLEM", 106, 151], ["l2", "ANATOMY", 13, 15], ["two", "OBSERVATION_MODIFIER", 34, 37], ["node embeddings", "OBSERVATION", 38, 53]]], ["Also, the conditional probability computed on the data is used for the drug-disease relationship.", [["the drug-disease relationship", "PROBLEM", 67, 96]]], ["As Graph Neural Network (GNN) models have been demonstrated [7, 19] their power to solve many tasks with graph-structured data, showing state-of-the-art performances, we use GNN-based approach for ADR detection.", [["ADR", "CHEMICAL", 197, 200], ["GNN", "PROTEIN", 174, 177], ["graph-structured data", "TEST", 105, 126], ["GNN", "TREATMENT", 174, 177], ["ADR detection", "PROBLEM", 197, 210]]], ["We verify that GNNs can learn node representations that are indicative of various relations between drugs and diseases.", [["node", "ANATOMY", 30, 34], ["GNNs", "SIMPLE_CHEMICAL", 15, 19], ["node", "MULTI-TISSUE_STRUCTURE", 30, 34], ["GNNs", "PROTEIN", 15, 19], ["drugs", "TREATMENT", 100, 105], ["diseases", "PROBLEM", 110, 118], ["node", "OBSERVATION", 30, 34], ["indicative of", "UNCERTAINTY", 60, 73]]], ["Then our model makes a prediction on whether a drug node and a disease node will have an ADR relation based on the learned node representations.IntroductionTo evaluate the performance of the proposed approaches, we conduct experiments with the newly generated dataset using the side effect resource database (SIDER).", [["node", "ANATOMY", 52, 56], ["disease node", "ANATOMY", 63, 75], ["node", "ANATOMY", 123, 127], ["node", "MULTI-TISSUE_STRUCTURE", 71, 75], ["node", "MULTI-TISSUE_STRUCTURE", 123, 127], ["a drug node", "PROBLEM", 45, 56], ["a disease node", "PROBLEM", 61, 75], ["the learned node representations", "TREATMENT", 111, 143], ["node", "OBSERVATION", 52, 56], ["node", "OBSERVATION", 71, 75], ["node", "OBSERVATION", 123, 127]]], ["The empirical results demonstrate the superiority of our proposed model, which outperforms other alternative machine learning algorithms with a significant margin in terms of the area under the receiver operating characteristic (AUROC) score and the area under the precision-recall curve (AUPRC) score.", [["a significant margin", "PROBLEM", 142, 162], ["significant", "OBSERVATION_MODIFIER", 144, 155], ["margin", "OBSERVATION_MODIFIER", 156, 162]]], ["Furthermore, our method unveils ADR candidates that are examined to be very useful information to the medical community.", [["ADR", "CHEMICAL", 32, 35], ["ADR", "SIMPLE_CHEMICAL", 32, 35]]], ["Therefore, our work does not demand case-by-case feature engineering that requires expertise.Related WorksThere have been numerous studies on ADR prediction in pre-marketing phases, attempting graph-based approaches on biomedical information sources [12, 15, 18, 22] .", [["ADR", "CHEMICAL", 142, 145], ["numerous studies", "TEST", 122, 138], ["ADR prediction", "TEST", 142, 156]]], ["These studies predicted potential side-effects of drug candidate molecules based on their chemical structures [15] and additional biological properties [12] .", [["These studies", "TEST", 0, 13], ["drug candidate molecules", "TREATMENT", 50, 74]]], ["Although such studies may play important roles in preventing ADRs in premarketing phases, capturing potential ADRs in real-world use cases has been considered very important.Related WorksA spontaneous and voluntary reporting system has been an important data source of the real world drug usages.", [["ADRs", "DISEASE", 61, 65], ["ADRs", "DISEASE", 110, 114], ["such studies", "TEST", 9, 21], ["ADRs in premarketing phases", "PROBLEM", 61, 88], ["ADRs", "PROBLEM", 110, 114]]], ["Most of the traditional ADR signal detection research used voluntary reporting systems with disproportionality analysis (DA), which measures disproportionality of observed drug-adverse event pairs existing in data and the null expectations [1, 2, 4] .", [["ADR", "CHEMICAL", 24, 27]]], ["Recently, large-scale clinical databases such as EHR (Electronic Health Records) or healthcare claims data have gained popularity as an alternative or additive data source in ADR signal detection research.", [["ADR", "CHEMICAL", 175, 178], ["large", "OBSERVATION_MODIFIER", 10, 15]]], ["Much of the studies applied machine learning techniques such as support vector machine (SVM), random forest (RF), logistic regression (LR) and other statistical machine learning methods to model the decision boundary to detect ADR in post-marketing phases [5, 6, 11, 14, 21] .Related WorksMore recently, researchers explored neural network-based models over clinical databases.", [["neural network", "ANATOMY", 325, 339], ["ADR", "CHEMICAL", 227, 230], ["neural network", "MULTI-TISSUE_STRUCTURE", 325, 339], ["the studies", "TEST", 8, 19], ["learning techniques", "TREATMENT", 36, 55], ["support vector machine", "TREATMENT", 64, 86], ["random forest (RF)", "TREATMENT", 94, 112], ["logistic regression (LR)", "TREATMENT", 114, 138], ["other statistical machine", "TREATMENT", 143, 168]]], ["Shang et al. [17] combined graph structure with the memory network to recommend a personalized medication.", [["a personalized medication", "TREATMENT", 80, 105]]], ["There also exists research for the recommendation, but the architectures are limited to the single use of instance symptoms [20, 23] , or patient history [9] .", [["patient", "ORGANISM", 138, 145], ["patient", "SPECIES", 138, 145], ["instance symptoms", "PROBLEM", 106, 123]]], ["However, none of these research explored graph neural network model for predicting the ADR reactions in the post-marketing phase.The Proposed FrameworkIn this section, we formulate our problem and describe how we apply graph structures for the task.", [["neural", "ANATOMY", 47, 53], ["ADR", "CHEMICAL", 87, 90], ["neural network", "MULTI-TISSUE_STRUCTURE", 47, 61], ["the ADR reactions", "PROBLEM", 83, 100], ["The Proposed FrameworkIn this section", "TREATMENT", 129, 166]]], ["We also present the process of training and prediction.Problem FormulationThe task is to predict the potential causal relationship between a given drug and a disease pair, which represents the prescription code and the diagnosis code in clinical data.", [["a disease pair", "PROBLEM", 156, 170]]], ["To consider the various relationships between drugs and diseases, we convert our clinical data into a novel graph structure that consists of drug and disease nodes.", [["disease nodes", "MULTI-TISSUE_STRUCTURE", 150, 163], ["drugs", "TREATMENT", 46, 51], ["diseases", "PROBLEM", 56, 64], ["drug and disease nodes", "PROBLEM", 141, 163], ["disease nodes", "OBSERVATION", 150, 163]]], ["The node representations and the edge weights are given according to the information retrieved from the clinical data NHIS-NSC in this study.", [["node", "ANATOMY", 4, 8], ["node", "MULTI-TISSUE_STRUCTURE", 4, 8], ["The node representations", "TREATMENT", 0, 24], ["the edge weights", "TREATMENT", 29, 45], ["this study", "TEST", 130, 140], ["node", "OBSERVATION", 4, 8]]], ["We first learn a node embedding that reflects the temporal proximity between homogeneous nodes, i.e., drug-drug and disease-disease node pairs.", [["node", "ANATOMY", 17, 21], ["a node embedding", "TREATMENT", 15, 31], ["homogeneous nodes", "PROBLEM", 77, 94], ["disease-disease node pairs", "PROBLEM", 116, 142], ["node", "OBSERVATION", 17, 21], ["temporal", "OBSERVATION_MODIFIER", 50, 58], ["homogeneous", "OBSERVATION_MODIFIER", 77, 88], ["nodes", "OBSERVATION", 89, 94], ["node pairs", "OBSERVATION", 132, 142]]], ["In order to model the proximity between two codes, we form drug/disease sequences from patients' records.Problem FormulationAfter the drug-disease graph is constructed, we build a GNN model that predicts the signal of side effects between any pairs of drug and disease.", [["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 87, 95], ["drug/disease sequences", "PROBLEM", 59, 81], ["the drug-disease graph", "PROBLEM", 130, 152], ["a GNN model", "TREATMENT", 178, 189], ["side effects", "PROBLEM", 218, 230], ["disease", "PROBLEM", 261, 268]]], ["The side effect labels, which are taken from the SIDER database, are given to a subset of drug-disease pairs in graph G. We define the label function l :Problem Formulationwhere V SIDER drug and V SIDER dis are the subsets of V drug and V dis registered in the SIDER database respectively, and E SIDER is the set of drug-disease pairs that are known to have side effect relation according to the SIDER database.Code Embedding Learning with Skip-Gram ModelMost large-scale clinical databases including NHIS-NSC, are collected in the form of longitudinal visit records of the patients.", [["patients", "ORGANISM", 574, 582], ["patients", "SPECIES", 574, 582], ["drug-disease pairs", "PROBLEM", 90, 108], ["V drug", "TREATMENT", 226, 232], ["drug-disease pairs", "PROBLEM", 316, 334], ["side effect", "OBSERVATION_MODIFIER", 4, 15], ["NSC", "ANATOMY", 506, 509]]], ["In this section, we explain how we process the patient's longitudinal records as sequential data and apply skipgram model to learn the code embeddings.Definition 1 (Drug/Disease Sequence).In the patient's longitudinal records, each patient can be treated as a sequence of hospital visits {vDefinition 1 (Drug/Disease Sequence).Tn } where n represents each patient in the data, and T n is the total number of visits of the patient.", [["patient", "ORGANISM", 47, 54], ["patient", "ORGANISM", 195, 202], ["patient", "ORGANISM", 232, 239], ["patient", "ORGANISM", 356, 363], ["patient", "ORGANISM", 422, 429], ["patient", "SPECIES", 47, 54], ["patient", "SPECIES", 195, 202], ["patient", "SPECIES", 232, 239], ["patient", "SPECIES", 356, 363], ["patient", "SPECIES", 422, 429], ["sequential data", "TEST", 81, 96], ["skipgram model", "TREATMENT", 107, 121]]], ["The size of each set is variable since the number of prescribed/diagnosed codes varies from visit to visit.", [["size", "OBSERVATION_MODIFIER", 4, 8], ["variable", "OBSERVATION_MODIFIER", 24, 32]]], ["With these sets of codes, we form a drug sequence Seq drug (n) and a disease sequence Seq disease (n) of n th patient by listing each of the codes in a temporal order, as it is described below (Here, we leave out the symbol n):Definition 1 (Drug/Disease Sequence).where p x \u2208 R Vp and d y \u2208 R V d are the one-hot vectors representing each of the medical codes in the sequences.", [["patient", "ORGANISM", 110, 117], ["patient", "SPECIES", 110, 117], ["a disease sequence Seq disease", "PROBLEM", 67, 97]]], ["V p and V d are the vocabulary size of the whole prescription and diagnosis codes within the data, respectively.", [["V d", "GENE_OR_GENE_PRODUCT", 8, 11], ["size", "OBSERVATION_MODIFIER", 31, 35]]], ["T p and T d represent the total number of prescription/diagnosis codes of the patient's record.", [["patient", "ORGANISM", 78, 85], ["patient", "SPECIES", 78, 85]]], ["In this way, we can build a corpus consisting of Seq drug or Seq disease , in which the proximity-based code embedding learning can be implemented.", [["Seq disease", "PROBLEM", 61, 72]]], ["We use Skip-gram [13] model to learn the latent representation of medical codes in our data, in a way that captures the temporal proximity between them.", [["Skip-gram", "TREATMENT", 7, 16]]], ["With Seq drug or Seq disease , we use the context window size of 16, meaning 16 codes behind and 16 codes ahead, and apply the Skip-gram learning with negative sampling scheme.", [["Seq disease", "PROBLEM", 17, 28], ["Seq disease", "OBSERVATION", 17, 28]]], ["The trained Skip-gram vectors are then used as the proximity-based code embeddings.Drug-Disease Graph ConstructionHere, we describe how we construct our unique Drug-disease graph from NHIS-NSC.", [["NHIS-NSC", "CELL", 184, 192], ["Skip-gram vectors", "DNA", 12, 29], ["The trained Skip-gram vectors", "TREATMENT", 0, 29], ["NSC", "ANATOMY", 189, 192]]], ["In Definition 2, we explain the concept of the Drug-disease graph.", [["the Drug-disease graph", "PROBLEM", 43, 65]]], ["Then, we explain the node representations and edge connections.Definition 2 (Drug-disease Graph).We construct a single heterogeneous graph G = (V, E) consisting of drug and disease nodes, where V = V drug \u222a V dis is the union of drug and disease nodes, and E = E drug \u222a E dis \u222a E inter is the union of homogeneous edges E drug and E dis (i.e. consisting of same type of nodes) and heterogeneous edges E inter (i.e. consisting of different types of nodes).Definition 2 (Drug-disease Graph).To represent v drug \u2208 V drug and v dis \u2208 V dis , we jointly use proximity-based node representation along with category-based node representation.", [["node", "ANATOMY", 21, 25], ["node", "ANATOMY", 569, 573], ["node", "ANATOMY", 615, 619], ["E = E", "SIMPLE_CHEMICAL", 257, 262], ["node", "MULTI-TISSUE_STRUCTURE", 615, 619], ["E dis", "DNA", 331, 336], ["the node representations", "TREATMENT", 17, 41], ["drug and disease nodes", "PROBLEM", 164, 186], ["disease nodes", "PROBLEM", 238, 251], ["proximity-based node representation", "TREATMENT", 553, 588], ["category-based node representation", "TREATMENT", 600, 634], ["node", "OBSERVATION", 21, 25], ["disease nodes", "OBSERVATION", 173, 186], ["nodes", "OBSERVATION", 370, 375], ["heterogeneous", "OBSERVATION_MODIFIER", 381, 394], ["edges", "OBSERVATION_MODIFIER", 395, 400], ["different types", "OBSERVATION_MODIFIER", 429, 444], ["nodes", "OBSERVATION", 448, 453], ["drug \u2208 V drug", "OBSERVATION", 504, 517], ["node", "OBSERVATION", 569, 573], ["node", "OBSERVATION", 615, 619]]], ["Proximitybased node representation is obtained by initial Skip-gram code embedding as in Sect.", [["node", "ANATOMY", 15, 19], ["Proximitybased node", "MULTI-TISSUE_STRUCTURE", 0, 19], ["node", "OBSERVATION", 15, 19]]], ["We denote a proximity-based drug node as v drug and a disease node as v dis .", [["node", "ANATOMY", 62, 66], ["v dis", "GENE_OR_GENE_PRODUCT", 70, 75], ["a proximity-based drug node", "TREATMENT", 10, 37], ["a disease node", "PROBLEM", 52, 66], ["drug node", "OBSERVATION", 28, 37], ["node", "OBSERVATION", 62, 66]]], ["Category-based node representation is designed to represent the categorical information of medical codes.", [["node", "ANATOMY", 15, 19], ["node", "MULTI-TISSUE_STRUCTURE", 15, 19], ["node", "OBSERVATION", 15, 19]]], ["We utilize the hierarchical structure of categorical codes (i.e. ATC and ICD-10 codes) by adopting the one-hot vector format.", [["ATC and ICD", "TREATMENT", 65, 76]]], ["Since there are multiple categories for each code, the category-based node representation is shown as a concatenation of one-hot vectors, thus, a multi-hot vector.", [["node", "ANATOMY", 70, 74], ["node", "MULTI-TISSUE_STRUCTURE", 70, 74], ["multi-hot vector", "DNA", 146, 162], ["a multi-hot vector", "TREATMENT", 144, 162], ["multiple", "OBSERVATION_MODIFIER", 16, 24], ["node", "OBSERVATION", 70, 74]]], ["Finally, the initial node representation of the Drug-disease graph are represented as the concatenation of the proximity-based node embeddings and the categorybased node embeddings.", [["node", "ANATOMY", 21, 25], ["node", "ANATOMY", 127, 131], ["node", "ANATOMY", 165, 169], ["node", "MULTI-TISSUE_STRUCTURE", 165, 169], ["Drug-disease graph", "DNA", 48, 66], ["the Drug-disease graph", "PROBLEM", 44, 66], ["the proximity-based node embeddings", "TREATMENT", 107, 142], ["the categorybased node embeddings", "TREATMENT", 147, 180], ["node", "OBSERVATION", 21, 25], ["based", "ANATOMY_MODIFIER", 121, 126], ["node embeddings", "OBSERVATION", 127, 142], ["node embeddings", "OBSERVATION", 165, 180]]], ["Following are the definitions for the drug and disease node representations.Definition 3 (Node Representationswhere v drug is a category-based drug node, v dis is a category-based disease node, v drug is an initial drug node, v dis is an initial disease node, and || is a vector concatenation function.", [["node", "ANATOMY", 55, 59], ["node", "ANATOMY", 148, 152], ["node", "ANATOMY", 220, 224], ["disease node", "MULTI-TISSUE_STRUCTURE", 47, 59], ["v dis", "GENE_OR_GENE_PRODUCT", 154, 159], ["v dis", "GENE_OR_GENE_PRODUCT", 226, 231], ["the drug and disease node representations", "PROBLEM", 34, 75], ["a category-based disease node", "PROBLEM", 163, 192], ["an initial drug node", "PROBLEM", 204, 224], ["an initial disease node", "PROBLEM", 235, 258], ["node", "OBSERVATION", 55, 59], ["drug node", "OBSERVATION", 143, 152], ["disease node", "OBSERVATION", 180, 192], ["drug node", "OBSERVATION", 215, 224], ["disease node", "OBSERVATION", 246, 258]]], ["Each v i drug represents the each level in the ATC code structure and v drug \u2208 R 104 .", [["Each v i drug", "TREATMENT", 0, 13], ["ATC", "ANATOMY", 47, 50]]], ["Because the ATC code structure is represented in 5 levels, a drug node vector is also represented as the concatenation of 5 one-hot vectors.", [["ATC code structure", "DNA", 12, 30], ["drug node vector", "DNA", 61, 77], ["5 one-hot vectors", "DNA", 122, 139], ["the ATC code structure", "PROBLEM", 8, 30], ["a drug node vector", "TREATMENT", 59, 77], ["node vector", "OBSERVATION", 66, 77]]], ["Similarly, each v i dis represents each of the first two levels in the ICD-10 code structure and v dis \u2208 R 126 .", [["the ICD", "TREATMENT", 67, 74], ["ICD", "OBSERVATION", 71, 74]]], ["We only use two classification levels of the ICD-10 code structure, therefore, the disease node vector is represented as the concatenation of 2 one-hot vectors.Definition 3 (Node RepresentationsFor homogeneous edges like E drug and E dis , we view the relationships between homogeneous nodes as the temporal proximity of two entities, meaning that two nodes are likely to be close together in the records.", [["ICD-10 code structure", "DNA", 45, 66], ["E dis", "DNA", 232, 237], ["the ICD", "TREATMENT", 41, 48], ["the disease node vector", "PROBLEM", 79, 102], ["homogeneous nodes", "PROBLEM", 274, 291], ["ICD", "OBSERVATION", 45, 48], ["node vector", "OBSERVATION", 91, 102], ["homogeneous", "OBSERVATION_MODIFIER", 274, 285], ["nodes", "OBSERVATION", 286, 291], ["temporal", "OBSERVATION_MODIFIER", 299, 307], ["nodes", "OBSERVATION", 352, 357]]], ["Therefore, using the proximity-based node embeddings, we compute l2 -distance between two node embeddings to estimate the temporal proximity.", [["node", "ANATOMY", 37, 41], ["node", "ANATOMY", 90, 94], ["l2", "DNA", 65, 67], ["the proximity-based node embeddings", "TREATMENT", 17, 52], ["two node embeddings", "TREATMENT", 86, 105], ["node embeddings", "OBSERVATION", 37, 52], ["l2", "ANATOMY", 65, 67], ["node", "OBSERVATION", 90, 94], ["temporal", "ANATOMY_MODIFIER", 122, 130], ["proximity", "ANATOMY_MODIFIER", 131, 140]]], ["For heterogeneous edges, which are the edges connecting drug nodes and disease nodes, are given as the conditional probability of drug prescription given the diagnosed disease.", [["nodes", "ANATOMY", 61, 66], ["disease nodes", "MULTI-TISSUE_STRUCTURE", 71, 84], ["heterogeneous edges", "PROBLEM", 4, 23], ["the edges connecting drug nodes", "PROBLEM", 35, 66], ["disease nodes", "PROBLEM", 71, 84], ["drug prescription", "TREATMENT", 130, 147], ["the diagnosed disease", "PROBLEM", 154, 175], ["heterogeneous", "OBSERVATION_MODIFIER", 4, 17], ["edges", "OBSERVATION", 18, 23], ["edges", "OBSERVATION_MODIFIER", 39, 44], ["drug nodes", "OBSERVATION", 56, 66], ["disease nodes", "OBSERVATION", 71, 84]]], ["The definitions of the two types of edges are given as follows:Definition 4 (Homogeneous Edges).For any node i, j \u2208 V drug (or V dis ), the edge weight w ij between two nodes are defined using Gaussian weighting function as follows:Definition 4 (Homogeneous Edges).for some parameters threshold and \u03b8. v i and v j are the proximity-based node embeddings of two nodes i and j.", [["node", "ANATOMY", 104, 108], ["nodes", "ANATOMY", 169, 174], ["node", "ANATOMY", 338, 342], ["v i", "GENE_OR_GENE_PRODUCT", 302, 305], ["v j", "GENE_OR_GENE_PRODUCT", 310, 313], ["the edge weight", "TEST", 136, 151], ["some parameters threshold", "TEST", 269, 294], ["node", "OBSERVATION", 104, 108], ["ij", "ANATOMY", 154, 156], ["nodes", "OBSERVATION", 169, 174], ["v j", "OBSERVATION_MODIFIER", 310, 313], ["node", "OBSERVATION", 338, 342], ["two", "OBSERVATION_MODIFIER", 357, 360], ["nodes", "OBSERVATION", 361, 366]]], ["Later, we additionally use edge-forming thresholds to control the sparsity of the graph.Definition 5 (Heterogeneous Edges).For any drug node i \u2208 V drug and any disease node j \u2208 V dis , the edge weight w ij between two nodes are given as:Definition 5 (Heterogeneous Edges).where n ij is number of patients' histories in the NHIS-NSC database that is recorded with a diagnosis j and a prescription i in tandem. n j is the number of patients' histories with the diagnosis j.A GNN-Based Method for Learning Graph StructureWe aggregate neighborhood information of each drug/disease node from the constructed graph using the Graph Neural Network (GNN) framework.", [["nodes", "ANATOMY", 218, 223], ["patients", "ORGANISM", 296, 304], ["patients", "ORGANISM", 430, 438], ["patients", "SPECIES", 296, 304], ["patients", "SPECIES", 430, 438], ["edge-forming thresholds", "TREATMENT", 27, 50], ["any disease node", "PROBLEM", 156, 172], ["the edge weight", "TEST", 185, 200], ["ij between two nodes", "TREATMENT", 203, 223], ["disease node", "PROBLEM", 569, 581], ["the constructed graph", "TEST", 587, 608], ["Heterogeneous", "OBSERVATION_MODIFIER", 102, 115], ["Edges", "OBSERVATION_MODIFIER", 116, 121], ["node", "OBSERVATION", 136, 140], ["ij", "ANATOMY", 203, 205], ["nodes", "OBSERVATION", 218, 223], ["ij", "ANATOMY", 280, 282], ["disease node", "OBSERVATION", 569, 581]]], ["In each layer of GNN, the weighted sum of neighboring node features in the previous layer is computed to serve as the node features (after applying a RELU nonlinearity \u03c3) as follows:A GNN-Based Method for Learning Graph Structurewhere N (i) denotes the set of neighbors of i th node, z i (l) denotes feature vector of i th node at l th layer, W denotes a learnable weight matrix and \u03b1 (l) ij denotes the normalized edge weight between i th and j th nodes at the l th layer.", [["node", "ANATOMY", 54, 58], ["node", "ANATOMY", 118, 122], ["GNN", "CANCER", 17, 20], ["node", "MULTI-TISSUE_STRUCTURE", 54, 58], ["node", "MULTI-TISSUE_STRUCTURE", 278, 282], ["GNN", "PROTEIN", 17, 20], ["neighboring node features", "PROBLEM", 42, 67], ["A GNN", "TEST", 182, 187], ["a learnable weight matrix", "TREATMENT", 353, 378], ["ij", "TREATMENT", 389, 391], ["layer", "OBSERVATION_MODIFIER", 8, 13], ["neighboring", "OBSERVATION_MODIFIER", 42, 53], ["node", "OBSERVATION", 54, 58], ["node", "OBSERVATION", 118, 122], ["node", "ANATOMY", 278, 282], ["node", "ANATOMY", 323, 327], ["ij", "ANATOMY", 389, 391], ["edge", "OBSERVATION_MODIFIER", 415, 419], ["nodes", "OBSERVATION", 449, 454], ["l th", "ANATOMY_MODIFIER", 462, 466], ["layer", "ANATOMY_MODIFIER", 467, 472]]], ["In the first layer, the initial drug/disease node representations are each passed through a nonlinear projection function to match their dimensions.A GNN-Based Method for Learning Graph StructureWe use two weighting schemes for \u03b1 (l) ij .", [["node", "ANATOMY", 45, 49], ["the initial drug/disease node representations", "PROBLEM", 20, 65], ["A GNN", "TEST", 148, 153], ["Learning Graph StructureWe", "TREATMENT", 171, 197], ["\u03b1 (l) ij", "TREATMENT", 228, 236], ["layer", "OBSERVATION_MODIFIER", 13, 18], ["disease node", "OBSERVATION", 37, 49], ["ij", "ANATOMY", 234, 236]]], ["The first variant follows the definition in [7] , and the weight is defined as follows:A GNN-Based Method for Learning Graph Structurewhere d i and d j are the degree of nodes i and j respectively, and w ij are the edge weights defined in Sect.", [["the weight", "TEST", 54, 64], ["A GNN", "TEST", 87, 92], ["Learning Graph", "TEST", 110, 124], ["ij", "TREATMENT", 204, 206], ["d j", "OBSERVATION_MODIFIER", 148, 151], ["nodes", "OBSERVATION", 170, 175], ["ij", "ANATOMY", 204, 206], ["edge", "OBSERVATION_MODIFIER", 215, 219]]], ["The weights are fixed for all layers.", [["The weights", "TEST", 0, 11], ["layers", "OBSERVATION_MODIFIER", 30, 36]]], ["The second weighting scheme instead learns the weighting scheme using attention mechanism [19] as follows:A GNN-Based Method for Learning Graph Structurewhere g is a single fully-connected layer with LeakyReLU nonlinearity that takes a pair of node features as input.", [["node", "ANATOMY", 244, 248], ["node", "MULTI-TISSUE_STRUCTURE", 244, 248], ["The second weighting scheme", "TREATMENT", 0, 27], ["A GNN", "TEST", 106, 111], ["LeakyReLU nonlinearity", "PROBLEM", 200, 222], ["node", "OBSERVATION", 244, 248]]], ["In the rest of this paper, we call the network with the first weighting scheme as GCN and the network with the second scheme as GAT.", [["GCN", "CANCER", 82, 85], ["GCN", "PROTEIN", 82, 85]]], ["We predict the ADR signal of a drug-disease pair using the learned embeddings from the GNN model with a single bilinear layer as follows:A GNN-Based Method for Learning Graph Structurewhere W p , b are the learnable weights, and vA GNN-Based Method for Learning Graph Structureare the node features of drug node i and disease node j at the last GNN layer.", [["node", "ANATOMY", 285, 289], ["node", "ANATOMY", 307, 311], ["disease node", "ANATOMY", 318, 330], ["GNN layer", "ANATOMY", 345, 354], ["GNN layer", "CANCER", 345, 354], ["a drug-disease pair", "PROBLEM", 29, 48], ["A GNN", "TEST", 137, 142], ["the learnable weights", "TEST", 202, 223], ["vA GNN", "TEST", 229, 235], ["Learning Graph", "TEST", 253, 267], ["drug node i", "PROBLEM", 302, 313], ["disease node j", "PROBLEM", 318, 332], ["node", "OBSERVATION", 285, 289], ["drug node", "OBSERVATION", 302, 311]]], ["The whole model is trained by minimizing the cross-entropy loss.Data PreprocessingAs we get the labels from the SIDER database and the edge weight from the NHIS-NSC database, we retrieve the drug and disease nodes over the joint set of two databases.", [["SIDER", "DNA", 112, 117], ["the cross-entropy loss", "PROBLEM", 41, 63], ["the edge weight", "TEST", 131, 146], ["the drug and disease nodes", "PROBLEM", 187, 213], ["disease nodes", "OBSERVATION", 200, 213], ["joint", "ANATOMY", 223, 228]]], ["The resulting dataset is composed of 607 drugs and 556 diseases, and the number of positive samples, indicating the drug-side effect relationships, are 28,746 pairs.", [["samples", "ANATOMY", 92, 99], ["556 diseases", "PROBLEM", 51, 63], ["positive samples", "PROBLEM", 83, 99]]], ["A negative sample is defined as a combination of drugs and diseases over the dataset, where the known 28,746 positive samples are excluded.", [["samples", "ANATOMY", 118, 125], ["samples", "CANCER", 118, 125], ["drugs", "TREATMENT", 49, 54], ["diseases", "PROBLEM", 59, 67], ["negative", "OBSERVATION", 2, 10]]], ["We randomly select negative samples, setting the size of negative samples same as the size of positive samples.Experimental SettingsSince we extract those combinations from the SIDER database, it is plausible to believe that they have not been reported as ADRs.", [["samples", "ANATOMY", 28, 35], ["samples", "ANATOMY", 103, 110], ["ADRs", "DISEASE", 256, 260], ["positive samples", "PROBLEM", 94, 110], ["ADRs", "PROBLEM", 256, 260], ["size", "OBSERVATION_MODIFIER", 49, 53], ["negative", "OBSERVATION", 57, 65], ["size", "OBSERVATION_MODIFIER", 86, 90], ["positive samples", "OBSERVATION", 94, 110]]], ["Although the labels are only given to the drug-disease pairs over the joint set of two databases, we make use of all the drugs and diseases in NHIS-NSC as graph nodes to utilize the relations among the drugs and diseases.Experimental SettingsTo predict the link between the drugs and diseases, we split drug-disease pairs from the ADR dataset into training, validation, and test sets, ensuring that the classes of diseases included in each set do not overlap.", [["NHIS-NSC", "CELL", 143, 151], ["graph nodes", "MULTI-TISSUE_STRUCTURE", 155, 166], ["the drug-disease pairs", "PROBLEM", 38, 60], ["all the drugs", "TREATMENT", 113, 126], ["diseases", "PROBLEM", 131, 139], ["NSC", "TREATMENT", 148, 151], ["the drugs", "TREATMENT", 198, 207], ["diseases", "PROBLEM", 212, 220], ["the drugs", "TREATMENT", 270, 279], ["diseases", "PROBLEM", 284, 292], ["validation, and test sets", "TEST", 358, 383], ["diseases", "PROBLEM", 414, 422], ["joint", "ANATOMY", 70, 75], ["diseases", "OBSERVATION", 414, 422]]], ["The reason we split the data without overlapping disease classes is to increase the usability of the ADR signal detection model.", [["overlapping disease classes", "PROBLEM", 37, 64], ["disease", "OBSERVATION", 49, 56]]], ["It is also because only a few classes of diseases exist in our dataset, and therefore there could be a data leakage if the same disease class exists in both training and validation.", [["diseases", "PROBLEM", 41, 49], ["a data leakage", "PROBLEM", 101, 115], ["the same disease class", "PROBLEM", 119, 141], ["few", "OBSERVATION_MODIFIER", 26, 29], ["diseases", "OBSERVATION", 41, 49], ["leakage", "OBSERVATION", 108, 115]]], ["The class of disease means the classification up to the third digit of ICD-10 codes.", [["disease", "PROBLEM", 13, 20], ["disease", "OBSERVATION", 13, 20], ["ICD", "OBSERVATION", 71, 74]]], ["Note that we make the inference very difficult by not letting the model know which classes of diseases are linked with drugs as ADRs.", [["ADRs", "DISEASE", 128, 132], ["diseases", "PROBLEM", 94, 102], ["drugs", "TREATMENT", 119, 124], ["ADRs", "PROBLEM", 128, 132]]], ["We use 80% of data for training, 10% for validation, and the remaining 10% for testing.Experimental SettingsTo control the sparsity of a graph, we build two types of graphs where the edge-forming threshold is either low or high.", [["training", "TREATMENT", 23, 31], ["validation", "TEST", 41, 51], ["testing", "TEST", 79, 86], ["Experimental Settings", "TREATMENT", 87, 108], ["edge", "OBSERVATION_MODIFIER", 183, 187], ["low", "OBSERVATION_MODIFIER", 216, 219], ["high", "OBSERVATION", 223, 227]]], ["When the edge-forming threshold is low, the graph has more edges, having more information as a result.", [["edge", "OBSERVATION_MODIFIER", 9, 13], ["low", "OBSERVATION_MODIFIER", 35, 38], ["more edges", "OBSERVATION_MODIFIER", 54, 64]]], ["The summary statistics of the constructed graphs and datasets are provided in Table 1 .EvaluationsTo verify the performance of the GCN-based approach, we compare GCN-based models with non-graph-based ML techniques.", [["GCN", "DNA", 131, 134], ["GCN", "DNA", 162, 165], ["the constructed graphs", "TEST", 26, 48], ["Evaluations", "TEST", 87, 98], ["non-graph-based ML techniques", "TREATMENT", 184, 213]]], ["We apply vanilla GCN and its variants to examine the effect of considering the edge types.", [["vanilla GCN", "CHEMICAL", 9, 20], ["vanilla GCN", "PROTEIN", 9, 20], ["vanilla GCN", "TREATMENT", 9, 20]]], ["The followings are the models used for the graph embedding learnings.", [["the graph embedding learnings", "TREATMENT", 39, 68]]], ["All the neural-network based models use two layers with a hidden dimension of 300.Evaluations-LR is a logistic regression (LR) approach with information of the graph topology.", [["neural", "ANATOMY", 8, 14], ["Evaluations", "TEST", 82, 93], ["LR", "TREATMENT", 94, 96], ["a logistic regression (LR) approach", "TREATMENT", 100, 135], ["the graph topology", "TEST", 156, 174], ["neural", "ANATOMY_MODIFIER", 8, 14], ["layers", "OBSERVATION_MODIFIER", 44, 50]]], ["The vector composed of initial node representations of the node itself and its neighbor nodes are input to the LR model.", [["node", "ANATOMY", 31, 35], ["node", "ANATOMY", 59, 63], ["neighbor nodes", "ANATOMY", 79, 93], ["node", "MULTI-TISSUE_STRUCTURE", 31, 35], ["node", "MULTI-TISSUE_STRUCTURE", 59, 63], ["neighbor nodes", "MULTI-TISSUE_STRUCTURE", 79, 93], ["The vector", "TREATMENT", 0, 10], ["initial node representations", "TREATMENT", 23, 51], ["initial", "OBSERVATION_MODIFIER", 23, 30], ["node", "OBSERVATION", 31, 35], ["node", "OBSERVATION", 59, 63], ["neighbor nodes", "OBSERVATION", 79, 93], ["LR model", "OBSERVATION_MODIFIER", 111, 119]]], ["The number of neighbors is limited to 10. -NN is a 2-layer fully-connected neural network which is solely based on the initial node representations. -GCN low is a graph convolution network, a representative GNN model that uses graph convolutions [7] .Evaluations-GAT low is a GNN that applies the attention mechanism on the node embeddings.", [["neural network", "ANATOMY", 75, 89], ["node", "ANATOMY", 127, 131], ["node", "ANATOMY", 324, 328], ["neural network", "MULTI-TISSUE_STRUCTURE", 75, 89], ["node", "MULTI-TISSUE_STRUCTURE", 127, 131], ["node embeddings", "MULTI-TISSUE_STRUCTURE", 324, 339], ["GCN", "DNA", 150, 153], ["GAT low", "DNA", 263, 270], ["GNN", "DNA", 276, 279], ["the initial node representations", "TREATMENT", 115, 147], ["GCN low", "PROBLEM", 150, 157], ["Evaluations", "TEST", 251, 262], ["GAT low", "PROBLEM", 263, 270], ["the node embeddings", "TREATMENT", 320, 339], ["node", "OBSERVATION", 127, 131], ["GCN low", "OBSERVATION", 150, 157], ["node", "OBSERVATION", 324, 328]]], ["Here we use GAT with two layers, where the number of heads are (4, 4) for each layer. -adrGCN low is an adapted version of GCN, that uses separate GCN layers according to the edge types and then aggregate them. -GCN high , GAT high , adrGCN high are the graph-based models applied to the sparser graph, i.e. the edge-forming threshold is high.EvaluationsAs shown in Table 2 , the proposed graph-based approaches surpass all the non-graph-based approaches.", [["GAT", "SIMPLE_CHEMICAL", 12, 15], ["GCN", "GENE_OR_GENE_PRODUCT", 123, 126], ["GCN layers", "TISSUE", 147, 157], ["GCN", "PROTEIN", 123, 126], ["GCN", "DNA", 212, 215], ["GAT with two layers", "TREATMENT", 12, 31], ["adrGCN low", "PROBLEM", 87, 97], ["GCN", "PROBLEM", 123, 126], ["separate GCN layers", "TREATMENT", 138, 157], ["GCN high", "PROBLEM", 212, 220], ["GAT high , adrGCN high", "PROBLEM", 223, 245], ["the graph", "TEST", 250, 259], ["the sparser graph", "TREATMENT", 284, 301], ["Evaluations", "TEST", 343, 354], ["layers", "OBSERVATION_MODIFIER", 25, 31], ["heads", "ANATOMY_MODIFIER", 53, 58], ["GCN", "OBSERVATION_MODIFIER", 212, 215], ["high", "OBSERVATION_MODIFIER", 216, 220], ["edge", "OBSERVATION_MODIFIER", 312, 316], ["high", "OBSERVATION_MODIFIER", 338, 342]]], ["The best AUROC performance is achieved when GCN is applied with the low edge-forming threshold.", [["GCN", "PROTEIN", 44, 47], ["low edge", "OBSERVATION_MODIFIER", 68, 76]]], ["To see the robustness of the proposed method, we also examine whether our model works well for the infrequent drug-ADR pairs.", [["ADR", "CHEMICAL", 115, 118]]], ["We evaluate model performance for the infrequent drug-ADR pairs, which are labeled as 'rare' or 'post-marketing' in SIDER.", [["ADR", "CHEMICAL", 54, 57]]], ["As a result, the best average test accuracy in infrequent drug-ADR pairs is achieved with adrGCN high (0.746), demonstrating that using multiple GCNs according to the edge types is useful to detect rare symptoms.", [["ADR", "CHEMICAL", 63, 66], ["GCNs", "CANCER", 145, 149], ["the best average test accuracy", "TEST", 13, 43], ["multiple GCNs", "TREATMENT", 136, 149], ["rare symptoms", "PROBLEM", 198, 211]]], ["According to the SIDER database, the ADRs with 'rare' or 'postmarketing' labels are reported with frequencies under 0.01.Newly-Described ADR CandidatesTo verify the power of the graph-based approach to discover ADR candidates which are unseen in the dataset, we extract the drug-disease pairs which are predicted to be positive with high probability-over 0.97 but labeled as negative (false positive).", [["ADRs", "DISEASE", 37, 41], ["ADR", "CANCER", 211, 214], ["SIDER", "DNA", 17, 22], ["the graph-based approach", "TREATMENT", 174, 198], ["ADR candidates", "TREATMENT", 211, 225], ["the drug-disease pairs", "PROBLEM", 270, 292]]], ["To demonstrate the genuine power of graph-based methods, we exclude the candidates that are also positively predicted by the baseline neural network, which does not use relational information.", [["neural network", "ANATOMY", 134, 148], ["neural network", "MULTI-TISSUE_STRUCTURE", 134, 148]]], ["As a result, clinical experts (M.D.) confirm that there exist pairs that are clearly considered to be real ADRs.", [["ADRs", "DISEASE", 107, 111]]], ["The pairs are listed in Table 3 .Newly-Described ADR CandidatesMany of the discovered pairs, including umbrella terms like edema, are rather symptoms and signs than diseases.", [["edema", "ANATOMY", 123, 128], ["edema", "DISEASE", 123, 128], ["edema", "PATHOLOGICAL_FORMATION", 123, 128], ["umbrella terms like edema", "PROBLEM", 103, 128], ["rather symptoms", "PROBLEM", 134, 149], ["signs than diseases", "PROBLEM", 154, 173], ["umbrella", "ANATOMY_MODIFIER", 103, 111], ["edema", "OBSERVATION", 123, 128]]], ["This can be explained by the fact that the SIDER database is less comprehensive to cover all the specific symptoms, that can be induced by taking medicine.", [["the SIDER database", "PROBLEM", 39, 57], ["the specific symptoms", "PROBLEM", 93, 114]]], ["Especially, cardiac murmur and abnormal reflex are frequent symptoms, but it is reasonable to say that the suggested pairs are ADRs.", [["cardiac", "ANATOMY", 12, 19], ["cardiac murmur", "DISEASE", 12, 26], ["ADRs", "DISEASE", 127, 131], ["cardiac", "ORGAN", 12, 19], ["cardiac murmur", "PROBLEM", 12, 26], ["abnormal reflex", "PROBLEM", 31, 46], ["frequent symptoms", "PROBLEM", 51, 68], ["ADRs", "PROBLEM", 127, 131], ["cardiac", "ANATOMY", 12, 19], ["murmur", "OBSERVATION", 20, 26], ["abnormal", "OBSERVATION_MODIFIER", 31, 39], ["reflex", "OBSERVATION_MODIFIER", 40, 46]]], ["For example, Dasatinib is used to treat leukemia and can have significant cardiotoxicity, which can lead to cardiac murmurs.", [["leukemia", "ANATOMY", 40, 48], ["cardiac", "ANATOMY", 108, 115], ["Dasatinib", "CHEMICAL", 13, 22], ["leukemia", "DISEASE", 40, 48], ["cardiotoxicity", "DISEASE", 74, 88], ["cardiac murmurs", "DISEASE", 108, 123], ["Dasatinib", "CHEMICAL", 13, 22], ["Dasatinib", "SIMPLE_CHEMICAL", 13, 22], ["leukemia", "CANCER", 40, 48], ["cardiac", "ORGAN", 108, 115], ["Dasatinib", "TREATMENT", 13, 22], ["leukemia", "PROBLEM", 40, 48], ["significant cardiotoxicity", "PROBLEM", 62, 88], ["cardiac murmurs", "PROBLEM", 108, 123], ["Dasatinib", "OBSERVATION", 13, 22], ["leukemia", "OBSERVATION", 40, 48], ["significant", "OBSERVATION_MODIFIER", 62, 73], ["cardiotoxicity", "OBSERVATION", 74, 88], ["cardiac", "ANATOMY", 108, 115], ["murmurs", "OBSERVATION", 116, 123]]], ["Hydroxycarbamide is a cytotoxic drug used for certain types of cancer, and it is known that cytotoxic medications can cause electrolyte imbalance leading to abnormal reflex.Newly-Described ADR CandidatesThere are also significant pairs such as alendronic acid and tetany in the third row.", [["cancer", "ANATOMY", 63, 69], ["Hydroxycarbamide", "CHEMICAL", 0, 16], ["cancer", "DISEASE", 63, 69], ["alendronic acid", "CHEMICAL", 244, 259], ["tetany", "DISEASE", 264, 270], ["Hydroxycarbamide", "CHEMICAL", 0, 16], ["alendronic acid", "CHEMICAL", 244, 259], ["Hydroxycarbamide", "SIMPLE_CHEMICAL", 0, 16], ["cancer", "CANCER", 63, 69], ["electrolyte", "SIMPLE_CHEMICAL", 124, 135], ["alendronic acid", "SIMPLE_CHEMICAL", 244, 259], ["Hydroxycarbamide", "TREATMENT", 0, 16], ["a cytotoxic drug", "TREATMENT", 20, 36], ["cancer", "PROBLEM", 63, 69], ["cytotoxic medications", "TREATMENT", 92, 113], ["electrolyte imbalance", "PROBLEM", 124, 145], ["abnormal reflex", "PROBLEM", 157, 172], ["significant pairs", "PROBLEM", 218, 235], ["alendronic acid and tetany in the third row", "PROBLEM", 244, 287], ["cancer", "OBSERVATION", 63, 69], ["abnormal", "OBSERVATION_MODIFIER", 157, 165], ["reflex", "OBSERVATION", 166, 172], ["ADR Candidates", "OBSERVATION", 189, 203], ["significant", "OBSERVATION_MODIFIER", 218, 229]]], ["Severe and transient hypocalcemia is a well-known side-effect of bisphosphonates, which can lead to symptoms of tetany.", [["hypocalcemia", "DISEASE", 21, 33], ["bisphosphonates", "CHEMICAL", 65, 80], ["tetany", "DISEASE", 112, 118], ["bisphosphonates", "CHEMICAL", 65, 80], ["bisphosphonates", "SIMPLE_CHEMICAL", 65, 80], ["Severe and transient hypocalcemia", "PROBLEM", 0, 33], ["bisphosphonates", "TREATMENT", 65, 80], ["symptoms", "PROBLEM", 100, 108], ["tetany", "PROBLEM", 112, 118], ["transient", "OBSERVATION_MODIFIER", 11, 20], ["hypocalcemia", "OBSERVATION", 21, 33], ["well-known side", "OBSERVATION_MODIFIER", 39, 54]]], ["Alendronic acid is classified as bisphosphonates, and therefore, tetany can be described as ADR of alendronic acid.", [["Alendronic acid", "CHEMICAL", 0, 15], ["bisphosphonates", "CHEMICAL", 33, 48], ["tetany", "DISEASE", 65, 71], ["alendronic acid", "CHEMICAL", 99, 114], ["Alendronic acid", "CHEMICAL", 0, 15], ["bisphosphonates", "CHEMICAL", 33, 48], ["alendronic acid", "CHEMICAL", 99, 114], ["Alendronic acid", "SIMPLE_CHEMICAL", 0, 15], ["bisphosphonates", "SIMPLE_CHEMICAL", 33, 48], ["ADR", "SIMPLE_CHEMICAL", 92, 95], ["alendronic acid", "SIMPLE_CHEMICAL", 99, 114], ["Alendronic acid", "TEST", 0, 15], ["bisphosphonates", "TREATMENT", 33, 48], ["alendronic acid", "TREATMENT", 99, 114]]], ["Ibandronic acid and etidronic acidin the last two rows are also bisphosphonates, and the paired symptoms are relevant to the usage of bisphosphonates.", [["Ibandronic acid", "CHEMICAL", 0, 15], ["etidronic acidin", "CHEMICAL", 20, 36], ["bisphosphonates", "CHEMICAL", 64, 79], ["bisphosphonates", "CHEMICAL", 134, 149], ["Ibandronic acid", "CHEMICAL", 0, 15], ["etidronic acidin", "CHEMICAL", 20, 36], ["bisphosphonates", "CHEMICAL", 64, 79], ["bisphosphonates", "CHEMICAL", 134, 149], ["Ibandronic acid", "SIMPLE_CHEMICAL", 0, 15], ["etidronic acidin", "SIMPLE_CHEMICAL", 20, 36], ["bisphosphonates", "SIMPLE_CHEMICAL", 64, 79], ["bisphosphonates", "SIMPLE_CHEMICAL", 134, 149], ["Ibandronic acid", "TREATMENT", 0, 15], ["etidronic acidin", "TREATMENT", 20, 36], ["bisphosphonates", "TREATMENT", 64, 79], ["the paired symptoms", "PROBLEM", 85, 104], ["bisphosphonates", "TREATMENT", 134, 149], ["acid", "OBSERVATION_MODIFIER", 11, 15]]], ["Unspecified edema may signify bone marrow edema caused by bisphosphonate use, and electrolyte imbalance, which can lead to abnormal reflex, can be caused by etidronic acid use.", [["edema", "ANATOMY", 12, 17], ["bone marrow", "ANATOMY", 30, 41], ["edema", "DISEASE", 12, 17], ["bone marrow edema", "DISEASE", 30, 47], ["bisphosphonate", "CHEMICAL", 58, 72], ["etidronic acid", "CHEMICAL", 157, 171], ["bisphosphonate", "CHEMICAL", 58, 72], ["etidronic acid", "CHEMICAL", 157, 171], ["edema", "PATHOLOGICAL_FORMATION", 12, 17], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 30, 41], ["bisphosphonate", "SIMPLE_CHEMICAL", 58, 72], ["etidronic acid", "SIMPLE_CHEMICAL", 157, 171], ["Unspecified edema", "PROBLEM", 0, 17], ["bone marrow edema", "PROBLEM", 30, 47], ["bisphosphonate use", "TREATMENT", 58, 76], ["electrolyte imbalance", "PROBLEM", 82, 103], ["abnormal reflex", "PROBLEM", 123, 138], ["etidronic acid use", "TREATMENT", 157, 175], ["edema", "OBSERVATION", 12, 17], ["may signify", "UNCERTAINTY", 18, 29], ["bone marrow", "OBSERVATION", 30, 41], ["edema", "OBSERVATION", 42, 47], ["bisphosphonate", "OBSERVATION", 58, 72]]], ["All these explanations show that the ADR pairs we extract are based on various relations among drugs and diseases.ConclusionIn this study, we propose a novel graph-based approach for ADR detection by constructing a graph from the large-scale healthcare claims data.", [["ADR", "CHEMICAL", 37, 40], ["ADR", "CHEMICAL", 183, 186], ["ADR", "SIMPLE_CHEMICAL", 37, 40], ["the ADR pairs", "PROBLEM", 33, 46], ["diseases", "PROBLEM", 105, 113], ["this study", "TEST", 127, 137], ["ADR detection", "TEST", 183, 196], ["a graph", "TEST", 213, 220], ["large", "OBSERVATION_MODIFIER", 230, 235]]], ["Our model can capture various relations among drugs and diseases, showing improved performance in predicting drug-ADR pairs.", [["ADR", "CHEMICAL", 114, 117], ["diseases", "PROBLEM", 56, 64]]], ["Furthermore, our model even predicts drug-ADR pairs that do not exist in the established ADR database, showing that it is capable of supplementing the ADR database.", [["ADR pairs", "PROBLEM", 42, 51]]], ["The explanation by clinical experts verifies that the graph-based method is valid for ADR detection.", [["ADR", "CHEMICAL", 86, 89], ["the graph", "TEST", 50, 59], ["ADR detection", "PROBLEM", 86, 99]]], ["In this study, we only make inferences within the labeled dataset, yet we plan to make inferences on unlabeled data to discover unknown ADR pairs, which will be a huge breakthrough in ADR detection.", [["ADR", "CHEMICAL", 136, 139], ["ADR", "CHEMICAL", 184, 187], ["ADR", "CANCER", 184, 187], ["this study", "TEST", 3, 13], ["unknown ADR pairs", "PROBLEM", 128, 145], ["a huge breakthrough in ADR detection", "PROBLEM", 161, 197]]]]}